0001437749-24-03492710-Q Vaxart, Inc. 20241113202411131623361623371623370 0001437749-24-034927 10-Q 76 20240930 20241113 20241113 Vaxart, Inc. 0000072444 2836 591212264 DE 1231 10-Q 34 001-35285 241454684 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 Aviragen Therapeutics, Inc. 20160413 Biota Pharmaceuticals, Inc. 20121113 NABI BIOPHARMACEUTICALS 20100719 10-Q 1 vxrt20240930_10q.htm FORM 10-Q vxrt20240930_10q.htm 0000072444 Vaxart, Inc. false --12-31 Q3 2024 0.0001 0.0001 5,000,000 5,000,000 0 0 0 0 0.0001 0.0001 350,000,000 250,000,000 228,176,446 227,476,324 153,959,853 153,452,833 700,122 507,020 248 55 2,455 103 284 1 0 0 1.0 2.8 0 0 0 0.5 4.5 4.5 0 6 false false false false 00000724442024-01-012024-09-30 xbrli:shares 00000724442024-11-06 thunderdome:item iso4217:USD 00000724442024-09-30 00000724442023-12-31 0000072444us-gaap:GovernmentContractMember2024-09-30 0000072444us-gaap:GovernmentContractMember2023-12-31 iso4217:USDxbrli:shares 0000072444vxrt:NonCashRoyaltyRevenueMember2024-07-012024-09-30 0000072444vxrt:NonCashRoyaltyRevenueMember2023-07-012023-09-30 0000072444vxrt:NonCashRoyaltyRevenueMember2024-01-012024-09-30 0000072444vxrt:NonCashRoyaltyRevenueMember2023-01-012023-09-30 0000072444us-gaap:GovernmentContractMember2024-07-012024-09-30 0000072444us-gaap:GovernmentContractMember2023-07-012023-09-30 0000072444us-gaap:GovernmentContractMember2024-01-012024-09-30 0000072444us-gaap:GovernmentContractMember2023-01-012023-09-30 0000072444us-gaap:GrantMember2024-07-012024-09-30 0000072444us-gaap:GrantMember2023-07-012023-09-30 0000072444us-gaap:GrantMember2024-01-012024-09-30 0000072444us-gaap:GrantMember2023-01-012023-09-30 00000724442024-07-012024-09-30 00000724442023-07-012023-09-30 00000724442023-01-012023-09-30 0000072444vxrt:CommonStockOutstandingMember2024-06-30 0000072444us-gaap:TreasuryStockCommonMember2024-06-30 0000072444us-gaap:AdditionalPaidInCapitalMember2024-06-30 0000072444us-gaap:RetainedEarningsMember2024-06-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 00000724442024-06-30 0000072444vxrt:CommonStockOutstandingMembervxrt:June2024OfferingMember2024-07-012024-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:June2024OfferingMember2024-07-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:June2024OfferingMember2024-07-012024-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:June2024OfferingMember2024-07-012024-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMembervxrt:June2024OfferingMember2024-07-012024-09-30 0000072444vxrt:June2024OfferingMember2024-07-012024-09-30 0000072444vxrt:CommonStockOutstandingMember2024-07-012024-09-30 0000072444us-gaap:TreasuryStockCommonMember2024-07-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0000072444us-gaap:RetainedEarningsMember2024-07-012024-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0000072444vxrt:CommonStockOutstandingMember2024-09-30 0000072444us-gaap:TreasuryStockCommonMember2024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2024-09-30 0000072444us-gaap:RetainedEarningsMember2024-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0000072444vxrt:CommonStockOutstandingMember2023-12-31 0000072444us-gaap:TreasuryStockCommonMember2023-12-31 0000072444us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000072444us-gaap:RetainedEarningsMember2023-12-31 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0000072444vxrt:September2021AtmMember2024-01-012024-09-30 0000072444vxrt:CommonStockOutstandingMembervxrt:September2021AtmMember2024-01-012024-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:September2021AtmMember2024-01-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:September2021AtmMember2024-01-012024-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:September2021AtmMember2024-01-012024-09-30 0000072444vxrt:RACapitalHealthcareFund2024Member2024-01-012024-09-30 0000072444vxrt:CommonStockOutstandingMembervxrt:RACapitalHealthcareFund2024Member2024-01-012024-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:RACapitalHealthcareFund2024Member2024-01-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:RACapitalHealthcareFund2024Member2024-01-012024-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:RACapitalHealthcareFund2024Member2024-01-012024-09-30 0000072444vxrt:June2024OfferingMember2024-01-012024-09-30 0000072444vxrt:CommonStockOutstandingMembervxrt:June2024OfferingMember2024-01-012024-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:June2024OfferingMember2024-01-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:June2024OfferingMember2024-01-012024-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:June2024OfferingMember2024-01-012024-09-30 0000072444vxrt:CommonStockOutstandingMember2024-01-012024-09-30 0000072444us-gaap:TreasuryStockCommonMember2024-01-012024-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-30 0000072444us-gaap:RetainedEarningsMember2024-01-012024-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-30 0000072444vxrt:CommonStockOutstandingMember2023-06-30 0000072444us-gaap:TreasuryStockCommonMember2023-06-30 0000072444us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000072444us-gaap:RetainedEarningsMember2023-06-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 00000724442023-06-30 0000072444vxrt:CommonStockOutstandingMember2023-07-012023-09-30 0000072444us-gaap:TreasuryStockCommonMember2023-07-012023-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0000072444us-gaap:RetainedEarningsMember2023-07-012023-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0000072444vxrt:CommonStockOutstandingMember2023-09-30 0000072444us-gaap:TreasuryStockCommonMember2023-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2023-09-30 0000072444us-gaap:RetainedEarningsMember2023-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 00000724442023-09-30 0000072444vxrt:CommonStockOutstandingMember2022-12-31 0000072444us-gaap:TreasuryStockCommonMember2022-12-31 0000072444us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000072444us-gaap:RetainedEarningsMember2022-12-31 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 00000724442022-12-31 0000072444vxrt:September2021AtmMember2023-01-012023-09-30 0000072444vxrt:CommonStockOutstandingMembervxrt:September2021AtmMember2023-01-012023-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:September2021AtmMember2023-01-012023-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:September2021AtmMember2023-01-012023-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:September2021AtmMember2023-01-012023-09-30 0000072444vxrt:The2023ShelfRegistrationMember2023-01-012023-09-30 0000072444vxrt:CommonStockOutstandingMembervxrt:The2023ShelfRegistrationMember2023-01-012023-09-30 0000072444us-gaap:TreasuryStockCommonMembervxrt:The2023ShelfRegistrationMember2023-01-012023-09-30 0000072444us-gaap:AdditionalPaidInCapitalMembervxrt:The2023ShelfRegistrationMember2023-01-012023-09-30 0000072444us-gaap:RetainedEarningsMembervxrt:The2023ShelfRegistrationMember2023-01-012023-09-30 0000072444vxrt:CommonStockOutstandingMember2023-01-012023-09-30 0000072444us-gaap:TreasuryStockCommonMember2023-01-012023-09-30 0000072444us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30 0000072444us-gaap:RetainedEarningsMember2023-01-012023-09-30 0000072444us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-30 0000072444vxrt:June2024OfferingMember2023-01-012023-09-30 0000072444vxrt:RegisteredDirectOfferingMember2024-01-012024-09-30 0000072444vxrt:RegisteredDirectOfferingMember2023-01-012023-09-30 0000072444vxrt:AtthemarketFacilityMember2024-01-012024-09-30 0000072444vxrt:AtthemarketFacilityMember2023-01-012023-09-30 0000072444vxrt:RACapitalHealthcareFund2024Member2023-01-012023-09-30 0000072444vxrt:June2024OfferingMember2024-06-012024-06-30 0000072444vxrt:June2024OfferingMember2024-06-30 0000072444vxrt:RACapitalHealthcareFund2024Member2024-01-012024-01-31 0000072444vxrt:RACapitalHealthcareFund2024Member2024-01-31 0000072444vxrt:TheSeptember2021AtmMember2021-09-152021-09-15 xbrli:pure 0000072444vxrt:TheSeptember2021AtmMember2024-01-012024-09-30 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-30 0000072444us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-30 0000072444us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-30 0000072444us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-30 0000072444us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-30 0000072444us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-30 0000072444us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-30 0000072444us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-30 0000072444us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0000072444us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0000072444us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0000072444us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-31 0000072444us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000072444us-gaap:CashMember2024-09-30 0000072444us-gaap:MoneyMarketFundsMember2024-09-30 0000072444us-gaap:USTreasurySecuritiesMember2024-09-30 0000072444us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-09-30 0000072444us-gaap:CashMember2023-12-31 0000072444us-gaap:MoneyMarketFundsMember2023-12-31 0000072444us-gaap:USTreasurySecuritiesMember2023-12-31 0000072444us-gaap:RoyaltyMember2024-09-30 0000072444vxrt:BARDAMember2024-09-30 0000072444vxrt:BARDAMember2023-12-31 0000072444vxrt:LaboratoryEquipmentMember2024-09-30 0000072444vxrt:LaboratoryEquipmentMember2023-12-31 0000072444us-gaap:OfficeEquipmentMember2024-09-30 0000072444us-gaap:OfficeEquipmentMember2023-12-31 0000072444us-gaap:LeaseholdImprovementsMember2024-09-30 0000072444us-gaap:LeaseholdImprovementsMember2023-12-31 0000072444us-gaap:ConstructionInProgressMember2024-09-30 0000072444us-gaap:ConstructionInProgressMember2023-12-31 0000072444vxrt:FacilityInBurlingameCaliforniaMember2023-12-31 utr:Y 0000072444us-gaap:DevelopedTechnologyRightsMember2024-01-012024-09-30 0000072444us-gaap:IntellectualPropertyMember2024-01-012024-09-30 0000072444us-gaap:DevelopedTechnologyRightsMember2024-09-30 0000072444us-gaap:DevelopedTechnologyRightsMember2023-12-31 0000072444us-gaap:IntellectualPropertyMember2024-09-30 0000072444us-gaap:IntellectualPropertyMember2023-12-31 0000072444us-gaap:RoyaltyMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember2024-01-012024-09-30 0000072444vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember2024-07-012024-09-30 0000072444vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember2023-07-012023-09-30 0000072444vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember2024-01-012024-09-30 0000072444vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember2023-01-012023-09-30 0000072444us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember2024-01-012024-09-30 0000072444us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember2024-07-012024-09-30 0000072444us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember2023-07-012023-09-30 0000072444us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember2023-01-012023-09-30 0000072444vxrt:The2024AtirrpvContractMembersrt:MaximumMember2024-09-30 0000072444vxrt:The2024AtirrpvContractMember2024-09-30 0000072444vxrt:The2024AtirrpvContractMember2024-07-012024-09-30 0000072444vxrt:The2024AtirrpvContractMemberus-gaap:GovernmentContractMember2024-07-012024-09-30 0000072444vxrt:The2024AtirrpvContractMemberus-gaap:GovernmentContractMember2024-01-012024-09-30 0000072444vxrt:The2024AtirrpvContractMemberus-gaap:GovernmentContractMember2024-09-30 0000072444vxrt:The2024AtirrpvContractMemberus-gaap:GovernmentContractMember2023-12-31 0000072444vxrt:The2024AsprbardaContractMember2024-01-12 0000072444vxrt:The2024AsprbardaContractMemberus-gaap:GovernmentContractMember2024-07-012024-09-30 0000072444vxrt:The2024AsprbardaContractMemberus-gaap:GovernmentContractMember2024-01-012024-09-30 0000072444vxrt:The2024AsprbardaContractMemberus-gaap:GovernmentContractMember2024-09-30 0000072444vxrt:The2024AsprbardaContractMemberus-gaap:GovernmentContractMember2023-12-31 0000072444us-gaap:GrantMember2022-11-30 0000072444vxrt:GrantMilestoneCompletionMember2023-07-012023-07-31 0000072444vxrt:HCRPMember2016-04-012016-04-30 0000072444vxrt:HCRPMembervxrt:RoyaltyPaymentInterestFirstPeriodMember2016-04-30 0000072444vxrt:HCRPMembervxrt:RoyaltyPaymentInterestSecondPeriodMember2016-04-30 0000072444vxrt:HCRPMember2024-01-012024-09-30 0000072444vxrt:HCRPMember2023-01-012023-12-31 0000072444vxrt:HealthcareRoyaltyIIILPMemberus-gaap:RoyaltyArrangementMember2023-12-31 0000072444vxrt:HealthcareRoyaltyIIILPMemberus-gaap:RoyaltyArrangementMember2024-01-012024-09-30 0000072444vxrt:HealthcareRoyaltyIIILPMemberus-gaap:RoyaltyArrangementMember2024-09-30 0000072444vxrt:RightOfUseForOfficeAndManufacturingFacilitiesWithInitialTermsExceedingOneYearMember2024-09-30 0000072444vxrt:LeaseForFacilityInSouthSanFranciscoCommencedInThirdQuarterOf2022Member2021-09-30 0000072444vxrt:LeaseForFacilityInSouthSanFranciscoCommencedInFirstQuarterOf2023Member2021-09-30 0000072444vxrt:HimmelbergVVaxartIncEtAlMember2022-07-272022-07-27 0000072444vxrt:HimmelbergVVaxartIncEtAlMember2022-11-022022-11-02 00000724442022-08-042022-08-04 0000072444202403-31 0000072444202406-11 0000072444vxrt:June2024OfferingMember2024-09-30 0000072444us-gaap:EmployeeStockOptionMember2024-09-30 0000072444us-gaap:EmployeeStockOptionMember2023-12-31 0000072444us-gaap:RestrictedStockUnitsRSUMember2024-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0000072444vxrt:The2019PlanMember2024-09-30 0000072444vxrt:The2019PlanMember2023-12-31 0000072444vxrt:The2024InducementAwardPlanMember2024-09-30 0000072444vxrt:The2024InducementAwardPlanMember2023-12-31 0000072444vxrt:CommonWarrantsMember2024-09-30 0000072444vxrt:CommonWarrantsMember2023-12-31 0000072444vxrt:ESPPMember2024-09-30 0000072444vxrt:ESPPMember2023-12-31 00000724442024-04-012024-04-30 0000072444vxrt:FirstSetOfWarrantsExpiringApril2024Member2024-09-30 0000072444vxrt:SecondSetOfWarrantsExpiringApril2024Member2024-09-30

0000072444vxrt:WarrantsExpiringMarch2025Member2024-09-30 0000072444vxrt:WarrantsExpiringFebruary2025Member2024-09-30 0000072444vxrt:The2019PlanMember2019-04-23 0000072444vxrt:The2019PlanMember2020-06-08 0000072444vxrt:The2019PlanMember2021-06-16 0000072444vxrt:The2019PlanMember2022-08-04 0000072444vxrt:The2019PlanMember2024-06-11 0000072444vxrt:The2024InducementAwardPlanMember2024-02-27 0000072444vxrt:The2024InducementAwardPlanMember2024-01-012024-09-30 0000072444vxrt:The2019PlanMember2024-01-012024-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-30 0000072444us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-09-30 0000072444us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-30 0000072444us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-01-012023-09-30 0000072444us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-09-30 0000072444us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0000072444us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-30 0000072444us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0000072444us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-30 0000072444us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0000072444us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-30 0000072444us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0000072444us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-30 0000072444us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30 0000072444vxrt:The2022EsppMember2022-08-04 0000072444vxrt:The2022EsppMember2024-06-11 0000072444vxrt:The2022EsppMember2024-01-012024-09-30 0000072444vxrt:The2022EsppMember2024-09-30 0000072444vxrt:The2022EsppMemberus-gaap:SubsequentEventMember2024-11-30 0000072444vxrt:The2022EsppMember2024-05-31 0000072444vxrt:The2022EsppMember2023-11-30 0000072444vxrt:The2022EsppMember2023-05-31 0000072444vxrt:The2022EsppMember2024-07-012024-11-30 0000072444vxrt:The2022EsppMember2023-12-012024-05-31 0000072444vxrt:The2022EsppMember2023-06-012023-11-30 0000072444vxrt:The2022EsppMember2022-12-012023-05-31 0000072444us-gaap:EmployeeStockOptionMember2024-07-012024-09-30 0000072444us-gaap:EmployeeStockOptionMember2023-07-012023-09-30 0000072444us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0000072444us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-30 0000072444us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-30 0000072444us-gaap:WarrantMemberus-gaap:CommonStockMember2024-07-012024-09-30 0000072444us-gaap:WarrantMemberus-gaap:CommonStockMember2023-07-012023-09-30 0000072444us-gaap:WarrantMemberus-gaap:CommonStockMember2024-01-012024-09-30 0000072444us-gaap:WarrantMemberus-gaap:CommonStockMember2023-01-012023-09-30 0000072444vxrt:EmployeeStockPurchasePlanMember2024-07-012024-09-30 0000072444vxrt:EmployeeStockPurchasePlanMember2023-07-012023-09-30 0000072444vxrt:EmployeeStockPurchasePlanMember2024-01-012024-09-30 0000072444vxrt:EmployeeStockPurchasePlanMember2023-01-012023-09-30 0000072444vxrt:TheSeptember2021AtmMember2021-09-152024-10-18 Â Table of Contents Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) Â â˜’ Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period endedÂ September 30, 2024 Â OR Â Â â˜ Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from Â to Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

common stock to satisfy tax withholding Â Â â€”Â Â Â â€”Â Â Â (193,102)Â Â (208)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (208) Â Â Â

September 30, 2024 or December 31, 2023. Â Â 7 Table of Contents Â VAXART, INC. Â Notes to the Condensed Consolidated Financial Statements (Unaudited) Â Â NOTEÂ 4.Â Â Balance Sheet Components Â Â (a) Cash,Â Cash Equivalents and Investments Â Cash, cash equivalents and investments consisted of the followingÂ (in thousands): Â Â Â AmortizedÂ Â Gross UnrealizedÂ Â EstimatedÂ Â Cash and CashÂ Â Short-TermÂ Â Â Cost Â Â Gains Â Â Losses Â Â Fair Value Â Â Equivalents Â Â Investments Â September 30, 2024 Â Â Â

September 30, 2024 (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (three months remaining) Â $1,108Â 2025 Â Â 4,511Â 2026 Â Â 5,031Â 2027 Â Â 5,207Â 2028 Â Â 5,389Â Thereafter Â Â 1,348Â Undiscounted total Â Â 22,594Â Less: imputed interest Â Â (4,393) Present value of future minimum payments Â Â 18,201Â Current portion of operating lease liability Â Â (2,882) Operating lease liability, net of current portion Â $15,319Â Â The Company is also required to pay for operating expenses related to the leased space. The operating expenses are incurred separately and were not included in the present value of lease payments.Â Operating lease expenses for the three and nineÂ months ended SeptemberÂ 30, 2024Â and 2023Â are summarized as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Lease cost Â Operating lease cost Â $1,554Â Â $1,554Â Â $4,661Â Â $4,617Â Short-term lease cost Â Â 10Â Â Â 10Â Â Â 29Â Â Â 41Â Variable lease cost Â Â 496Â Â Â 459Â Â Â 1,381Â Â Â 1,401Â Sublease income Â Â (20)Â Â â€”Â Â (54)Â Â -Â Total lease cost Â $2,040Â Â $2,023Â Â $6,017Â Â $6,059Â Â 12 Table of Contents Â Â VAXART, INC. Â Notes to the Condensed Consolidated Financial Statements (Unaudited) Â Â NOTE 8.Â Commitments and Contingencies Â Â (a) Purchase Commitments Â As of September 30, 2024, the Company had approximately $8.5Â million of non-cancelable purchase commitments, principallyÂ for contract manufacturing and clinical services which are expected to be paid within the next year.Â In addition,Â the Company has operatingÂ lease commitments asÂ detailed in Note 7. Â Â (b) Indemnifications Â InÂ the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with certain officers and directors which provide, among other things, that the Company will indemnify and advance expenses incurred in connection with certain actions, suits or proceedings to such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and the Companyâ€™s Bylaws. The Company currently has directorsâ€™ and officersâ€™ insurance. Â Â (c) Litigation Â FromÂ time to time the Company may be involved in legal proceedings arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it in excess of established reserves, in the aggregate, is indeterminable to its consolidated financial condition or cash flows. However, any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of managementâ€™s attention and resources that are needed to run the Company successfully, and could have a material adverse impact on its business, financial condition and results of operations. Â In August and September 2020, two substantially similar securities class actions were filed in the U.S. District Court for the Northern District of California. The first action, titled Himmelberg v. Vaxart, Inc. et al. was filed on August 24, 2020. The second action, titled Hovhannisyan v. Vaxart, Inc. et al. was filed on September 1, 2020 (together, the â€œPutative Class Actionâ€).Â By Order dated September 17, 2020, the two actions were deemed related. On December 9, 2020, the court appointed lead plaintiffs and lead plaintiffsâ€™ counsel. Â On January 29, 2021, lead plaintiffs filed their consolidated amended complaint.Â On July 8, 2021, all defendants moved to dismiss the consolidated amended complaint. On May 14, 2021, the court granted lead plaintiffsâ€™ request to amend the consolidated amended complaint and denied defendantsâ€™ motions to dismiss as moot. On June 10, 2021, lead plaintiffs filed a first amended consolidated complaint, and on August 9, 2021, lead plaintiffs filed a corrected first amended consolidated complaint. The first amended consolidated complaint, as corrected, named certain of Vaxartâ€™s current and former executive officers and directors, as well as Armistice Capital, LLC (â€œArmisticeâ€), as defendants.Â It claimed three violations of federal civil securities laws; violation of Section 10(b) of the Exchange Act and SEC Rule 10b-5, as against the Company and all individual defendants; violation of Section 20(a) of the Exchange Act, as against Armistice and all individual defendants; and violation of Section 20A of the Exchange Act against Armistice.Â The first amended consolidated complaint, as corrected, alleged that the defendants violated securities laws by misstating and/or omitting information regarding the Companyâ€™s development of a norovirus vaccine, the vaccine manufacturing capabilities of a business counterparty, and the Companyâ€™s involvement with Operation Warp Speed (â€œOWSâ€); and by engaging in a scheme to inflate Vaxartâ€™s stock price. The first amended consolidated complaint sought certification as a class action for similarly situated shareholders and sought, among other things, an unspecified amount of damages and attorneysâ€™ fees and costs.Â On July 8, 2021, all defendants moved to dismiss the first amended consolidated complaint. By Order dated December 22, 2021, the court granted the motion to dismiss by Armistice with leave to amend and otherwise denied the motions to dismiss. On July 27, 2022, lead plaintiffs filed a notice announcing that they had reached a partial settlement (the â€œPartial Settlementâ€) to resolve all claims against the Company and its current or former officers and/or directors in their capacity as officers and/or directors of the Company (the â€œSettling Defendantsâ€). Pursuant to the Partial Settlement, the Company agreed to a settlement amount of $12.0 millionÂ with $2.0 millionÂ to be paid by the Company and the remainder to be paid by the Companyâ€™s insurers.Â On November 2, 2022, the Company paid the $2.0 million settlement amount with respect to the Putative Class Action pursuant to the terms of the settlement agreement reached in that case.Â On November 14, 2022, lead plaintiffs filed a second amended consolidated class action complaint that purported to include new allegations to support claims against Armistice. By Orders dated January 25, 2023, the court approved the Partial Settlement and entered judgment dismissing with prejudice all claims asserted in the Putative Class Action against the Settling Defendants. Â On October 23, 2020, a complaint was filed in the U.S. District Court for the Southern District of New York, entitled Roth v. Armistice Capital LLC, et al.Â The complaint names Armistice and certain Armistice-related parties as defendants, asserting a violation of Exchange Act Section 16(b) and seeking the disgorgement of short-swing profits.Â The complaint purports to bring the lawsuit on behalf of and for the benefit of the Company and names the Company as a â€œnominal defendantâ€ for whose benefit damages are sought.Â Following discovery, a motion for summary judgment was filed by Armistice and the Armistice-related party defendants to dismiss the complaint. On March 27, 2024, the court granted the motion for summary judgment and dismissed all claims in the complaint in their entirety. On April 11, 2024, the Plaintiff timely filed a notice of appeal of the courtâ€™s decision to the Second Circuit Court of Appeals, commencing appellate proceedings.Â In June 2024, Plaintiff filed a motion to the court of appeals to stay the appeal pending efforts to re-instate the complaint in the district court, which was granted by the court of appeals.Â In July 2024, Plaintiff filed a motion with the district court seeking to set aside the judgment and to re-instate the complaint. On AugustÂ 15, 2024, the district court denied Plaintiffâ€™s motion to set aside the judgment. On September 10, 2024, Plaintiff re-filed its appeal with the Second Circuit Court of Appeals, which is currently pending. Â On January 8, 2021, a purported shareholder, Phillip Chan, commenced a pro se lawsuit in the U.S. District Court for the Northern District of California titled Chan v. Vaxart, Inc. et al. (the â€œOpt-Out Actionâ€), opting out of the consolidated Himmelberg v. Vaxart, Inc. et al. and Hovhannisyan v. Vaxart, Inc. et al. class actions, (together, the â€œPutative Class Actionâ€).Â Because this complaint is nearly identical to an earlier version of a complaint filed in the Putative Class Action, the Opt-Out Action has been stayed while the Putative Class Action is pending. Â 13 Table of Contents Â VAXART, INC. Â Notes to the Condensed Consolidated Financial Statements (Unaudited) Â NOTE 9.Â Â Stockholdersâ€™ Equity Â Â (a) Preferred Stock Â The CompanyÂ is authorized to issue 5,000,000 shares of preferred stock, $0.0001Â par value per share. The Companyâ€™s board of directors may, without further action by the stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 5,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock are currently outstanding, and the Company has no present plan to issue any shares of preferred stock. Â Â (b) Common Stock Â As of SeptemberÂ 30, 2024, the Company wasÂ authorized to issue 350,000,000 shares of common stock, $0.0001Â par value per share,Â which includes an increase of 100,000,000 on JuneÂ 11, 2024, when the Companyâ€™s stockholders approved an amendment to the Companyâ€™s certificate of incorporation to increase the number of authorized shares ofÂ common stock from 250,000,000 to 350,000,000 shares. Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Companyâ€™s directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders. Holders of common stock are entitled to receive such dividends, if any, as may be declared from time to time by the Companyâ€™s board of directors atÂ its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically. As of September 30, 2024, no dividends had been declared by the board of directors. Â In JuneÂ 2024, the CompanyÂ entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by the Company in an underwritten registered direct offering of 50,000,000 shares of the Companyâ€™s common stock, at a price of $0.80 per share. The gross proceeds to the Company from suchÂ offering wereÂ $40.0 million, and afterÂ deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds were $37.5Â million. Â In JanuaryÂ 2024, the CompanyÂ entered into the 2024 Securities Purchase AgreementÂ with RA Capital Healthcare Fund, L.P. pursuant toÂ which 15,384,615Â shares of the Company'sÂ common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65Â per share pursuant to the Companyâ€™s 2023Â Shelf Registration. The grossÂ proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, the net proceeds were $9.9 million. Â InÂ the event of the Companyâ€™s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Companyâ€™s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no sinking fund provisions applicable to the common stock. Â The Company had shares of common stock reserved for issuance as follows: Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Options issued and outstanding Â Â 21,407,462Â Â Â 17,938,726Â RSUs issued and outstanding Â Â 3,036,238Â Â Â 2,126,373Â 2019 Equity Incentive Plan available for future grant Â Â 16,957,020Â Â Â 5,685,806Â 2024 Inducement Award Plan available for future grant Â Â 1,727,500Â Â Â â€”Â Common stock warrants Â Â 140,596Â Â Â 227,434Â 2022 Employee Stock Purchase Plan Â Â 2,362,902Â Â Â 1,065,325Â Total Â Â 45,631,718Â Â Â 27,043,664Â Â The approved increase of reserved common stock for 2019 Equity Incentive Plan and 2022 Employee Stock Purchase Plan is detailed in Note 10. Â Â (c) Treasury Stock Â TheÂ Company generally withholds shares of its common stock to cover employees' portion of required tax withholdings when employee equity awards are issued or vest. These shares are valued at cost, which equals the market price of the common stock on the date of issuance or vesting. The Company had 700,122Â and 507,020Â treasury shares as of SeptemberÂ 30, 2024 and December 31, 2023, respectively. Â Â (d) Warrants Â In April 2024, 70,663Â of the warrants outstanding as of March 31, 2024, expired unexercised. The following warrants were outstanding as of September 30, 2024, all of which contain standard anti-dilution protections in the event of subsequent rights offerings, stock splits, stock dividends or other extraordinary dividends, or other similar changes in the Companyâ€™s common stock or capital structure, and none of which have any participating rights for any losses: Â Securities into which warrants are convertible Â Warrants Outstanding Â Â Exercise Price Â Expiration Date Â Â Â Â Â Â Â Â Â Â Common Stock Â Â 29,150Â Â $2.50Â March 2025 Common Stock Â Â 100,532Â Â $3.125Â February 2025 Common Stock Â Â 10,914Â Â $22.99Â December 2026 Total Â Â 140,596Â Â Â Â Â Â Â InÂ the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Companyâ€™s control, the holders of the unexercised common stock warrants exercisable forÂ $2.50 and those exercisable for $3.125 shall be entitled to receive cash consideration equal to a Black-ScholesÂ valuation, as defined in the warrant. If such Fundamental Transaction is not within the Companyâ€™s control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Companyâ€™s common stock, hence these warrants are classified as a component of permanent equity. Â 14 Table of Contents Â VAXART, INC. Â Notes to the Condensed Consolidated Financial Statements (Unaudited) Â Â NOTEÂ 10.Â Â Equity Incentive Plans Â On April 23, 2019,Â the Companyâ€™s stockholders approved the adoption of the 2019 Equity Incentive Plan (the â€œ2019 Planâ€), under which the Company is authorized to issue incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units (â€œRSUsâ€), other stock awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan is designed to secure and retain the services of employees, directors and consultants, provide incentives for the Companyâ€™s employees, directors and consultants to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which employees, directors and consultants may be given an opportunity to benefit from increases in the value of the Companyâ€™s common stock.Â Following adoption of the 2019 Plan, all previous plans were frozen, and on forfeiture, cancellation and expiration, awards under those plans are not assumed by the 2019 Plan. Â TheÂ aggregate number of shares of common stock authorized for issuance under the 2019 Plan was initially 1,600,000 shares, which was increased through an amendment to the 2019 Plan adopted by the Companyâ€™s stockholders (a â€œPlan Amendmentâ€) on June 8, 2020, to 8,000,000,Â by a Plan Amendment on June 16, 2021, to 16,900,000, by a Plan Amendment on August 4, 2022, to 28,900,000, and by a Plan Amendment on June 11, 2024, to 43,900,000. Further amendments to the 2019 Plan to increase the share reserve would require stockholder approval. Awards that are forfeited orÂ canceled generally become available for issuance again under the 2019 Plan. Awards have a maximum term of ten years from the grant date and may vest over varying periods, as specified by the Companyâ€™s board of directors for each grant. Â On February 27, 2024, the Companyâ€™s board of directors adopted the Vaxart, Inc. 2024 Inducement Award Plan (the â€œ2024 InducementÂ Planâ€).Â The 2024 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the board of directors or the independent members of the board of directors. The board of directors reserved 3,000,000 shares of the Companyâ€™s common stock for issuance under the 2024 Inducement Plan, subject to adjustment as provided in the plan document. The terms of the 2024 Inducement Plan are substantially similar to the terms of the 2019 Plan, with the exception that incentive stock options may not be issued under the 2024 Inducement Plan and equity awards under the 2024 Inducement Plan (including nonqualified stock options, restricted stock, restricted stock units, and other stock-based awards) may be issued only to an employee who is commencing employment with the Company or any subsidiary or who is being rehired following a bona fide interruption of employment by the Company or any subsidiary, in either case if he or she is granted such award in connection with his or her commencement of employment and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. Â A summary of stock option and RSU transactions in theÂ nine months ended September 30,Â 2024, is as follows: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Â

39% relative to placebo. Fluzone, the market-leading injectable quadrivalent influenza vaccine, reduced clinical disease byÂ 27%. Our tablet vaccine candidate also showed a favorable safety profile, indistinguishable from placebo. Â We also presented data from the study demonstrating that our vaccine candidate elicited a significant expansion of mucosal homing receptor plasmablasts to approximately 60% of all activated B cells. We believe these mucosal plasmablasts are a key indicator of a protective mucosal immune response and a unique feature of our vaccine candidates. Â WeÂ have also initiated early-stage development on novelÂ vaccine constructs containing our own antigens to develop a universal influenza vaccine candidate. We had previously produced a non-GMP oral vaccine candidate containing certain proprietary antigens from Janssen Vaccines & Prevention B.V.Â (â€œJanssenâ€) and tested the candidate in a preclinical challenge model.Â The preclinical study has been completed and we have submitted a report to Janssen. In August 2023, Janssen announced it would exit all vaccine and infectious disease R&D programs aside from an E. coli preventive vaccine and continuing to provide access to marketed HIV products.Â Vaxart is no longer pursuing a universal influenza vaccine using Janssen intellectual property.Â Â The Company intends toÂ work with governments around the world to create pandemic monovalent influenza vaccines for emergency use or stockpiling, if requested.Â We are also continuing development of our preclinical seasonal and universal influenza vaccine candidates. Â Â â— HPV Therapeutic Vaccine. CervicalÂ cancer is the fourth most common cancer in women worldwide and in the United States with about 13,000 new cases diagnosed annually in the United States according to the National Cervical Cancer Coalition. OurÂ first therapeutic oral vaccine candidate targets HPV 16 and HPV 18, the two strains responsible for 70% of cervical cancers and precancerous cervical dysplasia. Â We have tested our HPVÂ 16 vaccine candidate in two different HPVÂ 16 solid tumor models in mice. The HPV 16 vaccine candidate elicited T cell responses and promoted migration of the activated T cells into the tumors, leading to tumor cell killing. Mice that received our HPVÂ 16 vaccine candidate showed a significant reduction in volume of their established tumors. Â In October 2018, we filed a pre-IND meeting request with the FDA for our first therapeutic vaccine candidate targetingÂ HPV 16Â and HPV 18 and we subsequently submitted our pre-IND briefing package. We received feedback from the FDA in January 2019 to support submission of an IND application to support initiation of clinical testing. Â The Company remains engaged in discussions with regulatory agencies, governments, non-governmental organizations and other potential strategic parties to determine the best way to progress its HPV program. Â Antivirals Â Â â— Through the Merger, we acquired two royalty earning products, Relenza and Inavir. We also acquired three Phase 2 clinical stage antiviral compounds and subsequentlyÂ discontinued independent development of these compounds. However, for one of these, Vapendavir, we entered into an exclusive worldwide license agreement with Altesa Biosciences, Inc. (â€œAltesaâ€) in July 2021, permitting Altesa to develop and commercialize this capsid-binding broad-spectrum antiviral.Â Altesa is conducting a double-blind, randomized, placebo-controlled trial in participants with chronic obstructive pulmonary disease to evaluate the impact of Vapendavir on the development of lower respiratory tract symptoms following rhinovirus challenge. Â Â â— Relenza and Inavir are antivirals for the treatment of influenza,Â marketed by GlaxoSmithKline, plc (â€œGSKâ€)Â and Daiichi Sankyo Company, Limited (â€œDaiichi Sankyoâ€),Â respectively. We have earned royalties on the net sales of Relenza and Inavir in Japan. The last patent for Relenza expired in July 2019 and the last patent for Inavir expires in August 2036. Sales of these antivirals vary significantly by quarter, because influenza virus activity displays strong seasonal cycles, and by year depending on the intensity and duration of the flu season, the impact COVID-19 has had, and may continue to have,Â on seasonal influenza, and competition from other antivirals such as Tamiflu and Xofluza. Â 20 Table of Contents Â Financial Operations Overview Â Revenue Â Non-Cash Royalty Revenue Related to Sale of Future Royalties Â In April 2016, Aviragen sold certain royalty rights related to Inavir in the Japanese market for $20.0 million to HealthCare Royalty Partners III, L.P.Â (â€œHCRPâ€). Under the terms of our agreement with HCRP, during the first royalty interest period of April 1, 2016 through March 31, 2025, HCRP is entitled to the first $3.0 million and any cumulative remaining shortfall amount plus 15% of the next $1.0 million in royalties earned in each year commencing on April 1, with any excess revenue being retained by us.Â Further, during the second royalty interest period beginning April 1, 2025 and ending on December 24, 2029, HCRP is entitled to the first $2.7 million and any cumulative remainingÂ shortfall amountÂ plus 15% of the next $1.0 million in royalties, with any excess revenue being retained by us. A shortfall occurs when, during an annual period ending onÂ March 31st, for the first royalty interest period of April 1, 2016 through March 31, 2025,Â royalty payments fall below $3.0 million; andÂ $2.7 million for the second royalty interest period of April 1, 2025 and ending on December 24, 2029, excluding the period of April 1, 2028 through December 24, 2029.Â In the event there is a remaining cumulative remaining shortfall amount as of December 24, 2029,Â then, for so long as the Company continues to receive royalties from Daiichi Sankyo Company Limited (â€œDaiichi Sankyoâ€), the sum of those royalties will be paid to HCRP until theÂ cumulative remaining shortfall amount hasÂ been paid in full.Â Â For avoidance of doubt,Â we are not obligated to pay HCRP any royalty payment beyond what we areÂ paid byÂ Daiichi Sankyo.Â The cumulative remaining shortfall amount is the aggregate amount of the shortfall for each annual period, which was $6.0Â million as of SeptemberÂ 30, 2024. Â Revenue from Government Contracts Â In January 2024, we were awarded the 2024 ASPR-BARDA ContractÂ by HHS BARDA, with a base and all options value of $9.3 million. Under the 2024 ASPR-BARDA Contract, weÂ received an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare our XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. Revenue from government contracts recognized on the 2024 ASPR-BARDA Contract was $0.9Â million and $8.7Â million for the three and nineÂ months ended SeptemberÂ 30, 2024, respectively, based on the achievement of certain milestones under the 2024 ASPR-BARDA Contract. Â In June 2024, weÂ entered into the 2024 ATI-RRPV Contract. In September 2024, the 2024 ATI-RRPV Contract was modifiedÂ to increase funding and expand the scope to include the manufacture of a vaccine candidate targeting the KP.2 strain. Pursuant to the 2024 ATI-RRPV Contract (as modified), we will receive funding of up to $456.1Â million to conduct a Phase 2b comparative study evaluating our oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the FDAÂ and manufacture a COVID-19 vaccine candidate targeting the KP.2 strain. The 2024 ATI-RRPVÂ Contract currently makes available anÂ aggregate amount of up to $96.5Â million, consisting ofÂ fixed fee amounts totalingÂ $67.9Â million and reimbursement of costs incurred in trial preparation and execution activities. The 2024 ATI-RRPV ContractÂ further contemplates additional funding up toÂ $359.6Â million if weÂ and HHS BARDA decide to continue with the Phase 2b comparative study.Â Revenue from government contracts recognized on the 2024 ATI-RRPV Contract was $4.0Â million for the three months ended September 30, 2024 and $4.2Â million for the nineÂ months ended SeptemberÂ 30, 2024, based on costs incurred and the achievement of a firm fixed-price milestone under the 2024 ATI-RRPV Contract. Â Grant Revenue Â In November 2022, we accepted a grant (the â€œBMGF Grantâ€) of $3.5 million to performÂ research and development work for the Bill & Melinda Gates Foundation and received $2.0Â million in advance that was recorded as restricted cash and deferred revenue. We received an additional $1.5Â million inÂ July 2023Â upon completion of certain milestones. WeÂ recognizeÂ revenue under research contracts only when a contractÂ isÂ executed and the contract price is fixed or determinable. Revenue from the BMGF Grant wasÂ recognized in the period during which the related costs wereÂ incurred and the related servicesÂ rendered, asÂ the applicable conditions under the contractÂ were met. Costs of contract revenue were recorded as a component of operating expenses in the condensed consolidated statements of operations and comprehensive loss. WeÂ fully recognizedÂ revenue from the BMGF Grant during the year ended December 31, 2023. Â Research and Development Expenses Â Research and development expenses represent costs incurred on conducting research, such as developing our tablet vaccine platform, and supporting preclinical and clinical development activities of our tablet vaccine candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following: Â Â â— employee-related expenses, which include salaries, benefits and stock-based compensation; Â Â â— expenses incurred under agreements with contract research organizationsÂ (â€œCROsâ€), that conduct clinical trials on our behalf; Â Â â— expenses incurred under agreements with contract manufacturing organizations (â€œCMOsâ€), that manufacture product used in the clinical trials; Â Â â— expenses incurred in procuring materials and for analytical and release testing services required to produce vaccine candidates used in clinical trials; Â Â â— process development expenses incurred internally and externally to improve the efficiency and yield of the bulk vaccine and tablet manufacturing activities Â Â â— laboratory supplies and vendor expenses related to preclinical research activities; Â Â â— consultant expenses for services supporting our clinical, regulatory and manufacturing activities; and Â Â â— facilities, depreciation and allocated overhead expenses. Â We do not allocate our internal expenses to specific programs. Our employees and other internal resources are not directly tied to any one research program and are typically deployed across multiple projects. Internal research and development expenses are presented as one total. We have incurred significant external costs for CROs that conduct clinical trials on our behalf, and for CMOs thatÂ manufacture our tablet vaccine candidates, although these costs have decreased sinceÂ 2022 since we now perform the majority of our manufacturing activities in-house. We have captured these external costs for each vaccine program. We do not allocate external costs incurred on preclinical research or process development to specific programs. Â 21 Table of Contents TheÂ following table shows our period-over-period research and development expenses,Â identifying external costs that were incurred in each of our vaccine programs and, separately, on preclinical research and process development for the three and nineÂ months ended SeptemberÂ 30, 2024 and 2023Â (in thousands):Â Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â External program costs: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Norovirus program Â $ 821 Â Â $ 1,648 Â Â $ 2,560 Â Â $ 9,065 Â COVID-19 program Â Â 1,513 Â Â Â 884 Â Â Â 7,849 Â Â Â 2,876 Â Other programs Â Â 2 Â Â Â â€” Â Â Â 16 Â Â Â â€” Â Preclinical research Â Â 216 Â Â Â 68 Â Â Â 1,596 Â Â Â 698 Â Process development Â Â 106 Â Â Â 103 Â Â Â 189 Â Â Â 887 Â Total external costs Â Â 2,658 Â Â Â 2,703 Â Â Â 12,210 Â Â Â 13,526 Â Internal costs Â Â 12,408 Â Â Â 12,299 Â Â Â 39,349 Â Â Â 39,911 Â Total research and development Â $ 15,066 Â Â $ 15,002 Â Â $ 51,559 Â Â $ 53,437 Â Â We expect to incur significant research and development expenses in 2024Â and beyond as we advance our tablet vaccine candidates into and through clinical trials, pursue regulatory approval of our tablet vaccine candidates and prepare for a possible commercial launch, all of which will also require a significant investment in manufacturing and inventory related costs. To the extent that we enter into licensing, partnering or collaboration agreements,Â aÂ significant portion of such costs may be borne by third parties. Â The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our tablet vaccine candidates. The probability of successful commercialization of our tablet vaccine candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our tablet vaccine candidates. Â General and Administrative Expense Â General and administrative expenses consist of personnel costs, insurance, allocated expenses and expenses for outside professional services, including legal, audit, accounting, public relations, market research and other consulting services. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of rent, depreciation and other facilities-related expenses. Â Results of Operations Â The following table presentsÂ period-over-period changes inÂ selected items in the condensed consolidated statements of operations and comprehensive lossÂ for theÂ three and nine months ended September 30, 2024 and 2023Â (in thousands, except percentages): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â % Change Â Â 2024 Â Â 2023 Â Â % Change Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

nineÂ months ended SeptemberÂ 30, 2024, we recorded interest income of $1.9Â million, a 7%Â decreaseÂ from the $2.1Â million interest income recorded in the nineÂ months ended SeptemberÂ 30, 2023. The decrease is primarily due to theÂ decrease in our cash, cash equivalents and investments balance. Â Non-cash interest expenseÂ related toÂ sale of future royalties representingÂ imputed interest on the unamortized portion of the sale of future royaltiesÂ liability, increased to $0.6Â million for the three months ended SeptemberÂ 30, 2024, from the $0.2 millionÂ for the three months ended SeptemberÂ 30, 2023, and to $2.0Â million for the nineÂ months ended SeptemberÂ 30, 2024, from the $0.6Â million for the nineÂ months ended SeptemberÂ 30, 2023, due to an increase in non-cash royalty revenue payableÂ to HCRP.Â Â Provision for Income Taxes Â The following tableÂ summarizes the period-over-period changes inÂ our provision for income taxes for the three and nineÂ months ended SeptemberÂ 30,Â 2024 and 2023Â (in thousands, except percentages): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â % Change Â Â 2024 Â Â 2023 Â Â % Change Â Foreign withholding tax on royalty revenue Â $ 2 Â Â $ 23 Â Â Â (91)% Â $ 33 Â Â $ 38 Â Â Â (13)% Foreign taxes payable on intercompany interest Â Â 16 Â Â Â 16 Â Â Â â€” % Â 48 Â Â Â 46 Â Â Â 4 % State income taxes Â Â â€” Â Â Â â€” % Â 3 Â Â Â 3 Â Â Â â€” % Provision for income taxes Â $ 18 Â Â $ 39 Â Â Â (54)% Â $ 84 Â Â $ 87 Â Â Â (3)% Â * Percentages greater than 100% or not meaningful Â The provision for income taxes was $18,000Â and $39,000Â forÂ the three months ended September 30,Â 2024 and 2023, respectively, and $84,000Â and $87,000 for the nineÂ months ended SeptemberÂ 30, 2024 and 2023, respectively. The tax charge relatesÂ to interest on an intercompany loan from a foreign subsidiary and a 5% withholding tax on royalty revenue earned on sales of Inavir in Japan, which is potentially recoverable as a foreign tax credit but expensed because we record a 100% valuation allowance against our deferred tax assets.Â The amount of income tax expense recorded is directly proportional to Inavir royalties, including the portion that we pass through to HCRP. Â Liquidity and Capital Resources Â Our primary sourceÂ of financing is from the sale and issuance of common stockÂ in public offerings as well as funding from HHS BARDA.Â In the past, we have also obtained funds from the issuance of common stock warrants, secured debt andÂ preferred stock and from collaboration agreements. Â In SeptemberÂ 2021, weÂ entered intoÂ a Controlled Equity OfferingÂ Sales AgreementÂ (the â€œSeptember 2021 ATMâ€), underÂ which weÂ may offer and sell, from time to time through sales agents, shares of ourÂ common stockÂ having an aggregate offering price of up to $100 million. We incurred direct expenses and paidÂ sales commissions of up to 3.0% of gross proceeds from the sale of shares under the September 2021 ATM. In the nineÂ months ended SeptemberÂ 30, 2024, 7,719,641Â shares were issued and soldÂ under the September 2021 ATM for gross proceeds of $9.1Â million, which,Â after deducting sales commissions and expenses incurred to date, resulted in net proceeds of $8.8Â million. Effective October 18, 2024, the Company terminated the September 2021 ATM and discontinued all offers and sales of common stock thereunder. Â In JuneÂ 2024, we entered into the 2024 ATI-RRPV Contract. In September 2024, the 2024 ATI-RRPV Contract was amended to increase funding and expand the scope to include the manufacture of a vaccine candidate targeting the KP.2 strain. Pursuant to the 2024 ATI-RRPV Contract, weÂ will receive funding of up to $456.1Â million to conduct a Phase 2b comparative study evaluating our oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration and manufacture a COVID-19 vaccine candidate targeting the KP.2 strain. As of SeptemberÂ 30, 2024, we received $65.4 millionÂ of cash payments under the 2024 ATI-RRPV Contract. Subsequent to SeptemberÂ 30, 2024, through the filing date of this Quarterly Report on Form 10-Q, we have received $0.6Â million under the 2024 ATI-RRPV Contract. Â In JuneÂ 2024, weÂ entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by us in an underwritten registered direct offeringÂ of 50,000,000 shares of ourÂ common stockÂ at a price of $0.80 per share. The gross proceeds to usÂ from such offering wereÂ $40.0 million, and afterÂ deducting the underwriting discounts and commissions and other offering expenses paidÂ by us, the net proceeds were $37.5Â million. Â In JanuaryÂ 2024, we entered into a securities purchase agreementÂ (the â€œ2024 Securities Purchase Agreementâ€) with RA Capital Healthcare Fund, L.P. pursuant toÂ which 15,384,615Â shares of our common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65Â per share. The gross proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, theÂ net proceeds were $9.9 million. Â In January 2024, we were awarded the 2024 ASPR-BARDA ContractÂ with a base and all options value of $9.3 million. Under the 2024 ASPR-BARDA Contract, weÂ received an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare our XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. The 2024 ASPR-BARDA Contract originally had a period of performance term that was set to expire in July 2024, but we entered into an amendment in July 2024 that extended the period of performance expiration date into October 2024. As of SeptemberÂ 30, 2024, we received approximately $9.3Â million ofÂ cash payments under the 2024 ASPR-BARDA Contract. Â 24 Table of Contents Â As of September 30, 2024, we had approximately $58.7Â million of cash,Â cash equivalents and short-term investments. We believe our existing funds are sufficient to fund us for at least one year from the date of issuance of this Quarterly Report. To continue operations thereafter, we expect that we will need to raise further capital, through the sale of additional securities or otherwise. Our future capital requirements and the adequacy of our available funds will depend on many factors, most notably our ability to successfully commercialize our products and services. Â WeÂ may fund a significant portion of our ongoing operations through partnering and collaboration agreementsÂ which, while reducing our risks and extending our cash runway, will also reduce our share of eventual revenues, if any, from our vaccine candidates. We may be able to fund certain activities with assistance from government programs.Â We may also fund our operations through debt financing, which would result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. Â However, due to several factors, including those outside managementâ€™s control, there can be no assurance that weÂ will be able to complete additional financing transactions. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, managementâ€™s plans include further reducing or delaying operating expenses. Â Our future funding requirements will depend on many factors, including the following: Â Â â— the timing and costs of our planned preclinical studies for our product candidates; Â Â â— the timing and costs of our planned clinical trials of our product candidates; Â Â â— our manufacturing capabilities, including the availability of contract manufacturing organizations to supply our product candidates at reasonable cost; Â Â â— the amount and timing of royalties received on sales of Inavir; Â Â â— the number and characteristics of product candidates that we pursue; Â Â â— the outcome, timing and costs of seeking regulatory approvals; Â Â â— revenue received from commercial sales of our future products, which will be subject to receipt of regulatory approval; Â Â â— the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into; Â Â â— the amount and timing of any payments that may be required in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other intellectual property rights; Â Â â— our ability to stay listed on The Nasdaq Capital Market; and Â Â â— the extent to which we in-license or acquire other products and technologies. Â Cash Flows Â The following table summarizes our cash flows for the periods indicatedÂ (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Net cash used in operating activities Â $ (37,419) Â $ (56,932) Net cash (used in) provided by investing activities Â Â (31,727) Â Â 28,848 Â Net cash provided by financing activities Â Â 56,426 Â Â Â 15,309 Â Â Â Â Â Â Â Â Net decrease in cash, cash equivalents and restricted cash Â $ (12,720) Â $ (12,775) Â Net Cash Used in Operating Activities Â We experienced negative cash flow from operating activities for theÂ nine months ended September 30, 2024Â and 2023, in the amounts of $37.4Â million and $56.9Â million, respectively. The cash used in operating activities in the nine months ended September 30,Â 2024, was due to cash used to fund a net lossÂ of $55.0Â million andÂ an increaseÂ in working capital of $3.8Â million, partially offset by adjustments for net non-cash income related to depreciation and amortization,Â amortization of discount on investments, net, stock-based compensation, non-cash interest expense related to sale of future royalties and non-cash revenue related to sale of future royalties totaling $13.7Â million. The cash used in operating activities in theÂ nine months ended September 30,Â 2023,Â was due to cash used to fund a net lossÂ of $65.1Â millionÂ and aÂ decrease in working capital of $8.4Â million, partially offset by adjustments for net non-cash income related to depreciation and amortization,Â amortization of discount on investments, net, stock-based compensation, non-cash interest expense related to sale of future royalties and non-cash revenue related to sale of future royalties totaling $16.5Â million. Â 25 Table of Contents Â Net Cash (Used in) Provided byÂ Investing Activities Â In theÂ nine months ended September 30,Â 2024, we used $31.2Â million of cashÂ to purchase investments, net of maturities, and used $0.5Â million of cashÂ to purchase property and equipment. In theÂ nine months ended September 30,Â 2023,Â weÂ received $30.7Â million from maturities ofÂ marketable securities,Â net ofÂ purchases, and used $1.9Â millionÂ to purchase property and equipment, net of disposals. Â Net Cash Provided by Financing Activities Â In theÂ nine months ended September 30,Â 2024, we received net proceeds of $37.5Â million from the sale of our common stock under the June 2024 Offering, net proceeds of $8.8Â million from the sale of our common stock under the September 2021Â ATM andÂ net proceeds of $9.9Â million from the sale of our common stock under the 2024 Securities Purchase Agreement,Â partially offset by $0.2Â million from common stock acquired to settle employee tax withholding liabilities.Â In theÂ nine months ended September 30,Â 2023,Â we received net proceeds of $13.6Â millionÂ from the sale of 16,000,000 shares of our common stock, $1.4 million from the sale of common stockÂ under the September 2021Â ATM and $0.3 million from the issuance of common stock under the employee stock purchase plan. Â Contractual Obligations and Commercial Commitments Â We have the following contractual obligations and commercial commitments as ofÂ September 30, 2024 (in thousands): Â Contractual Obligation Â Total Â Â < 1 Year Â Â 1 - 3 Years Â Â 3 - 5 Years Â Â > 5 Years Â Â Â Â Â Â Â Â

market risk for changes in interest rates relates primarily to our investments in marketable debt securities. The primary objective of our investment activities is to preserve principal, maintain liquidity that is sufficient to meet cash needs and maximize total return without significantly increasing risk. To achieve this goal, we maintain our excess cash and cash equivalents in money market funds and marketable debt securities. We do not enter into investments for trading or speculative purposes and we hold no equity securities. We presently have no borrowings or lines of credit.Â Â Specifically, as of September 30, 2024, we had cash, cash equivalents and short-term investments of approximately $58.7Â million, which consist of primarily bank deposits, money market funds and U.S. government securities.Â All of our investments must satisfy high credit rating requirements at the time of purchase. Such interest-earning instruments carry a degree of interest rate risk,Â however, because our investments are rated highly and mostly short-term, we believe that our exposure to risk of loss due to interest rate changesÂ is not significant. Â Exchange Rate Sensitivity Â Our royalty revenue, which is calculated in U.S. dollars, is based on sales in Japanese yen, so a 1% increase in the strength of the U.S. dollar against the yen would lead to a 1%Â reduction in royalty revenue and related accounts receivable. All our other revenue and substantially all of our expenses, assets and liabilities are denominated in U.S. dollars and, as a result, we have not experienced significant foreign exchange gains or losses recently and do not anticipate that foreign exchange gains or losses will be significant in the near future. Â 27 Table of Contents Â ItemÂ 4.Â Â Controls and Procedures Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our principalÂ executive officer and principal accounting and financial officer, hasÂ evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended)Â as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our management has concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2024. Â Changes in Internal Control over Financial Reporting Â There was no material change in our internal control over financial reporting that occurred during the quarter ended September 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â Inherent Limitations on Effectiveness of Controls Â Our management, including our principalÂ executive officer and principal accounting and financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Vaxart have been detected. Â 28 Table of Contents Â PART II OTHER INFORMATION Â Â ItemÂ 1.Â Â Legal Proceedings Â The information included in â€œNote 8. Commitments and Contingenciesâ€”(c) Litigationâ€ to the Condensed Consolidated Financial Statements in PartÂ I, ItemÂ 1 is incorporated by reference into this Item. Â We may alsoÂ from time to time be involved in legal proceedings arising in connection with our business. Based on information currently available, we believeÂ that the amount, or range, of reasonably possible losses in connection with any pending actions against usÂ in excess of established reserves, in the aggregate, is notÂ material to our condensed consolidated financial condition or cash flows. However, any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of managementâ€™s attention and resources that are needed to run our business successfully, and could have a material adverse impact on our business, financial condition and results of operations. Â Â ItemÂ 1A.Â Â Risk Factors Â You should consider the risks and uncertainties described under ItemÂ 1A of PartÂ I of our Annual Report on Form 10-K for the fiscal year endedÂ DecemberÂ 31, 2023, which we filed with the Securities and Exchange Commission on March 14, 2024,Â together with all other information contained or incorporated by reference in this Quarterly Report on Form 10-Q, when evaluating our business and our prospects. There are no material changes to the risk factors set forth in PartÂ I, ItemÂ 1A, in our Annual Report on FormÂ 10-K for the year endedÂ DecemberÂ 31, 2023, except as described below. Â A significant portion of the funding to further develop our COVID-19 vaccine candidate is currently expected to come from HHS BARDA funds. If HHS BARDA were to eliminate, reduce, delay, or object to funding available to us under the 2024 ATI-RRPV Contract, this could have a significant, negative impact on our revenues and cash flows, and we may be forced to suspend or terminate the continued development of the product candidate or obtain alternative sources of funding. Â InÂ June 2024, we entered into the 2024 ATI-RRPV ContractÂ with Advanced Technology International, the Rapid Response Partnership Vehicleâ€™s Consortium Management Firm funded by HHS BARDA. In September 2024, the 2024 ATI-RRPV Contract was amended to increase funding and scope. The 2024 ATI-RRPV Contract currently makes available anÂ aggregate amount of up to approximately $96.5Â million, consisting of a fixed fee of approximately $67.9Â million and reimbursement of costs incurred in trial preparation and execution activities. The 2024 ATI-RRPV ContractÂ further contemplates additional funding up to approximately $359.6Â million if the Company and HHS BARDA decide to continue with the related study. As of SeptemberÂ 30, 2024, we have recognized $4.2Â million in revenue pursuant to the 2024 ATI-RRPV Contract based on costs incurred. Â We anticipate that a significant portion of the funding to further develop our COVID-19 vaccine candidate will come from the remaining amounts to be received under the 2024 ATI-RRPV Contract. The 2024 ATI-RRPV ContractÂ provides that the government has the right to determine whether to fund the continued performance of the study after the initial funding. If the 2024 ATI-RRPV ContractÂ is terminated or suspended, or if there is any government decision not to continue funding or reduction or delay in funding under the 2024 ATI-RRPV Contract, our revenues and cash flows would be significantly and negatively impacted and we may be forced to seek alternative sources of funding, which may not be available on no-dilutive terms, terms favorable to us, or at all. Â Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock. Â Our common stock is listed on The Nasdaq Capital Market, which imposes, among other requirements, a $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Our common stock traded for less than $1.00 for 30 consecutive trading days, and we received notice of this from the Listing Qualifications Department of The Nasdaq Stock Market on July 2, 2024.Â Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a 180-calendar day grace period, or until December 30, 2024,Â to regain compliance with the minimum bid price requirement. The minimum bid price requirement would be met if our common stock hadÂ a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day grace period. If at any time during this 180-calendar day period the bid price of the Companyâ€™s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq staff stated that it will provide the Company with a written confirmation of compliance and the matter will be closed. However, under Nasdaq Listing Rule 5810(c)(3)(A), the Nasdaq staff may exercise its discretion to extend this ten-day period as discussed in Rule 5810(c)(3)(H). Â Alternatively, if we fail to regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180-calendar day period, we may be eligible for an additional 180-calendar day compliance period, provided (i) we meet the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the $1.00 minimum bid price requirement) and (ii) we provide written notice to Nasdaq of our intention to cure this deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event we do not regain compliance with Rule 5550(a)(2) prior to the expiration of the initial 180-calendar day period, and if it appears to the Staff that we will not be able to cure the deficiency, or if we are not otherwise eligible, the Staff stated that it will provide us with written noticeÂ that our securities are subject to delisting from The Nasdaq Capital Market. At that time, we may appeal the delisting determination to a Hearings Panel.Â There can be no assurance that we will be able to regain compliance or that Nasdaq will grant us a further extension of time to regain compliance, if necessary. Â The delisting of our common stock from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future, or at all. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholdersâ€™ ability to sell or purchase our common stock when they wish to do so. Further, if our common stock were to be delisted from The Nasdaq Capital Market, our common stock would cease to be recognized as a covered security and we would be subject to additional regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we take to restore our compliance with the Nasdaq minimum bid requirement would stabilize the market price or improve the liquidity of our common stock, prevent our common stock from falling below the Nasdaq minimum bid price required for continued listing again, or prevent future non-compliance with Nasdaqâ€™s listing requirements. Â There can be no assurance that we will continue to meet the minimum bid price requirement, or any other requirement in the future. If we fail to meet the minimum bid price requirement, or other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholdersâ€™ equity or market values of our common stock, our common stock could be delisted. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected, and the market price of our common stock could decrease. Â Unless our common stock continues to be listed on a national securities exchange it will become subject to the so-calledÂ â€œpenny stockâ€Â rules that impose restrictive sales practice requirements. Â If we are unable to maintain the listing of our common stock on Nasdaq or another national securities exchange, our common stock could become subject to the so-called â€œpenny stockâ€ rules if the shares have a market value of less than $5.00 per share. The SEC has adopted regulations that define a penny stock to include any stock that has a market price of less than $5.00 per share, subject to certain exceptions, including an exception for stock traded on a national securities exchange. The SEC regulations impose restrictive sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and â€œaccredited investorsâ€ as defined by relevant SEC rules. These additional requirements may discourage broker-dealers from effecting transactions in securities that are classified as penny stocks, which could severely limit the market price and liquidity of such securities and the ability of purchasers to sell such securities in the secondary market. This means that if we are unable to maintain the listing of our common stock on a national securities exchange, the ability of stockholders to sell their common stock in the secondary market could be adversely affected. Â If a transaction involving a penny stock is not exempt from the SECâ€™s rule, a broker-dealer must deliver a disclosure schedule relating to the penny stock market to each investor prior to a transaction. The broker-dealer also must disclose the commissions payable to both the broker-dealer and its registered representative, current quotations for the penny stock, and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealerâ€™s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the customerâ€™s account and information on the limited market in penny stocks. Â Â 29 Table of Contents Â Item 2.Â Â Unregistered Sales of Equity Securities and Use of Proceeds Â None. Â Â Item 3.Â Defaults Upon Senior Securities Â Not applicable. Â Â Item 4.Â Â Mine Safety Disclosures Â Not applicable. Â Â Â Item 5.Â Other Information Â During the quarter ended SeptemberÂ 30, 2024, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1 trading arrangement,â€ each as defined in Item 408 of Regulation S-K. Â 30 Table of Contents Â Â ItemÂ 6.Â Â Exhibits Â Â Â Incorporated by Reference Exhibit Number Description of Document Schedule/Form File Number Exhibit Filing Date Â Â Â Â Â Â 3.1 Restated Certificate of Incorporation of Aviragen Therapeutics, Inc. Form 10-K 001-35285 3.1 September 13, 2016 Â Â Â Â Â Â 3.2 Certificate of Amendment to Restated Certificate of Incorporation of Aviragen Therapeutics, Inc. Form 8-K 001-35285 3.1 February 20, 2018 Â Â Â Â Â Â 3.3 Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc. Form 8-K 001-35285 3.2 February 20, 2018 Â Â Â Â Â Â 3.4 Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc. Form 8-K 001-35285 3.1 April 24, 2019 Â Â Â Â Â Â 3.5 Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc. Form 8-K 001-35285 3.1 June 9, 2020 Â Â Â Â Â Â 3.6 Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc. Form 10-Q 001-35285 3.3 August 8, 2022 Â Â Â Â Â Â 3.7 Amended and Restated Bylaws of Vaxart, Inc., effective as of October 18, 2023 Form 8-K 001-35285 3.1 October 23, 2023 Â Â Â Â Â Â 3.8 Certificate of Amendment to Restated Certificate of Incorporation of Vaxart, Inc. Form 8-K 001-35285 3.1 June 13, 2024 Â Â Â Â Â Â 10.3 *^ Modification No. 3, dated September 27, 2024, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 31 Table of Contents Â 31.1 * Certification of Principal Executive Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â 31.2 * Certification of Principal Financial Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â 32.1 Â§ Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â 101.INS * Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document Â Â Â Â Â Â Â Â Â Â 101.SCH * Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â Â Â 101.CAL * Inline XBRL Taxonomy Extension Calculation LinkbaseÂ Document Â Â Â Â Â Â Â Â Â Â 101.DEF * Inline XBRL Taxonomy Extension Definition LinkbaseÂ Document Â Â Â Â Â Â Â Â Â Â 101.LAB * Inline XBRL Taxonomy Extension Label LinkbaseÂ Document Â Â Â Â Â Â Â Â Â Â 101.PRE * Inline XBRL Taxonomy Extension Presentation LinkbaseÂ Document Â Â Â Â Â Â Â Â Â Â 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â Â Â Â Â * Filed herewith. Â Â Â Â Â Â Â Â Â Â # Management contract or compensation plan or arrangement. Â Â Â Â Â Â§ In accordance with Item 601(b)(32)(ii) of Regulation S-KÂ and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Managementâ€™s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certification furnished in Exhibit 32.1 hereto is deemed to accompany this Quarterly Report on Form 10-QÂ and will not be deemed â€œfiledâ€ for purposes of Section 18 of the Exchange Act. Such certification will not be deemedÂ to be incorporated by reference into any filing under the Securities Act or the Exchange Act, exceptÂ to the extent that the registrant specifically incorporates it by reference. Â Â ^ Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily and actually treats the omitted information as private or confidential. Â Â 32 Table of Contents Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Â Â VAXART, INC. Â Â Â Â Â Dated: November 13, 2024 Â By:Â /s/ STEVEN LO Â Â Â Steven Lo Â Â Â President andÂ Chief Executive Officer Â Â Â (Principal Executive Officer) Â Â Â Â Â Dated: November 13, 2024 Â By:Â /s/ PHILLIP LEE Â Â Â Phillip Lee Â Â Â Chief Financial Officer Â Â Â (Principal Financial and Accounting Officer) Â Â Â Â Â Â 33 EX-31.1 2 ex_716493.htm EXHIBIT 31.1 ex_716493.htm Exhibit 31.1 Â CERTIFICATION Â Â I, Steven Lo, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Vaxart, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Date: November 13, 2024 Â By: Â /s/ STEVEN LO Â Â Â Steven Lo Â Â Â President and Chief Executive Officer Â Â Â (Principal Executive Officer) Â Â EX-31.2 3 ex_716494.htm EXHIBIT 31.2 ex_716494.htm Exhibit 31.2 Â Â Â CERTIFICATION Â Â I, Phillip Lee, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Vaxart, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to

make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Date: November 13, 2024 Â By: Â /s/ PHILLIP LEE Â Â Â Phillip Lee Â Â Â Chief FinancialÂ Officer Â Â Â (Principal FinancialÂ and AccountingÂ Officer) Â Â EX-32.1 4 ex_716495.htm EXHIBIT 32.1 ex_716495.htm Exhibit 32.1 Â CERTIFICATION Â Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and SectionÂ 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§ 1350), Steven Lo, President and Chief Executive Officer of Vaxart, Inc. (the â€œCompanyâ€), and Phillip Lee,Â Chief Financial OfficerÂ of the Company, each hereby certifiesÂ that, to his knowledge: Â Â (1) The Companyâ€™s Quarterly Report on Form 10-Q for the period ended September 30, 2024,Â to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d) of the Exchange Act; and Â Â (2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report. Â Â Â Date: November 13, 2024 Â By: /s/ STEVEN LO Â Â Â Steven Lo Â Â Â President and Chief Executive Officer Â Â Â (Principal Executive Officer) Â Â Â Â Date: November 13, 2024 Â By: /s/ PHILLIP LEE Â Â Â Phillip Lee Â Â Â Chief Financial Officer Â Â Â (Principal Financial and AccountingÂ Officer) Â Â A signed original of this written statement required by SectionÂ 906 of 18 U.S.C. Â§ 1350 has been provided to Vaxart, Inc. and will be retained by Vaxart, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Â This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. Â Â Â Â Â Â Â Â Â Â EX-10.3 5 ex_743953.htm EXHIBIT 10.3 ex_743953.htm Exhibit 10.3 Â SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS AS [***]. Â September 27, 2024 Â Vaxart Biosciences Inc 170 Harbor Way Ste 300 South San Francisco, California 94080 Â Attention:Â Â Â Â Â Â Â Â Â [***], General Counsel, Senior Vice President Â Subject:Â Â Â Â Â Â Â Â Â Modification No. 03 to RRPV Project Award No. 01; RRPV-24-04-NGVx-003 Â Reference:Â Â Â Â Â Â Â Â Â RRPV Base Agreement No. 2024-606 Â Dear [***]: Â Â Â Â Â Â Â Â Â In accordance with the terms and conditions of the referenced RRPV Base Agreement, Modification No. 03 hereby amends the Project Award No. 01 as follows: Â DESCRIPTION OF MODIFICATION Â Â 1) The Project Agreement Ceiling clause of the Project Award is hereby amended to read as indicated in bold below:Â Â Â 4. PROJECT AGREEMENT CEILING The total estimated ceiling for this Project Awardee is $456,119,279 (this is an increase of $3,234,802) broken out as follows: Â Firm Fixed Price The total fixed amount for the services to be provided by the Project Awardee are as follows: Â Fixed Amount (Milestone 2 Only)Â Â Â Â Â Â Â Â Â

end of the study, the two different vaccines will be compared for relative protection against infection. (WBS 1.2.3.2) Â Vaxart will conduct an analysis to identify immune correlates of protection and assess the relative importance of the correlates. (WBS 1.2.4) Â â— Statistician with significant immune correlate analysis will develop an analysis plan to examine the relative importance of the correlates. (WBS 1.2.4.1) Â â— At the end of the study, the data will be compiled on the various immune parameters, and correlates of protection analyzed against both symptomatic and asymptomatic infection. If more analysis of secondary endpoints is needed, additional samples may be added in the analysis. (WBS 1.2.4.2) Â â— Vaxart will employ machine learning to refine the understanding risk factors and immune correlates are steps. (WBS 1.2.4.3) Â Vaxart will perform all of the required safety laboratory screening to provide a study subjects baseline of these parameters as well as monitoring during the study. (WBS 1.2.5) Â â— CBC, Coagulation and Chem 7 testing per study protocol will be conducted (WBS 1.2.5.1) Â â— Urine and pregnancy testing per study protocol will be conducted (WBS 1.2.5.2) Â â— Repeat testing as required per study protocol will be conducted (WBS 1.2.5.3) Â Task Area #3 â€“ Clinical (WBS 1.3) Vaxartâ€™s clinical efforts encompasses all activities and tasks to be performed in the execution of the phase 2b clinical trial for study initiation of XBB sentinel group of 400 participants. Â Vaxart will complete all of the activities required for clinical trial site start-up. (WBS 1.3.1) Â â— A comprehensive set of documents that provide critical information about the study and ensure regulatory compliance will be prepared. These documents include the study protocol, informed consent forms, investigator's brochure, case report forms, institutional review board (IRB) approvals, clinical trial agreements, financial disclosure forms, source documents, adverse event reporting forms, and monitoring plans. (WBS 1.3.1.1) Â â— Site contract negotiation will be completed. This will include finalization of details including site payment, indemnification, intellectual property rights, publication rights, and data ownership. (WBS 1.3.1.2) Â â— Site budget negotiation will be completed. This will include finalization of the budget for activities such as participant recruitment, study visits, data collection, site personnel costs, and any additional expenses related to the trial. (WBS 1.3.1.3) Â â— Regulatory binders will be compiled and sent to clinical sites participating in the trial. These include study protocol, investigator's brochure, informed consent forms, IRB approvals, financial disclosure forms, and other regulatory submissions. (WBS 1.3.1.4) Â â— Site initiation visits (SIVs) will be conducted to ensure that the research site is ready to initiate the study. During SIVs, representatives from the sponsor or contract research organization (CRO) will meet with the site staff to review study procedures, data collection methods, and regulatory requirements. (WBS 1.3.1.5) Â â— Investigational product will be shipped to investigative sites. Based on the site's enrollment needs, the sponsor or contract research organization (CRO) will generate drug shipment orders. These orders specify the quantity of investigational product required. The orders are then processed through an Interactive Web Response System (IWRS), which helps manage and track drug supplies. The IWRS assigns unique randomization numbers and treatment codes to participants, ensuring blinded allocation. The drug is then packaged, labeled, and shipped to the investigative sites following regulatory and logistical requirements. The site receives the shipment, confirms its integrity, and maintains appropriate storage and accountability records for the investigational product throughout the trial. (WBS 1.3.1.6). Â o The shipment of IP for the initial 400 sentinel participants of XBB to a handful of sites will be ordered manually. The remaining unused XBB material will be quarantined in the system until further guidance and concurrence by BARDA to dispose of or destroy as provided to the CRO and subsequently to the sites. Â â— All other required laboratory and essential supplies will be shipped to investigative sites. These supplies can include items such as laboratory kits, specimen collection materials, study-specific laboratory tests, shipping containers, and labeling materials. The CRO ensures the timely provision of these supplies, often in accordance with the study protocol and specific requirements outlined by the sponsor. (WBS 1.3.1.7) Â Vaxart will enroll eligible volunteers first in the sentinel cohort (400) and ensure that they are randomized and assigned to a treatment group. (WBS 1.3.2) Â â— Potential participants will undergo pre-screening including an initial evaluation to determine their eligibility (WBS 1.3.2.1) Â â— Various efforts to identify and enroll eligible participants will be undertaken. These may include developing targeted recruitment strategies and advertisements to reach the intended participant population. Participant recruitment vendors may be engaged to assist with recruitment campaigns, utilizing various channels such as online platforms, social media, print media, and community outreach. BARDA, ASPR, and HHS logos are not allowable in any source of materials for recruitment (WBS 1.3.2.2) Â â— If necessary, trial volunteerâ€™s past medical or surgical history to confirm eligibility into the study will be requested. (WBS 1.3.2.3) Â â— ParticipantÂ informed consent will be obtained. (WBS 1.3.2.4) Â â— Screening visits will be performed. (WBS 1.3.2.5) Â â— Sites and investigators will verify participantÂ eligibility for clinical trials by conducting a thorough evaluation. (WBS 1.3.2.6) Â â— ParticipantsÂ will be randomized using the Interactive Web Response System (IWRS) which will assign unique identification numbers and determines treatment allocation based on the randomization schedule. (WBS 1.3.2.7) Â Vaxart will complete all the activities required to ensure clinical conduct of the trial. (WBS 1.3.3) Â â— Study visits will be performed as per the clinical trial protocol. Site visits will involve scheduling the visit, preparing study materials, administering assessments, and addressing studyÂ participantsâ€™Â questions. Investigators oversee the visit, conducting physical examinations, reviewing data, making treatment decisions, and ensuring protocol adherence. (WBS 1.3.3.1) Â â— Safety monitoring will be conducted throughout as per the clinical trial protocol. The safety monitoring process during study visits will include AE reporting, safety assessments, protocol adherence, and proactive pharmacovigilance measures. Study coordinators will systematically collect information on adverse events (AEs) or any untoward medical occurrences experienced by participants during or after the study visit. AEs can range from mild side effects to serious adverse reactions. These events will be documented, assessed for severity and causality, and reported to the appropriate regulatory authorities and the trial sponsor as per the established reporting timelines and guidelines. (WBS 1.3.3.2) Â o As recommended by the FDA, a DSMB committee will convene and review safety data of the initial 400 participants in the sentinel cohort, after they complete Day 31 (Visit 3). The raw data and the DSMB recommendation will then be submitted to BARDA and the FDA. Â â— Biosamples will be collected as per the clinical trial protocol. Trained healthcare professionals will conduct phlebotomy to draw blood, and participants provide urine samples as required. After collection, the biosamples will be processed, labelled and stored until shipping. Biosamples will be transported to designated laboratories using specialized containers that maintain required temperatures. The collection of PBMC (Peripheral Blood Mononuclear Cell) samples involves a specialized process to obtain these immune cells from the blood for research purposes. Trained healthcare professionals will perform venipuncture to draw blood from the participant. The sample will be processed, labeled and then cryopreserved or immediately used for various immune-based assays or research investigations. (WBS 1.3.3.3) Â â— An interim analysis will be conducted. To perform the analysis, data cut-offs will be established, specifying the point at which data is frozen and analyzed to minimize bias. Source data verification will be conducted. Biostatistical analysis will then be applied to evaluate treatment outcomes, safety profiles, and efficacy trends, providing insight into participant responses and potential risks. (WBS 1.3.3.4) Â Vaxart will oversee routine and for-cause monitoring visits during the conduct of the clinical trial to ensure compliance with the study protocol, regulatory requirements, and Good Clinical Practice (GCP) guidelines. (WBA 1.3.4) Â â— Clinical Research Associates (CRAs) will travel as necessary to conduct routine monitoring visits. During these visits, CRAs review study data, source documents, and participant records, ensuring compliance with protocols and regulations. Additionally, they will provide support and training to site personnel, address any issues or queries, and ensure adherence to Good Clinical Practice (GCP) standards. (WBS 1.3.4.1) Â â— Clinical Research Associates (CRAs) will conduct source data verification (SDV) to review and confirm the accuracy of data recorded in source documents against the study database. CRAs will cross-reference source documents like medical records and lab reports with case report forms (CRFs) to identify discrepancies or errors. Data queries are raised to resolve any issues, ensuring data accuracy and compliance with the study protocol and regulatory standards. CRAs also assess participant safety and provide guidance to site personnel, ultimately upholding data quality and the integrity of the clinical trial while safeguarding participant well-being. (WBS 1.3.4.2) Â â— Meetings with investigators will be conducted as necessary to ensure planning, coordination and to discuss essential trial-related topics. The sponsor or CRO schedules the meetings and prepares an agenda, covering aspects such as trial progress, protocol compliance, safety updates, data quality, participant retention, and investigational product management. During the meetings, investigators provide updates on recruitment, safety data, and protocol adherence while addressing challenges and proposing strategies for participant retention. (WBS 1.3.4.3) Â â— Monitoring or trip reports will be prepared by Clinical Research Associates (CRAs) after conducting routine monitoring visits to research sites. These reports will include a detailed account of the visit, including site activities, data verification, source document review, and any findings or discrepancies identified. They will document participant safety assessments, compliance with the study protocol and regulatory guidelines, and any issues or concerns raised during the visit. (WBS 1.3.4.4) Â â— Ongoing site supplies management will be performed during the clinical trial. These activities involve systematic inventory monitoring, timely replenishment, and distribution of essential materials and investigational products to research sites. (WBS 1.3.4.5) Â Vaxart will undertake a comprehensive clinical data management program that will include the collection, validation, and analysis of participant data to ensure its accuracy, completeness, and confidentiality. (WBS 1.3.5) Â â— Query resolution activities will include identification and rectification of discrepancies or missing information in study data. Data managers or clinical research associates (CRAs) review the data for inconsistencies and raise queries to the site personnel or data entry personnel to seek clarification or corrections. These queries are documented and communicated to the site, and the site responds with the necessary information to resolve the query. (WBS 1.3.5.1) Â â— A statistical analysis plan (SAP) will be developed and finalized prior to database unblinding. The effort will begin with defining the trial's primary and secondary objectives, study endpoints, and the statistical methods to be employed. The SAP outlines the data handling procedures, data transformations, and imputation methods for missing data. Additionally, it specifies the statistical tests and models to be used, sample size calculations, and adjustments for multiple comparisons. The SAP also addresses subgroup analyses, sensitivity analyses, and any predefined interim analysis if applicable. (WBS 1.3.5.2) Â â— Programming specifications for biostatistical analysis will be developed. This effort involves collaboration between biostatisticians and programmers and will result in final programming specifications are established, ensuring robust and reliable data analysis for the clinical trial. (WBS 1.3.5.3) Â â— Method validation will be completed to ensure the statistical methods used for data analysis are appropriate, accurate, and reliable. (WBS 1.3.5.4) Â â— PI attestation will be completed. During this process, the PI reviews and confirms the appropriateness and accuracy of the statistical methods used for data analysis. The PI then provides a formal attestation, verifying that the statistical methods are aligned with the study objectives, are appropriate for the data collected, and comply with regulatory requirements. (WBS 1.3.5.5) Â â— Tables, figures and listings generation will be generated. Once approved, the TFLs are included in the clinical study report (CSR) and submitted to regulatory authorities as part of the trial documentation, providing a comprehensive representation of the trial's results and data. (WBS 1.3.5.6) Â â— A topline data report will be prepared. This report will summarize and presents key findings and results from a clinical trial in a concise and high-level manner. This report focuses on the primary objectives and key secondary endpoints of the trial, providing a snapshot of the trial's outcomes without delving into detailed analyses or subgroup findings. (WBS 1.3.5.7) Â Vaxart will complete database lock in which includes the process of finalizing and freezing the study database to prevent further modifications to the data. (WBS 1.3.6) Â â— Soft lock will be initiated with the temporary suspension of data entry or editing capabilities in the study database, allowing specific authorized personnel to address critical data-related issues or queries. (WBS 1.3.6.1) Â â— Hard lock will be completed including the final and permanent closure of the study database after all data entry, editing, and review processes are completed. (WBS 1.3.6.2) Â Pending BARDA and FDA approval of the safety data and DSMB recommendation for the initial 400 participant sentinel cohort, the remaining participants will be enrolled. Â Task Area #4 â€“ Regulatory (WBS 1.4) Vaxart will prepare FDA submissions, keep track of relevant legislation, advise on legal and scientific requirements and limitations, and provide regulatory support for the evaluation of data for this study. Â â— In compliance with FDA regulations, Vaxart will prepare and submit for this study Annual Reports, Certificate of Analysis, Protocol(s), and pharmacovigilance documents. These submissions will be submitted under US FDA IND 27602 - VXA- CoV2-3.1-S, an oral SARS-CoV-2 vaccine E1-/E3-deleted replication defective recombinant adenovirus 5 with dsRNA adjuvant. (WBS 1.4.1) Â â— In compliance with FDA regulations, Vaxart will submit all required annual regulatory submissions within [***] of the anniversary date of our approved IND 27602. This report will contain new information collected over the past year pertaining to the safety, effectiveness, and labeling of our vaccine in this study. (WBS 1.4.2) Â â— Vaxart will notify the appropriate regulatory authorities regarding the safety of the vaccine. The safety of the vaccine will be evaluated through the reporting of solicited symptoms of reactogenicity for [***] following each study drug administration. Because the vaccine contains a double stranded RNA (dsRNA) adjuvant, MAAEs will be collected through [***] post last dose to address the theoretical potential for induction of autoimmune or auto-inflammatory diseases, as is standard for this class of vaccines. ParticipantsÂ will also be monitored for exposure to SARS-CoV2 and symptomatic SARS-CoV2 infection (COVID-19). (WBS 1.4.3) Â Task Area #5 â€“ CMC (WBS 1.5) Vaxart will complete all activities and GMP documentation, ensuring that clinical trial material will be ready to support the 400-participant safety lead in study and the 10,000 participant PhIIb head-to-head clinical trial with an mRNA comparator targeting the KP.2 COVID variant. Â â— A KP.2 RVB (research virus bank) will be completed prior to use in GMP manufacturing of KP.2 clinical trial material. Â â— KP.2 GMP Bulk Drug Substance Material will be manufactured, tested, and released with appropriate methods at sufficient quantities to ensure the supply of the entire PhIIb trial is from a single lot. Â â— KP.2 GMP Drug Product will be manufactured, tested, and released with appropriate methods at sufficient quantities to ensure the supply of the entire PhIIb trial is from a single lot. Â â— All GMP material will be placed on appropriate stability studies. Â â— Vaxart will utilize industry standard risk mitigation practices and manufacture additional clinical trial material above the amount required to supply the 10,000 participant PhIIb clinical trial. Â â— Vaxart XBB COVID vaccine clinical trial materials will be kitted with appropriate comparator and placebo materials and distributed to the clinical sites supporting the 400-participant safety lead in study per protocol. Â â— Vaxart KP.2Â COVID vaccine clinical trial materials will be manufactured, kitted with appropriate comparator and placebo materials, and distributed to clinical sites in time to support initiation of the 10,000 participant PhIIb head-to-head clinical trial with an mRNA comparator vaccine per protocolÂ shipped to the depot to allow for further distribution. Â PHASE 2: Additional Characterization of Immune Responses Vaxart will expand on the durability of the immune responses initially characterized by tracking mucosal samples from vaccinated individuals for a year, and assessing cross-reactivity over time. Â Task Area #1 â€“ Analytical (WBS 2.1) Vaxart will conduct extended immune analysis of the vaccines in human subjects. Â â— As part of phase 1, additional samples in a small subpopulation of subjects at [***] will have been collected. The mucosal (and serum) immune responses of these samples will be measured in order to examine durability, particularly against multiple different coronaviruses as well as new SARS-CoV-2 variants. (WBS 2.1.1) Â â— Vaxart will use flow cytometry to determine the changes to the memory pool in the subpopulation of patients using the samples collected in phase 1. B cell clones will be sequenced from the memory pools and used to characterize the diversity of the response based on vaccine and infection history. (WBS 2.1.2) Â â— Vaxart will analyze antibodies from the task in 2.1.2 and their diversity tested for binding and neutralizing various SARS-COV-2 variants and other coronaviruses. (WBS 2.1.3) Â Task Area #2 â€“ Clinical (WBS 2.2) Vaxart will complete all required close-out procedures for the clinical trial. Â â— Vaxart will complete all required reports including an amended CSR that the discusses the analysis in option 2 will be completed; a full final report describing all the Phase 2 analyses, any additional reports to BARDA and regulatory agencies on the conduct of the trial as required. (WBS 2.2.1) Â â— Vaxart will complete site closeout and unused vaccine will be returned or destroyed; and documents will be properly shipped and stored. (WBS 2.2.2) Â â— Vaxart will undertake essential document reconciliation in which records from the trial will be verified by medical monitors and database experts. Discrepancies will be resolved before finalizing the data. (WBS 2.2.3) Â â— Vaxart will employ an Electronic Trial Master File (eTMF) which leverages software and server technology to guide and assist the setup, collection, storage, tracking and archival of essential clinical study documents. (WBS 2.2.4) Â â— Vaxart will prepare an amended clinical study report which will include the additional analysis conducted under Phase 2. (WBS 2.2.5) Â 4.0 Deliverables Â Â 1. Meetings #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 1.1Â Post Award TeleconferenceÂ [***] [***] 1.2Â Kickoff MeetingÂ Â [***] [***] 1.3Â Weekly TeleconferenceÂ [***] [***] 1.4Â Technical, Subgroup, Ad Hoc Teleconference(s)Â [***] [***] 1.5Â Periodic Review MeetingsÂ [***] [***] 1.6Â FDA Meetings and InteractionsÂ [***] [***] 1.7Â Daily check-in with BARDA in the event of a PHEÂ [***] [***] Â Â 2. Technical Reporting: General Â #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 2.1Â Project Management Plan (PMP)Â [***] [***] 2.4Â Gantt Chart/Timeline of the projectâ€¯Â [***] [***] 2.5Â Communication PlanÂ [***] [***] 2.6Â Performer LocationsÂ [***] [***] 2.7Â Pandemic/Public Health Emergency Facility and Operational Management PlanÂ [***] [***] 2.8Â Request for Information (RFI) ResponsesÂ [***] [***] 2.9Â Monthly & Annual Technical Progress Reports/Annual MeetingÂ [***] [***] 2.10Â Draft and Final Technical Progress ReportÂ [***] [***] Â Â 3. Physical Inventory Deliverables #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 3.1Â Draft and Final Nonclinical Study Report(s)Â [***] [***] 3.2Â Nonclinical Study ProtocolsÂ [***] [***] 3.3Â Nonclinical Study Final Data Submission PackageÂ [***] [***] Â Â 4. Technical Reporting: Clinical Trials #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 4.1Â Clinical Trial ProtocolsÂ [***] [***] 4.2Â Clinical Trial Documentation1Â [***] [***] 4.3Â ClinicalTrials.Gov Posting and Results ReportingÂ [***] [***] 4.4Â Draft and Final Clinical Study Report(s)Â [***] [***] 4.5Â Project-Specific First Site Activated for First Subject First VisitÂ [***] [***] 4.6Â Clinical Report During Active Enrollment Periods2Â [***] [***] 4.7Â Access to Electronic Systems Used in Trial ConductÂ [***] [***] 4.8Â Blinded Safety Reports, Medical Data Listing, CIOMS Report, Pharmacovigilance Database ListingÂ [***] [***] â€¯4.9Â Specimen Collection for Future UseÂ [***]

[***] â€¯4.10Â Clinical Trial Final Study PackageÂ [***] [***] 4.11Â Data Exchange Package(s) Submitted to Regulatory Agency(s)â€¯Â [***] [***] â€¯4.12Â Clinical Trial DatasetsÂ [***] [***] â€¯4.13Â Additional Data Package(s)Â Â [***] [***] Â Â 5. Technical Reporting: Quality Assurance Â #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 5.1Â Quality Management Plan (QMP)Â [***] [***] 5.2Â BARDA AuditÂ [***] [***] 5.3Â FDA Inspections/Site visitsÂ [***] [***] 5.4Â Quality Assurance Audits and SubPerformer Monitoring VisitsÂ [***] [***] 5.5Â Risk Management Plan (RMP)Â [***] [***] 5.6Â Integrated Master Schedule (IMS)Â [***] [***] 5.7Â Deviation Notification and Mitigation StrategyÂ [***] [***] 5.8Â Incident ReportÂ [***] [***] Â Â 6. Advanced R&D Products Â #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 6.1Â Technical DocumentsÂ [***] [***] 6.2Â PublicationsÂ [***] [***] 6.3Â Performer Clinical Publication Timeline and USG Right to Publish DataÂ Â Â [***] [***] 6.4Â Performerâ€¯Nonclinicalâ€¯Â Publication Timeline and USG Right to Publish DataÂ [***] [***] Â Â 7. Regulatory Deliverables Â #Â DeliverableÂ Deliverable DescriptionÂ Reporting Procedures and Due DatesÂ 7.1Â Regulatory Strategy/PlanÂ [***] [***] 7.2Â FDA CorrespondenceÂ Â [***] [***] 7.3Â FDA SubmissionsÂ [***] [***] Â Â 5.0 Milestone Payment Schedule MS # Task # Description Due Date Government Funds Authorized PHASE 1 Â Â 1.1 Project Management [***] Â Â 1 1.1 Project Kick Off [***] $[***] Y 2 Â CRO Initiation. Subcontract Execution: [***] [***] $[***] Y 3 1.1 PM Plans [***] $[***] Y 4 1.1.1 Weekly Meetings - 110 total ($[***] ea) [***] $[***] Â 5 1.1.1 Weekly Meetings - 10 total ($[***] ea) [***] $[***] Y 5.1 1.1.1 Weekly Meetings â€“Â [***] ($[***] ea) [***] $[***] Y 6 Â PM Meetings at Vaxart [***] $[***] Y 7 Â PM Meetings at Vaxart [***] $[***] Y 8 Â PM Meetings at Vaxart [***] $[***] Â 9 Â PM Meetings at Vaxart [***] $[***] Â 10 Â PM Meetings at Vaxart [***] $[***] Â 11 Â PM Meetings at Vaxart [***] $[***] Â 11.1 Â PM Subcontract â€“Â [***] [***] $[***] Y 11.2 Â PM Subcontract â€“Â [***] [***] $[***] Y 11.3 1.1.3 Risk Management [***] $[***] Y 12 1.1.4 Monthly Cost Accounting/Invoicing [***] $[***] Â 12.1 Â 2 Invoices [***] $[***] Y 12.2 Â 3 Additional Invoices [***] $[***] Y 12.3 Â Financial Management & Reporting [***] $[***] Y 12.4 Â Accounting Subcontract â€“Â [***] [***] $[***] Y 12.5 Â Accounting Subcontract â€“Â [***] [***] $[***] Y 13 1.1.1 Monthly Technical & Business Reports [***] - Â Â 1.2 Analytical Â Â Â Â 1.2.1 Serum & T Cells Â Â Â 14 Â Start Up Meeting [***] $[***] Y 15 Â Log Samples [***] $[***] Y 16 Â Complete Sample Shipment [***] $[***] Â 17 Â Results Tabulated & Sent to Vaxart [***] $[***] Â Â 1.2.2 Mucosal Analysis Â Â Â 18 Â Start Up [***] $[***] Y 18.1 Â Initial Start Up [***] $[***] Y 19 Â Order & Receive Materials [***] $[***] Y 20 Â Controls & Qualification Complete [***] $[***] Y 21 Â Complete Nasal Analysis [***] $[***] Â 22 Â Complete Saliva analysis [***] $[***] Â 23 Â Complete additional analysis [***] $[***] Â Â 1.2.3 Infection & Efficacy Â Â Â 24 Â Start Up [***] $[***] Y 24.1 Â Task Kick-Off [***] $[***] Y 25 Â Lab Kit Replenishment [***] $[***] Â 25.1 Â Lab Kit Replenishmentâ€“Â first shipment [***] $[***] Y 26 Â Site to Central Lab Shipment [***] $[***] Â 26.1 Â Site to Central Lab Shipment â€“Â first shipments [***] $[***] Y 27 Â Central Lab: 3 shipments / 6 months [***] $[***] Â 28 Â Statistical Analysis [***] $[***] Â 29 Â Analysis Complete [***] $[***] Â 30 Â Phase 2b Relative Efficacy & Infectious Report [***] - Â Â 1.2.4 Correlates Â Â Â 31 Â Machine Learning & Programming [***] $[***] Â 32 Â Statistical Analysis [***] $[***] Â 33 Â Verification / Analysis Complete [***] $[***] Â 34 Â Correlates of Protection Report [***] - Â Â 1.3 Clinical Â Â Â Â 1.3.1 Site Start Up [***] Â Â 35 Â Essential Documents Complete [***] $[***] Y 35.1 Â Essential Documents 50% Complete [***] $[***] Y 36 Â Site Contracts Complete [***] $[***] Y 37 Â Regulatory Binders Complete [***] $[***] Y 37.1 Â Regulatory Binders Draft [***] $[***] Y 38 Â Site Initiation Visits [***] $[***] Â 38.1 Â SIV â€“Â Initial Sites [***] $[***] Y 38.2 Â SIV â€“Â Additional Sites [***] $[***] Â 39 Â IP Shipments to Sites [***] $[***] Â 39.1 Â IP Shipment to Sites â€“Â Initial Sites [***] $[***] Y 40 Â Lab & Other Supplies to Sites [***] $[***] Â 40.1 Â Lab & Other Supplies to Sites â€“Â Initial Sites [***] $[***] Y 41 Â Study Meetings/Training [***] $[***] Y 41.1 Â Study Meetings/Training â€“Â Initial Sites [***] $[***] Y Â 1.3.2 Enrollment Â Â Â 45 Â 1st Person In [***] - Â 46 Â Biosample Collection [***] $[***] Â 46.1 Â Biosample Collection â€“Â 400 subjects [***] $[***] Y 47 Â Interim Analysis [***] $[***] Â 48 Â Source Data Verification [***] $[***] Â 48.1 Â SDV â€“Â 400 subjects [***] $[***] Y 49 Â Sites Supplies Management [***] $[***] Â 50 Â First 5,000 Patients Dosed [***] $[***] Â 50.1 Â Last Person Dosed [***] $[***] Â 51 Â Conclusion of Follow Up [***] $[***] Â 52 Â Unblinded Monitoring [***] $[***] Â Â 1.3.4 Site Monitoring Â Â Â 53 Â Routine Monitoring Visit - 2-3 Visits Per Site (360 visits) Â Â Â 54 Â Routine Monitoring Visits, Quarter 1 [***] $[***] Y 55 Â Routine Monitoring Visits, Quarter 2 [***] $[***] Y 56 Â Routine Monitoring Visits, Quarter 3 [***] $[***] Â 57 Â Routine Monitoring Visits, Quarter 4 [***] $[***] Â 58 Â Routine Monitoring Visits, Quarter 5 [***] $[***] Â 59 Â Routine Monitoring Visits, Quarter 6 [***] $[***] Â 60 Â Routine Monitoring Visits, Quarter 7 [***] $[***] Â 61 Â Routine Monitoring Visits, Quarter 8 [***] $[***] Â 62 Â Routine Monitoring Visits, Quarter 9 [***] $[***] Â 63 Â Routine Monitoring Visits, Quarter 10 [***] $[***] Â 64 Â Routine Monitoring Visits, Quarter 11 [***] $[***] Â 65 Â Routine Monitoring Visits, Quarter 12 [***] $[***] Â Â 1.3.5 Data Management / Statistics Â Â Â 66 Â Statistical Analysis Plan [***] $[***] Y 66.1 Â SAP â€“Â Initial Work [***] $[***] Y 67 Â Programming Specification, Dvlpt, & Review [***] $[***] Y 67.1 Â Set up of TLF shells for 1stÁ DSMB review [***] $[***] Y 68 Â Method Validation [***] $[***] Y 69 Â TFL Generation [***] $[***] Â Â 1.3.6 Database Lock Â Â Â 70 Â Soft Lock [***] $[***] Â 71 Â Hard Lock [***] $[***] Â Â Â Data Safety Monitoring Board Â Â Â 72 Â DSMB Meetings (6/14/2024-11/23/2026) Â Â Â 73 Â DSMB Meeting [***] $[***] Y 74 Â DSMB Meeting [***] $[***] Y 75 Â DSMB Meeting [***] $[***] Y 76 Â DSMB Meeting [***] $[***] Â 77 Â DSMB Meeting [***] $[***] Â 78 Â DSMB Meeting [***] $[***] Â 79 Â DSMB Meeting [***] $[***] Â 80 Â DSMB Meeting [***] $[***] Â 81 Â DSMB Meeting [***] $[***] Â 82 Â DSMB Meeting [***] $[***] Â Â Â BARDA Update Meetings Â Â Â 83 Â Year 1 Meeting - BARDA [***] $[***] Â 84 Â Year 2 Meeting - BARDA [***] $[***] Â 85 Â Year 3 Meeting - BARDA [***] $[***] Â Â Â Reporting Â Â Â 86 Â Annual Report 1 [***] - Â 87 Â Annual Report 2 [***] - Â 88 Â Annual Report 3 [***] - Â Â 1.4. Regulatory (6/2024-7/1/2027) Â Â Â 89 1.4.2 FDA Annual Report 1 [***] $[***] Y 90 1.4.2 FDA Annual Report 2 [***] $[***] Â 91 1.4.2 FDA Annual Report 3 [***] $[***] Â 92 1.4.1 Regulatory Interactions - Quarter 1 [***] $[***] Y 93 Â Regulatory Interactions - Quarter 2 [***] $[***] Y 94 Â Regulatory Interactions - Quarter 3 [***] $[***] Y 95 Â Regulatory Interactions - Quarter 4 [***] $[***] Â 96 Â Regulatory Interactions - Quarter 5 [***] $[***] Â 97 Â Regulatory Interactions - Quarter 6 [***] $[***] Â 98 Â Regulatory Interactions - Quarter 7 [***] $[***] Â 99 Â Regulatory Interactions - Quarter 8 [***] $[***] Â 100 Â Regulatory Interactions - Quarter 9 [***] $[***] Â 101 Â Regulatory Interactions - Quarter 10 [***] $[***] Â 102 Â Regulatory Interactions - Quarter 11 [***] $[***] Â 103 Â Regulatory Interactions - Quarter 12 [***] $[***] Â Â Â 1.5 CMC / KP.2 Manufacturing - FFP Â Â Â 104 Â Manufacturing Start [***] $[***] Y 105 Â Research Virus Bank manufacturing [***] Â Â Â Â KP.2 Bulk Drug Substance manufacture, test, and release Â Â Â 106 Â Lot A [***] $[***] Y 107 Â Lot B [***] Â Â Â Â KP.2 GMP Drug Product manufacture, test, and release Â Â Â 108 Â Lot A [***] $[***] Y 109 Â Lot B [***] $[***] Y 110 Â Stability Studies [***] Â Â 111 Â Kitting and Distribution to depot [***] $[***] Y PHASE 2 Â Â 112 Â Kick Off / Program Initiation [***] $[***] Â 113 Â Materials & Supplies Acquisition [***] $[***] Â 114 1.1.1 Sample Processing [***] $[***] Â 115 1.1.1 Durability Sample Analysis [***] $[***] Â 116 1.1.1 Flow Analysis [***] $[***] Â 117 1.1.2 Sequence Memory Cells [***] $[***] Â 118 1.1.3 Produce Clones [***] $[***] Â 119 1.1.3 Complete Clone Analysis [***] $[***] Â 120 1.2 Phase 2 Final Report [***] - Â 121 Â Final Technical and Business Status Report [***] - Â Â Â Â Â Total $456,119,279 Â Â Â Â Â Contract Type CPFF Â Â Note: Upon project initiation, only certain milestones have been authorized and are labeled as such. Â 6. Data Rights Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 (US patents 7,879,602 and 8,222,224). Vaxart has also filed for patent protection on their COVID-19 vaccine candidates. All intellectual property is fully owned by Vaxart, without any encumbrances. Vaxart anticipates that it will utilize intellectual property (including patented inventions) in the performance of any contract that either has been developed at private expense (and in which Vaxart has ownership in the case of patented invention pursuant to FAR 52.227-11 or data pursuant to FAR 52.227-14), developed by a third-party (in which Vaxart has appropriate license rights) or pursuant to a prior government contract (in which case Vaxart has ownership rights as determined by that contract). Vaxart will provide a more detailed statement of rights in intellectual property for government review and approval (including any declarations of rights in intellectual property by Vaxartâ€™s subcontractors) and does not anticipate any impediments in Vaxartâ€™s ability to develop the vaccine technology based upon intellectual property that will be utilized in performance. Â Technical Data to Be Furnished with Restrictions Basis for Assertion Asserted Rights Category Name of Asserting Organization Milestone Affected [***] Vaxart development prior to contract at private expense Limited rights Vaxart, Inc. N/A; background Â Â Â EX-101.SCH 6 vxrt-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization and Nature of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Fair Value of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Revenue link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Equity Incentive Plans link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 4 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 7 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 9 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 10 - Equity Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 1 - Organization and Nature of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 4 - Balance Sheet Components - Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 5 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 7 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 7 - Leases - Lease Liabilities Payment Obligations (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 7 - Leases - Operating Lease Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 9 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 10 - Equity Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Options (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 12 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 vxrt-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vxrt-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vxrt-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Fair Value of Financial Instruments Note 4 - Balance Sheet Components Risk-free interest rate Unrealized gain on available-for-sale investments, net of tax us-gaap_GrantsReceivable Grants Receivable Note 6 - Liabilities Related to Sale of Future Royalties Note 7 - Leases Note 9 - Stockholders' Equity Note 10 - Equity Incentive Plans The September 2021 ATM [Member] Related to the September 2021 ATM. Note 11 - Net Loss Per Share Attributable to Common Stockholders Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) Unrealized gain on available-for-sale investments Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) Expected volatility Note 4 - Balance Sheet Components - Intangible Assets (Details) Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 4 - Balance Sheet Components - Accrued Liabilities (Details) Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) Note 7 - Leases - Lease Liabilities Payment Obligations (Details) Expected term (in years) (Year) Note 7 - Leases - Operating Lease Expenses (Details) vxrt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details) Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) Note 10 - Equity Incentive Plans - Assumptions of Options (Details) Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details) Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) Notes To Financial Statements us-gaap_LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party Notes To Financial Statements [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Granted, Weighted average grant date fair value (in dollars per share) Forfeited, Weighted average grant date fair value (in dollars per share) US Treasury Securities [Member] us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, Weighted average grant date fair value (in dollars per share) Balance, Weighted average grant date fair value (in dollars per share) Commercial Paper, Not Included with Cash and Cash Equivalents [Member] At-the-market Facility [Member] Related to at-the-market facility. vxrt_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour Thereafter Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares) Government Contract [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value us-gaap_PaymentsToAcquireInvestments Purchases of investments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Grant [Member] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Proceeds from maturities of investments vxrt_RoyaltyInterestCovenantShortfallInRoyaltyPayments Royalty Interest, Covenant, Shortfall in Royalty Payments Represents the covenant for royalty interest relating to shortfalls in royalty payments. vxrt_RoyaltyInterestCovenantCumulativeRemainingShortfallAmount Royalty Interest, Covenant, Cumulative Remaining Shortfall Amount Represents the covenant for the cumulative remaining shortfall amount in a royalty interest agreement. Calculated using the aggregate amount of remaining shortfall for each annual period. Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Weighted average exercise price, balance (in dollars per share) Weighted average exercise price, balance (in dollars per share) Weighted average exercise price, forfeited (in dollars per share) Weighted average exercise price, canceled (in dollars per share) Financial Instrument [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Number of RSUs outstanding (in shares) Number of RSUs outstanding (in shares) Royalty Payment, Interest, Second Period [Member] Represents the second period of royalty repayment interest. Weighted average exercise price, granted (in dollars per share) Royalty Payment, Interest, First Period [Member] Represents the first period of royalty repayment interest. Weighted average exercise price, exercised (in dollars per share) RA Capital Healthcare Fund 2024 [Member] Represents the securities purchase agreement with RA Capital Healthcare Fund, L.P. in the year 2024. Other accrued current liabilities Total Accrued compensation Lessee, Operating Leases [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures Number of RSUs outstanding, forfeite (in shares) Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Number of options outstanding, beginning balance (in shares) Number of options outstanding, balance (in shares) Number of RSUs outstanding, granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Number of options outstanding, canceled (in shares) Acquisition of property and equipment included in accounts payable and accrued expenses Proceeds from sale of property and equipment Other liabilities, current portion Cash, Cash Equivalents and Investments [Table Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Non Cash Royalty Revenue [Member] Non cash usage-based right to asset. Accrued professional and consulting services us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Shares available for grant, balance (in shares) Shares available for grant, balance (in shares) vxrt_NoncashRevenueRelatedToSaleOfFutureRoyalties Non-cash revenue related to sale of future royalties Amount of non-cash accounted for as Revenue in relation to the sale of future royalties. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Authorized (in shares) vxrt_GrossProceedsFromIssuanceOfCommonStock Gross Proceeds from Issuance of Common Stock The gross cash inflow from the additional capital contribution to the entity before deducting underwriting discounts, commission, and offering expenses. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Developed Technology Rights [Member] us-gaap_Assets Total assets Supplemental disclosure of non-cash investing and financing activity: Lease for Facility in South San Francisco Commenced in Third Quarter of 2022 [Member] Represents lease for facility in South San Francisco, California commenced in third quarter of 2022. Plan Name [Axis] vxrt_GovernmentAssistanceAwardAmountInitialAwardFixedFee Government Assistance Award, Amount, Initial Award Fixed Fee Amount of government assistance initial fixed fee awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Common Warrants [Member] Represents information pertaining to common warrants. Intellectual Property [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_SubleaseIncome Sublease income Lease for Facility in South San Francisco Commenced in First Quarter of 2023 [Member] Represents lease for facility in South San Francisco, California in first quarter of 2023. Laboratory Equipment [Member] Property, plant, and equipment classified as laboratory equipment. Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] The 2024 Inducement Award Plan [Member] Relating to the 2024 Inducement Award Plan. The 2019 Plan [Member] Represents information pertaining to the 2019 Equity Incentive Plan. Award Type [Domain] Award Type [Axis] Net loss Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Less: accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Total Intangible assets, net Intangible assets, net Schedule of Common Stock Reserved for Issuance [Table Text Block] Tabular disclosure of common stock reserved for issuance. Restricted Stock Units (RSUs) [Member] Intangible assets, gross Share-Based Payment Arrangement, Option [Member] HealthCare Royalty Partners III, L.P. [Member] Represents the legal entity, HealthCare Royalty III, L.P. Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Accrued clinical and manufacturing expenses Amount of accrued clinical and manufacturing expenses due within one year. Revenue [Text Block] The entire disclosure for revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation Property and equipment, net Property and equipment, net Goodwill Goodwill vxrt_RoyaltyPercentage Royalty Percentage Royalty percentage received on net sales. BARDA [Member] This item represents contractual agreements with the U.S. Office of Biomedical Advanced Research and Development Authority ("BARDA"). Property and equipment, gross us-gaap_GovernmentAssistanceAwardAmount Government Assistance, Award Amount us-gaap_Dividends Dividends, Total vxrt_RoyaltyWithholdingTax Royalty Withholding Tax Percentage of tax withheld from royalty income. Cash flows from investing activities: Estimated Fair Value Earnings Per Share [Text Block] Provision for income taxes Income Tax Expense (Benefit) Other accrued liabilities us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Daiichi Sankyo Collaboration and License Agreement [Member] Royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") in 2009. Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] us-gaap_OperatingExpenses Total operating expenses Liabilities Related to Sale of Future Royalties [Text Block] The entire disclosure for the liabilities related to the sale of future royalties per the royalty interest acquisition agreement. General and administrative Restricted cash vxrt_FinitelivedIntangibleAssetRemainingLife Finite-Lived Intangible Asset, Remaining Life (Year) The remaining life of finite-lived intangible assets. vxrt_RoyaltyInterestAdditionalRoyaltiesDueEachYear Royalty Interest, Additional Royalties Due Each Year Amount of additional royalties due each year. vxrt_RoyaltyInterestPercentageOfAdditionalRoyaltiesDueEachYear Royalty Interest, Percentage of Additional Royalties Due Each Year Percentage of additional royalties due each year. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Royalty [Member] HCRP [Member] HealthCare Royalty Partners are purchasers of royalty rights. vxrt_DebtNoncashRoyaltyRevenuePaid Non-cash royalty revenue paid to HCRP The 2023 Shelf Registration [Member] Related to the 2023 shelf registration. Non-cash interest expense recognized Amount of non-cash interest expense recognized in relation to the sale of future royalties. us-gaap_AllocatedShareBasedCompensationExpense Stock-based compensation Registered Direct Offering [Member] Represents the registered direct offering. vxrt_OpenMarketSaleAgreementMaximumAggregateOfferingPrice Open Market Sale Agreement, Maximum Aggregate Offering Price The maximum aggregate offering price pursuant to the open market sale agreement. vxrt_LiabilityRelatedToSaleOfFutureRoyalties Total liability related to sale of future royalties, start of period Total liability related to sale of future royalties, end of period Amount of liability associated with the sale of future royalties. vxrt_LesseeOperatingLeaseNumberOfLeases Lessee, Operating Lease, Number of Right-of-Use Leases Number of right-of-use operating leases. Amendment Flag Comprehensive loss: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss City Area Code vxrt_OpenMarketSaleAgreementSalesCommissionPercentage Open Market Sale Agreement, Sales Commission, Percentage The percentage of sales commission pursuant to the open market sale agreement. Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_TreasuryStockSharesAcquired Repurchase of common stock to satisfy tax withholding (in shares) us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Current Fiscal Year End Date Variable lease cost us-gaap_LeaseCost Total lease cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease cost Lease, Cost [Table Text Block] Document Period End Date Operating lease liabilities arising from obtaining right-of-use assets us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term (Year) Entity File Number us-gaap_IncreaseDecreaseInPrepaidExpensesOther Prepaid clinical services, long-term Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status Investments and Cash us-gaap_AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stock-based compensation Entity Tax Identification Number Entity Central Index Key Depreciation and amortization Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Offering costs Additional offering costs under the June 2024 Offering Investments and Cash, Fair Value Disclosure Represents the fair value amount of investments and cash. us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_TreasuryStockValueAcquiredCostMethod Repurchase of common stock to satisfy tax withholding Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code us-gaap_TreasuryStockCommonValue Treasury stock at cost, 700,122 shares as of September 30, 2024 and 507,020 shares as of December 31, 2023 Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Trading Symbol Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Issuance of common stock under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Local Phone Number Issuance of common stock upon exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Number of options outstanding, exercised (in shares) us-gaap_GainLossOnDispositionOfAssets Loss on disposal of equipment us-gaap_TableTextBlock Notes Tables Issuance of common stock under ESPP Release of common stock for vested restricted stock units (in shares) Issuance of common stock upon exercise of stock options Release of common stock for vested restricted stock units Number of options outstanding, granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Number of options outstanding, forfeited (in shares) Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Issuance of common stock (in shares) Stock Issued During Period, Shares, New Issues (in shares) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity Issuance of common stock Stock Issued During Period, Value, New Issues Accumulated deficit Research and development Accumulated other comprehensive income (loss) Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member] Represents information regarding right of use for office and manufacturing facilities with initial terms exceeding one year. Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash [Member] Change in operating assets and liabilities: Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Operating lease liability, net of current portion Operating lease liability, net of current portion us-gaap_OperatingLeaseLiability Present value of future minimum payments Subsequent Event Type [Axis] Current portion of operating lease liability Current portion of operating lease liability Subsequent Event Type [Domain] Subsequent Events [Text Block] Right-of-use assets, net Operating Lease, Right-of-Use Asset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Undiscounted total us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear 2024 (three months remaining) us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2028 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2026 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2027 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2026 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Facility in Burlingame, California [Member] Related to facility in Burlingame, California. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2025 Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2024 (three months remaining) Prepaid clinical services, long-term Prepaid Expense Other, Noncurrent us-gaap_Revenues Revenues Operating expenses: Total assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Warrants Expiring February 2025 [Member] Represents information related to warrants expiring February 2025. Warrants Expiring March 2025 [Member]

Represents information related to warrants expiring March 2025. us-gaap_Depreciation Depreciation
vxrt_WarrantExercisePriceToBeEntitledToReceiveCashConsiderationFundamentalTransaction Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share) The exercise price per share or per unit of warrants necessary to be entitled to receive cash consideration equal to Black-Scholes valuation, as defined in the warrant, in the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) us-gaap_FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure, Total us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Money market funds, Fair Value Equity [Text Block] Investments, Fair Value Disclosure Treasury Stock, Common, Shares (in shares) Treasury Stock, Common, Shares (in shares) Interest income Common stock: $0.0001 par value; 350,000,000 shares authorized as of September 30, 2024 and 250,000,000 shares authorized as of December 31, 2023; 228,176,446 shares issued and 227,476,324 shares outstanding as of September 30, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023 Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) us-gaap_TangibleAssetImpairmentCharges Tangible Asset Impairment Charges Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Product and Service [Axis] us-gaap_PaymentsForLegalSettlements Payments for Legal Settlements Other current assets Product and Service [Domain] Statistical Measurement [Axis] Litigation Case [Axis] Litigation Case [Domain] Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred stock, shares issued (in shares) Other prepaid Prepaid rent us-gaap_PrepaidRent us-gaap_PrepaidRoyalties Prepaid Royalties Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Prepaid insurance us-gaap_PrepaidInsurance Fair Value, Inputs, Level 3 [Member] Other income (expense), net Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Deferred revenue Unbilled receivable from government contracts Unbilled Receivables, Current Construction in Progress [Member] Cash flows from operating activities: Revenue [Policy Text Block] Statement [Line Items] Accounts receivable us-gaap_NumberOfReportableSegments Number of Reportable Segments us-gaap_CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-Term Investments Revenue: Short-term investments Additional paid-in capital AOCI Attributable to Parent [Member] Leasehold Improvements [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Current assets: Fair Value Disclosures [Text Block] us-gaap_GovernmentContractReceivableUnbilledAmounts Government Contract Receivable, Cash and cash equivalents Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period Cash, cash equivalents and restricted cash at beginning of the period Cash, cash equivalents and restricted cash at end of the period us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Amortization of discount on investments, net us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies (Note 8) Sale of Stock [Axis] Sale of Stock [Domain] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] us-gaap_OperatingIncomeLoss Operating loss Other income (expense): us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Second Set of Warrants Expiring April 2024 [Member] Represents information pertaining to a second set of warrants expiring in April 2024. Counterparty Name [Axis] First Set of Warrants Expiring April 2024 [Member] Represents information pertaining to a first set of warrants expiring in April 2024. Counterparty Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Stockholdersâ€™ equity: The 2022 ESPP [Member] Represents the 2022 Employee Stock Purchase Plan. vxrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants Shares available for grant, granted (in shares) Represents the decrease in the shares available for grant attributable to shares granted during the period. Shares available for grant, canceled (in shares) Represents the change in the shares available for grant attributable to shares canceled during the period under the plan. Shares available for grant, forfeited (in shares) Represents the change in the shares available for grant attributable to shares forfeited during the period under the plan. Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Shares acquired to settle employee tax withholding liabilities Grant Milestone Completion [Member] Represents the completion of milestones under grants. Employee Stock Purchase Plan [Member] Represents employee stock purchase plan. us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity Proceeds from issuance of common stock under the employee stock purchase plan Proceeds from Stock Plans Retained Earnings [Member] Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Treasury Stock, Common [Member] Additional Paid-in Capital [Member] Common Stock [Member] Himmelberg V. Vaxart, Inc. et al. [Member] Represents the Himmelberg V. Vaxart, Inc. et al. Equity Components [Axis] Equity Component [Domain] Securities into which warrants are convertible (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] vxrt_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased Number of RSUs outstanding, release (in shares) Number of non-option equity instruments released by participants. Royalty Arrangement [Member] Securities into which warrants are convertible (in shares) Released, Weighted average grant date fair value (in dollars per share) Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were released. Deferred Revenue Arrangement Type [Axis] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes Deferred Revenue [Domain] National Tax Agency, Japan [Member] Deferred government revenue Deferred Revenue, Current Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Domain] Foreign Tax Jurisdiction [Member] Office Equipment [Member] Document Quarterly Report Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Research and Development Expense [Member] Government Assistance, Type [Axis] Government Assistance, Type [Domain] Current portion of liability related to sale of future royalties vxrt_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent Current portion Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to the selling costs of future royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Statement of Income Location, Balance [Axis] Liability related to sale of future royalties, net of current portion Long-term portion Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to the selling costs of future royalties. Used to reflect the noncurrent portion of the liabilities (due after one year or beyond the normal operating cycle, if longer). Statement of Income Location, Balance [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Non-cash interest expense related to sale of future royalties Non-cash interest expense related to sale of future royalties Amount of non-cash accounted for as interest expense on liability in relation to the sale of future royalties. vxrt_ProceedsFromSaleOfFutureRoyaltiesNet Proceeds from Sale of Future Royalties, Net The cash inflow from the sales of future royalties net pf deferred financing costs. vxrt_ClassOfWarrantOrRightExpirationsInPeriod Class of Warrant or Right, Expirations in Period (in shares) Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements. us-gaap_SharePrice Share Price (in dollars per share) Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares) us-gaap_PurchaseObligation Purchase Obligation Prepaid clinical and manufacturing expenses vxrt_PrepaidClinicalAndManufacturingExpenses Amount of asset related to consideration paid in advance for clinical and manufacturing expenses. Statement [Table] Statement of Financial Position [Abstract] Shares used to compute net loss per share - basic and diluted (in shares) Net loss per share - basic and diluted (in dollars per share) Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Axis] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] September 2021 ATM [Member] Represents September 2021 ATM offering. June 2024 Offering [Member] Represents June 2024 Offering. Fair Value, Assets Measured on Recurring Basis [Table Text Block] vxrt_IncreaseDecreaseInUnbilledReceivable Unbilled receivable from government contracts The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts. Cash flows from financing activities: Other long-term liabilities Common Stock Outstanding [Member] Represents common stock outstanding. vxrt_GovernmentAssistanceAdditionalFundingPossible Government Assistance, Additional Funding Possible Additional amount of funding possible if study continues for government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. The 2024 ASPR-BARDA Contract [Member] Represents The 2024 ASPR-BARDA Contract. The 2024 ATI-RRPV Contract [Member] Represents The 2024 ATI-RRPV Contract.
vxrt_GovernmentAssistanceAwardAmountInitialAward Government Assistance, Award Amount, Initial Award Initial amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balances Balances Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Gross unrealized losses Gross unrealized gains vxrt_CommonStockIncreaseInSharesAuthorized Common Stock, Increase in Shares Authorized (in shares) The number of increase in shares authorized of common stock. ESPP [Member] Related to ESPP. Amortized Cost EX-101.PRE 10 vxrt-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 slide1.jpg begin 644 slide1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ # _X0 B17AI9@ 34T *@ @ 0$2 , M ! $ # _VP!# (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8' M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M# P,# P,# P,# S_P 1" $Z U(# 2(A$! Q$! \0 'P 04! 0$! M 0$ $" P0%!@<("0H+_\0 M1 @$# P(P4%! 0 %] 0(# M 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0 M $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)! M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4 ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#] **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FB0;L4ZOR?_X.=?&>M>$)/@>=’UG6-(^T?V]Y MOV&]EMO-Q_9N-VQAG&3C/3)]30!^L%%?RC_\+I\:_P#0Z>,/ _!Y=?_'*/^%T M^-?^AT\8? ^#RZ_\ CE '|7%%?RC_/"Z?&O_$.GC#_P>77_ ,,/\ P>77_P \;>,%^NN77_QRG+\:_&;#(\:>,"#W_MRZ M_P#CE '|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§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ˆ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

__(GZDX;^ZWY4?@WY5^77_#WGXU_]!;1/_!4O_P 52_\ #WCX MV?\ 05T7_P %2_\ Q5'_ !&KA_M/_P !7^8?\2X\6?\ 3K_P-_\ R)^HGX-^ M5'X-^5?EW_P]X^-G_05T7_P5+_\ %4?\/>/C9_T%=%_\%2__
!5'_$:N'^T_ M_ 5_F'_$N/%G_3K_,#?_P B?J)^#?E1^#?E7Y=_\/>/C9_T%=% \%2__%4? M\/>/C9_T%=%_\%2__%4?\1JX?[3_ / 5_F'_ !+CQ9_TZ_\ W_\B?J)^#?E M1^#?E7Y=_P##WCXV?]!71?\
P5+_ /%4?\/>/C9_T%=%_P#!4O\ \51_Q&KA M_M/_ ,!7^8?\2X\6?]. O_W _/(GZB?@WY4?@WY5^7?_]X^-G_$%=%_\ M!4O_ ,51_P />/C9_P!!;0__ 5)_P#%4?\ $:N'^T__ %?YA_Q+CQ9_P!. MO_
W_P#(GZB?@WY4?@WY5^7?_#WCXV?]!71?_!4O_P 51_P]X^-G_05T7_P5 M+_ \ %4_^(U9!VG_X"O\ ,/\ B7'BS_IU_P"!O_Y$_43\& *C\& *OR[_X>\?&S_H*Z_M+_X*E_\ BJ/^(U9!VG_X"O\ ,/\ B7'BS_IU_P"!O_Y$_43\& *C\& *OR[_M
.O'QL_Z"NB_P#@J7_XJC_A[Q\;/^@KHO\ X*E_^*H_X>\ &S_H*Z+_ "I M?_BJ/^(U9!VG_X"O\ ,/\ B7'BS_IU_P"!O_Y$_43\& *C\0\>265CXMD=O[/NT M40V^J+U\L+G"RJ,X4<,!Q@\'[2/-?HF1Y_@\WPJQ6"ES1?WI]FNC/R3B7AG, M,AQTLOS*'+./S371Q?5/O\FDT<;^#?E1^#?E7:"BO9/GSB_P;\]/P;\]2[2B@
M#B_P;\]/P;\]2[2B@#B_P;\]/P;\]2[2B@#B_P;\]M:' R%X.#U\ (UU5% #4 M^[3J ,"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** MB/\XJN^IVZM@W$*D=07% 'Y/_ +7C M_%#X:_? ?VI/$6BS>*->\&^,O&\ AW4=-
A>5I_#5S&FGO9ZG: #(MY-SP3A3P M?(<9"N*^F/BQ^UW\4/#/[::7Q-HMU%;-?:V+ M\"'+:M+=9V@1I]BVR F0&OL7^T+;_GY@_P" HH_M&V88^U0_A(!0!\'?2[5_ MQ@T_X6:#X@UIQIIOA?
PYXJ\9:UHM[XB'@QKE/!MC87%^EN9$#E9'NGB@C$TB MK&@"@*?7^<;'>OZ2NDZQ\3O[)UZVF;0)+6#3-*MFNAK"L M) 3'),EK:O&DI+Q_VLHR?+%??=7]I0?\ /U# _ !2?;
[4#'VJ'\9!0!\0?LY M?%?XD:GJ?PK\,^';RQ\-Z;KDWC76-;1]$>\:Y6PU^-(H8V>0&%YHY95WGDN-K ML53(4KS/@/\ X*(_$WXC> E72]2T^W\1:7\'I];UV;5/"U\MGIOB6*^MH)ED M$4!DQ"DDV^.-7$>
S*54Y_08ZE;G_EZ@_P" HH_M&V) X^H>/^F@H \._P"" M>?QU\0?M _!'4-4\227EUJ&DZ]>:2E_):0Q6^J11>6RSVTT!\F[A^>7*L_M1^./#C:]I-[J7]AKX*OQH^NZW)IT$<):\OU-C=&: M8_9[>-
=.4O),RNB37,7[J3;Y3<_J/Q_\>77A#P7XT:S75/6&D6GCC3-.MS%, M(-*4TM?$.BHFKR);'2+VZF3SVL;6T, MR3P1!2D+B+<$E5V!#7O@S\4?%?C+XQ?""]\2>+M2TV'5O#WB.QN=-2"'UT_7
M]0LK^VAB8HT987#P+//LC<$+^%(4Q&)0WT[_:=O\ \ 4/_?T4O]HVV[/VJ#_O MZ* +5%5?[6M_^?FW_P"_@H_M:W_Y^;?_+^"@"U157^UK?\ Y^;?_OX*/[6M M_P#GYM_^_@H M455_MM:W_P"?
FW_[^"C^UK?_)^;?_OX* +5%5?[6M_^?FW_M _@H_M:W_Y^;?\ [^"@"U157^UK? GYM_\ OX*/[6M_^?FW_P"_@H M455_MM:W_.?FW_[^"C^UK?\ Y^;?_OX* +5%5?[6M_\
GYM_^_@H_M:W_P"?FW_[M^"@"U157^UK? GYM_P#OX*/[6M_^?FW_ _@H M455_MM:W_Y^;?_ +^"C^UK M?_GYM_\ OX* +5%5?[6M_^?FW_ _@H_M:W _?FW_[^"(#;O^%?#/\ P7 _
MY((X7_[#R_\ I--7V^VJV^?^/B ?]M!7SS^WK^REV*^3XVR^OCZO\ ]%,T'_P6O_\ ':/^(7\2?] [^?YC XC MIP9_T%_^2S_^1/AFBON; AQ[J_\T4S0?_!:_P#\=H_X<>ZO_P!%,T'_ ,%K
M_P#QVC_B%_$G_0. O7^8_P#B.G!G_07_.2S_P#D3X9HK[F_X<>ZO_T4S0?_M 6O_P#':/\ AQ[J_P#T4S0?_!:_ P =H_XA?Q)_T#0[U_F'_$=.#/\ H+_\ MEG_\B?#-%?O\ ,/\ B.G!G_07_P"2S_\
D3X9HK[F_P"'"NK_/13-!_\%K__ M !VC_AQ[J_\T4S0?_!:_P#\=H_XA?Q)_P!' [^]?YA_Q'3@S_H+_ /)9_P#R M)\,T5]S?\./=7_Z*9H/_ (+7_P#CM' #CW5_^BF:#_X+7_\ CM' _!"_B3_H M'?
WK_/^(Z<&?]!? DL__D3X9HK[F_X<>ZO_-%,T' P6O\ ':/^"'NK_\ M13-!_P#!: _\ \=H_XA?Q)_T#0[U_F'_$=.#/^@O _EG_P#(GPS17W- PXJU M?_HIF@_^"U__ ([1_P_/=7 _BF:#_X+7_^.T?
\0OXD_P"@=_>O\P_XCIP9_M_P!!?_DL_P#Y$^&:*^YO^'"VK_\ 12]!_P#!:W_QVH)?^"(^L17^Q_\ "R-% M8/C)73&PO_D2C_B%_$G_$#OU_F/_B.7!G_$%K_P !G_\ (GQ!17W- P _M/=7
.BF:#_X+7_^.T?\,/=7_P"BF:#_ _"U_P#X[3_XA?Q)_P! [^]?YD?\ M1SX,_P"@O_R6?_R)\,T5]S?\./=7_P"BF:#_ _"U_P#X[1_PX]U?_HIF@_\ M@M?_ ..T?\0OXD_Z!W]Z_P P_P"(Y\&?]!?_)+/_P"1/AFBON;_
(<>ZO\ M]%,T' P6O_\ ':/^"'NK_P#13-!_\%K_/QVC_B%_$G_$#OU_F'_$<^#/^ M@O\ \EG_ /(GPS17W- PXJU?_HIF@_\ @M?_ ..T?\,/=7_Z*9H/_@M?_P". MT?\
$+^)/^@=_>O\P_XCGP9_T%_^2S_^1/AFBON; AQ[J_\T4S0?_!:_P#\ M=H_X<>ZO_P!%,T' ,%K_P#QVE_Q"_B3_H'?WK_,?_$=.#/^@O\ \EG_ /(G MPS17W-_PXJU?_HIF@_\ @M?_ ..T?
\./=7_Z*9H/_@M?_P".T?\ $+^)/^@= M_>O\Q_\ $=.#/^@O_P EG_\ (GPS17W- P _/=7 _BF:#_X+7_^.T?\,/=7_M_P"BF:#_ _"U_P#X[1_Q"_B3_H'?WK_,/^(Z<&?]!?\ Y+/ .1/AFBON; A MQ[J__13-!_\
!:_ ,=H_P"'"NK_/13-!_\%K__!VC_B%_$G_0. O7^8?\ M1TX_P"@O_R6?_R)\,T5]S?\./=7_P"BF:#_ _"U_P#X[1_PXJU?_HIF@_\ M@M?_ ..T?\0OXD_Z!W]Z_P P_P"(Z<&?]!?_)+/_P"1/AFBON;_ (P&'
M[']QWJ=MJWBJWMPE[=0H55S_"&)/SN%P"X #$$X&:\G_8>_8#\-?LC6MQJ5WJ M%GXB\779:-]3,:QK:Q9.(H5))3(^\2CM?51\MV M]66XC\E.JJFIVRC_(^8/^_@H_M:W_Y^;?\
[^"OU@_#RU157^UK? GYM_\ MOX*/[6M_^?FW_P"_@H M455_M:W_.?FW_[^"C^UK?\ Y^;?_OX* +5%5?[6 MM_\ GYM_^_@H_M:W_P"?FW_[^"@"U157^UK? GYM_P#OX*=%J$,LFU9H6;T5
MP30!8HHHH **** "BBB@ HHHH **** &M_45QJR,7$G^^?YUV#?U%Z7K LJM*/7Y0<\?2I+R]M].A\RXF@MX\XWRN$7/ MIDX%?,L?P?UJT_:'E\4R^'U.GKX^+^?;Z1(NJ&)[<(L_G\[[+<0' 0#C);Y3
M7H7[9_ANX\4?"W38;?3[S4%AUZQFN([?2CJC)"CDNYMP&\Q5[J1CUKPXYI6= M&I4E3LXWLKO5=<]ZIE="->E252ZDM7V?5:'K%M>0WT"S020SQMT>)@ZMSC@
MC@\@BDAO[>XGEACFMY)H.)8UD!:(_P"T,Y7\O%?V>_ M[X,^/H:Q\+ZM'82?VBVH:AJ^B_8 M[VQ+R;E47L;'*_CD;&T'>R@J0RX-;U[?GWM=VV[(PHY=2FJOOVY-K MZ7^_T_IZ'T=?
ZG:Z5&K75S:VJL=H::58U)]BQ%3(RR(K+M96&01SD>HKR/\ M:H^'.I?$K4_ 5G8Z?IM\(=7FEN&U/3&O["V3{),H::,,OREB "64;B*[CX,? M#S_A4OPUT;P[]N?
4/[*B\LSLGEJQ+%B%7)V(N[:JY.U0!DXK6&*K.O*FX>[' M[5]W9.UOG^!G5PE&.&A54[RD]K;*[5["7WG10SQW*;HGCD7)7SO[F2&WNK.XEB_UB13*[QOJ Y'/'UKBOV8]#0/#OPN%K?6=U87'
M]KZE(8KB$Q/L:^G=6VL <,K!@>A!!^OCWP#^$&M^#/B]X>UW4/#ZVMM>7NNP M^=9Z3):WL)DG=XWOY3GS(656\LX0 LAR:YZF958^R<87Y]]J-5Y>9U4\JHR= M5.I\&VVNC??
R_$^?F[BYCLX6DFDCAC7J[L%49X&2?PIY(4'.T -_M@^ M'=:^)&CZ'X3TKP_J&M6,J7,EWJIBD^SPI##&?+1IF^16,SQ.%/+")L#N.Z^" M.J:IXD^$&@R>(M/NM/UI;);34K:[B,;&:,>5(Q5NJN5+
\AE8$9!K>GCG/$S MH3::TNET=KWUUZ?F=!8ZY8ZG*T=K>6= MU(H+%(9UD8 =\ _YS4MSJ%O9S11S7%O\"YVQK)(%,A)%!/)^E>6?LX_"> Q\ M>,?B%=P^&K716N-?
DBL)DTX6IDLS;VQ"Q,%&8=ZL<+\FX$]0:XOX\>!EN_B' MXXDUOP5K'BZ;7M+MX/"EU::>;Q-/=865HQ+_ ,ND@G/F>82H((.XE2%PJ9C7
MAAXU90U;:MK9)7L]KZVMZG12RRA/$.DIOE23OI=MVNNVE[_(^C&.P$G:NWDY M[5!8ZK::IO\ LMU:W0C(#F&99-N>F=I.,UC:#I>J6'PHLK'59FOM:ATA(+R5 M"7-Q<"$*[#NQ+
[CGN37AO['OPDUCX9>+]%N-4T&'3_[2\'QQK)I^E26,<,B2 M(SQ7N<[KDY4JQ*G D&WDD56S"I&K3@H.TMWVV\GW,Z&74IT:E1U$G%Z+OOJO M+0^CI+Z&)W5I85>-/,=6<<'GV-.BFCN(EDC9)
(Y!N5E.Y6!Z$$<$ M5X_^U\ ":Z\PXS7 MKUE9PZ?:16]O#*;V]NBQ11(H58U48"@#@ 8QVQ751KU1TY1LHVUOO=7_+ M?
S.6OAZ5.A3JPES2E>Z[6=OQZ>0Z>XCM8FDFDCAC7&6=@JC/'4^^!^-'GQFX M:'='YRKN,>X;P,XSCKBL'XK> +;XJ_#37/#ET=D.L64EOO/_ "R8CY'SV*MM
M8'U45PO[+.FZJK[Z]XT\4Z9>Z1KFN?9=.%M>P-#-#!:1;&.ULD*]P]Q(#W!0 M\\5-;%(8B-%1NI*]^UKW_1+U*HX.G/#2KN5G%VMWNU:VO:[>7:YB6X MCA:2%9I 62,N-
S@8R0.^,\XZ4Z25(8V=V2.- 2S.=H4>Y[5\X_%6U\9W7[2T M?C&Q*:O>:7X+N[+3;2>-3OFMY%=;YXH"-\RM]H3YH\@?9B?FP,>D_M1^&K_M ,1^ K&.TL;C6-.L]8M;K5]-MOWDNHV<;YDB"?\
+09VL8_J$?-T/+',Y2 MC5:@_<>GFN^W>^U]#KJ933C.C%U%::3>]T>CMOO9K>VM_4]"M;J*]MUFADCF MA?[KQL&5OH1Q276H6]B8_/FMX?-;;'YD@3S#Z#/4^PK@OV?=-TFTMM?N-#\'
MZIX.T>\O4D@@O(39+=L(E#RQVA ^S+D8QM4N1N(YS7#_ !L\(VK_ !AUR^\6 M>"-9\=:3J>BV]KH"6.GF]%E,IE\^,''C22,T1$QVX ^^-N*JICJD(E2E)'*LL:N MC(Z,
RLIW!@>X(ZUS&K:9._P/O+,6=U%=MH3P+:&8WAI+S4K738 MU:ZN+:U5SA3-(L88^@+$5\M_ WX5^,/ ?B?X36=QI>IS>'=]QJSF:"3S- NG MN)8YK>0%?
W<;NZNF[&"SCTKO_P!LSPM+XFM_!+#3KZ_M;/69)KIH- .N"W4V MLJAGM@K!AN*@$C@G.A!';WIEKJ-O?&3R9[>;R M6V/Y#+.%/A3I]O:VUQ##_ &6(T@6Q&ERC]V00+R M'
0D=@:\5_8\|$WO@?X@7EM;^&=0L=%CT812:EJ>A_V5J*3K,NVVF9&\]J;. M78SHI/RGYR' KKJ8^<*M*=)=2W>KM]R_'9'#3P-.=*I/FLX;))?Z['T=1117 MJ'DA1110 4444 !&13?+IU% !BC%%%%D
8HQ1119 &*,44460!BBBBC0 Q1B MBB@ Q1BBB@ Q1BBB@ Q1BBB@ HQ110 8HQ110 8HQ110 8HQ110 8 MHQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110 8HQ110
&*,4 M4460!BC%%%&@!BD.:6B@!OETX# HHH **** "BBB@ HHHH **** "K6AC;J\ M'U/_ *":JU:T+_D+P_4_ ^@F@#J4^X/I2TB?<'TI: "BBB@ HHHH **** "BB MB@!KPN#<2$6\S L2"$/K7644
0.QHN_%NDZ?K MUOI=QJ>G0ZI>+OM[.2X1;B=>>>50G+=)CT^^O&U33DM=-D:&[F-R@CM77&Y)&SA&&1D'!&1 M5+4?BAX9T2VAN+SQ%H5I;W$CQ1237\4:2.AVNJDM@E3P0.0>M
7*']GW7_/M MZC6&UD4A621B<*P) ()!!(% &/\ V;.:%XY8Y5#HZ$,K*>001U!]:GH X_P#L^Z_Y]KC_M +X/^%']GW7_ #[7' ?!_P *[*B@#C_[/N/^?6;_+]G_"C^S[K_))KC_O@
M_P"%;EEXLTG4=>NM)AU+3YM4L55[FSCN$:XMU;!4N@.Y0:'K MVOWFDV.LZ3>:II^?M5G!=QR7%M@X.]%)9<$@<@=/NC_P NT\ 'P?*[/NO\ MGVN/^^#_ (5V%% 7.\
(/NO^?:X_P"^# _A1_9]U_P ^UQ_WP?\ "NPHH X_M^S[K_GVN/^^# _A1_9]U_S[7'_?!_PKL** ./_L^Z_P"?:X_[X\ A1_9]U_S M"\ WR?*/L%S_S[W'_?!_PKKB:^6_\ @]9^
MTEXO_9E^$OAW5O!^H0Z=>:AK(LYWDM8[@-'Y$KXPX('S*#D<\5Y><9M1RS!S MQM=-P@KNVKW2TNU^9ZV0Y+7S;,*66X5KGJ2Y8\S:5WW:3?X,]V_L^Y_T)[C_M +X/^%'V"Y_Y][C_ +X/^%?
E2\(@K*_YJ7_@X_[X/^%?E3_P /8OCE_P!#59]?^@3;_P@Q M-'_#V+XY?]#59]?^@3;_/Q-'_$:\A_EJ?\ @*_^2#_B6WBO^:E_X'+_ ./0/ MU6^P7/\ S[W'_?!_PK]?^'L7QR_ZGJSZ_\
0)M__B:/ M^'L7QR_Z&JSZ_P#0)M__ (FC_B>>0_RU/_5_P#)!_Q+;Q7_ #4O_Y?_('Z MK?8+G_GWN/\ O@_X4?8+G_GWN/\ O@_X5^5/_#V+XY?]#59]?^@3;_\ Q-'_ M]B^.7_ $-5GU_Z!-O_/$T?
\1KR'^6I_X"O_D@_P");>* YJ7_ ('+_P"0 M/U6^P7/_#[W'_?!_P *\/L%S_P ^_\ WR?* *G_A[%\Q?'+_ *&JSZ_] FW_/B:/^(UY#_+4_\ 5 \D'_$MO%?\U+_ ,#E M_P#('ZK?8+G_)][C_O@_P"%
(JK,KA6BD5FZ*5.37Y5?\8OCE_T-5G_ "B MW_\ B:CE_P"']_QNFE61O$]BS)C:3I%OQ_X[2_XC9D7\M3[E_P#)#_XENXL_ MFI?^?R/\U:^P7' /O- P!\ "C[!?\ [Y/^%'V"X_Y]Y\
OD_X5^5)_P"'L7QRQ_R- M5G_X*+?_ .)H/_!6+XY8_P"1JL__46_P#\31_Q&O(?Y:G_ ("O_DA_\2V\ M6?S4O_Y? ('ZK?8+C_GWG_[Y\ A1]@N\ GWG_ .^3_A7Y4G_@K%\ M+/YJ7_@0_P M3_P%?_)!_P
2V\6? MS4O_ .7_P @?JM]@N?^?>X_[X/^%'V"Y_Y][C_O@_X5^5/ _]B^.7_ $-5 MGT_Z!-O_/$T?\8OCE_T-5GT_Z!-O\ _$T?\1KR'^6I_P" K_Y(/^);>* Y_MJ7_@Q?'+_H:K/I M_P!
FW_^)H_X>Q?'+_H:K/I_T";?_P"M_XC7D/\M3_P%?\ R0?\2V\5_P U M+_P.7_R!^JWV"Y_Y][C_+X/^%'V"Y_Y][C_+X/^%?E3_P]B^.7_0U6?3_H M$V_ ,31_P /8OCE_P!#59]/^@3;_P#Q-'_$:\A_EJ?^
K_Y(/\ B6WBO^:E_M_P"!R_\ D#]5OL%S_P ^]Q_WP?\ "C[!<_\ /OQ?'+_H:K/I_P! FW_^)H_XC7D/\M3_ ,!7_P D'_$M MO%?\U+_P.7_R!^JW]GW7_/MQ;;R,Z/\?^.TO^(V9%_+4_\ 5_\ MD/\ XEMXK_FI?
^?IR_P#D#]6_[/N?^?>?_O@_X4GV"Y_Y][C_ +X/^%?E3_P] MC^.7_0U6?_@HM_\ XF@?\%8_CEC_)&JS_\ !3;_/Q-/_B->0_RU/\ P%?_ M "0O^);>* YJ7_@*_P":E_X'+_Y_5;[!<_\]Q_WP?
/L%S_S[W'_?!_PK M\J1_P5C^,6/^1JL__!3;_P#Q-'_#V/XY ?\ (U6?_@IM_P#XFC_B-F0_RU/N M7_R0?\2V\5_S4O\ P.7_ ,@?JM]@N1_R[W'_ 'P?/L%S_S[W'_?!_PK*^4 M/^">G_!3UOC)?Q^#?
B)=6MMXGF<_V=J6U88=3!Y\IE&%24=%P,,!V;AOMG<' M7W%?HV0\08/.,*L7@I7B]T]&GV:Z,_'^)N%\PR#'2R_,HARO\ 9]U_S[7'_?!_PH_L^Z_Y]KC_ +X/^%=VCF5KK9-!+//V>O%'Q<\?
>,O&8U7PGXGM(/*MUTP_9A:1IK2G?I/V-8F#(#& M28RRA_-YY_\ :)_9UU+5+KXY^'=2^"_B;QC\9/'WBN;4? ?CVUTI)K?3;1Q; M"Q=6=)SIPLO**M$61F\DE582C/Z+3>+[&.&20M=!8;>*
[;%G,3YZCM'Q:RL/,D"E0#MY7YURXR]\D$$ ^'O MC1^S+XPE_:X/@*U\ZIJGPW^-6M:!XR\8ZK#9_\ $IMKC24;[?;S$#:C7QM- M+&&QO'G#&.0CD<@D'-?I-%XEM)KF&%3<>9<3RVJ?Z-
*,21[BV25PH^4X8 MD*W&TG(S#'XPT^6QCN%^U&&&6S>]7-G,&,28W979G=R,(1O/.%/ #YC_ &0O M@U\5OA_^S!I/AVUT72?#VAZYXBU:YDT/7-8NH=4*^';J\=[6RMI;7?MN8K9 MVP/,'E,4
8%3CPFZ_9#O/ W[.NO:3#$X\21Z+X3^/FI:]IFDR>$)/%-G>Z:8 M)(89[G3GN8)[VU/F[EDB>1Q*(Y"&59&7]%I?%=C;";4'81[=@)"5[Q61;>*+26XAA3[3YEQ/-;I_HLJCS(MV\$E<*/E.&)"MQM)R,
MQ1^.+&33TNE-Z87L6U ?Z%/N,*XR=NS=OY'[O&\ W- R@G K?QE9Q:A<6K M-=>;9V:W\)O HV&\@N9C$5MCYTJK,I9H_L^P8EA=SMXV'A'Q9XHMVMJ%U'PWX@\9
M:OX=@T_07CUZ]GNI=0B@9IW9EDA83K,BK#AREN9L+]=N,;?XONYXSGBDM]?M[AHU7S]TS2JN;>1JV_CC0?C-%I-M>?$2\N(]8TJ'27>.231[O1&BA_M.:]N%01+=!S>E0S)(
M&CM1$H0L&\KT73/BEX"\ >&]%T:Z^(FDII=O>VT32:+J.KW$NLK?OA9=TD:& MW,'EF.2=_L3*\I+A@K#[2'BJQ>U\[_2/+-F+[_CUEW>4?;;G=_L?? V:DN=? MM[5YE?SO]'DBC?
%O(W,I"IC\C+#)&0O\6 ": /GGQ)X1\;:UXIURSL9O%WA M_3;B]\1WOF:-;K9 :Y5ALOL+-((LME_-*'(,A0JQ= RGWGX5:AJFK_*WPW>: MY"]OK5UI=K-
J$3Q>4T=PT2F52G&TARPV]NE7TUVW>XCA_?%FN&M1F"3'F*A< M\[<8V@_,?E)X!)(%%OXCM[@1A/M'[X2E/W$@SY;;7SE>.>F?O#EG_ $67=Y39QQLSNX/R?>'=14ESXA@MS.K>=NMIHH'Q!
(WS M2%0F,*0+O56<\[< 84_,2%) MP 22 6P>)K:>.%E^T8F2216[9H U**R/^$KM5A:3=<; M%MDNV_T67/EOD+QMR6^4Y7[PXR!D9EE\00PO,K>=NMYX[9\02'YY-NW!"\CY MURPRJ\Y(P<
&E16:GB"!F&-6GW37#VRYMY,;T5F;)VX PIPQ(4\ $D@&.+Q M1:SP1R*UQMDA>X7-M*#L0@-P5R#R,*1D]@>P!K45DR>*+6)9&8W.V.WCNFQ; M2G*2$A<#;R0_O'"E<';ROSKEAE1SD MC!P
:5%9L?B*WDGAC4W!::>2W7-O(!O0,6R=N /E.&)"GC!.1F&/Q7:RV:7 M:X\N2W:\'^BRY\M<;N-N=W(PI&X]AZ &Q167+XFMX3+O-Q^YABF;%M(V5D9E M7&%Y.5.0.5X)
!!*OXBMUEE3,VZ.ZG6/[B3_%C*K#G;@KAA\PRH.03D$ T MZ*S4\0033PQKY^Z::2\,V\@&^/.[}*X ^4X)(#=B6UHUZ M/]%E\!HSQMSNY'R8W'TH V**R[GQ;VLDJR>=^X2*1\6\C<2,57&%YY!R!D
MKP2 "#0?$-NLQCS-N6Y%H?\ 1Y,>84#CG;C;@CYON@\9R"* -$MDU\1?\%R. M?@+X/_[&$?\ I-/7V?#XAM[FXAC3SMT[RQIF"1?FC)#9)7 &0<$D!NV:_; MD_9VL_VUO"/ACPS;>))?#UW'<_VU
\ND3W FB6%T*L,QB-OW@(#D,<$;>X^5 MXTRZOCLEKX7#1YIRC9+:[NG^A]?X?YIALMXAPF/Q9AOE*A,$388?.N2N0O.XC!Q7_ !"_B+_H' \ )E_F M'_$>.#/^@E_^ 3_R/A+#?
Y%&&_R*^[(_^"*,TT\<*_$Y=\ET]DN?"TX'FHC. MV3YV N%;#GY"< $D@%L/_!%22Y$+\3EQ<0RW"9*SK\D9 ?.9?E.6&%."PR M0#S4_P#$+^(_^@?_ ,FC_F' !'G&B\)?\ X!/_ "/A7#?
Y%&&_R*^YG_X(MMM#9R3M\3OW<=I'>MCPG<%A$^0OR^;DM\IRGWUXR!D58D_X(F7$4TT;?$Z/=M;W$5J^/"\Q'F2;2N\L,OSKEAE5YR1@X/^(8<1_]_\ Y-'_#'_,1XX_ Z M"7_X!/\ R/A'#?
Y%&&_R*^[(O^")\\\4:_$U=TUU)9IGPM.!YB*S-DF; 7" M-ASA6X)) ,<7_!%AIDCD7XGC;-;R7:Y*7_=(5#9!EX;YAA3\S8CS75&&#YV"N'7+C*CD$@@@' $+N(O^@?_ ,F7^8?\1XX_ P"@E_\ @$_\
MCX1PW^11AO\ (K[L@_X(GS7,T*1_$Y=TUS+:)GPM,!YD8;?DF4 +\C8;D-\PPA^<]E.#B?^(8<1_\ M0/\ ^31_S' Q'C@S_H)?_@$\CX8PW^11AO\BONJZ_XJRV44K2?$Y<0PQ3O
ML*SL=LK%4P!*23E3E1EE&"P (-/;_@B9,MQ)&?B?%OBNDLV \+S8\UD5P ?.M.P5VL/G*R@Y!.00*_P"(7\1_]__),O\Q?\IXX+_P"@A_\ @$_\CX2PW^11 MAO\ (K[KM_\
@BC/=S0QQ_$U=UQ/+;IN\+3K\\6X/DF8!0"IPQPK<;2&_R*,-_D M5]UVW_!%&:\EMXX_B:NZZDFBCW>%IUP8B5?),P"@$'!; 88VYR,P?\.8B-.^ MU?\ \ "SF\G[
=1_Y%*YW>0!G.WS=V_P#Z9XWG^[4_\0PXC_Z!_P#R:/\ F'_$ M>.#/^@E_^ 3_,CX;PW^11AO\BONRJ_XGS:<;A9/B=&6M3"LFSPM._K;4Q MMF.[GKC.T3_ ,+.C\S[5]CQ_P (O-CS?+\SKYV-
NW^/[F>, M[N*K_B%_$?\ T#^_3+_/^(\<&?]!+_\ G_D?">&_P BC#?Y%?=E9_11FOY M+=8?BK$4 M#_@B;,UR(O\ A9R;VNS9#_BEYL>:$,AY\[&W:#_W,\9SQ5?\0OXC_Z! P#R M9?YA_P 1XX+_
.@E_P#@$_\ (^$\-_D48;_(K[JL_P#@BG+?O"L?Q.7_$A9 MG3?X5G7Y8F"OG,HV_,1@-@L.5R.:CD_X(O-#9R7!^)W[N.Q&H,1X3N&80G.# MM\W)?@_NP-_^S1_Q"_B/_H'_/)E_F' !'C@O\ Z"'_ . 3_P
CX9PW^11A MO\BONRZ_XGS6LLR\35#0SQ6S;?"T[/*5V8(F((^9=Q&#@3_@B?-+ M,J+\3EW2736:Y\+S >;J,YY\W&W"M_W"< $D@$_XA?Q%_T#_P#DR_S#_B/_M!3_02_\ P"?
^1\)X;_(HMPX17W5:_P#!%62$\$E_$Y<7$4TZ;_"LZ_)$RJ^< MRC:6Y0GPI<*?+C*A\@S<-E MAA3AFY*@@$B#4O\ @C0VEI(TGQ.4K';W38*W&1&Y(4@*4EFX.4'$#N!FI_MXAAQ'_T#_P#DT?\ ,?
\ Q'C@S_H)?_@$_P#(^'L-_D48;_(K[LF\GS6\TD M;?$Y=T-S':-CPO,P\R0*R\B7!7#+E@=JG()!!PZ#_@B7/,@9&:_XA?Q'_T# M_P#DR_S%_P 1XX+_ .@A_P#@$_\ (^%\-_D48;_(K[LE_P"'')\T,\D3?$Y?,
MBNDLVQXF7B8ZJZC(EP5VL,N#M!R"000'6W_1.FNY(5C^)T>9[B6WCSX7#M4;XBP?),W RC88X5N-1.IF?^(8<1_P#0'_Y-'_?_$>.#/\ H)?_(!/_(^$ M<- D4Y?
EZU]R+_P1>9[&.X X6=^YDLWOU)\)W ;R4V[LKYN0WS#'$;SSA3@X MDN_^"*LMD;CS/B:NZV2%Y,>%9VXE8JF,2_-R#D+DKU; JO\ B%_$?_0/_P"3 M1_S#_B/'!G_02_\ P"?^1\5^"?"&K^/?
%VG:1H%G=7^M7\ZQVEO;#]ZTG4$' M^'&"Q;HH!)P 37[@?LU^%O%7@WX*^']/\:Q'KOB:UMPEY>1H5#MV!)Y8JN% M+X&X@M@9KR;]BG]B/PK^QO;7DTEY]X@\67ER-/N-5;3I(A&& D2*)?
FV1[64 ML^X@MP6&-H^@;3Q-:W3PK']JW3R31)NM9%YB8J^&? M];)*,J^,D_:36L4_=BNE[:-^9_+7C-XF8?BC%QP^ @O8TG[LFO>DWO:ZNH]E MNJV;$0VK^-.K"7QS8FQ%SNO/):Q;40?
L,VXPC!)V[-V[G_5XWGLM2W'B^TMI M)U=KK=;F$28M96QYK;8\87YLGKC.T=F>,YXIMKXLM+IXUC-UNF,ZINM95YA;9)G*\8;H3] M\B^)M4\1Z]?>&5M9#=ZQJL=_6Q:[(&T$4 ?
3]WJ5O8&+SYHH?.D$47F.%QST1< M]6.#P.35CSA7QOX L?'VJ_8;C6+3QIJWA_2_$7AK5H3J.GWS744K?:(;YD6Y M47+JDI@9@(HHT4LZ11QY:CX/:7\8];2UL?$FN>.ENKRZTI/$RPZ+<:?'979F
MF-Z+:[EN)5DA9 J,UG'';JGEM&R2%@@ #[):3!Z&E5MRU\Q?!;P7XDL/C]X'U M?Q'1'XXFFATCQ+HD-S<37DEN%AUQ7'?\ H!!?^"X_Y'K?_#>_QF_Z M*-XC_P"_J?\ Q'- WO\9O^BC>(_P#OZG_Q->2!
<8H"XQ3_-9,U_Z")_\ M@3_S#_47AW_H!!?^"X_Y'K?_WO\9O^BC>(_P#OZG_Q-'_#>_QF_P"BC>(_ M^_J?_$UY(%QB@+C%+_63-?\ H(G_.!/_/]1>'?^@&E_P""'X_Y'K?\ PWO\ M9O\
HHWB/_OZG_Q-'_#>_P 9O^BC>(_^_J?_!->2!<8H"XQ3_UDS7_H(G_X M$_/\ 47AW_H!!?^"X_P"IZW_PWO\ &;_HHWB/_OZG_P 31_PWO\9O^BC> M(_\ OZG_,37DFW>:-O\\TO]9,U_P"@B?\
X$_\P_U%X=_Z :7_(+C_D>M_P#+>_QF_Z*-XC_^_J?_$T?\-[_!F_Z*-XC_[^I_\ $UY)M_GFC;_/-/\ MUDS7_H(G_P"!/_/]1>'?^@&E_X+C_D>M_\ #>_QF_Z*-XC_ _J?_$T?\-[M_&;_ **-
XC_[^I_\37DFW^>:-O\ /-+_ %DS7_H(G_X$_P#,/]1>'?\ H!!? M^"X_Y'K?_#>_QF_Z*-XC_P"_J?\ Q'- WO\9O^BC>(_P#OZG_Q->2;?YYH MV_SS3_UDS7_H(G_X$_\ /\ 47AW_H!!?^"X_P"1ZW_PWO\
&;_HHWB/_OZG_M_P 31_PWO\9O^BC>(_\ OZG_,37DFW^>:-O\\TO]9,U_P"@B?\ X$_\P_U%X= Z :7_(+C_D>M_P#+>_QF_P"BC>(_^_J?_$TUOV\C6[!F^(GB(LO(/FI M_P#$UY-
M^7%&,YH_UDS7_H(G_P"!/_/?HO#W3_TO_!(_P#OZG_Q-'_#>_QF_P"BC>(_^_J? M_$UY(5SF@KG-/_63-?\ H(G_.!/_/]1>'O^@&E_P""'X_Y'K?\ PWO\9O\ MHHWB/_OZG_Q-'_#>_P 9O^BC>(_^_J?
_!->2%(_\ MOZG_,37DA7.:"N_P"@&E_X+C_D>M_\-[_& M;_HHWB/_+^I_P#$T?\ #>_QF_Z*-XC_ _J?_$UY(5SFEI?ZR9K_P!!$\ MP)_YA_J+P]_T TO_7'_(]:_P"&]_C-
_P!%&\1_]_4_^)H_X;W^_W_11O$?_M_?U/_B:\DV_RQ1M_EBG_*R9K_T$3_\G_F'_47AW_H!I?^"X_Y'K?_WO M\9O^BC>(_P#OZG_Q-'_#>_QF_P"BC>(_^_J?_$UY)M_EBC;_ "Q2_P!9,U_Z M")_^!\
S#_47AW_*:7_@^\1ZW_PWO\9O^BC>(_\ OZG_,31_P -[_&;_M_HHWB/\ [^I_\37DFW^6*-O\L4_]9,U_Z")_^!/_##_%%X=_Z :7_@\N\ MD>M_\-[_!F_Z*-XC_[^I_\ $T?\-[_&;_HHWB/
+^I_P#$UY)M_EBC;_+% M3_K+FO\ T$3_/_G_F'^HO#O_0#2_P#!G[U./_':\FV_RQ2@?R]*/]9,U_P"@B?\ X$_\Q?ZB M\/=,%2_\%Q_R/6O^&]_C-_T4;Q%_W\3_.)H_P"&]_C-_P!%&\1_]_4_^)KR
M4+C*0+C%'^LN:_]!$_)_YC_U%X=_Z :7_@N/^1ZW_P-[_&;_HHWB/\ M[^I_\31_PWO\9O\ HHWB/_OZG_Q->2!<8H"XQ1_K+FO\ $3_M_P"@G_F'^HO# MO_0#2_\ !M_P#+>_QF_P"BC>(_ M^_J?_$T?\-[_!F_Z*-XC_[^I_\ $UY(%QB@+C%'_63-?^@B?_@3_P_P!I_P"X_Y'K?\ PWO\9O\ MHHWB/_OZG_Q->2!<8H"XQ3_P!9_U_Z"
)_\ M@3_S#_47AW_H!!?^"X_P"IZW_PWO\ &;_HHWB/_OZG_P 31_PWO\9O^BC> M(_\ OZG_,37DFW^>:-O\\TO]9,U_P"@B?\ X$_\P_U

MO%=K8RW"R1ZBS6TL$3[-/GD!,S!4VE4(=06&YER(QDN5)&H47]/NCVK%MO'NB77A.YUY=4L6T>S M,XGO/-'DQ&!VCEW-T&QT=3Z%30 __A.;%K%KCR]6\M+%-0(_LNZW^4^< +Y>
MXR_*"8O&5&1F6Z\5VUG)<*T>H,UI<06TFRQG<%IB@0J50[U!==SKE4&XN M5"L1S?P^ .:%\&?%7Q)>:3X=\06FK:EIJ[[JWA1 ,MN%/S@J-I(=#@\D,"!@Y MKJ=!US3
!)IWVK3;RUU"U\V6'SK>59(]\(_$&G^%-,6[U"ZM[&U::&V$LSA4,D MLBQ1)D]VD=% [E@.]:"Q*R ,M &1_P)O8BUDF\O5-D=G'?D?V9<[O+DW!0% M\O)D^4YB \Q>-RC(S/<>*;>VEN%:/4-UO^:
,>;QG9P+([1ZIMBM8KML:;H;KBYEM$)LU4/&&++%F*85/D.UV(1^ K,6 M7, 4'3+E9/+3;D%#'N$GS#$1'F-SA3@XV/+7],4>4O MJWO0!DS^,+2V,VZ/4O\
1X(;EMNG7#925F50N$.Y@4.Y!ED&"P4,I+G\56L< MTT?EZANAO$L6Q83E3(Z*X(.S#1X<9E&8U.X%@58#4\M?2CREVXV^U &;#XHM MI;FWA6._W7$\UNA-C.JAXMV[.K%].2Z\O5O++Q;4
M0#I=T)/*7&04\O<).1B(CS#SA3@UM>4H[>U'EK^N?QH R[KQ9:V3W"M'J#?9 MXX97V6,[@B5F5=I5#N(*G+8DBPG*^84$@(. MS!CVL,RC]V#E2P8$#4\M?
2@QJ/X?:@#*A\2VMU<6\:QWVZZDFBC+6,Z*&B)5 M]S% $!(.UF(#C!4L'#7A7[7WP#\. M@>#]-T_5=0\3#N5Y& &OHJII,[3O&(G M38T3Q%A)A\^5M\TG^"OH9A@].O6OBS_@LUXRUCP9\
(_#,VCZMJ6D3RZXJ22V M-T]L[K]GF."R$$C.#BOF>+L1A3CR]O'FY\O=\N[M=\M?"(^._CH?\SIXP_\ !U+_ /P=7'_Q=?SG_K=PA_T+ M/_)V?
UY_Q#SQ$_Z'7_DI]WVO_!&#P#>7%O&GC+QH&NC,J%]/$:@Q-M;_P!D_;O^$P\?>3]A_M"]C-YWE8SM\ÒR-_F_],=O MF_[%?#/_O;QS.TW.XC#_P '-Q_\71_PO?QUV\:^,,]>=:N/_BZ/];N$/^A9
M_P"3L\/ B'GB)_T.O_)3[ON/^"+W@.UFN$;QCXV9K5H48QZ?O4F5MJ;2L1#C M)^8J2$'+;1S2#_@B_P" C7M'^MSY9;"[MOQ KPG]AK_@I'X@^ 'C3[!XQU35/$/A'5) +E[N=[FYTQ^GFQELLR]-R9Y
R M.1AOU<\)^*-.\;^'+35-+NK>^TV_A6:">)]R2(1D$'TK]*X1RO@_/\.ZN'PT M8SCO%MW7GOJO,_&^/,Z\0^%,6J&-QLY0E\,XVY9=UJM&NJ?J?#EI_P $7/ = M]+;I'XP\<;KE9F3?
IOE@")@K[BT0*$DC:&P7&2NX D5Y/^-'OP_BTIKS_A+_ M !]Y*V2RG6'8R>402!Y?D;_ #>.8L>8.ZBOOW RWOUHVCVZYKZ_B''#G_0 M+'[W_F?_P#$7../^@Z?X?Y'P3/ ,$6O =O,/&^ZWGA@3;M
MVL(L,@WCE&Q=N-H]*/^(;\.?] L?O?^8?\1=XP_Z#I_A_D? L M/_!&/P#<"$KXO\=_OK>:[7=I17"1,JL#F'Y7)<;4.'<9*JP5B"?__((S> 8+ M22X;Q?X\\N&UCO&"Z2S/L!Z"DVKGH.N:/^; M\.?] L?O?
^8?\1N?O;:/;IB@JI'04_^(<<.?] L?O?^8?\ $7>,/^@Z?X?Y'P(G M_!&CP!)"DG_"8>/-LEI+>KG26!$<94,")/R)/F&V,X=ADJI .(-1_P"".?@+ M37^;QEXZ9%@AN'VZ7N;;*Q5<*(26;@[D +(,%@H(-?
H)M7VK%U@;?$%KC_9_MG3_XAOPW_P! T?O?^8_^(O<8?]!T_P /\CXAD_X(N^ TN9H6\8>.-\%U'9L1 MIN5,CHKJ0PBPR8<9D!**(N M'+$Q (AV-M=L*_R[2VY< >QC4^G3%*44CM1_Q#?
AS_H&C][_P_XB[QA_T'M3_#_ "/@(_\ !&SX?BT6?_A+_'WER64FH# B4-N\I-NX%?)W"3YAB(CS&YPI MP<27?_!&'P'9K/O\8>.O]'2%WV:7O.)6*IC;"=Q!!W! [Z:W6/QAXY5KJ:>"/? MIGE@-"S*Y8M"
BDJ=K-A9!@H6#*3][^6I/Z=*4Q CM1_Q#7AO_H%C^/^8?\ M$?>,/^@Z?X?Y'P"?^"-?P_%E]H_X2_Q]Y;6+:CC^QWW^4N,C;Y&[S>1B"'F' MLIQ4MU_P1>\!VK3*WC+QU^Y\C=LTO?\
ZYMB8Q"=V#[];GRQR^TQ12>WITI2BD=J/^(;\-_] T?O?^8?\1=X MP_Z#I_A_D? 4O_!&WX?PV)N6\7>/O+%@=2!P-8OY(&;_TQ \W_ &*G MN/\ @BYX#MI9%;QAXXW0O!SVS3-XS,P5,$0D$
D;B,B,9+E0":^]=H]NN:7 M]1_Q#CAS_H%C][_,Q_\1=XP_Z#I_A_D?I(_P""+7@/[1Y/_"8^-MWVO[#G M^SOE\S9YF=WE8\O;_P M,[-KWR[MW%-M/^",/@&]:!4\8>.@;@3[-^E[,>2^Q
M]VZ$;7#8#4V TABYA()P$\G_\P_XBYQA_P!!T_P_R/@J/_@BSX#EG$8\8>-PQNVLAG3= MJ^8$+DY,6/+P#B3.PG"AMQ J.V_X(Q^ ;MH-OB[QX/M$<\B;]**8$+!7W9A&MTDD;0V#(,E P!
(^^2JD]!Z4N!Z"G_P 0XX<_Z!8_>_\ ,/\ B+O&'_0=/\/\ MCX#?_@C1\VKZ2-X_X2[QYY<-BNH,!I+%S$V[51#N:7Y3F)09!QE1N7+-6_X M(V>])NFA?QCXV++<16S%--W+OE*A-I$1#*-XW."43DN5
./O_8H_/-8WB=<M75]!TY_F*/\ B&_#G_0+'[W_)C_.(O<8?]!T_P_P CXCA_X(M> [BY2-?& M'C?=)=/9C=INU=Z*S$DF(}A3B0_(QP Q) ,-M_P1F\ 7*6[+XO\>?Z1#-<)
MNTEE(6(JKA@8;+6TCO7"Z2S,8Y-VT*HAR\GR-F M-077Y=RC@51V'K0$5>PJ?^(;\.?] L?O?^8?\1=XP_Z#I_A_D?!-O_P1;\!W,T,: M^,/' ::YEM%WZ;L7?&&+$DQ *GR';(<(_&UCN7,4'_!&CP#-
;V\B^+O'FVZM M9;Q-VDLK!(RH8,##E'^===L; ._S;5;:U/OLJI_A6@JI'04_^(<<.?] L?O?^ M8_\ B+O&'_0=/\/\CX&F_P"",G@&WAN)&\7>/"MK;173[=)9B4E+!0H$)+N- MAW(N70;2P4,N7W'
1;\!VL\D;^,/&^Z.ZCM&*:;N7?(%*D1%/F&9!E%. M0S @@?>P50.@H"J/X5H_XAQPY_T"Q^] YA Q%WC#_H.G^'^1\$VO_!%OP'=S M0QKXP\<;IKB:U7?INQ0\6K,26B 5/D.USA'XVEMPS'#_ ,$9O
$UI;S+XO\ M'GEW%G)?H&TEE81IMR&4P[ED^<8B8"1OFPIVMC[Z**>PH*J>P]:/^(<<.?\ M0+'[W_F+_B+G&'_0=/\ #_(^!KC_ ((R> ;43[O&'CH_9HH9GV:47RLK,J!< M0G>7-8MJ*@Z.P<1
2"OD[EE^88A($IYPG!Q)^%/%84%5/8>M'_$..'/^ M@6/WO_,?_$7>,/\ H.G^'^1\#W/_1B\ VAF5O&'CK_$=#8>$+2!+(TWY?,"3.[RL>7M/^LS MY>[Y=V[BOO?]!2!5\
(]*/^(<<.?] L?O?^8O\ B+G&'_0=/\/\CX)M?^"+ MG@.\EC1/&'C@--+/"N_3-@#0L5?),0 4E3M8X608*%@03#' _,$:_A_+8)7)I_P#:0!T=@XAP#@H8-PEY_P!21YO4;,@UJ^%%/84;1Z#KFC_B&_#G
M_0+'[W_F'_$7>,/^@Z?X?Y'PKX=_X([?#GPOXIANM2U[QEK5GIT]NJQ8MI[> M3=B5MJ(6CBW,N3A]A^1\TOP_!;Z;8VES:V]O,NFP10Z=,D,16+ M>
,)M6,*,"3B/.%#;N<Z#8!VINP!Z8S7NY/PWEN5*2P%)4^;>V[^;N[>1\S MGW%F;YU*,\TKRJ..BOLK[Z*R^8Y5+_-^E24 8%%>X?/A1110 4444 %%%% ! M1110 4444 ?"6D? OXF3?&C7M-T^3Q]X-
\.^+OC5K&H:OJ6B,MM)<:._AZ)8 MIO,96 B>ZC6,.!N#C*E6 8<=X7_99^*GQBU[PGXB\96OCF]\56WP6\3:#*^I M3K#"VI27(MK6"<8"B2>W;>YR/,,2.V"O/Z.E :0(H_\ UT ?G3-XG^.GAKX2
M_P!AZ#X/^,%K)JG@GP;9Z(EK:I"X?NK*Z:'5O.S*#$[1!/E4.98R& (!([S MX<:?\?A^W=K5QKVL>.X_#IU[5533X]$BD\.R:#Y#_P!GE;LW@C2;=Y.1%;&Y M\T.')BRQ^VO*4?GGK1Y*X^[0!^>?
PZTSX[_#;X5PZAXDD^.7C:;6OA#_&AJ MVE17BP:A#X2D1MQM;654#6LAB>4.1N9D1G;>ZY.)XF'Q[M%/V6/!.C:(WQ^U
M+Q%'HVNWU]K=U#+%>OKBK$UG:O;^8DWV8&27R9)YS"5@(DBG=T4?I/Y2^E'D MKCI0!S?PDO=6U/X7^&[C7DDCUZXTJUFU))(Q&R7+0H905 4[]W & :Z:D5= MM+0
45DZCX@72Y1HVAOIO)M&NB8;1Y%8*<%5*CYI#V0?,>PIMUXJCLWN%:VU M)_LY@'!_=E(V[5SVC;@?-MZN1]P1>Z7(2=1M+J6::-W0K%;QB2X 5CM9I].^#?CR'X:1Z
M9)X:\83Z/>>+HKB72;O6++[7:6*V)1G2*&]2$1&Y"L8FNY>2TOE[CL'U!_PD M$;'?Q_9]0W-=FSS]DDV[@A?>3C'EX&-_W=V%SGBFVWB..YDA5;;4D\YIT!>S MD7;Y3%6W9' ;&4)^^.5R*
/E/X8[?;=KO#);7$3MF83*V$&MX+^!7C#4[464Y>+YCN^D%\90/9>?]AU8* MUBNH;#1\V_:>=FW;GSAWB^^/2I+SQ%#;/#--TS2=\037&D+J_P#8EY#K\;/I[G5YI;+S M&EO4
4626RQN$N'VLT;>2 PDJ!U_P/K7AK]E#7-+U#2;NUDTGQ;+JT\;%+C[M?I@\0_VA(\:Q.Q*O:%QL8!\[@4Z!OR[BUN(PLLTD7F;4#+'M"K=T?X#?%.M:*'Q!=?
\)9)J6I:1ZMJENCURUM[36;B:\1[22W*3&=7CA#]T'D%MY;/8@D4J M8_JM?$,;W4RE4KY3 $,,9#-G*@\N,D9 H ^>]#_9OU+P7^UM8^)#X=U. ^*Z/ M?'W\)E++W+ZPLYTJ"YT_3"9]LUQO\DW5O>!E
9]\F[RRK%QZE^R-IEUI/[//AU; MN.> W N+RWAF0I);6LUQ+-;Q,IY4I"\:8/(VXKKCXKACMI)/L>K;8[..]VBP MFW%7+ (!C/F#:2X0V^H-]GN8K5BEG(P=I-F&4X^9!O& MYQ\][7R1M.
#6HK)B\2K+=PQ?9]0#37,EJ";.155D5F+LV,+&=I"N?E8E0^2 M14<'BV.XM8YOLNJ*LEO+A6T^42*J8RA7;D2G/$?9N<#@'T ; ME%8]QXI2W$VZUU-O)@AG.VRD;<)&90JX'+J5)91RH*D@
@'TI\2HD\J?9]2S# M=I9,192%69E5MZG',0W@&0?*'K G*G !KT5DP>(UGNH(OL^H*UQ/+ "UI(JH M8]V69L853M^5CPV1=GQ(J%/&D;Z[\2):/.K6NHN;=(9#Y=G(X<2,5 4@?,RE$]-TW6IO%6EVNGJ-
>C^Q6!^T/MA9?**.C'S"'/[K&_(Z5\OQEEE?, M,GKX/#*\Y*R3:75=6?7\ YQALIS_V88MODIR3;2N[>B/QS P** 1Z_P"" M+W@&RGN(V\4>/&^R^3N:.TB=7\UBHV$0G=M(RV,[
03@4W_AS!X!%VU^_"4> M/MWVO[%G[)%MW>7UF_=/*QQYGW=WRYSQ7\S?\ $'^(OY8_^!+_ #/[0_XF M(X1_GG_X QX3Z:PPM?I!9_\ !%WP#?7%&OBKQZANC,%:2TB18_*;:=Y,/R[MCRI.-
XY7(YJK_P .1GSO\ IEC? M[4?\0@XB DC_.!+_/^)B.$?YY_^ , /GPKX6U'QKXAL']TBSN-2U/491!: MVT"[I)W/0 ?S[9)XK]B/^"?Q[+FK?LK? ^+1=:UFXU+4+R7[9-[]UMIK-R M8H?;G+'.\"W(
ZG*_95_88\"?LA:[JM]IL>NZ[KDC0P?;[VU\QX8Y3MV0;$"[M5@8\S[I; SDU^Q^&W MAW+)KX[']J])-))Z177R;?W(_GCQ@\78\3-9=EJMAHM.\E:4I+K;=)7]7UT- M>
(Y+4^L>S\1)>36ZK;ZA&;E9F!DM)$">4P4[B1\I8G*@XW@$C(%0OXTCCTPW M7V/6"BV*ZAL_^;S21!/E[,9\WCF/&X>E?KQ^#F]163/XCCM[BXC^SZ@S6\L M,+%+21EM?\C%;?
\!_G3H_%T;P1R?8]6Q) M:RW@!L)0P6,J"A&,B0[OE0_P!P#@UE:YXFCAU..9K75"(88)\1V,K,PD8@* MH RS+CYE'*@Y(&10!U]%9+^)%2YEB^SZ@S0W26I86DA4LZJP=3C#1@, 7'R@ MA@2""*+?
Q)'<-;]+?4%^U7$ULI>TD4(T1<%GR/E1MAVL>'W+@G<,@&M16&/& M4?V59OL>K;6LI+W,_9\N*F,H1MSYIW<1_>.#@'!IJSXJ2T24FVU)O)2%SLL MI&+^:Q4!0!R5QEP.4')P* -
FBLF3QG[J74D/V?4-T=VEH6^QR%"S(KAPV,&,! M@"X^4,"I(((1+7Q*MY+;JEOJ4?VF:>%3):2(J&)F4ER1\JMM)1CPX4*X?2_&ND MZYXEU/1[/4+6XU311&;ZU1LR6OF#*;A[CFJOQ ^*?A[X665K<>(=4M]+AO)3
M# TBLWFN%W$ *">%Y^@J98BDH.IS*RT;OI>]K7]1QPU5S5/E?,[.*SO9]_N MU/1/^$GL_P#GJ?\ OAO*!XGL_\GJ?^^&_PKC]!URS\4Z1:ZAIMU;WUC?1" M:WN++P\&X=8TZ\AN]+N(VECN8\
[71<@D<9_A/Y52J0;Y;JY+HU%'F:=O^'_R. MT_X2:SQ_K3_WPW^%'_"2V8_Y:M_WPW^%>8^ /CCX3^*>J7%EX>URUU2ZLT+S M1Q1R*8P" <[E
'++QUY%;B^);&3Q))HZW49U2&V6\DML_.L+,460\8P6S_\UU5AS MD5-.O3G'FBTUM=.Y53#U(2Y9III7:L[V.S;Q+9G_ ;'_OVW^% \36?_#U/ M _?#?X5YWX_\ BIX=^%EI;S^(M9L=)CNF*0>>_P
TQ7[VU0"QP.I P,C.*U]) MUBSU_2[>^L;JWO;.ZC$L%Q!()(YD/1E8<$?2JC6IN3FBFKK==294:B@JC3Y7L M[:/YG?7\)/9_\]3_-\-_A1_PD]G_P]3_WPW^%:E?SK: MV-A"UQ<3,"5BC499CCG@
]C5RDDKO8B,6WRK--)O=;M=-@U"UFOKRR_M""%3N:2VW!?-';;EAR3SSC--US MQQH_AK6])TV_U"UL[[7)7AT^"5L/=NB[F51Z@<_IUQ6?MZ=N>ZM=+?]S18>J MY2SP9TMY,M&IR%;:
M<$J>S#*GL:C_P#"2V>/]:?^^C_+_PI1XG ML_\ GL?^_;?X5YSX_P#BQX,^%D%O)XBUK3]'%X6$ G?YY=N-Q^C)P,C)Q@9&
M2,UM:=J=MJVGPWEK<0W5G<1B:*>%Q)'*A&0RL."".Q_[]M_A1_PDUG_SV;_OAO\ "N.\,^(K'QAH5KJ6 MEW,-]87R"2">/[DJYQD9&>HK+LOBQX:U*UMYK?6K&:.ZU(Z/&48D-> L#!TR
M),JW!XX^F5]8I))N2UV\T"P]1WM%Z;Z;>O;9GHO_DUG_SV/_?MO*7_A)K M/'^N/_?MO*X?QAXSTOX?^'9M6UJ^AT[3[8[];B4':A9@JC@$\L0*C\&>.]) M^(>B?
VEHMYJ%CYC1>:J,@W#&\1A@#D9'.,<]Z?M8<_L[KFWMUMW#ZO4Y/:Q_[X;_"O=M.^,OA76O\,WANU\0: M7<:.] 71[-]I_[X;_H_X2>S_P"]I_[X;_"N:V"C8*T,SI?^$GL_^>I_ M[X;_
H_X2>S_P">I_[X;_"N:V"C8* .B;Q)9M_RT;_OEO\ "O'/VM_V8/#W M[7V@Z?H^N:IJVFV6GW@OHY;_QJ[.(G3!\Q&XPY/ SD"O0=@HV"N/&Y?0QE&6
M'Q*4H25FGL_4[LOS#$8'$1Q6$DXSB[QDMT^Z/DK_(?)/_#EOX8_]CXX_P"_EM_\8#_,$7/AB?^9R\;_\?=O_/K?^MZ* M/^(=_]L?Z^8?\14XL_P"@^I_X$>/_+*W[!?PZ_9\17FL:3<:GK6M7>
M7'>:HDDM(^98MD:!=W\1P6(XSCBOH%/$EFBX\P_P#?#?X5SU!7-?29=E>$ MP%%8?!TU"*Z+^OS/D,VSC&YGB'BL?4E4J/1RD[NRV7R.D_X2>S_YZG_OAO\ M"C_A)(/_)ZG_OAO*YK8*-
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
M=_&6N3P[=+UC3],M[23S5)D>$3B4;>H \Q.HP<\5E?&/X-W7Q2^)_@ZY^TZM MI^EZ3;Z@+R[TS4FLKF)I%B\L!E(L?\(_=P#//_QX4?\"/7G M_// ,>%>?
4RZC.FZ,KVWI<]*GFM:%95H[]/*NUK)+Z\TG7ETW5M:NKN&ZCUV'^SA#(BA6>TW[_#,KUVY&0>U>Z?\ "/79/^K_M /'A1_PCUT#_*K_,>%1_9=)1I)-KV>VW;KI^)L1:*T?B$WZZU#;2?
Z39B>03PF1BY200F- M8E\OD*Y^\,L.X^.7PPUCXC^) !,NE:A>Z1'I.HW%Q=W]FT'GVL;VLD:[!,KJ MV6(7 1C@YKU+_A'[S; J^G;<*\/ A'KS_GG_ /"L:>3T8T)8>[<6T]7U33] M):.QT5<\KSKQQ-DI)-
*RTLTUJ$]+T1S'PW\!:?\+O!6EZ#IGG?8=+C\M'F? M?(^269V. *Q8L3@ <],=/,OV8OAUXD^'&J:A;:UI.OVL,CWD@FEUV&ZTXB2Z M,J>5;*Y:-BISN(Q]X2=Z]S_X1^_YYK_WV*5O#MT1_JU]?
O"MI8"$ITYKW>2Z M5K6L[;W3?3H]U?5;KN][^AY3\5?#WB32_BKH7BSP_HJ M>(OL>FWFEW-E]NCM)$\YXI$E#280@-$589W8((!K:^ ?@*\^%OP,\,^'[Z2& M2^TVT"7#0G,?
F.O=@IJ@%B,]\9KO!X=O!_RS_P#'Q1_PCUU_SR_>%53P%.- M:5=-W=].FMK]+ZVZBJ9A4G0CAVE:-M=;NU]TUMI=[+U/.?@]X*U+PXCF]CJ?4 M(_*37/$61EVYW?=93G&.>M>A?\([>?__ "(*/^$?
O/\ GG_X\'J.#IQA M&$;^ZfKU%+.*CE*:M=]S[6T_R/*?B1X5\0;-\8-\)9:#HL7B;[/L^D3:>;V M.TF@+R)(LT:R?(<[2K D'&.9O74_"[0[SP[\/M+L]0T_0=+O88R9K\1HS'86 M[.Q:;$#S@9Y/&3DX&
<5UO_"/7?\ SQ7\6%'_CIX3_J_P W%%'!PA5=5-WE_MK;2RV\K],Y-7'3J48TG%>[97UNTOG;2_:Y3J&_LH=3LIK6ZC6:UN8VAFC89$ MB,"&4^O!(O[UI?\ "/7G_/%?^^UH_P"$?O/^>?\
X*ZI14DXO8Y8S<7='B? M/+WP=UWX=W.K7/B;:]U:V]OH.DR>>LQ?3[7>8Y#[CK2-)EE//M<@5@_M"?! MSQ\)2OB1=:UH<6BQP>&[:T;0U9/WMU<),EQ*8V5O&L19HTA)D&"O3 ^:OHK_ M
(1^_YY_P#CPH_X1^\Q_J__!X5Y=3)Z,L.W*R=]'9M]_Q__]B.>UXXEX MI*/,U;9V6VB7G;\6<-\;_EU\6?@WK_A^VF6PNM9T]H(VD.5B<@$*Q7^'(VG M':)YK,^&T7B35?%K:AKO@W0/#-
O9:;MC'*MQ'>7TS[PQ5)(*EJ.9"L-Q:!P MH&*]+_X1ZQ_JQ_WT*4>'KO'^K_\>%=$L#!UHUKNZ2736VU]._:QQQQ\HT)4 M:*S:;WNKVO:SMY:IGDGQ"\\>(]#^,UOXPT+0:?Q1'-
HC:)-9/>QVDMLPE\P2 M*TGRE&W%7&0V$& -[#X=Z'=:!\/=+L;VRT73[RWM DUMH\1BL:=R,E(5/(0$ M\9Z]>,XKJ_\A'K&; J5_P"^A1_PC]X?O1_^/BBG@80G*:;]Z^FEE>JU!:7^]
MCJ9A.=.$++W:*^MVEM?6VGDD<#^SOX1OO 'P5\,Z-]T*V^HZ::B&XC619%1M MQ/WE)!Z]C7C.C_LL^*/#GBKPOJEA'##!/XJEU37[$W"8 2YN'@NT.['F&&4(MZC+$*/C*M7U)_P (]>?\\ \ QX4?\
([=8_U7_CPKGK910JPA"5 _<5D_NW]4K M*5A\\O%*=2<+?O'>2:T;UZ>5[KS1YK^TWX)U3X@_!R^TW1K:2\U!KJTG2*.Z M2U=EBN(Y'VR.0J-M4X)/!Q6K\(-/O]*\#6]OJ5GK5C<1328CU;4TU*Z9,Y#-
M*C$$)N[M(6TM9?*]]> MYR2S";PRPUE9-M/6]W:_6W1=/F?/_A/X3^+0#OQY^W:?IO\ 8OA]!7N[_40= M62\T^^CE#[9;>W93-W3NRLY4J@RXRV0:IT3_.*N'P[=L?\ 5#YOJI:!X>O/
M^>*_]]K4X+!PPRDH-OF=]>GIHK(_=CIXEQ?\ /%?^^UH MIT5<_P"$=NA_RS7_+[6H'T^:.X\EL;^OWOZI*&[:@1458_L6?\ Z9_] %H_ ML6?_*9_] %J>>/X/<.5E>BK'IBS_P#3/_OXM'IBS_\ 3/\
M[^+1SQ[ARLKT58_L6?\ Z9_] %H_L6?_*9_] %HYXIPY65Z*L?V+/\ ]_^ M_BT?V+/_-_^ BT<\>X/<.5E> MBK'IBS_] \ QXM'IBS_/3/_OXM/'N'*RO15C^QQ9_^F?\ W\6C^Q9_^F?_M
\6CGCW#E97HJTNA7#__'5C;Z?4+<^GS6\ZPLJB20#;SGD\"J33V0(:*N'P M9_U:_@XXH_X1Z_P">*_\ ?:?T 4Z*N?\(]>?\ /%?^^UH_X1Z_P">*_\ M?:T 4Z*N?\(]>?\ /%?^^UH_X1Z_P">*_\ ?:T
4Z*N?\(]>?\ /%?^^UH_MX1Z_P">*_\ ?:T 4Z*N?\(]>?\ /%?^^UH_X1Z_P">*_\ ?:T 4Z*N?\(] M>?\ /%?^^UH_X1Z_P">*_\ ?:T 4Z*N?\(]>?\ /%?^^UH_X1Z_P">*_\ M?:T 4Z*N?\(]>?\ /%?
^^UH_X1Z_P">*_\ ?:T 4Z*N?\(]>?\ /%?^^UH_MX1Z_P">*_\ ?:T 4Z*N?\(]>?\ /%?^^UJ&\TR:QD59%52_W1NSGM0!#15P M^';S/^K4_P# Q1_PCUY_SQ7_ +[6@"G15S_A'KS_
)XK_P!]K1_PCUY_SQ7_M +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_ +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_M +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_ +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_M +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_ +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_M +[6@"G15S_A'KS_)XK_P!]K1_PCUY_SQ7_ +[6@"G5K0O^0O#]3_Z":=_PCUY_SQ7_ +[6K&DZ+<6NHQ2/M&%52 ?#W@[QAX@OQ$EC;Z/\[\Z9XANF639I=R!$QC?"Y) GB.5!'SCGKC%\8 M?MS_E\ 9_?&1O .N>-
])TGQ7'<6UH]G=+)$DZ\80^*/&GDV;4O#&DVGC:ZL]"U*U:*Q4275 MDDRXK.3,#YR%B$3T6O3-=_X)YWWQI_:P^+.O>,=?\5:,\/O$VJ>'M0MM"TJ_M_0[7]/WJ]/[WQ^U
MWEQ#9V=I$T\]Q-((XH(U!9G=FP%4 $DG@ 5\:ZIX)^*'Q0\,:O=>'=<\8:Y; M^%=8E\.:#)IWB6:&WUJ" SL+VY;[3://M,\=M)(EP6$U@6V7"EHVZ+3?AUX_ M^+>L>,(X1XBM8KJ:O/IEUNTE6
/3(/17RKIGPH^,&NZUXBNKFW\6>'[*4M(OK4VMIXFVS(6-]UF+0F\F MMXYUB2=&>,"T"R-L$DBG[54VG_"CXO0?*74O,L]6_M:;2;*SB@'B"X^VE4U> MZGFPYU$R+/\ 9)(UQ :.#PGVG X /JWS>/\
"D,W^R:^>-3^&WQ,/[,WAO0[MA=4O-=M]?F_M0VFN7*WHTW[1=>1MN%OK>:5EC-INWW@;:K$F=E\]2EX8^!_O M4_LG1]2U/6]:7Q3IJ>'X\)XCN&T_:<"1ZFTD'F>7.&)D/[U69B RX;YB ?0&
MH^-=*TN>]BNM4TVTDTNV2]O$FNDC:TMW,BI-("?DC8Q2@,V 3&X!RIQ["XR^ M,5\]_"+]G?QO/X]M5\0:3KMKI]Y:^'HM>O-9\1C6)KVYTR?4;N=XMTLI$$UU
M)9[$Q&/+:3,41&RIO#GP/^6H2_8]2O/&%FLDUE'XBO#XPF9=._$'P!XFN/CWHM]#;^*M M4\,P6VG160TIQ1)IUOI5Q*%=3>37T/FJ;M)8&MU562X+-$ZD0AS*?,_'P(^ M+6O>/:<>)KSQ-
IOAN[U(3:S':^+:V-Y"(-360V[K>RR+:EY[/9Y7V4L8PQM; MXU-#_MXAN(9[I8K&^2>9)5OKB4VTUPDRQ>;$/W9/V:'#;P#ZB23=3J:B[>U.H *** M*

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lG\ ;\:?LX?$BWUZQU6^U2W:$=[MI]Y=22PWL.>5Y)VL/X7'0^HR#^M'P+_:$_M*^#]*\2^'+I9;>;;'/ O'G6 M

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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended Sep. 30, 2024	Nov. 06, 2024
Document Information [Line Items]		
Entity Central Index Key	0000072444	
Entity Registrant Name	Vaxart, Inc.	
Amendment Flag	false	
Current Fiscal Year End Date	--12-31	
Document Fiscal Period Focus	Q3	
Document Fiscal Year Focus	2024	
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	001-35285	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	59-1212264	
Entity Address, Address Line One	170 Harbor Way, Suite 300	
Entity Address, City or Town	South San Francisco	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	94080	
City Area Code	650	
Local Phone Number	550-3500	
Title of 12(b) Security	Common Stock, $0.0001 par value	
Trading Symbol	VXRT	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		227,479,811

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 22,035	$ 34,755
Short-term investments	36,676	4,958
Accounts receivable	591	3,008
Unbilled receivable from government contracts	3,085	0
Prepaid expenses and other current assets	4,069	2,815
Total current assets	66,456	45,536
Property and equipment, net	9,476	11,731
Prepaid clinical services, long-term	60,116	0
Right-of-use assets, net	21,536	24,840
Intangible assets, net	3,740	4,289
Goodwill	4,508	4,508
Other long-term assets	842	926
Total assets	166,674	91,830
Current liabilities:		
Accounts payable	2,524	1,584
Other accrued current liabilities	6,764	5,634
Current portion of operating lease liability	2,882	2,703
Current portion of liability related to sale of future royalties	2,747	3,803
Total current liabilities	80,364	13,724
Operating lease liability, net of current portion	15,319	17,385
Liability related to sale of future royalties, net of current portion	2,128	2,623
Other long-term liabilities	421	293
Total liabilities	98,232	34,025
Commitments and contingencies (Note 8)		
Stockholders' equity:		
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023	0	0
Common stock: $0.0001 par value; 350,000,000 shares authorized as of September 30, 2024 and 250,000,000 shares authorized as of December 31, 2023; 228,176,446 shares issued and 227,476,324 shares outstanding as of September 30, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023	23	15
Additional paid-in capital	533,503	467,731
Treasury stock at cost, 700,122 shares as of September 30, 2024 and 507,020 shares as of December 31, 2023	(574)	(366)
Accumulated deficit	(464,537)	(409,574)
Accumulated other comprehensive income (loss)	27	(1)
Total stockholders' equity	68,442	57,805
Total liabilities and stockholders' equity	166,674	91,830
Government Contract [Member]		
Current liabilities:		
Deferred government revenue	$ 65,447	$ 0

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance

Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	350,000,000	250,000,000
Common stock, shares issued (in shares)	228,176,446	153,959,853
Common stock, shares outstanding (in shares)	227,476,324	153,452,833
Treasury Stock, Common, Shares (in shares)	700,122	507,020

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:				
Revenues	$ 4,933	$ 2,101	$ 13,515	$ 4,134
Operating expenses:				
Research and development	15,066	15,002	51,559	53,437
General and administrative	4,342	4,921	16,757	17,144
Total operating expenses	19,408	19,923	68,316	70,581
Operating loss	(14,475)	(17,822)	(54,801)	(66,447)
Other income (expense):				
Interest income	1,022	723	1,941	2,076
Non-cash interest expense related to sale of future royalties	(631)	(207)	(2,045)	(573)
Other income (expense), net	22	(55)	26	(59)
Loss before income taxes	(14,062)	(17,361)	(54,879)	(65,003)
Provision for income taxes	18	39	84	87
Net loss	$ (14,080)	$ (17,400)	$ (54,963)	$ (65,090)
Net loss per share - basic and diluted (in dollars per share)	$ (0.06)	$ (0.11)	$ (0.28)	$ (0.45)
Shares used to compute net loss per share - basic and diluted (in shares)	227,452,883	152,026,112	193,655,660	145,810,175
Comprehensive loss:				
Net loss	$ (14,080)	$ (17,400)	$ (54,963)	$ (65,090)
Unrealized gain on available-for-sale investments, net of tax	43	13	28	288
Comprehensive loss	(14,037)	(17,387)	(54,935)	(64,802)
Non Cash Royalty Revenue [Member]				
Revenue:				
Revenues	40	446	662	754
Government Contract [Member]				
Revenue:				
Revenues	4,893	0	12,853	0
Grant [Member]				
Revenue:				
Revenues	$ 0	$ 1,655	$ 0	$ 3,380

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	June 2024 Offering [Member] Common Stock Outstanding [Member]	June 2024 Offering [Member] Treasury Stock, Common [Member]	June 2024 Offering [Member] Additional Paid-in Capital [Member]	June 2024 Offering [Member] Retained Earnings [Member]	June 2024 Offering [Member] AOCI Attributable to Parent [Member]	June 2024 Offering [Member]	September 2021 ATM [Member] Common Stock Outstanding [Member]	September 2021 ATM [Member] Treasury Stock, Common [Member]	September 2021 ATM [Member] Additional Paid-in Capital [Member]	September 2021 ATM [Member] Retained Earnings [Member]	September 2021 ATM [Member]	The 2023 Shelf Registration [Member] Common Stock Outstanding [Member]	The 2023 Shelf Registration [Member] Treasury Stock, Common [Member]	T Re [A [
Balances (in shares) at Dec. 31, 2022														
Balances at Dec. 31, 2022														
Additional offering costs under the June 2024 Offering											$ (103)			
Issuance of common stock upon exercise of stock options (in shares)														
Issuance of common stock upon exercise of stock options														
Release of common stock for vested restricted stock units (in shares)														
Release of common stock for vested restricted stock units														
Repurchase of common stock to satisfy tax withholding (in shares)														
Repurchase of common stock to satisfy tax withholding														
Stock-based compensation														
Unrealized gain on available-for-sale investments														
Net loss														
Issuance of common stock (in shares)							1,362,220	0				16,000,000		
Issuance of common stock							$ 1	$ 0	$ 1,429	$ 0	1,430	$ 1		$ 1
Issuance of common stock under ESPP (in shares)														
Issuance of common stock under ESPP														
Balances (in shares) at Sep. 30, 2023														
Balances at Sep. 30, 2023														
Balances (in shares) at Jun. 30, 2023														

Balances at Jun. 30, 2023											
Release of common stock for vested restricted stock units (in shares)											
Release of common stock for vested restricted stock units											
Repurchase of common stock to satisfy tax withholding (in shares)											
Repurchase of common stock to satisfy tax withholding											
Stock-based compensation											
Unrealized gain on available-for-sale investments											
Net loss											
Balances (in shares) at Sep. 30, 2023											
Balances at Sep. 30, 2023											
Balances (in shares) at Dec. 31, 2023											
Balances at Dec. 31, 2023											
Additional offering costs under the June 2024 Offering						$ (2,455)					(248)
Issuance of common stock upon exercise of stock options (in shares)											
Issuance of common stock upon exercise of stock options											
Release of common stock for vested restricted stock units (in shares)											
Release of common stock for vested restricted stock units											
Repurchase of common stock to satisfy tax withholding (in shares)											
Repurchase of common stock to satisfy tax withholding											
Stock-based compensation											
Unrealized gain on available-for-sale investments											
Net loss											
Issuance of common stock (in shares)	50,000,000	0					7,719,641	0			
Issuance of common stock	$ 5	$ 0	$ 37,540	$ 0		37,545	$ 1	$ 0	$ 8,801	$ 0	$ 8,802
Issuance of common stock under ESPP (in shares)											
Issuance of common stock under ESPP											
Balances (in shares) at Sep. 30, 2024											
Balances at Sep. 30, 2024											
Balances (in shares) at Jun. 30, 2024											
Balances at Jun. 30, 2024											
Additional offering costs under the June 2024 Offering	$ 0	$ 0	$ (10)	$ 0	$ 0	$ (10)					
Issuance of common stock upon exercise of stock options (in shares)											
Issuance of common stock upon exercise of stock options											
Release of common stock for vested restricted stock units (in shares)											
Release of common stock for vested restricted stock units											
Repurchase of common stock to satisfy tax withholding (in shares)											
Repurchase of common stock to satisfy tax withholding											
Stock-based compensation											
Unrealized gain on available-for-sale investments											
Net loss											
Balances (in shares) at Sep. 30, 2024											
Balances at Sep. 30, 2024											

Condensed Consolidated Statements of	3 Months Ended	9 Months Ended

Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
September 2021 ATM [Member]			
Offering costs		$ 248	$ 103
The 2023 Shelf Registration [Member]			
Offering costs			$ 284
RA Capital Healthcare Fund 2024 [Member]			
Offering costs		55	
June 2024 Offering [Member]			
Offering costs	$ 10	$ 2,455	

XML 19 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:		
Net loss	$ (54,963,000)	$ (65,090,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	6,614,000	6,293,000
Loss on disposal of equipment	0	55,000
Amortization of discount on investments, net	(473,000)	(510,000)
Stock-based compensation	9,146,000	10,417,000
Non-cash interest expense related to sale of future royalties	2,045,000	573,000
Non-cash revenue related to sale of future royalties	(3,596,000)	(314,000)
Change in operating assets and liabilities:		
Accounts receivable	2,417,000	(404,000)
Unbilled receivable from government contracts	(3,085,000)	0
Prepaid expenses and other assets	(1,170,000)	2,760,000
Prepaid clinical services, long-term	(60,116,000)	0
Accounts payable	940,000	(2,699,000)
Other accrued liabilities	(625,000)	(6,092,000)
Net cash used in operating activities	(37,419,000)	(56,932,000)
Cash flows from investing activities:		
Purchases of property and equipment	(510,000)	(1,975,000)
Proceeds from sale of property and equipment	0	120,000
Purchases of investments	(48,717,000)	(27,497,000)
Proceeds from maturities of investments	17,500,000	58,200,000
Net cash (used in) provided by investing activities	(31,727,000)	28,848,000
Cash flows from financing activities:		
Proceeds from issuance of common stock upon exercise of stock options	30,000	17,000
Shares acquired to settle employee tax withholding liabilities	(208,000)	(39,000)
Proceeds from issuance of common stock under the employee stock purchase plan	312,000	298,000
Net cash provided by financing activities	56,426,000	15,309,000
Net decrease in cash, cash equivalents and restricted cash	(12,720,000)	(12,775,000)
Cash, cash equivalents and restricted cash at beginning of the period	34,755,000	46,013,000
Cash, cash equivalents and restricted cash at end of the period	22,035,000	33,238,000
Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets:		
Cash and cash equivalents	22,035,000	33,159,000
Restricted cash	0	79,000
Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period	22,035,000	33,238,000
Supplemental disclosure of non-cash investing and financing activity:		
Operating lease liabilities arising from obtaining right-of-use assets	0	296,000
Acquisition of property and equipment included in accounts payable and accrued expenses	87,000	14,000
June 2024 Offering [Member]		
Cash flows from financing activities:		
Net proceeds from issuance of common stock	37,545,000	0
Registered Direct Offering [Member]		
Cash flows from financing activities:		
Net proceeds from issuance of common stock	0	13,603,000
At-the-market Facility [Member]		
Cash flows from financing activities:		
Net proceeds from issuance of common stock	8,802,000	1,430,000
RA Capital Healthcare Fund 2024 [Member]		
Cash flows from financing activities:		
Net proceeds from issuance of common stock	9,945,000	0
Grant [Member]		
Change in operating assets and liabilities:		
Deferred revenue	0	(1,921,000)
Government Contract [Member]		
Change in operating assets and liabilities:		
Deferred revenue	$ 65,447,000	$ 0

XML 20 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Nature of Business	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements	
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	

NOTE 1. Organization and Nature of Business

General

Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, under the name West Coast Biologicals, Inc. The Company changed its name to Vaxart, Inc. (“Private Vaxart”) in July 2007, and reincorporated in the state of Delaware. In February 2018, Private Vaxart completed a business combination with Aviragen Therapeutics, Inc. (“Aviragen”), pursuant to which Aviragen merged with Private Vaxart, with Private Vaxart surviving as a wholly-owned subsidiary of Aviragen (the “Merger”). Pursuant to the terms of the Merger, Aviragen changed its name to Vaxart, Inc. (together with its subsidiaries, the “Company” or “Vaxart”) and Private Vaxart changed its name to Vaxart Biosciences, Inc.

In June 2024, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by the Company in an underwritten registered direct offering of 50,000,000 shares of the Company’s common stock, at a price of $0.80 per share. The gross proceeds to the Company from such offering were $40.0 million, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds were $37.5 million.

In January 2024, the Company entered into a securities purchase agreement (the “2024 Securities Purchase Agreement”) with RA Capital Healthcare Fund, L.P. pursuant to which 15,384,615 shares of the Company's common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65 per share pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-270671) (the “2023 Shelf Registration”). The gross proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, the net proceeds were $9.9 million.

In September 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “September 2021 ATM”), pursuant to which it may offer and sell, from time to time through Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (together, the “sales agents”), shares of its common stock having an aggregate offering price of up to $100 million. The Company filed a prospectus supplement with the SEC on September 16, 2021, a subsequent prospectus supplement with the SEC on May 9, 2023 and paid sales commissions of up to 3.0% of gross proceeds from the sale of shares. In the nine months ended September 30, 2024, 7,719,641 shares were issued and sold under the September 2021 ATM for gross proceeds of $9.1 million, which, after deducting sales commissions and expenses incurred to date, resulted in net proceeds of $8.8 million. Since September 30, 2024, the Company has not raised any additional capital under the September 2021 ATM. Effective October 18, 2024, the September 2021 ATM was terminated as further detailed in Note 12.

The Company’s principal operations are based in South San Francisco, California, and it operates in one reportable segment, which is the discovery and development of oral recombinant protein vaccines,

based on its proprietary oral vaccine platform.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

Notes to Financial Statements

Significant Accounting Policies [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 2. Summary of Significant Accounting Policies

Basis of Presentation, Liquidity and Going Concern – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the SEC assuming the Company will continue as a going concern.

The Company is a clinical-stage biotechnology company with no product sales. Its primary source of capital is from the sale and issuance of common stock and common stock warrants as well as funding from the Biomedical Advanced Research and Development Authority ("HHS BARDA"), a division of the Administration for Strategic Preparedness and Response ("ASPR") within the United States ("U.S.") Department of Health and Human Services. As of September 30, 2024, the Company had cash, cash equivalents and short-term investments of $58.7 million.

Based on management's current plan, the Company expects to have cash runway into 2026. The Company will be dependent upon raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan. There can be no assurance that the Company will be successful raising additional capital in order to continue as a going concern.

The condensed consolidated balance sheet as of December 31, 2023, included in this document, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to these rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and footnotes related thereto for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2024 (the "Annual Report"). Unless noted below, there have been no material changes to the Company's significant accounting policies described in Note 2 to the consolidated financial statements included in the Annual Report. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year or any future periods.

Basis of Consolidation – The unaudited condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation.

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.

Concentration of Credit Risk – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating.

Revenue Recognition

Revenue from Government Contracts

Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned ("firm fixed-price milestone"). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned ("cost-plus-fixed-fee"). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed, as detailed in Note 5.

Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.

Recent Accounting Pronouncements

The Company has reviewed all significant newly-issued accounting pronouncements that are not yet effective and concluded that they are either not applicable to its operations or their adoption is not expected to have a material impact on its financial position or results of operations.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments

Notes to Financial Statements

Fair Value Disclosures [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 3. Fair Value of Financial Instruments

Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities.

Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity.

The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2 – Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3 – Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

The following table sets forth the fair value of the Company's financial assets that are measured on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands):

	Level 1	Level 2	Level 3	Total
September 30, 2024				
Financial assets:				
Money market funds	$ 18,558	$ —	$ —	$ 18,558
U.S. Treasury securities	—	34,019	—	34,019
Commercial paper	—	2,657	—	2,657
Total assets	$ 18,558	$ 36,676	$ —	$ 55,234

	Level 1	Level 2	Level 3	Total
December 31, 2023				
Financial assets:				
Money market funds	$ 31,403	$ —	$ —	$ 31,403
U.S. Treasury securities	—	4,958	—	4,958
Total assets	$ 31,403	$ 4,958	$ —	$ 36,361

The Company held no financial liabilities measured on a recurring basis as of September 30, 2024 or December 31, 2023.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 4. Balance Sheet Components

(a) Cash, Cash Equivalents and Investments

Cash, cash equivalents and investments consisted of the following (in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Short-Term Investments
September 30, 2024						
Cash at banks	$ 3,477	$ —	$ —	$ 3,477	$ 3,477	$ —
Money market funds	18,558	—	—	18,558	18,558	—
U.S. Treasury securities	33,997	22	—	34,019	—	34,019
Commercial paper	2,652	5	—	2,657	—	2,657
Total	$ 58,684	$ 27	$ —	$ 58,711	$ 22,035	$ 36,676

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Short-Term Investments
December 31, 2023						
Cash at banks	$ 3,352	$ —	$ —	$ 3,352	$ 3,352	$ —
Money market funds	31,403	—	—	31,403	31,403	—
U.S. Treasury securities	4,959	—	(1)	4,958	—	4,958
Total	$ 39,714	$ —	$ (1)	$ 39,713	$ 34,755	$ 4,958

As of September 30, 2024 and December 31, 2023, all investments were available-for-sale debt securities with remaining maturities of 12 months or less.

(b) Accounts Receivable

Accounts receivable consists of $0.55 million of government contract receivables from HHS BARDA, and $40,000 royalty receivable totaling $0.59 million as of September 30, 2024 and a total of $3.0 million of accounts receivable for royalties as of December 31, 2023. For further information on HHS BARDA receivables, see Note 5.

An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company has provided no allowance for credit losses as of September 30, 2024 and December 31, 2023.

(c) Unbilled Receivable from Government Contracts

Unbilled receivable, which was earned and not yet billed, consists of government contracts from HHS BARDA of $3.1 million and zero as of September 30, 2024 and December 31, 2023, respectively, as detailed in Note 5.

(d) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	September 30, 2024	December 31, 2023
Prepaid clinical and manufacturing expenses	$ 1,637	$ 984
Prepaid insurance	488	258
Prepaid rent	517	488
Other prepaid	988	752
Other current assets	439	333
Prepaid expenses and other current assets	$ 4,069	$ 2,815

(e) Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

	September 30, 2024	December 31, 2023
Laboratory equipment	$ 13,714	$ 13,448
Office and computer equipment	1,120	1,105
Leasehold improvements	4,089	3,985
Construction in progress	141	24
Total property and equipment	19,064	18,562
Less: accumulated depreciation	(9,588)	(6,831)
Property and equipment, net	$ 9,476	$ 11,731

Depreciation expense was $1.0 million for each of the three months ended September 30, 2024 and 2023, and $2.8 million for each of the nine months ended September 30, 2024 and 2023. There were no impairments of the Company's property and equipment recorded in the three and nine months ended September 30, 2024 or 2023.

(f) Prepaid Clinical Services, Long-Term

Prepaid clinical services, long-term were $60.1 million and zero as of September 30, 2024 and December 31, 2023, respectively. The long-term prepaid clinical services represent amounts the Company has paid to clinical research organizations that will be utilized in over one year.

(g) Right-of-Use Assets, Net

Right-of-use assets, net are comprised of facilities of $21.5 million and $24.8 million as of September 30, 2024 and December 31, 2023, respectively. The right-of-use of additional leased premises in California commenced in 2023, resulting in an additional $3.1 million right-of-use assets recorded in the year ended December 31, 2023.

(h) Intangible Assets, Net

Intangible assets are comprised of developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. As of September 30, 2024, developed technology and intellectual property had remaining lives of 5.1 years and 3.3 years, respectively. As of September 30, 2024, there have been no indicators of impairment. Intangible assets consist of the following (in thousands):

	September 30, 2024	December 31, 2023
Developed technology	$ 5,000	$ 5,000
Intellectual property	80	80
Total cost	5,080	5,080
Less: accumulated amortization	(1,340)	(791)
Intangible assets, net	$ 3,740	$ 4,289

Intangible asset amortization expense was $0.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.5 million for each of the nine months ended September 30, 2024 and 2023.

As of September 30, 2024, the estimated future amortization expense by year is as follows (in thousands):

Year Ending December 31,	Amount
2024 (three months remaining)	$ 182
2025	732
2026	731
2027	731
2028	727
Thereafter	637
Total	$ 3,740

(i) Goodwill

Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, was $4.5 million as of both September 30, 2024 and December 31, 2023. As of September 30, 2024, there have been no indicators of impairment.

(j) Deferred Government Revenue

Deferred government revenue represents amounts received from HHS BARDA contracts where the earnings process is not yet complete. The Company will recognize deferred government revenue once the earnings process is complete. Deferred government revenue was $65.4 million and zero as of September 30, 2024 and December 31 2023, respectively.

(k) Other Accrued Current Liabilities

Other accrued current liabilities consist of the following (in thousands):

	September 30, 2024	December 31, 2023
Accrued compensation	$ 4,511	$ 4,576
Accrued clinical and manufacturing expenses	1,309	312
Accrued professional and consulting services	371	211
Other liabilities, current portion	573	535
Total	$ 6,764	$ 5,634

XML 24 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Revenue

Notes to Financial Statements

Revenue [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 5. Revenue

Royalty Revenue Related to Sale of Future Royalties

The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir in Japan. Based on information provided by Daiichi Sankyo, the Company believes the expiration of the last patent related to Inavir is in August 2036, at which time royalty revenue will cease. The Company's royalty revenue is seasonal, in line with the flu season, so the majority of the Company's royalty revenue and non-cash royalty revenue related to the sale of future royalties are earned in the first and fourth fiscal quarters. The royalty revenue related to Inavir recognized for the nine months ended September 30, 2024 and 2023, was zero. The Company recognized non-cash royalty revenue related to the sale of future royalties of $40,000 and $0.4 million for the three months ended September 30, 2024

and 2023, respectively, and $0.7 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. Both royalty revenue and the non-cash royalty revenue related to the sale of future royalties are subject to a 5% withholding tax in Japan, for which $2,000 and $23,000 was included in income tax expense for the three months ended September 30, 2024 and 2023, respectively, and $33,000 and $38,000 for the nine months ended September 30, 2024 and 2023, respectively, further detailed in Note 6.

Revenue from Government Contracts

The Company recognized revenue from government contracts with HHS BARDA of $4.9 million and $12.9 million for the three and nine months ended September 30, 2024, respectively, consisting of revenues from the 2024 ASPR-BARDA Contract (as defined below) and the 2024 ATI-RRPV Contract (as defined below) described in more detail below. Unbilled receivable from government contracts consists of government revenue from HHS BARDA, which was earned and not yet billed. As of September 30, 2024, the amount of unbilled receivable was $3.1 million and deferred revenue was $65.4 million.

2024 ATI-RRPV Contract

In June 2024, the Company entered into an agreement (as modified, the "2024 ATI-RRPV Contract") with Advanced Technology International, the Rapid Response Partnership Vehicle's Consortium Management Firm funded by HHS BARDA, which was modified in September 2024 to increase funding and provide for the manufacturing of a vaccine candidate targeting the KP.2 strain. Pursuant to the 2024 ATI-RRPV Contract, the Company will receive funding of up to $456.1 million to conduct a Phase 2b comparative study evaluating the Company's oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration and manufacture a COVID-19 vaccine candidate targeting the KP.2 strain. The 2024 ATI-RRPV Contract currently makes available an aggregate amount of up to $96.5 million, consisting of fixed fee amounts totaling $67.9 million and reimbursement of costs incurred in trial preparation and execution activities. The 2024 ATI-RRPV Contract further contemplates additional funding up to $359.6 million if the Company and HHS BARDA decide to continue with the Phase 2b comparative study. The Company accounts for the 2024 ATI-RRPV Contract under Accounting Standards Codification 958-605 and recognizes revenue as the firm fixed-price milestone is earned and allowable cost-plus-fixed-fees are incurred. Reimbursable costs under the 2024 ATI-RRPV Contract primarily include direct labor, subcontract costs, materials, travel, and approved overhead and indirect costs. The 2024 ATI-RRPV Contract contains terms and conditions that are customary for contracts with HHS BARDA of this nature, including the U.S. government having the right to terminate the contract for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. Revenue from government contracts recognized on the 2024 ATI-RRPV Contract was $4.0 million for the three months ended September 30, 2024 and $4.2 million for the nine months ended September 30, 2024, based on costs incurred and the achievement of a firm fixed-price milestone under the 2024 ATI-RRPV Contract. Deferred government revenue represents amounts that have been received from HHS BARDA and the earnings process is not yet complete. Deferred government revenue in current liabilities was $64.8 million and zero as of September 30, 2024 and December 31, 2023, respectively.

Management believes that if the 2024 ATI-RRPV Contract were to be terminated prior to completion of the Phase 2b comparative study, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Cost reimbursement payments to the Company are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited will be recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.

2024 ASPR-BARDA Contract

In January 2024, the Company was awarded a contract (as amended, the "2024 ASPR-BARDA Contract") by HHS BARDA with a base and all options value of $9.3 million. Under the 2024 ASPR-BARDA Contract, the Company received an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company's XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. The 2024 ASPR-BARDA Contract originally had a period of performance term that was set to expire in July 2024, but the Company entered into an amendment in July 2024 that extended the period of performance expiration date into October 2024. The Company accounts for the 2024 ASPR-BARDA Contract under Accounting Standards Codification 958-605 and recognizes revenue as donor-imposed conditions are met. Revenue from government contracts recognized on the 2024 ASPR-BARDA Contract was $0.9 million and $8.7 million for the three and nine months ended September 30, 2024, respectively, based on the achievement of certain milestones under the 2024 ASPR-BARDA Contract. Deferred government revenue represents amounts that have been received from HHS BARDA and the earnings process is not yet complete. Deferred government revenue in current liabilities was $0.6 million and zero as of September 30, 2024 and December 31, 2023, respectively.

Grant Revenue

In November 2022, the Company accepted a $3.5 million grant to perform research and development work for the Bill & Melinda Gates Foundation (the "BMGF Grant") and received $2.0 million in advance that was recorded as restricted cash and deferred revenue. The Company received an additional $1.5 million in July 2023 upon completion of certain milestones. The Company recognizes revenue under research contracts only when a contract is executed and the contract price is fixed or determinable. Revenue from the BMGF Grant was recognized in the period during which the related costs were incurred and the related services rendered, as the applicable conditions under the contract were met. Costs of contract revenue were recorded as a component of operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company recognized revenue from the BMGF Grant of zero and $1.7 million for the three months ended September 30, 2024 and 2023, respectively, and zero and $3.4 million for the nine months ended September 30, 2024 and 2023, respectively. The Company fully recognized revenue from the BMGF Grant during the year ended December 31, 2023.

XML 25 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Liabilities Related to Sale of Future Royalties

Notes to Financial Statements

Liabilities Related to Sale of Future Royalties [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 6. Liabilities Related to Sale of Future Royalties

In April 2016, Aviragen entered into a Royalty Interest Acquisition Agreement (the "RIAA") with HealthCare Royalty Partners III, L.P. ("HCRP"). Under the RIAA, HCRP made a $20.0 million cash payment to Aviragen in consideration for acquiring certain royalty rights ("Royalty Rights") related to the approved product Inavir in the Japanese market. The Royalty Rights were obtained pursuant to the collaboration and license agreements (the "License Agreement") and a commercialization agreement that the Company entered into with Daiichi Sankyo. Per the terms of the RIAA, during the first royalty interest period of April 1, 2016 through March 31, 2025, HCRP is entitled to the first $3.0 million and any cumulative remaining shortfall amount plus 15% of the next $1.0 million in royalties earned in each year commencing on April 1, with any excess revenue being retained by the Company. Further, during the second royalty interest period beginning April 1, 2025 and ending on December 24, 2029, HCRP is entitled to the first $2.7 million and any cumulative remaining shortfall amount, plus 15% of the next $1.0 million in royalties, with any excess revenue being retained by the Company. A shortfall occurs when, during an annual period ending on March 31st, for the first royalty interest period of April 1, 2016 through March 31, 2025, the Company's royalty payments fall below $3.0 million; and $2.7 million for the second royalty interest period of April 1, 2025 and ending on December 24, 2029, excluding the period of April 1, 2028 through December 24, 2029. In the event there shall remain any cumulative remaining shortfall amount as of December 24, 2029, any royalties received from Daiichi Sankyo subsequently by the Company would be payable to HCRP until the cumulative remaining shortfall amount has been paid.

For avoidance of doubt, the RIAA states, in the event there is a remaining cumulative remaining shortfall amount as of December 24, 2029, the Company shall not be obligated to pay HCRP any royalty payment beyond what the Company is paid from Daiichi Sankyo. The cumulative remaining shortfall amount is the aggregate amount of the remaining shortfall for each annual period, which was $6.0 million and $7.0 million as of September 30, 2024 and December 31, 2023, respectively.

Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction was accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. To record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement and the payments that will be passed through to HCRP over the life of this agreement. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The royalties earned in each period that will be passed through to HCRP are recorded as non-cash royalty revenue related to sale of future royalties, with any excess not subject to pass-through being recorded as royalty revenue. When the pass-through royalties are paid to HCRP in the following quarter, the imputed liability related to sale of future royalties is commensurately reduced. The Company periodically assesses the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company adjusts the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP's share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability, including the related interest, is fully amortized.

The following table shows the activity within the liability account during the nine months ended September 30, 2024 (in thousands):

Total liability related to sale of future royalties, start of period	$	6,426
Non-cash royalty revenue paid to HCRP		(3,596)
Non-cash interest expense recognized		2,045
Total liability related to sale of future royalties, end of period		4,875
Current portion		(2,747)
Long-term portion	$	2,128

XML 26 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Leases

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

9 Months Ended
Sep. 30, 2024

NOTE 7. Leases

The Company has obtained the right of use for office and manufacturing facilities under six operating lease agreements with initial terms exceeding one year. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.

In September 2021, the Company executed a lease for a facility in South San Francisco, California, with an initial term expiring on March 31, 2029. This lease has two separate components, one commenced in the third quarter of 2022 and the other in the first quarter of 2023, resulting in an additional right of use asset of $15.0 million and $3.1 million, respectively.

As of September 30, 2024, the weighted average discount rate for operating leases with initial terms of more than one year was 9.8% and the weighted average remaining term of these leases was 4.4 years. Discount rates were determined using the Company's marginal rate of borrowing at the time each lease was executed or extended.

The following table summarizes the Company's undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than 12 months as of September 30, 2024 (in thousands):

Year Ending December 31,		
2024 (three months remaining)	$	1,108
2025		4,511
2026		5,031
2027		5,207
2028		5,389
Thereafter		1,348
Undiscounted total		22,594
Less: imputed interest		(4,393)
Present value of future minimum payments		18,201
Current portion of operating lease liability		(2,882)
Operating lease liability, net of current portion	$	15,319

The Company is also required to pay for operating expenses related to the leased space. The operating expenses are incurred separately and were not included in the present value of lease payments. Operating lease expenses for the three and nine months ended September 30, 2024 and 2023 are summarized as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Lease cost				
Operating lease cost	$ 1,554	$ 1,554	$ 4,661	$ 4,617
Short-term lease cost	10	10	29	41
Variable lease cost	496	459	1,381	1,401
Sublease income	(20)	—	(54)	-
Total lease cost	$ 2,040	$ 2,023	$ 6,017	$ 6,059

XML 27 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments and Contingencies

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

9 Months Ended

Sep. 30, 2024

NOTE 8. Commitments and Contingencies

(a) Purchase Commitments

As of September 30, 2024, the Company had approximately $8.5 million of non-cancelable purchase commitments, principally for contract manufacturing and clinical services which are expected to be paid within the next year. In addition, the Company has operating lease commitments as detailed in Note 7.

(b) Indemnifications

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with certain officers and directors which provide, among other things, that the Company will indemnify and advance expenses incurred in connection with certain actions, suits or proceedings to such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and the Company's Bylaws. The Company currently has directors' and officers' insurance.

(c) Litigation

From time to time the Company may be involved in legal proceedings arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it in excess of established reserves, in the aggregate, is indeterminable to its consolidated financial condition or cash flows. However, any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of management's attention and resources that are needed to run the Company successfully, and could have a material adverse impact on its business, financial condition and results of operations.

In August and September 2020, two substantially similar securities class actions were filed in the U.S. District Court for the Northern District of California. The first action, titled *Himmelberg v. Vaxart, Inc. et al.* was filed on August 24, 2020. The second action, titled *Hovhannisyan v. Vaxart, Inc. et al.* was filed on September 1, 2020 (together, the "Putative Class Action"). By Order dated September 17, 2020, the two actions were deemed related. On December 9, 2020, the court appointed lead plaintiffs and lead plaintiffs' counsel.

On January 29, 2021, lead plaintiffs filed their consolidated amended complaint. On July 8, 2021, all defendants moved to dismiss the consolidated amended complaint. On May 14, 2021, the court granted lead plaintiffs' request to amend the consolidated amended complaint and denied defendants' motions to dismiss as moot. On June 10, 2021, lead plaintiffs filed a first amended consolidated complaint, and on August 9, 2021, lead plaintiffs filed a corrected first amended consolidated complaint. The first amended consolidated complaint, as corrected, named certain of Vaxart's current and former executive officers and directors, as well as Armistice Capital, LLC ("Armistice"), as defendants. It claimed three violations of federal civil securities laws; violation of Section 10(b) of the Exchange Act and SEC Rule 10b-5, as against the Company and all individual defendants; violation of Section 20(a) of the Exchange Act, as against Armistice and all individual defendants; and violation of Section 20A of the Exchange Act against Armistice. The first amended consolidated complaint, as corrected, alleged that the defendants violated securities laws by misstating and/or omitting information regarding the Company's development of a norovirus vaccine, the vaccine manufacturing capabilities of a business counterparty, and the Company's involvement with Operation Warp Speed ("OWS"); and by engaging in a scheme to inflate Vaxart's stock price. The first amended consolidated complaint sought certification as a class action for similarly situated shareholders and sought, among other things, an unspecified amount of damages and attorneys' fees and costs. On July 8, 2021, all defendants moved to dismiss the first amended consolidated complaint. By Order dated December 22, 2021, the court granted the motion to dismiss by Armistice with leave to amend and otherwise denied the motions to dismiss. On July 27, 2022, lead plaintiffs filed a notice announcing that they had reached a partial settlement (the "Partial Settlement") to resolve all claims against the Company and its current or former officers and/or directors in their capacity as officers and/or directors of the Company (the "Settling Defendants"). Pursuant to the Partial Settlement, the Company agreed to a settlement amount of $12.0 million with $2.0 million to be paid by the Company and the remainder to be paid by the Company's insurers. On November 2, 2022, the Company paid the $2.0 million settlement amount with respect to the Putative Class Action pursuant to the terms of the settlement agreement reached in that case. On November 14, 2022, lead plaintiffs filed a second amended consolidated class action complaint that purported to include new allegations to support claims against Armistice. By Orders dated January 25, 2023, the court approved the Partial Settlement and entered judgment dismissing with prejudice all claims asserted in the Putative Class Action against the Settling Defendants.

On October 23, 2020, a complaint was filed in the U.S. District Court for the Southern District of New York, entitled *Roth v. Armistice Capital LLC, et al.* The complaint names Armistice and certain Armistice-related parties as defendants, asserting a violation of Exchange Act Section 16(b) and seeking the disgorgement of short-swing profits. The complaint purports to bring the lawsuit on behalf of and for the benefit of the Company and names the Company as a "nominal defendant" for whose benefit damages are sought. Following discovery, a motion for summary judgment was filed by Armistice and the Armistice-related party defendants to dismiss the complaint. On March 27, 2024, the court granted the motion for summary judgment and dismissed all claims in the complaint in their entirety. On April 11, 2024, the Plaintiff timely filed a notice of appeal of the court's decision to the Second Circuit Court of Appeals, commencing appellate proceedings. In June 2024, Plaintiff filed a motion to the court of appeals to stay the appeal pending efforts to re-instate the complaint in the district court, which was granted by the court of appeals. In July 2024, Plaintiff filed a motion with the district court seeking to set aside the judgment and to re-instate the complaint. On August 15, 2024, the district court denied Plaintiff's motion to set aside the judgment. On September 10, 2024, Plaintiff re-filed its appeal with the Second Circuit Court of Appeals, which is currently pending.

On January 8, 2021, a purported shareholder, Phillip Chan, commenced a *pro se* lawsuit in the U.S. District Court for the Northern District of California titled *Chan v. Vaxart, Inc. et al.* (the "Opt-Out Action"), opting out of the consolidated Himmelberg v. Vaxart, Inc. et al. and Hovhannisyan v. Vaxart, Inc. et al. class actions, (together, the "Putative Class Action"). Because this complaint is nearly identical to an earlier version of a complaint filed in the Putative Class Action, the Opt-Out Action has been stayed while the Putative Class Action is pending.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Equity

Notes to Financial Statements

Equity [Text Block]

9 Months Ended

Sep. 30, 2024

NOTE 9. Stockholders' Equity

(a) Preferred Stock

The Company is authorized to issue 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company's board of directors may, without further action by the stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 5,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock are currently outstanding, and the Company has no present plan to issue any shares of preferred stock.

(b) Common Stock

As of September 30, 2024, the Company was authorized to issue 350,000,000 shares of common stock, $0.0001 par value per share, which includes an increase of 100,000,000 on June 11, 2024, when the Company's stockholders approved an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock from 250,000,000 to 350,000,000 shares. Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company's directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders. Holders of common stock are entitled to receive such dividends, if any, as may be declared from time to time by the Company's board of directors at its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically. As of September 30, 2024, no dividends had been declared by the board of directors.

In June 2024, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by the Company in an underwritten registered direct offering of 50,000,000 shares of the Company's common stock, at a price of $0.80 per share. The gross proceeds to the Company from such offering were $40.0 million, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds were $37.5 million.

In January 2024, the Company entered into the 2024 Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. pursuant to which 15,384,615 shares of the Company's common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65 per share pursuant to the Company's 2023 Shelf Registration. The gross proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, the net proceeds were $9.9 million.

In the event of the Company's voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Company's assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no sinking fund provisions applicable to the common stock.

The Company had shares of common stock reserved for issuance as follows:

	September 30, 2024	December 31, 2023
Options issued and outstanding	21,407,462	17,938,726
RSUs issued and outstanding	3,036,238	2,126,373
2019 Equity Incentive Plan available for future grant	16,957,020	5,685,806
2024 Inducement Award Plan available for future grant	1,727,500	—
Common stock warrants	140,596	227,434
2022 Employee Stock Purchase Plan	2,362,902	1,065,325
Total	45,631,718	27,043,664

The approved increase of reserved common stock for 2019 Equity Incentive Plan and 2022 Employee Stock Purchase Plan is detailed in Note 10.

(c) Treasury Stock

The Company generally withholds shares of its common stock to cover employees' portion of required tax withholdings when employee equity awards are issued or vest. These shares are valued at cost, which equals the market price of the common stock on the date of issuance or vesting. The Company had 700,122 and 507,020 treasury shares as of September 30, 2024 and December 31, 2023,

respectively.

(d) Warrants

In April 2024, 70,663 of the warrants outstanding as of March 31, 2024, expired unexercised. The following warrants were outstanding as of September 30, 2024, all of which contain standard anti-dilution protections in the event of subsequent rights offerings, stock splits, stock dividends or other extraordinary dividends, or other similar changes in the Company's common stock or capital structure, and none of which have any participating rights for any losses:

Securities into which warrants are convertible	Warrants Outstanding	Exercise Price	Expiration Date
Common Stock	29,150	$ 2.50	March 2025
Common Stock	100,532	$ 3.125	February 2025
Common Stock	10,914	$ 22.99	December 2026
Total	140,596		

In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company's control, the holders of the unexercised common stock warrants exercisable for $2.50 and those exercisable for $3.125 shall be entitled to receive cash consideration equal to a Black-Scholes valuation, as defined in the warrant. If such Fundamental Transaction is not within the Company's control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company's common stock, hence these warrants are classified as a component of permanent equity.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

NOTE 10. Equity Incentive Plans

On April 23, 2019, the Company's stockholders approved the adoption of the 2019 Equity Incentive Plan (the "2019 Plan"), under which the Company is authorized to issue incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), other stock awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan is designed to secure and retain the services of employees, directors and consultants, provide incentives for the Company's employees, directors and consultants to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which employees, directors and consultants may be given an opportunity to benefit from increases in the value of the Company's common stock. Following adoption of the 2019 Plan, all previous plans were frozen, and on forfeiture, cancellation and expiration, awards under those plans are not assumed by the 2019 Plan.

The aggregate number of shares of common stock authorized for issuance under the 2019 Plan was initially 1,600,000 shares, which was increased through an amendment to the 2019 Plan adopted by the Company's stockholders (a "Plan Amendment") on June 8, 2020, to 8,000,000, by a Plan Amendment on June 16, 2021, to 16,900,000, by a Plan Amendment on August 4, 2022, to 28,900,000, and by a Plan Amendment on June 11, 2024, to 43,900,000. Further amendments to the 2019 Plan to increase the share reserve would require stockholder approval. Awards that are forfeited or canceled generally become available for issuance again under the 2019 Plan. Awards have a maximum term of ten years from the grant date and may vest over varying periods, as specified by the Company's board of directors for each grant.

On February 27, 2024, the Company's board of directors adopted the Vaxart, Inc. 2024 Inducement Award Plan (the "2024 Inducement Plan"). The 2024 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the board of directors or the independent members of the board of directors. The board of directors reserved 3,000,000 shares of the Company's common stock for issuance under the 2024 Inducement Plan, subject to adjustment as provided in the plan document. The terms of the 2024 Inducement Plan are substantially similar to the terms of the 2019 Plan, with the exception that incentive stock options may not be issued under the 2024 Inducement Plan and equity awards under the 2024 Inducement Plan (including nonqualified stock options, restricted stock, restricted stock units, and other stock-based awards) may be issued only to an employee who is commencing employment with the Company or any subsidiary or who is being rehired following a bona fide interruption of employment by the Company or any subsidiary, in either case if he or she is granted such award in connection with his or her commencement of employment and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.

A summary of stock option and RSU transactions in the nine months ended September 30, 2024, is as follows:

	Shares Available For Grant	Number of Options Outstanding	Weighted Option Average Exercise Price	Unvested RSU Shares Outstanding	Weighted RSU Average Grant Date Fair Value
Balance as of January 1, 2024	5,685,806	17,938,726	$ 2.90	2,126,373	$ 1.37
Authorized under 2024 Inducement Plan	3,000,000				
Authorized under 2019 Plan	15,000,000				
Granted	(7,167,480)	5,248,437	$ 1.12	1,919,043	$ 1.14
Exercised		(38,030)	$ 0.78		
Released				(571,884)	$ 1.51
Forfeited	1,872,626	(1,435,332)	$ 2.29	(437,294)	$ 1.43
Canceled	293,568	(306,339)	$ 3.81		
Balance as of September 30, 2024	18,684,520	21,407,462	$ 2.50	3,036,238	$ 1.19

As of September 30, 2024, there were 21,407,462 options outstanding with a weighted average exercise price of $2.50, a weighted average remaining term of 6.83 years, and an aggregate intrinsic value of $538,000. Of these options, 12,618,062 were vested, with a weighted average exercise price of $3.02, a weighted average remaining term of 5.40 years, and an aggregate intrinsic value of $379,000.

The Company received $30,000 for the 38,030 options exercised during the nine months ended September 30, 2024, which had an intrinsic value of $7,000, and received $17,000 for the 54,720 options exercised during the nine months ended September 30, 2023, which had an intrinsic value of $31,000. The aggregate intrinsic value represents the total pre-tax value (i.e., the difference between the Company's stock price and the exercise price) of stock options outstanding as of September 30, 2024, based on the Company's common stock closing price of $0.85 on September 30, 2024, which would have been received by the option holders had all their in-the-money options been exercised as of that date.

The weighted average grant date fair value of options awarded in the nine months ended September 30, 2024 and 2023, was $1.01 and $0.78, respectively. Their fair values were estimated using the following assumptions:

	Nine Months Ended September 30,	
	2024	2023
Risk-free interest rate	3.7% - 4.4%	3.5% - 4.2%
Expected term (in years)	6.00	5.50 - 6.00
Expected volatility	128.9% - 130.8%	127.8% - 133.8%
Dividend yield	—%	—%

The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options, RSUs and ESPP was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development	$ 1,814	$ 2,404	$ 5,489	$ 6,142
General and administrative	661	1,439	3,657	4,275
Total stock-based compensation	$ 2,475	$ 3,843	$ 9,146	$ 10,417

As of September 30, 2024, the unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs expected to vest was $15.9 million, which the Company expects to recognize over an estimated weighted average period of 2.3 years.

On August 4, 2022, the 2022 Employee Stock Purchase Plan (the "2022 ESPP") was approved by the Company's stockholders. The Company initially reserved 1,800,000 shares of the Company's common stock for purchase under the 2022 ESPP, which was increased by 1,800,000 shares through an amendment to the 2022 ESPP adopted by the Company's stockholders on June 11, 2024, to 3,600,000 shares. The 2022 ESPP generally has a six-month offering period comprised of one purchase period. In May 2024, the 2022 ESPP had a one-time modification following the end of the six-month offering period ended May 31, 2024, to commence the follow-on offering period on July 1, 2024 for a five-month offering period. The purchase price of the stock is equal to 85% of the lesser of the market value of such shares at the beginning of the six-month offering period or the end of such offering period. During the nine months ended September 30, 2024, the Company received $0.3 million and issued 502,423 shares under the 2022 ESPP. As of September 30, 2024, 2,362,902 shares are available and reserved for future issuance under the 2022 ESPP.

The estimated fair value used for the five-month offering period beginning July 1, 2024 and ending November 30, 2024, was $0.28 per share. The estimated fair value used for the six-month offering period beginning December 1, 2023 and ending May 31, 2024 was $0.27 per share. The estimated fair value used for the six-month offering period beginning June 1, 2023 and ending November 30, 2023 was $0.54 per share. The estimated fair value used for the six-month offering period beginning December 1, 2022 and ending May 31, 2023 was $0.46 per share. As of September 30, 2024, the unrecognized stock-based compensation cost related to outstanding ESPP expected to be recognized is $41,000 by November 30, 2024. The fair value of the 2022 ESPP shares was estimated using the Black-Scholes option pricing model using the following assumptions:

	Five-Month Offering Period Ending November 30,	Six-Month Offering Period Ending May 31,	Six-Month Offering Period Ending November 30,	Six-Month Offering Period Ending May 31,
	2024	2024	2023	2023
Risk-free interest rate	5.3%	5.3%	5.4%	4.6%
Expected term (in years)	0.42	0.50	0.50	0.50
Expected volatility	102.0%	75.2%	98.6%	84.7%
Dividend yield	—%	—%	—%	—%

XML 30 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share Attributable to Common Stockholders

9 Months Ended

Sep. 30, 2024

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE 11. Net Loss Per Share Attributable to Common Stockholders

The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net loss	$ (14,080)	$ (17,400)	$ (54,963)	$ (65,090)
Shares used to compute net loss per share – basic and diluted	227,452,883	152,026,112	193,655,660	145,810,175
Net loss per share – basic and diluted	$ (0.06)	$ (0.11)	$ (0.28)	$ (0.45)

No adjustment has been made to the net loss in the three and nine months ended September 30, 2024 and 2023, as the effect would be anti-dilutive due to the net loss.

The following potentially dilutive weighted average securities were excluded from the computation of weighted average shares outstanding because they would have been antidilutive:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Options to purchase common stock	21,568,098	18,151,747	20,435,908	17,019,217
Restricted stock units to purchase common stock	3,090,220	3,629,741	2,763,739	2,840,178
Warrants to purchase common stock	140,596	227,434	164,150	227,434
Employee Stock Purchase Plan	368,002	337,496	279,880	379,720
Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation	25,166,916	22,346,418	23,643,677	20,466,549

XML 31 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Subsequent Events

9 Months Ended
Sep. 30, 2024

Notes to Financial Statements

Subsequent Events [Text Block]

NOTE 12. Subsequent Events

On October 8, 2024, the Company provided notice to the sales agents to terminate the September 2021 ATM, effective October 18, 2024. The Company will not incur any termination penalties as a result of the termination of the September 2021 ATM.

Following such termination, the Company may not offer or sell any additional shares of its common stock under the September 2021 ATM or the related prospectus and prospectus supplement. From September 15, 2021 to October 18, 2024, the Company sold 17,501,561 shares of common stock for aggregate gross proceeds of approximately $28.6 million pursuant to the September 2021 ATM.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

3 Months Ended
Sep. 30, 2024

9 Months Ended
Sep. 30, 2024

Insider Trading Arr Line Items

Material Terms of Trading Arrangement [Text Block]

Item 5. Other Information

During the quarter ended September 30, 2024, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Item 408 of Regulation S-K.

Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

XML 33 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended
Sep. 30, 2024

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Basis of Consolidation – The unaudited condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating.

Revenue [Policy Text Block]

Revenue Recognition

Revenue from Government Contracts

Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned ("firm fixed-price milestone"). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned ("cost-plus-fixed-fee"). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed, as detailed in Note 5.

Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The Company has reviewed all significant newly-issued accounting pronouncements that are not yet effective and concluded that they are either not applicable to its operations or their adoption is not expected to have a material impact on its financial position or results of operations.

XML 34 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	Level 1	Level 2	Level 3	Total
September 30, 2024				
Financial assets:				
Money market funds	$18,558	$ —	$ —	$18,558
U.S. Treasury securities	—	34,019	—	34,019
Commercial	—	2,657	—	2,657

paper				
Total assets	$18,558	$36,676	$ —	$55,234

	Level 1	Level 2	Level 3	Total
December 31, 2023				
Financial assets:				
Money market funds	$31,403	$ —	$ —	$31,403
U.S. Treasury securities	—	4,958	—	4,958
Total assets	$31,403	$4,958	$ —	$36,361

XML 35 R23.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Cash, Cash Equivalents and Investments [Table Text Block]

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Short-Term Investments
September 30, 2024						
Cash at banks	$ 3,477	$ —	$ —	$ 3,477	$ 3,477	$ —
Money market funds	18,558	—	—	18,558	18,558	—
U.S. Treasury securities	33,997	22	—	34,019	—	34,019
Commercial paper	2,652	5	—	2,657	—	2,657
Total	$ 58,684	$ 27	$ —	$ 58,711	$ 22,035	$ 36,676

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Short-Term Investments
December 31, 2023						
Cash at banks	$ 3,352	$ —	$ —	$ 3,352	$ 3,352	$ —
Money market funds	31,403	—	—	31,403	31,403	—
U.S. Treasury securities	4,959	—	(1)	4,958	—	4,958
Total	$ 39,714	$ —	$ (1)	$ 39,713	$ 34,755	$ 4,958

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	September 30, 2024	December 31, 2023
Prepaid clinical and manufacturing expenses	$ 1,637	$ 984
Prepaid insurance	488	258
Prepaid rent	517	488
Other prepaid	988	752
Other current assets	439	333
Prepaid expenses and other current assets	$ 4,069	$ 2,815

Property, Plant and Equipment [Table Text Block]

	September 30, 2024	December 31, 2023
Laboratory equipment	$ 13,714	$ 13,448
Office and computer equipment	1,120	1,105
Leasehold improvements	4,089	3,985
Construction in progress	141	24
Total property and equipment	19,064	18,562
Less: accumulated depreciation	(9,588)	(6,831)
Property and equipment, net	$ 9,476	$ 11,731

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	September 30, 2024	December 31, 2023
Developed technology	$ 5,000	$ 5,000
Intellectual property	80	80
Total cost	5,080	5,080
Less: accumulated amortization	(1,340)	(791)
Intangible assets, net	$ 3,740	$ 4,289

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year Ending December 31,	Amount
2024 (three months remaining)	$ 182
2025	732
2026	731
2027	731
2028	727
Thereafter	637
Total	$ 3,740

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2024	December 31, 2023
Accrued compensation	$ 4,511	$ 4,576
Accrued clinical and manufacturing expenses	1,309	312
Accrued professional and consulting services	371	211
Other liabilities, current portion	573	535
Total	$ 6,764	$ 5,634

XML 36 R24.htm IDEA: XBRL DOCUMENT

Note 6 - Liabilities Related to Sale of Future Royalties (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

Total liability related to sale of future royalties, start of period	$ 6,426
Non-cash royalty revenue paid to HCRP	(3,596)
Non-cash interest expense recognized	2,045
Total liability related to sale of future royalties, end of period	4,875
Current portion	(2,747)
Long-term portion	$ 2,128

XML 37 R25.htm IDEA: XBRL DOCUMENT

Note 7 - Leases (Tables)

9 Months Ended

Sep. 30, 2024

Notes Tables

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Year Ending December 31,	
2024 (three months remaining)	$ 1,108
2025	4,511
2026	5,031
2027	5,207
2028	5,389
Thereafter	1,348
Undiscounted total	22,594
Less: imputed interest	(4,393)
Present value of future minimum payments	18,201
Current portion of operating lease liability	(2,882)
Operating lease liability, net of current portion	$ 15,319

Lease, Cost [Table Text Block]

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Lease cost				
Operating lease cost	$ 1,554	$ 1,554	$ 4,661	$ 4,617
Short-term lease cost	10	10	29	41
Variable lease cost	496	459	1,381	1,401
Sublease income	(20)	—	(54)	-

Total lease cost	$ 2,040	$ 2,023	$ 6,017	$ 6,059

XML 38 R26.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Equity (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Common Stock Reserved for Issuance [Table Text Block]

	September 30, 2024	December 31, 2023
Options issued and outstanding	21,407,462	17,938,726
RSUs issued and outstanding	3,036,238	2,126,373
2019 Equity Incentive Plan available for future grant	16,957,020	5,685,806
2024 Inducement Award Plan available for future grant	1,727,500	—
Common stock warrants	140,596	227,434
2022 Employee Stock Purchase Plan	2,362,902	1,065,325
Total	45,631,718	27,043,664

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Securities into which warrants are convertible	Warrants Outstanding	Exercise Price	Expiration Date
Common Stock	29,150	$ 2.50	March 2025
Common Stock	100,532	$ 3.125	February 2025
Common Stock	10,914	$ 22.99	December 2026
Total	140,596		

XML 39 R27.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Shares Available For Grant	Number of Options Outstanding	Weighted Option Average Exercise Price	Unvested RSU Shares Outstanding	Weighted RSU Average Grant Date Fair Value
Balance as of January 1, 2024	5,685,806	17,938,726	$ 2.90	2,126,373	$ 1.37
Authorized under 2024 Inducement Plan	3,000,000				
Authorized under 2019 Plan	15,000,000				
Granted	(7,167,480)	5,248,437	$ 1.12	1,919,043	$ 1.14
Exercised		(38,030)	$ 0.78		
Released				(571,884)	$ 1.51
Forfeited	1,872,626	(1,435,332)	$ 2.29	(437,294)	$ 1.43
Canceled	293,568	(306,339)	$ 3.81		
Balance as of September 30, 2024	18,684,520	21,407,462	$ 2.50	3,036,238	$ 1.19

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine Months Ended September 30, 2024	2023
Risk-free interest rate	3.7% - 4.4%	3.5% - 4.2%
Expected term (in years)	6.00	5.50 - 6.00
Expected volatility	128.9% - 130.8%	127.8% - 133.8%
Dividend yield	—%	—%

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30, 2024	2023	Nine Months Ended September 30, 2024	2023
Research and development	$ 1,814	$ 2,404	$ 5,489	$ 6,142
General and administrative	661	1,439	3,657	4,275
Total stock-based compensation	$ 2,475	$ 3,843	$ 9,146	$ 10,417

Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]

	Five-Month Offering Period Ending November 30, 2024	Six-Month Offering Period Ending May 31, 2024	Six-Month Offering Period Ending November 30, 2023	Six-Month Offering Period Ending May 31, 2023
Risk-free interest rate	5.3%	5.3%	5.4%	4.6%
Expected term (in years)	0.42	0.50	0.50	0.50
Expected volatility	102.0%	75.2%	98.6%	84.7%
Dividend yield	—%	—%	—%	—%

XML 40 R28.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended
Sep. 30, 2024

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30, 2024	2023	Nine Months Ended September 30, 2024	2023
Net loss	$ (14,080)	$ (17,400)	$ (54,963)	$ (65,090)
Shares used to compute net loss per share – basic and diluted	227,452,883	152,026,112	193,655,660	145,810,175
Net loss per share – basic and diluted	$ (0.06)	$ (0.11)	$ (0.28)	$ (0.45)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30, 2024	2023	Nine Months Ended September 30, 2024	2023
Options to purchase common stock	21,568,098	18,151,747	20,435,908	17,019,217
Restricted stock units to purchase common stock	3,090,220	3,629,741	2,763,739	2,840,178
Warrants to purchase common stock	140,596	227,434	164,150	227,434
Employee Stock Purchase Plan	368,002	337,496	279,880	379,720
Total potentially dilutive securities excluded from denominator of the diluted earnings per share computation	25,166,916	22,346,418	23,643,677	20,466,549

XML 41 R29.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Nature of Business (Details Textual) $ / shares in Units, $ in Thousands

	Sep. 15, 2021 USD ($)	1 Months Ended Jun. 30, 2024 USD ($) $ / shares shares	9 Months Ended Jan. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	37 Months Ended Oct. 18, 2024 USD ($) shares
Number of Reportable Segments				1		
June 2024 Offering [Member]						
Stock Issued During Period, Shares, New Issues (in shares) | shares		50,000,000				
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.8		$ 0.8		
Proceeds from Issuance or Sale of Equity		$ 40,000				
Proceeds from Issuance of Common Stock		$ 37,500		$ 37,545	$ 0	
RA Capital Healthcare Fund 2024 [Member]						

Stock Issued During Period, Shares, New Issues (in shares) | shares			15,384,615		
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.65		
Proceeds from Issuance of Common Stock			$ 9,900	$ 9,945	$ 0
Gross Proceeds from Issuance of Common Stock			$ 10,000		
The September 2021 ATM [Member]					
Stock Issued During Period, Shares, New Issues (in shares) | shares				7,719,641	17,501,561
Proceeds from Issuance or Sale of Equity				$ 9,100	$ 28,600
Proceeds from Issuance of Common Stock				$ 8,800	
Open Market Sale Agreement, Maximum Aggregate Offering Price	$ 100,000				
Open Market Sale Agreement, Sales Commission, Percentage	3.00%				

XML 42 R30.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	Sep. 30, 2024 USD ($)
Cash, Cash Equivalents, and Short-Term Investments	$ 58.7

XML 43 R31.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Recurring [Member]		
Financial Liabilities Fair Value Disclosure, Total	$ 0	$ 0

XML 44 R32.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Money Market Funds [Member]		
Money market funds, Fair Value	$ 18,558	$ 31,403
Fair Value, Recurring [Member]		
Total assets	55,234	36,361
Fair Value, Recurring [Member] | US Treasury Securities [Member]		
Investments, Fair Value Disclosure	34,019	4,958
Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]		
Investments, Fair Value Disclosure	2,657	
Fair Value, Recurring [Member] | Money Market Funds [Member]		
Money market funds, Fair Value	18,558	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]		
Total assets	18,558	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]		
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]		
Investments, Fair Value Disclosure	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]		
Money market funds, Fair Value	18,558	31,403
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]		
Total assets	36,676	4,958
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]		
Investments, Fair Value Disclosure	34,019	4,958
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]		
Investments, Fair Value Disclosure	2,657	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]		
Money market funds, Fair Value	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]		
Total assets	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]		
Investments, Fair Value Disclosure	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]		
Investments, Fair Value Disclosure	0	
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]		
Money market funds, Fair Value	$ 0	$ 0

XML 45 R33.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accounts Receivable, after Allowance for Credit Loss	$ 590,000		$ 590,000		$ 3,000,000
Accounts Receivable, Allowance for Credit Loss	0		0		0
Unbilled Receivables, Current	3,085,000		3,085,000		0
Depreciation	1,000,000	$ 1,000,000	2,800,000	$ 2,800,000	
Tangible Asset Impairment Charges	0	0	0	0	
Prepaid Expense Other, Noncurrent	60,116,000		60,116,000		0
Operating Lease, Right-of-Use Asset	21,536,000		21,536,000		24,840,000
Amortization of Intangible Assets	100,000	$ 200,000	500,000	$ 500,000	
Goodwill	4,508,000		4,508,000		4,508,000
Goodwill, Impairment Loss			$ 0		
Developed Technology Rights [Member]					
Finite-Lived Intangible Asset, Remaining Life (Year)			5 years 1 month 6 days		
Intellectual Property [Member]					
Finite-Lived Intangible Asset, Remaining Life (Year)			3 years 3 months 18 days		
Facility in Burlingame, California [Member]					
Operating Lease, Right-of-Use Asset					3,100,000
BARDA [Member]					
Unbilled Receivables, Current	3,100,000		$ 3,100,000		0
Government Contract [Member]					
Accounts Receivable, after Allowance for Credit Loss	550,000		550,000		
Deferred Revenue, Current	65,447,000		65,447,000		$ 0
Royalty [Member]					
Prepaid Royalties	$ 40,000		$ 40,000		

XML 46 R34.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022

$ in Thousands				
Cash and Cash Equivalents, at Carrying Value	$ 22,035		$ 33,159	
Cash and cash equivalents	22,035	$ 34,755	$ 33,238	$ 46,013
Gross unrealized gains	27			
Gross unrealized losses	0	(1)		
Short-term investments	36,676	4,958		
Investments and Cash	58,684	39,714		
Investments and Cash, Fair Value Disclosure	58,711	39,713		
US Treasury Securities [Member]				
Cash and cash equivalents	0			
Amortized Cost	33,997	4,959		
Gross unrealized gains	22			
Gross unrealized losses	0	(1)		
Estimated Fair Value	34,019	4,958		
Short-term investments	34,019	4,958		
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]				
Cash and cash equivalents	0			
Amortized Cost	2,652			
Gross unrealized gains	5			
Gross unrealized losses	0			
Estimated Fair Value	2,657			
Short-term investments	2,657			
Cash [Member]				
Cash and Cash Equivalents, at Carrying Value	3,477	3,352		
Money market funds, Fair Value	3,477	3,352		
Cash and cash equivalents	3,477	3,352		
Money Market Funds [Member]				
Cash and Cash Equivalents, at Carrying Value	18,558	31,403		
Money market funds, Fair Value	18,558	31,403		
Cash and cash equivalents	$ 18,558	$ 31,403		

XML 47 R35.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid clinical and manufacturing expenses	$ 1,637	$ 984
Prepaid insurance	488	258
Prepaid rent	517	488
Other prepaid	988	752
Other current assets	439	333
Prepaid expenses and other current assets	$ 4,069	$ 2,815

XML 48 R36.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 19,064	$ 18,562
Less: accumulated depreciation	(9,588)	(6,831)
Property and equipment, net	9,476	11,731
Laboratory Equipment [Member]		
Property and equipment, gross	13,714	13,448
Office Equipment [Member]		
Property and equipment, gross	1,120	1,105
Leasehold Improvements [Member]		
Property and equipment, gross	4,089	3,985
Construction in Progress [Member]		
Property and equipment, gross	$ 141	$ 24

XML 49 R37.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Intangible assets, gross	$ 5,080	$ 5,080
Less: accumulated amortization	(1,340)	(791)
Intangible assets, net	3,740	4,289
Developed Technology Rights [Member]		
Intangible assets, gross	5,000	5,000
Intellectual Property [Member]		
Intangible assets, gross	$ 80	$ 80

XML 50 R38.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2024 USD ($)
2024 (three months remaining)	$ 182
2025	732
2026	731
2027	731
2028	727
Thereafter	637
Total	$ 3,740

XML 51 R39.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued compensation	$ 4,511	$ 4,576
Accrued clinical and manufacturing expenses	1,309	312
Accrued professional and consulting services	371	211
Other liabilities, current portion	573	535
Total	$ 6,764	$ 5,634

XML 52 R40.htm IDEA: XBRL DOCUMENT

Note 5 - Revenue (Details Textual) -	1 Months Ended	3 Months Ended	9 Months Ended

USD ($)	Jul. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jan. 12, 2024	Dec. 31, 2023	Nov. 30, 2022
Revenues		$ 4,933,000	$ 2,101,000	$ 13,515,000	$ 4,134,000			
Income Tax Expense (Benefit)		18,000	39,000	84,000	87,000			
The 2024 ATI-RRPV Contract [Member]								
Government Assistance Award, Amount, Initial Award Fixed Fee		67,900,000		67,900,000				
Government Assistance, Additional Funding Possible		359,600,000		359,600,000				
The 2024 ATI-RRPV Contract [Member] | Maximum [Member]								
Government Assistance, Award Amount		456,100,000		456,100,000				
Government Assistance, Award Amount, Initial Award		96,500,000		$ 96,500,000				
The 2024 ASPR-BARDA Contract [Member]								
Government Assistance, Award Amount						$ 9,300,000		
Foreign Tax Jurisdiction [Member] | National Tax Agency, Japan [Member]								
Royalty Withholding Tax				5.00%				
Income Tax Expense (Benefit)		2,000	23,000	$ 33,000	38,000			
Royalty [Member] | Daiichi Sankyo Collaboration and License Agreement [Member]								
Royalty Percentage				4.00%				
Non Cash Royalty Revenue [Member]								
Revenues		40,000	446,000	$ 662,000	754,000			
Non Cash Royalty Revenue [Member] | Daiichi Sankyo Collaberation and License Agreement [Member]								
Revenues		40,000	400,000	700,000	800,000			
Government Contract [Member]								
Revenues		4,893,000	0	12,853,000	0			
Government Contract Receivable, Unbilled Amounts		3,100,000		3,100,000				
Deferred Revenue, Current		65,447,000		65,447,000			$ 0	
Government Contract [Member] | The 2024 ATI-RRPV Contract [Member]								
Revenues		4,000,000		4,200,000				
Deferred Revenue, Current		64,800,000		64,800,000			0	
Government Contract [Member] | The 2024 ASPR-BARDA Contract [Member]								
Revenues		900,000		8,700,000				
Deferred Revenue, Current		600,000		600,000			$ 0	
Grant [Member]								
Revenues		$ 0	$ 1,655,000	$ 0	$ 3,380,000			
Deferred Revenue, Current								$ 2,000,000
Grants Receivable								$ 3,500,000
Grant Milestone Completion [Member]								
Revenues	$ 1,500,000							

XML 53 R41.htm IDEA: XBRL DOCUMENT

Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual) - HCRP [Member] - USD ($) $ in Millions	1 Months Ended Apr. 30, 2016	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023
Proceeds from Sale of Future Royalties, Net	$ 20.0		
Royalty Interest, Covenant, Cumulative Remaining Shortfall Amount		$ 6.0	$ 7.0
Royalty Payment, Interest, First Period [Member]			
Royalty Interest, Covenant, Shortfall in Royalty Payments	$ 3.0		
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%		
Royalty Interest, Additional Royalties Due Each Year	$ 1.0		
Royalty Payment, Interest, Second Period [Member]			
Royalty Interest, Covenant, Shortfall in Royalty Payments	$ 2.7		
Royalty Interest, Percentage of Additional Royalties Due Each Year	15.00%		
Royalty Interest, Additional Royalties Due Each Year	$ 1.0		

XML 54 R42.htm IDEA: XBRL DOCUMENT

Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - USD ($) $ in Thousands	9 Months Ended Sep. 30, 2024	Dec. 31, 2023
Current portion	$ (2,747)	$ (3,803)
Long-term portion	2,128	$ 2,623
HealthCare Royalty Partners III, L.P. [Member] | Royalty Arrangement [Member]		
Total liability related to sale of future royalties, start of period	6,426	
Non-cash royalty revenue paid to HCRP	(3,596)	
Non-cash interest expense recognized	2,045	
Total liability related to sale of future royalties, end of period	4,875	
Current portion	(2,747)	
Long-term portion	$ 2,128	

XML 55 R43.htm IDEA: XBRL DOCUMENT

Note 7 - Leases (Details Textual) $ in Thousands	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2021 USD ($)
Operating Lease, Right-of-Use Asset	$ 21,536	$ 24,840	
Operating Lease, Weighted Average Discount Rate, Percent	9.80%		
Operating Lease, Weighted Average Remaining Lease Term (Year)	4 years 4 months 24 days		
Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member]			
Lessee, Operating Lease, Number of Right-of-Use Leases	6		
Lease for Facility in South San Francisco Commenced in Third Quarter of 2022 [Member]			
Operating Lease, Right-of-Use Asset			$ 15,000
Lease for Facility in South San Francisco Commenced in First Quarter of 2023 [Member]			
Operating Lease, Right-of-Use Asset			$ 3,100

XML 56 R44.htm IDEA: XBRL DOCUMENT

Note 7 - Leases - Lease Liabilities Payment Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
2024 (three months remaining)	$ 1,108	
2025	4,511	
2026	5,031	
2027	5,207	
2028	5,389	
Thereafter	1,348	
Undiscounted total	22,594	
Less: imputed interest	(4,393)	

Present value of future minimum payments	18,201	
Current portion of operating lease liability	(2,882)	$ (2,703)
Operating lease liability, net of current portion	$ 15,319	$ 17,385

XML 57 R45.htm IDEA: XBRL DOCUMENT

Note 7 - Leases - Operating Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating lease cost	$ 1,554	$ 1,554	$ 4,661	$ 4,617
Short-term lease cost	10	10	29	41
Variable lease cost	496	459	1,381	1,401
Sublease income	(20)	0	(54)	0
Total lease cost	$ 2,040	$ 2,023	$ 6,017	$ 6,059

XML 58 R46.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	Nov. 02, 2022	Jul. 27, 2022	Sep. 30, 2024
Purchase Obligation			$ 8.5
Himmelberg V. Vaxart, Inc. et al. [Member]			
Litigation Settlement, Amount Awarded to Other Party		$ 12.0	
Payments for Legal Settlements	$ 2.0		

XML 59 R47.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				9 Months Ended				
	Aug. 04, 2022	Jun. 30, 2024	Apr. 30, 2024	Jan. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Jun. 11, 2024	Mar. 31, 2024	Dec. 31, 2023
Preferred Stock, Shares Authorized (in shares)					5,000,000				5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001				$ 0.0001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0				0
Common Stock, Shares Authorized (in shares)					350,000,000		350,000,000	250,000,000	250,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.0001				$ 0.0001
Common Stock, Increase in Shares Authorized (in shares)	100,000,000								
Dividends, Total					$ 0				
Treasury Stock, Common, Shares (in shares)					700,122				507,020
Class of Warrant or Right, Expirations in Period (in shares)			70,663						
Warrants Expiring March 2025 [Member]									
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)					$ 2.5				
Warrants Expiring February 2025 [Member]									
Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)					3.125				
June 2024 Offering [Member]									
Stock Issued During Period, Shares, New Issues (in shares)		50,000,000							
Shares Issued, Price Per Share (in dollars per share)		$ 0.8			$ 0.8				
Stock Issued During Period, Value, New Issues		$ 40,000			$ 37,545				
Proceeds from Issuance of Common Stock		$ 37,500			37,545	$ 0			
RA Capital Healthcare Fund 2024 [Member]									
Stock Issued During Period, Shares, New Issues (in shares)				15,384,615					
Shares Issued, Price Per Share (in dollars per share)				$ 0.65					
Stock Issued During Period, Value, New Issues					9,945				
Proceeds from Issuance of Common Stock				$ 9,900	$ 9,945	$ 0			
Gross Proceeds from Issuance of Common Stock				$ 10,000					

XML 60 R48.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2024	Feb. 27, 2024	Dec. 31, 2023
Common stock reserved for issuance (in shares)	45,631,718		27,043,664
Common Warrants [Member]			
Common stock reserved for issuance (in shares)	140,596		227,434
The 2019 Plan [Member]			
Common stock reserved for issuance (in shares)	16,957,020		5,685,806
The 2024 Inducement Award Plan [Member]			
Common stock reserved for issuance (in shares)	1,727,500	3,000,000	0
Share-Based Payment Arrangement, Option [Member]			
Common stock reserved for issuance (in shares)	21,407,462		17,938,726
Restricted Stock Units (RSUs) [Member]			
Common stock reserved for issuance (in shares)	3,036,238		2,126,373
ESPP [Member]			
Common stock reserved for issuance (in shares)	2,362,902		1,065,325

XML 61 R49.htm IDEA: XBRL DOCUMENT

Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)	Sep. 30, 2024 $ / shares shares
Securities into which warrants are convertible (in shares)	140,596
First Set of Warrants Expiring April 2024 [Member]	
Securities into which warrants are convertible (in shares)	29,150
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 2.5
Second Set of Warrants Expiring April 2024 [Member]	
Securities into which warrants are convertible (in shares)	100,532
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 3.125
Warrants Expiring March 2025 [Member]	
Securities into which warrants are convertible (in shares)	10,914
Securities into which warrants are convertible (in dollars per share) | $ / shares	$ 22.99

XML 62 R50.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans (Details Textual) - USD ($)	9 Months Ended												
	Sep. 30, 2024	Sep. 30, 2023	Nov. 30, 2024	Jun. 11, 2024	May 31, 2024	Feb. 27, 2024	Dec. 31, 2023	Nov. 30, 2023	May 31, 2023	Aug. 04, 2022	Jun. 16, 2021	Jun. 08, 2020	Apr. 23, 2019
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	45,631,718						27,043,664						
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)	21,407,462						17,938,726						
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.5						$ 2.9						

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	6 years 9 months 29 days									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 538,000									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)	12,618,062									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.02									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)	5 years 4 months 24 days									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 379,000									
Proceeds from Stock Options Exercised	$ 30,000	$ 17,000								
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	38,030	54,720								
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 7,000	$ 31,000								
Share Price (in dollars per share)	$ 0.85									
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.01	$ 0.78								
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 15,900,000									
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 3 months 18 days									
Proceeds from Stock Plans	$ 312,000	$ 298,000								
The 2019 Plan [Member]										
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			43,900,000					28,900,000	16,900,000	8,000,000 1,600,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	16,957,020				5,685,806					
The 2024 Inducement Award Plan [Member]										
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,727,500			3,000,000 0						
The 2022 ESPP [Member]										
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,362,902		3,600,000					1,800,000		
Share Price (in dollars per share)				$ 0.27		$ 0.54	$ 0.46			
Proceeds from Stock Plans	$ 300,000									
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)	502,423									
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 41,000									
The 2022 ESPP [Member] | Subsequent Event [Member]										
Share Price (in dollars per share)		$ 0.28								

XML 63 R51.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details) - $ / shares	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Shares available for grant, balance (in shares)	5,685,806	
Number of options outstanding, beginning balance (in shares)	17,938,726	
Weighted average exercise price, balance (in dollars per share)	$ 2.9	
Shares available for grant, granted (in shares)	(7,167,480)	
Number of options outstanding, granted (in shares)	5,248,437	
Weighted average exercise price, granted (in dollars per share)	$ 1.12	
Number of options outstanding, exercised (in shares)	(38,030)	(54,720)
Weighted average exercise price, exercised (in dollars per share)	$ 0.78	
Number of RSUs outstanding, release (in shares)	(571,884)	
Released, Weighted average grant date fair value (in dollars per share)	$ 1.51	
Shares available for grant, forfeited (in shares)	1,872,626	
Number of options outstanding, forfeited (in shares)	(1,435,332)	
Weighted average exercise price, forfeited (in dollars per share)	$ 2.29	
Shares available for grant, canceled (in shares)	293,568	
Number of options outstanding, canceled (in shares)	(306,339)	
Weighted average exercise price, canceled (in dollars per share)	$ 3.81	
Shares available for grant, balance (in shares)	18,684,520	
Number of options outstanding, balance (in shares)	21,407,462	
Weighted average exercise price, balance (in dollars per share)	$ 2.5	
The 2024 Inducement Award Plan [Member]		
Authorized (in shares)	3,000,000	
The 2019 Plan [Member]		
Authorized (in shares)	15,000,000	
Restricted Stock Units (RSUs) [Member]		
Number of RSUs outstanding (in shares)	2,126,373	
Balance, Weighted average grant date fair value (in dollars per share)	$ 1.37	
Number of RSUs outstanding, granted (in shares)	1,919,043	
Granted, Weighted average grant date fair value (in dollars per share)	$ 1.14	
Number of RSUs outstanding, forfeite (in shares)	(437,294)	
Forfeited, Weighted average grant date fair value (in dollars per share)	$ 1.43	
Number of RSUs outstanding (in shares)	3,036,238	
Balance, Weighted average grant date fair value (in dollars per share)	$ 1.19	

XML 64 R52.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans - Assumptions of Options (Details) - Share-Based Payment Arrangement, Option [Member]	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Expected term (in years) (Year)	6 years	
Minimum [Member]		
Risk-free interest rate	3.70%	3.50%
Expected term (in years) (Year)		5 years 6 months

Expected volatility	128.90%	127.80%
Maximum [Member]		
Risk-free interest rate	4.40%	4.20%
Expected term (in years) (Year)		6 years
Expected volatility	130.80%	133.80%

XML 65 R53.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation	$ 2,475	$ 3,843	$ 9,146	$ 10,417
Research and Development Expense [Member]				
Stock-based compensation	1,814	2,404	5,489	6,142
General and Administrative Expense [Member]				
Stock-based compensation	$ 661	$ 1,439	$ 3,657	$ 4,275

XML 66 R54.htm IDEA: XBRL DOCUMENT

Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details) - The 2022 ESPP [Member]	5 Months Ended		6 Months Ended	
	Nov. 30, 2024	May 31, 2024	Nov. 30, 2023	May 31, 2023
Risk-free interest rate	5.30%	5.30%	5.40%	4.60%
Expected term (in years) (Year)	5 months 1 day	6 months	6 months	6 months
Expected volatility	102.00%	75.20%	98.60%	84.70%
Dividend yield	0.00%	0.00%	0.00%	0.00%

XML 67 R55.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net loss	$ (14,080)	$ (17,400)	$ (54,963)	$ (65,090)
Shares used to compute net loss per share - basic and diluted (in shares)	227,452,883	152,026,112	193,655,660	145,810,175
Net loss per share - basic and diluted (in dollars per share)	$ (0.06)	$ (0.11)	$ (0.28)	$ (0.45)

XML 68 R56.htm IDEA: XBRL DOCUMENT

Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	25,166,916	22,346,418	23,643,677	20,466,549
Share-Based Payment Arrangement, Option [Member]				
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	21,568,098	18,151,747	20,435,908	17,019,217
Restricted Stock Units (RSUs) [Member]				
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	3,090,220	3,629,741	2,763,739	2,840,178
Warrant [Member] | Common Stock [Member]				
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	140,596	227,434	164,150	227,434
Employee Stock Purchase Plan [Member]				
Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)	368,002	337,496	279,880	379,720

XML 69 R57.htm IDEA: XBRL DOCUMENT

Note 12 - Subsequent Events (Details Textual) - The September 2021 ATM [Member] - USD ($) $ in Millions	9 Months Ended	37 Months Ended
	Sep. 30, 2024	Oct. 18, 2024
Stock Issued During Period, Shares, New Issues (in shares)	7,719,641	17,501,561
Proceeds from Issuance or Sale of Equity	$ 9.1	$ 28.6

EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A, ")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^;/5>A M6$G:A/@01AKBG'/F<|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

(8O_\/P"U:+FJ%#*:(&V"V^T@M8A-WLF4V8GN>5;S:L[6*U/QWFM MX0W/NE^=IW1=KFU!,.XLO";'6>D% WE&,,!R *J=3@F-@NFD^.,F)PRU=I1!V>S=,P(O.4TFG/
MI\VE0Q_1\60Z#@LF-C?:*RCJ5U ?\KPP' :[L#DQ."MJE+%M ;NR\T#35CT1 MA?D>0W78A7$R>;!!>WU$G]%'$J1&(Q_WY8>8.8%3>HX2*!LR*%H?',:!.5!;*9V%
M<1C1L8)U&@;+83S'2 ='Y'Y1-43;'3R*"G;HC?F(M8,=L89[CMZ60BDG;U*' M+++@VS9G4^75"R?]%TYL.:(F.<\)UA9&<1I:IQ0.LRA)@ZD%W"LH^D(%U=;X
M"T,X\2S#8>6E&_M+IY4E:#;RF2[WC=.,IT.F_#;V1Q%%I-N<-L M7)N+P1=?\[G]=R;OBUI!"[N&,<'[!(I;[K]@[V^TV+8?@>^$UD]I+S>V4'27[@ * H !@ M !X;"|W;W)KBEM2KB?!&H
M &FEFK:+2:BLV[6;&&+5L3/;@6Z_?L=.FO%-Z7I1_''>D^<].6"/UE(]ZX)2 M@UY*+O38*XRI;GU?9P4MB>]D)B@K864A5$@-3M?1UI2C)G:CD?HAQWR\)$]YD MY-
9F:C*2M>%,T)E"NBY+HG[?42[78R_P7A<>V+(P=L&?C"]RI'-]'JN9@IG? M90_66Z*L3?P4$X7L.;F0:Z_ MT-908O-EDFOW'ZW;6.RAK-9&EJT8"$HFFD_RTA9B0Q#$1P1A*PC?
*HA:0>2, M-F3.UCTQ9#)2'Z&GU$'Y"/= '+>N0;@+*I M_;P%N&L PB, EI^3S.0!TX>;1Y%;CD8 M= X&ESMX6Y,/IG"09#VX[B_0(\:0?&231,[0.DN@P_;"C'UY.?T'#P]82..T M']E38,O"?
B18B)-P$!VQ$.!_AQ\^:>(IW'QTK7ZC>6.C,74#QYZS<\9"FWR3 M+(6^#L_= P?B$ISB<+=__(UCW-ZAOA&U9$(C3A<@Q+T4J,JCF6M),C*S&PO=V]R:W-
H965T&ULK5I=4^,V%/TKFG2G M S,+L>1O"IE9$G>[,]TM TO[T.F#2 3QU+%22PEL?WTEQ\2Q?"U@JQ>(G7./ M=#]T?:3X_)%7?
XLE8Q(]K8I27(R64J[/QF,Q7[(5%:=\S4KUS3VO5E2JR^IA M+-85HXO::%6,B>=%XQ7-R]'DO+YW54W.^486>C/#H M^<9U_K"4^L9X?S3D([V8VK#P_/
MI#_7SBMGJ]A@4U[\D2_D\F*4C-""W=--(;_YXR^L<2C4Z'->B/HO>FRPW@C- M-T+R56.L9K#*R[U_^M0$XL! \< &I#$@ID$P8. W!OYK1P@:;@^"U(X2-0>WZ M>.=
[';@9E71R7O%'5&FT8M,?ZNC7UBI>>:D+Y496ZMMHQ.T.W-#!Vl.T;O4%ZBKTN^$=CQO)G>YFQP9F)R//O-2+@7* MU"07@/W,;I]:L,=H71(KX0U;GR+?>X^(1P)@/M/7F_N0._]O].R[
M1^\$P]^7CE_S^0-\UVS+R@T[@_*ZLPQ@2]W\SL2:SMG%2!628-66C28__H C M]RV&"89?3O6VQ11*Q$".IKUA3U2@8Z/_32%8 MG!"SH %8&"1FS\T
6!2I46%GL==*/<_>4>6254]2S?F*H:,FO\=@5VV8+55 MIVPSIVR9*]9N3@ID-[:6X*=2,L4KF[2 N<#]=>29M34%4'%OK4%4:6#6'X B M7AP-E!]I72565[_P\F1.Q5*YVOCO]:
[QCMUSE>3&;TF?!O(<0%W8BWHN M0[C8C\R'+(13?3@VE06$BY1.&4IW]VRQ5:Y-KBJ^S>NC%N7_R^Z' 45K/FH! MC)^:;O#"((U\ MTU$ IW*;>@/.ML(1VY7CL[-
(:0LDEE35]XD^RLKG._F<%QO=ZH[R$BUX4=#] M 'D.1F@W7G(X4^_4,R4U#,.]V@=A)#'# \(.VF$W.JW&Q':1>:/=%&@C=MU> M%?Y:A4/WN=<&K?Y6P)'JBT1"XB D26+N?
0$H#HE'(HQ-T09!4$*PRCRS*@! MT$"I5 _'0Y%KI2I.K>*M>^BF@P4+-ZOB?;-P<\DV<\J6N6+K'@2V8II8A:&U MJ36F+S8U$!F&0@)*V: M)78UVU^/H)^ 7E25X,>FKQ N]A-
3ID(X50F^J5,A7*2VFF3 [5:I$KM252(> M3;6(OZZ5^3?4'$.B/S^SU1VK_@*CX/0XV"G;S"E;YHJMFYU659@NX_DB560 MOSD)+MEF3MDR5VS=)+3JGMC5O>U@GO3U==![*@"8(#
(;01\4F1NB# #%X< Q M(6GE/+'+^8]\RZI2MWG]FZ&LZ%S:5[^5[LV%YY)MYI0M<\7634R[]2#Q]Z]^ MZZ[ES4EPR39SRI:Y8NLFH=WA$/L.Q[KZ^_N#($E[NJ>/Z@E"8*-!DK"G!VU,
M7?_:?0BQGYE_K&CYPGIWN@5QRC9SRI:Y8NO^_-YNP07SI>;[U!WBQ.,A.V69. MV3)7;-TDM%LCW[XUL]WWQC0:7LE3 (*CWCGMRT09 /'!Q%SNXX,WA5:L>]A?
MT1)HSC>EW+WYL;^[?PWL0_WRDW'_$I]-,7!_AL^RW4M>+?WNG;//M'K(2X$* M=[^&\DYCU9:JW6M&PO=V]R:W-H965T&ULM=U[<]I8FL?QMT)EI9GJL8==
',.;#I5//N=8HOT<#O#3A^_KS6_;^RS;-7[_ MNEQM?WUWO]L]_.O]^^W-??9UOOUE_9"M]G]SM]Y\G>_VWVZ^O-\^;++Y[=-! M7Y?OU6:S_?IK?+%Z]_'#TY\%FX\?
UH^[Y6*5!9O&]O'KU_GFCZMLN?[^ZSOE MW?,?A(LO][O#'Q7H^23]_M-?[^MW\T_M8%P B6+LEWR$&SVW[U_46X77[/5=K%>-3;9W;_O#.5? MQE5;/1SQ5)(NLN_;G[YN"Z6S^OU;X=OG-M?
WS4/4\]6VNO]O9\2=]';R;]7+[]. &]V-M\UWCYG&[6W\]'KR?P=?%ZI=_Y[\?S\1/ M!^Q_T.H#U.,!:O& ,!K>((YPYH^P]H M%PY0+\\T'GM6;H\'G#YVK/4/1[0?
>U94IK/5Z[YVO.DO%SLXM4^^X,K MSY=;*5[OCG+ND.<+KI2N>/?<(<^77"E>\XYV[I#GBZZ4KOK9,_9\V97B==(KQ:O?.3?>WL;Y3GJZ\6K[[6/G?(\)57BU=?/7O&
MGJ^^^NJKKSY??;5X]95SEU)]OOK]T]5__^,7\=-O\=Y\-_X8;/^WM@ MX8NG5O!T_/Z7]V)U:%O1;K/_V\7^N-W'3^O5[;X)9;>-_5?;!7)Q.]_MOXEV M^__LN]-NVUC?
[.];W_QVOU[>9IOM?S7,?S\N=G\T_IZLYH^WBWWU/QH7C23]

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jFS#W871#M<3E2 M*$FTBUI/2;Z'>].=M;$=]T0>]=$_@,&ON1+]3AJR>/V(+)DT'0%#,(0YEFA M- @C#RI166OPV-)[CN>[]-^-V"4ZDMC(#);/*8DL,B8#S&$V9S&/*+XKK6I[MM8+0(%LC$0%<0H|!2MN:RKU&8-X"I@P-BIGZ.*VJWE')JO/:UJE$P(E (X;Y M<.%$<.6(#:?./*"V]III$3@ 5U/2VG-F(+_H\VK<;!+OP!N[7<7%L?-WM=IAJMMYIZW>7&-,@8/H6I?RF)MT+FH)(+-ER/F+F:'\K5X3?8JJD>-JJ[E1HKM-C.LW;D2)JI46EGLCN1.,XMF" CXWCC:$>[#\?S_Z%<D:Z+N*\V;$3"]YL4Z M-=BDD8[$DTWZ?Q.W0=1=+T-%/(3*X?FQZKA>E(=2^@QR^QY I|/"%@ M&!-.S2@E^J'-+?8UX3A^&88|GW*HB[W)0!?[- $<-R"J_?V\3RLV=^G/YJZ1 M'\28L/^?YVE?&2!.)PA=RM/9@K+TF8':!$59"EU33WV4DZ=DNTQW$O9I?&/" MW\G@[V:N\YVT?-$?_T:;IO<,JM$[%C\UD,H2#>W9N7W]4(+>Q+"!<+@W]XDF M8K/ #*:,:A,&LW: 9H4/0!A#MJH ,N.:]F&VD#"'"Y3OFQ+FZ7@#44+&;(> MQ3^+I5I9]'0A,6R24"I%Y]:-7[I?MT1O %Q(6A<['7>\=A>,M8*QP+C921K4 MF:9M;?-AP0QVPI%6_YZ^V_M*26D,Z:)9P")<_]M8GCJS:6CJT#0(V;X7LDGO M.3,7P/OT:$N61 38EU\UNMGL7/K7/H5MR^ZC*ZX+|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|L?2\/FISZ3'Q4&]321_&,VE33M*7B<28V)6DG^#X7I*(6KO6'2&/IH/S[.83J9W4]<=M_WVM=T+@E19^]|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|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}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|/$.E M/!'+N.LYHZ&D!^ZNG|@O0N_D 6='>%@LK/@D0^LV8+ MUFWZZ64QZ=4 &+]06NI!"P9($8?U:OQW==#^=-\R):T2!\X@=X=#>8Y2_?9.^ M3SX=$#L=Q$X/L>Y-NOMOO\8[C2<%606:&%XV[< M(^#I\VC\%L?I<)[V"6/0AOY/NC"*?2[UAFU>5$!H^:<5WH CH KAS-2-T(_\M"S_N@S^'Z=%H?]D7NO:-.MYQ1(UV$WSOH#"MILX,+Q-$" Y"@ &0 'AL+W=O-6'LS!*%ES_F",53+SA,04HR582!Z>,0E4FJ(=!B_=YQ>3,5/%6";V;:YR*5KH>"0[X$R3)60IS(0A+4==)R:FO[G&SX]W M;(N:+3S"-H KSE0FX1-+,&G!+]WX#PZ\KY4U\L*]O$7H)+S%L@>#X 3"(!RVMQ=,9_B*<09/M@>4;O#[;\$7[P$IAT9KOFF_8SF=>\7-9DAAGGGZ')8I']*+W M[_KCX&.;V/|$]D+ZL)$^=+%'5T2AR F%.Q2%!+YINW)P?X=/"A:4QP^_VM+A M/..MZ>A -H(>?%.9+N&*U9]0\RVZ](01HM?A=T6$%@IH+C#H^Z,+N]:V_A*= M ./0'Q/H0S]8CYZ'83 !1Y!'39!SC3?5!0MY6G_16+G"=>A)'!_24G:FEHW M[X90B6U)=,(ZW]EQ(W;<2:RY8CDK;KUNZJ-ZG;".>L\:O6?.H+YR=M]IP&[N MHX*=L(Z"}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

M8,:5OBBZ(PK+.8JN+3NWB%C80W,+\$7??['6\V91LUS"1P@&;K_T)N3#X,P M",_W=JWRH3?MP4Q8VB\@#66]J&[9UC**73\X>RM>\K)$82%4I-+8MOK03?JG M;Z2&1P-U%U:4N,EILH>JWW?#*(;C%;G"K"U(8 L2_6]!M'WL1^\4I%7^LR"Q M>Z;1[TMQ&'9Y&NU>EL2-D@ .W5YO9]KHXB[M3)60\9JI9O!T]W8OFBFU:MY M,_-OB5A2)J' A7;U>Z=]!T0S1QM!\A+:[4K_>E 8 ZU?&ULQ5C[;]LV$/Y7"*\H4D"-]7ZDB8$\FJY N@5-VF$8 M]@,CT[80251)*H_]]?N.DA4G=04#'3 @L/BX.][==W<\YO!>]EN]$L*PAZJL M]=%D94QS,)WJ?"4JKO=E(VKL+*2]N,%4+:>Z48+/+5-53GW7C:<5+^K)[-"N M7:K9H6Q-6=3B4C'=5A57CR>BE/=`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|G.>] MA8\O"GY3E-W=O)L#\ _XB;A?:T1E#7AVV%*81;;5PI<:K#71#E<; MI%I?/\ M@0N)LD 60'#/F:,X@E);*0[*BOZG 20X,CN&BN?_.,_-U1#T0?MHB1@$?]_ M-5*QD\2AS=$X"+B*/NX3BL#_NX^ZU^43>O=D_<;6D M5K$4"["Z^PG:"=6]@[N)D8U]>]Y(@Y>L':X$GPM%!-A?2#S!^@D=,/PS8O8O M4$L#!!0 (.Z";5FMQUN$QP(![& 9 >&PO=V]R:W-H965TBVAVD/)KD! MJXZ=V4Z!_?K93DB91'G8"_''/>>>8_M>1ALA7]0;4<.V8%R-O;76Y740]'2-M!5&7HD1N=G(A"Z+-5*X"54HDF0,5+(C"L!\4A'(0&;FUF4Q&HM*,CIVA!QGFI&)Z+C;WV/CI6;Y4,.5^85/'l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|FV4?W!ZP8;#= 6,1"1.(U(ZL= $Y(%*4E8#,^! M>9D/C% 6DR)<(%Z00+CQJRD*O[&+!K$KVI-?*KS9NY.P-$# N+[OOT=DZ=9 M*T2C3LKE@R)C*:%Q0L+4AU<8%PM3$}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|/-8&YHP_ _HD"MM(7\H]8P]ZY]/R MK-'6/:(A74B-(.KGD7#-K8^=2&Q>T7NF\U#-S/H'FK0RPQZAQKT,X/^H=71,:AT@RG7#^@[6]'TAHFOL581"6(MQ;GDZFB@[.3TBDF*,/H-7?,U MB8~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|RJ\OMEG3H!/-]2LVS5.<]=MB(5\SI)\SXX3<\RCB(IT=MR1!14G0,\>/5XF83+5\V/%U!R,B9P#/1;6&W]\ M3]B2A.GH<6GN3*RNY@T%*_3P/.OA>0N:GY?41+UN?TMRYXD/+ L&%C*"XQ9'MS2GJ/EU=R9N*5FQ.CL!@PY-T$["[9Y16F#EF*;3$]W(LU?-O,%-O$C,R7KO7$9UIWZCH-=4M&(/+>I!-^L=,/7+H%KU^;TO$"K/=7]%0 M[K>JUL@-'3GTW9G55KD-MD.6[9";[0Z[L,*E*OX=EYAYM#> A]J#?CO$YG] M[@)J+Y$VN!!9+D1M<"$J0U_%EWGWJ0\MS5(D:HTBT1'CWYU5[>71!AHBBX;(MC8;UQS_:CX5.DV*BEO50:ZR'W7(V2G--12MVR=(<"Z3XB,: MRVRX-6;#1\[=V9UY6TJ6K&/ENJPF^H.NYGC,L1MB^XT*29K(0^W!GGXYPQZ M=P&UUT8KCT%SST';8$%]["Z+_BUG@1'S'EW5G57AMM0""V$(C= M$'0_)NZ?EW:5VX3-:)^KD70LS;.+K[SRR6(*0S[1.<]G4(L7[!9;VC^")[M1^2)*\6C='-.R90*8Z _GW&NWG;,:R?9:T:C_P%02P,$% @ [H)M6?E\ ME3A?!@ .RL !D !X;"]W;W)K&ULK5IM<^(VM$/XK&MKIW.TDAVTP(2EA!K#=9N9>,LFEG4ZG'Q2S@.9LB\H"DO[ZRB_!& L! M=WL?+F"TSR,]JUU[UQILN/B6+@ D>8FC)+UM+:1MD7T3.&YF MD(_X@\$FW?E,LJ4\<_XM^W(WO6U9V8P@@E!F%$]6]6<,$HBA#4O/XMP1M;3DS MP]W/;^A!OGBUF&>:PH1'?[*I7-RV^BTRA1E=1?*!;WZ!?G_9%,.M]3DM$JY2R>/26,T=9DGQE[Z40NP8*!R]@5,:./L&W0,&G=*@LV?@'&+HE@;= M4QGF M[.3P,Y= NN22C&E$DQ#(8[Z?)SQ>\@02F9)W'DC*HI1\A1>YHM%[-?CIT2/O M?GX_:$LUA0RH'99TXX+..4#7(9]X(A[X2P%/CNSL3VM3?.X%SMC]+YF'2!B:XFN+L5W#4* M_I0\LRB"Z8[@Z069K(10"52GK]N80D#KWE;KMGE%K#Q1MR&CV6**3MM<@M/=BJI"VUX@][3BOB>?T->/\)IYV7&!GJUK2[MVFIW9=3N*TWF3&U.,DI3=8^_BY>4"?64J&]W"RKFH,T%5T=SP=$1WM$1_M$1M@7%IWRE9:L)-;:B MD?O<*#^5U<=D#9JL!\+\>JOXM5'Q+TL0*L;3.?D(JFZX'G)<\EGET]IN7]U MFE\WH]5V.QK-C>SG:GXJJX_)&FA8N_WNX<<'VZI* LO\ !%S(=E_>8XE?$;NM$EG+'-H\46(V,^^>\N6X6J;4)5X-GJM+O!H\W;C O.;O3"#V3IEE&S7]C?/I M1CTE:*6S&TOMNE9?HYV1X]QM>RJMCTH;G$!;U]BI-'9.TOAB]!9VZ!G7C'7F MHB:H:%Z)UC/<,%$)RRTNN.JNM$V%XX>K"B2_4$_17"1<(C/G\M,GY*_OX$ M\3.(?0^Q"S')JAH'BJ:CXH68*5W5W5I;Y0 U8PB1@$%TUB5[]N78Z)YJ&@^*EJA5;W>M4BL"BN:CH@5VL^72V:NWZXZL.B^VN?4R'CUX(W.$O8O)JAH'BJ:CXH68*57W16;1W\W-8Y^S6%TVS![.^Q\ATI4F^E?&7:[.AH:7U4VD"S MV@.QY%1='^=8UVX<-(BE:[.HA0-!0&B/+#'=N9*&B>;AH/BI:@(56=W/5>'+, MC2>L%]\E3:WGZ>KB#;7;="*KC\H:8*'575:UG)QC+:<9J,27)<,U)"LP)\). M\ZV*V^U>;3R#VD,ZF==*Y0VB@ MHOFH:$66MVU552',7=UWEZ/%BYF^O?O<;NGNKJ4AMJA^8T4A^5-.]"*[S1 MWCG;%X.8YZH_Q\X[IUL7TSL377/?O&+\YQ5O#%L=)/M5,Q9DI((9HK*^G"E%B:*DYK%%\F7^&ULM9K1;MLV%(9?A?"*H0/26J1DV>X< ZVE;KUH$=1M M=S'L@K&96*@DNB0=-WOZ4;(CF2+#6.OI32)9Y_PD/\GD^4W-]EQ\E1O&%/I>MY*6\'&R4VKX;#N5JPPHJ7_(M*_65&RX*JO2IN!W*K6!T72<5^9 $03PL:%8. MYK/ZLRLQG_&=RK.270DD=T5!Q?T;EO/]Y0 /'C[XF-UN5/7!<#[;TENV9.KSM]DKHLV&CLLX*5LJ,ETBPF\O!;_PJ#8,JH8[XDK&]/#E&U5"N.?]:G;O;7PZ" MJDB2!'!/(N0GA,2$\-R$Z)D3G)HR."720AX>QU^ 2]NA\)O@>B2I:JU4' M-?TZ6_/*RN!!62]AKV8Z3\T_<,50A%Z@-S2GY8JA9?UX>4GE26=27%E1N M$"W7AX/TVRZ[HWE]K?KP77G'I"KJ\^<)4S3+Y6\ZZ_,R0<^?_8:>H:Q$GS9\ M)W6TGV5[G75]G!U[.&:0P_)(SU'CO3D M_-9=Z>GYK1,S?:CO5'.[2'.[2*T7/:+WZ*VX0%3?-2K$?5;>HB\TWS$?ZH-Z M7*M7<\C=G) @',V&=Z=$O7VHIJY7E%Q#CBR!SSNC-;;5-_G!5(LM!1(S$(\:Q*-^B'-]SIR,1Q;CH(/8CGB!.T^3MS=]P0&)&>#B!ESL!;?<<*%> M*"8*O70TBXN+6VQ1">-X''?8V5'1=-3YEB7>+O6E!R1FT!LW],9>>J?K\<-*MX6(WMJB,)O$DZK"SH\+I&'>B$F^/^L(#$C/@31IXD][P+M!;FHG#FHJ23*[T M]W@GG,OKQ,%TC#M?U(4=53$-.TR]>W+%$C,8#IMF$Z]3#\OT2<[!VIF]VC) M5CN1J8Q)]/=[5EPS\8^+HU>PY]@7D&()I%@*)&;<%1RTE7\ 5_8+#?]IQ?J1Z%S-J\"Q#4VX"JI5!]NC6!6&_#>I1KV+!5FS@1UB M%:S^#O7&!Z1FXFL-%?8[JE2JK*!*I-\&?M89=PZY>PWS"=7_=CVPXY&=IA+H:@Q@E*S6386B?L]TX+7A1,K#*;HRNZ9>(" M?> *O2M7^6ZM\U]IC:>W_-\-9F,X;Y%&:A: JJ60JF9M[#U;]AOX/K59;9!MLV9B2'>6@*JE4&HFZM;M8;_=.Z,NL\T:B4=650%IUA)0M11*S43[S$[*A."J5F[@NT;H]XW5R/ZHT\[>7\C?7> @#URV%JCU@U(S M4;?6CYDQ ^8K_OSY?8L_4+4$5"V%4C/01.LBB=|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|:= M8$&ULK59M3]LP$/XK5H8FD"D M22!"UT:"5A-(8ZHH;!^F?7#3:QAV)GMM+!?O[,3HI:&,J1^2?QRS^/G[N*[M#-9"/]H$0).GC'$U=!*M\[[KJCB!C*ISD0/'G860&=4XE4M7Y1+HW((RYQ]> MUW$SFG(G&MBUB8P&HM

LY3"11!591N7S%3"Q'CHMYV7A+ETFVBRXT2"G2YB" M?L@G$F=NS3)/,^ J%9Q(6 R=RU9_U#/VUN!'"FNU,2;&DYD0CV9R,Q\ZGA$$ M#&)M&"B^5C "Q@P1ROA3<3KUD0:X.7YA_V[1\U]F5,%(L)_I7"=#I^>0.2QH MP?2=6%]#Y4_;\,6"?LDZ\K6B[T$!",Q:)HR=8*[#],Q.3XZ(40^$86B?*X&KD9UY@PWKI1%KK0U6W8M6 ML]:PUAI^-* <=)/&<.?TH+LC<=EZ;/_$!D6P'H MU 'H'.RC[^PDH.UYK[/TCM&6R&XMLON>2*SZV 8*RLA$8KZD?MZ;G[U\'\W/ M@3KW9*4E[34J!|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|*&PO=V]R:W-H965TM$"77UVMB() MT"88-F"'HFFW:\6F8Z&RY$ERTKW]*-GUTL0I>F/KP)_ ^2(GT="?5DZX #'FN.M= SKS*FN?9IG5=04WTE&Q"X4TI54X-3M?%UHX 63E1S/PJ"S*\[$!Y\ZM;N MU'PJ6\.9@#M%=%O75/V]!2YW,R_TA7:A;NV:8R=L&?3QNZ@168Q^9.X*+ZVL #. MK2/$^-//] (9/6N'^^,7[9Q<[QK*F&A:2_V:%J6;>1X\44-*6FWNY^P)]/*GU METNNW9/L>MO (WFKC:Q[.1+43'1O^MSG84|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|8GADB5R+16Z[0V.]V#A+E(& 7! M.%F.I[(K-}PPFSD# ;'7.0.!<)HR 8)_#) M7N'3'Z[IY0!@.RP0[5D*[:KF2:/B#75#$15:9%[6=5H;F=9!PEPDC(@G Z5 M07W"<_!1)1X-4(7G/:5)NBJSHAU]9&+H(F5"|UH5S3B9UX;F=: T%TJC*!HO MSX/S|4K+D<## _>S3S71F3MN=#Y!S.RL223.A- M*LZ$T!TISH32*HO'*5FME MJ$|C"""G=M8UDF9":1:49D-I3D7C>@I-T%&XT+041>,E6YL\BMSEL>.$^9/XZ<+?>O0'!V5?O.K$0=%HNF31 .V,?/:67B0OUU"7"$HSH30+2K.A M-=*)'6UIDB|\ZZVJQR7&>EZHW#-E5PR"9H MU33PK:K980|K\/EM 4UKFKL.=$5=*(VB:+QF:H-*D3M4N|)VT(>;GN_/5SYY M|\+/O;W% ^O!4$7OZ1M[T>+U]0_KS4ES39<).8.825|NU0TPI*,Z$'T"TJSH30' M2G.A-(JB|;M ;8(18MA2Z7'-)9QDB:":59%>VX6Q|>UUZH M$P:EN5 :1=%X?=9NF"*WP[[D9?? 62U=D)]3=U:G2]@NUO] T$T]SH#0;2G.@ M-!=*HR@:K^K: E/D'ICLFE%Y:&?Q"CPGD9D@:#8T!$/326-H:AC-D:XMX(UT MP26CT)5UH32*HO&7E|?NE"IWITY6/OQH5?Z-NDH/2C.A- M*LZ$T!TISH32* MHO'[1&V)J7)+3%8WY:&=Q:NTJIOO-3NNFX)V(Y&Y*F@W%K1SH"OK0FD41>,U M4IM+:FMSJ95;*L=UU@W458+2+"C-AM(<*,V%TBB*Q@NZMII4'[_2|I:6;Q: MLYJ-)X);C 0-Q6OV4110|K@,/9IF -=31=*HR@:KXI:G%'EYHRHW.W8G/G/ MWF/ SLBWZ-$/ K;SU<4J@KHV%8T[+RV\M@Z:UFJ:UH:F=: T%TJC*!HOS=]2 M4>66C,F>6)+DTJLJV!FYW>3OQ1=WR%F=-=CT1@Q\.&S>B69"\UJM|\K0O Z4 MYJI- ^KHZU-40EY:M7.CMKZW2'1Y__>2"=/VEF#4+<&2K.@-!M**EH7&!TIS!6O1Z,1_A@NBUBZ(VOI. M('DGWO'Z=WG:SBI$TDPHS8+2;"C-@=)<*(VB:/R$,;6UH\FM'>F4,5 /1A/< M3B0JH-"LEB#K6'BZ&YK6@=)<*(VB:+SB:N-$DQLGG7IQ.:NS!)N6AO"6=FA6 M]V56&YK5@=+%;"=|E\4Y8RG) 9RU!W14VHS7:,"C-@=)< M*(VB:+R$#4V9O^\#T;=CYVYKS]#5]H&!.-D-O3LEFG6;9@B9:>7UX8]HV[+QM MV(G;?H:YHM7FBB8W5[IUFU 7!4HSH30+2K.A- =*?HK$NH(P.EV5"; Z6Y4!I%T;:ZI[,ZQZR9%D^%" E\^*2 MGNU4U?NE^PFZ0G"[JJ/I7IAD M &N=F+,=:+,_IV4D:"$W3IHKVWD <_ #PS_MD9|(SV7/R0&T0%]S%+Y-C:*+6] MLFT9;C FLL>WF.A?5ES$1.FF6-MR*Y!$F2AFMN%6&<0TR3_)O<%B".!]JD7>(7 >ZV@7PCZIP+_&<&@$ PR M,OE0,@X!460R$GP/PO36;N8B@YFI]?!I8N9]H83^E6]=FGSA"L&'W^ /2I:4 M4451PAP941B!XK @#(&OX#*95J4"8\P?"LC[O U2$,@E_XKU*"?N@/3Y-YS/X M^P(C)8I_=/OK(H#W[S|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|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

*U%Z55 Z7LQI6:=.,^-ESN M?60M]O9OO@R?#G?ZN|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|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

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Statements4 falsefalseR5.htm004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)Sheethttp://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unauditedCondensed Consolidated Statements of Stockholders' Equity (Unaudited)Statements5 falsefalseR6.htm005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)Sheethttp://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticalsCondensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)Statements6 falsefalseR7.htm006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements7 falsefalseR8.htm007 - Disclosure - Note 1 - Organization and Nature of BusinessSheethttp://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-businessNote 1 - Organization and Nature of BusinessNotes8 falsefalseR9.htm008 - Disclosure - Note 2 - Summary of Significant Accounting PoliciesSheethttp://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policiesNote 2 - Summary of Significant Accounting PoliciesNotes9 falsefalseR10.htm009 - Disclosure - Note 3 - Fair Value of Financial InstrumentsSheethttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instrumentsNote 3 - Fair Value of Financial InstrumentsNotes10 falsefalseR11.htm010 - Disclosure - Note 4 - Balance Sheet ComponentsSheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-componentsNote 4 - Balance Sheet ComponentsNotes11 falsefalseR12.htm011 - Disclosure - Note 5 - RevenueSheethttp://www.vaxart.com/20240930/role/statement-note-5-revenueNote 5 - RevenueNotes12 falsefalseR13.htm012 - Disclosure - Note 6 - Liabilities Related to Sale of Future RoyaltiesSheethttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royaltiesNote 6 - Liabilities Related to Sale of Future RoyaltiesNotes13 falsefalseR14.htm013 - Disclosure - Note 7 - LeasesSheethttp://www.vaxart.com/20240930/role/statement-note-7-leasesNote 7 - LeasesNotes14 falsefalseR15.htm014 - Disclosure - Note 8 - Commitments and ContingenciesSheethttp://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingenciesNote 8 - Commitments and ContingenciesNotes15 falsefalseR16.htm015 - Disclosure - Note 9 - Stockholders' EquitySheethttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equityNote 9 - Stockholders' EquityNotes16 falsefalseR17.htm016 - Disclosure - Note 10 - Equity Incentive PlansSheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plansNote 10 - Equity Incentive PlansNotes17 falsefalseR18.htm017 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common StockholdersSheethttp://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholdersNote 11 - Net Loss Per Share Attributable to Common StockholdersNotes18 falsefalseR19.htm018 - Disclosure - Note 12 - Subsequent EventsSheethttp://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-Note 12 - Subsequent EventsNotes19 falsefalseR20.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes20 falsefalseR21.htm995465 - Disclosure - Significant Accounting Policies (Policies)Sheethttp://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policiesSignificant Accounting Policies (Policies)Policieshttp://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies21 falsefalseR22.htm995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tablesNote 3 - Fair Value of Financial Instruments (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments22 falsefalseR23.htm995467 - Disclosure - Note 4 - Balance Sheet Components (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tablesNote 4 - Balance Sheet Components (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components23 falsefalseR24.htm995468 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tablesNote 6 - Liabilities Related to Sale of Future Royalties (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties24 falsefalseR25.htm995469 - Disclosure - Note 7 - Leases (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-7-leases-tablesNote 7 - Leases (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-7-leases25 falsefalseR26.htm995470 - Disclosure - Note 9 - Stockholders' Equity (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tablesNote 9 - Stockholders' Equity (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity26 falsefalseR27.htm995471 - Disclosure - Note 10 - Equity Incentive Plans (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tablesNote 10 - Equity Incentive Plans (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans27 falsefalseR28.htm995472 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)Sheethttp://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tablesNote 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)Tableshttp://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders28 falsefalseR29.htm995473 - Disclosure - Note 1 - Organization and Nature of Business (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textualNote 1 - Organization and Nature of Business (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business29 falsefalseR30.htm995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textualNote 2 - Summary of Significant Accounting Policies (Details Textual)Details30 falsefalseR31.htm995475 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textualNote 3 - Fair Value of Financial Instruments (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables31 falsefalseR32.htm995476 - Disclosure - Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-detailsNote 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)Details32 falsefalseR33.htm995477 - Disclosure - Note 4 - Balance Sheet Components (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textualNote 4 - Balance Sheet Components (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables33 falsefalseR34.htm995478 - Disclosure - Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-detailsNote 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details)Details34 falsefalseR35.htm995479 - Disclosure - Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-detailsNote 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)Details35 falsefalseR36.htm995480 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-detailsNote 4 - Balance Sheet Components - Property and Equipment, Net (Details)Details36 falsefalseR37.htm995481 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-detailsNote 4 - Balance Sheet Components - Intangible Assets (Details)Details37 falsefalseR38.htm995482 - Disclosure - Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-detailsNote 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details)Details38 falsefalseR39.htm995483 - Disclosure - Note 4 - Balance Sheet Components - Accrued Liabilities (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-detailsNote 4 - Balance Sheet Components - Accrued Liabilities (Details)Details39 falsefalseR40.htm995484 - Disclosure - Note 5 - Revenue (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textualNote 5 - Revenue (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-5-revenue40 falsefalseR41.htm995485 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textualNote 6 - Liabilities Related to Sale of Future Royalties (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables41 falsefalseR42.htm995486 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-detailsNote 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details)Details42 falsefalseR43.htm995487 - Disclosure - Note 7 - Leases (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-7-leases-details-textualNote 7 - Leases (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-7-leases-tables43 falsefalseR44.htm995488 - Disclosure - Note 7 - Leases - Lease Liabilities Payment Obligations (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-detailsNote 7 - Leases - Lease Liabilities Payment Obligations (Details)Details44 falsefalseR45.htm995489 - Disclosure - Note 7 - Leases - Operating Lease Expenses (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-detailsNote 7 - Leases - Operating Lease Expenses (Details)Details45 falsefalseR46.htm995490 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textualNote 8 - Commitments and Contingencies (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies46 falsefalseR47.htm995491 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textualNote 9 - Stockholders' Equity (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables47 falsefalseR48.htm995492 - Disclosure - Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-detailsNote 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details)Details48 falsefalseR49.htm995493 - Disclosure - Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-detailsNote 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)Details49 falsefalseR50.htm995494 - Disclosure - Note 10 - Equity Incentive Plans (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textualNote 10 - Equity Incentive Plans (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables50 falsefalseR51.htm995495 - Disclosure - Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-detailsNote 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)Details51 falsefalseR52.htm995496 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Options (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-detailsNote 10 - Equity Incentive Plans - Assumptions of Options (Details)Details52 falsefalseR53.htm995497 - Disclosure - Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-detailsNote 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details)Details53 falsefalseR54.htm995498 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-detailsNote 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details)Details54 falsefalseR55.htm995499 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-detailsNote 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details)Details55 falsefalseR56.htm995500 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details)Sheethttp://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-detailsNote 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details)Details56 falsefalseR57.htm995501 - Disclosure - Note 12 - Subsequent Events (Details Textual)Sheethttp://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textualNote 12 - Subsequent Events (Details Textual)Detailshttp://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-57 falsefalseAll ReportsBookAll Reports vxrt-20240930.xsdvxrt-20240930_cal.xmlvxrt-20240930_def.xmlvxrt-20240930_lab.xmlvxrt-20240930_pre.xmlvxrt20240930_10q.htm slide1.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vxrt20240930_10q.htm": { "nsprefix": "vxrt", "nsuri": "http://www.vaxart.com/20240930", "dts": { "schema": { "local": ["vxrt-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["vxrt-20240930_cal.xml"] }, "definitionLink": { "local": ["vxrt-20240930_def.xml"]

```
}, "labelLink": { "local": [ "vxrt-20240930_lab.xml" ] }, "presentationLink": { "local": [ "vxrt-20240930_pre.xml" ] }, "inline": { "local": [ "vxrt20240930_10q.htm" ] } }, "keyStandard": 257, "keyCustom": 39, "axisStandard": 25, "axisCustom": 0, "memberStandard": 32, "memberCustom": 34, "hidden": { "total": 48, "http://fasb.org/us-gaap/2024": 37, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 6, "http://www.vaxart.com/20240930": 1 }, "contextCount": 278, "entityCount": 1, "segmentCount": 68, "elementCount": 469, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 924, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.vaxart.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R3": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R5": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockOutstandingMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockOutstandingMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_SubsidiarySaleOfStockAxis-June2024OfferingMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "longName": "007 - Disclosure - Note 1 - Organization and Nature of Business", "shortName": "Note 1 - Organization and Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "longName": "009 - Disclosure - Note 3 - Fair Value of Financial Instruments", "shortName": "Note 3 - Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "longName": "010 - Disclosure - Note 4 - Balance Sheet Components", "shortName": "Note 4 - Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "longName": "011 - Disclosure - Note 5 - Revenue", "shortName": "Note 5 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:RevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:RevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "longName": "012 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties", "shortName": "Note 6 - Liabilities Related to Sale of Future Royalties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.vaxart.com/20240930/role/statement-note-7-leases", "longName": "013 - Disclosure - Note 7 - Leases", "shortName": "Note 7 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "longName": "014 - Disclosure - Note 8 - Commitments and Contingencies", "shortName": "Note 8 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "longName": "015 - Disclosure - Note 9 - Stockholders' Equity", "shortName": "Note 9 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "longName": "016 - Disclosure - Note 10 - Equity Incentive Plans", "shortName": "Note 10 - Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "longName": "017 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders", "shortName": "Note 11 - Net Loss Per Share Attributable to Common Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "longName": "018 - Disclosure - Note 12 - Subsequent Events", "shortName": "Note 12 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name":
```

"ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995465 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "longName": "995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables)", "shortName": "Note 3 - Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "longName": "995467 - Disclosure - Note 4 - Balance Sheet Components (Tables)", "shortName": "Note 4 - Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "longName": "995468 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Tables)", "shortName": "Note 6 - Liabilities Related to Sale of Future Royalties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "longName": "995469 - Disclosure - Note 7 - Leases (Tables)", "shortName": "Note 7 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables", "longName": "995470 - Disclosure - Note 9 - Stockholders' Equity (Tables)", "shortName": "Note 9 - Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "vxrt:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "longName": "995471 - Disclosure - Note 10 - Equity Incentive Plans (Tables)", "shortName": "Note 10 - Equity Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "longName": "995472 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)", "shortName": "Note 11 - Net Loss Per Share Attributable to Common Stockholders (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "longName": "995473 - Disclosure - Note 1 - Organization and Nature of Business (Details Textual)", "shortName": "Note 1 - Organization and Nature of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "d_2024-06-01_2024-06-30_SubsidiarySaleOfStockAxis-June2024OfferingMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-06-01_2024-06-30_SubsidiarySaleOfStockAxis-June2024OfferingMember", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-7", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R30": { "role": "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "longName": "995475 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual)", "shortName": "Note 3 - Fair Value of Financial Instruments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "longName": "995476 - Disclosure - Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-09-30_CashAndCashEquivalentsAxis-MoneyMarketFundsMember", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R33": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "longName": "995477 - Disclosure - Note 4 - Balance Sheet Components (Details Textual)", "shortName": "Note 4 - Balance Sheet Components (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R34": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "longName": "995478 - Disclosure - Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details)", "shortName": "Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R35": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "longName": "995479 - Disclosure - Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "vxrt:PrepaidClinicalAndManufacturingExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "vxrt:PrepaidClinicalAndManufacturingExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "longName": "995480 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)", "shortName": "Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",

"order": "36", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details", "longName": "995481 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets (Details)", "shortName": "Note 4 - Balance Sheet Components - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "longName": "995482 - Disclosure - Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details)", "shortName": "Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details", "longName": "995483 - Disclosure - Note 4 - Balance Sheet Components - Accrued Liabilities (Details)", "shortName": "Note 4 - Balance Sheet Components - Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual", "longName": "995484 - Disclosure - Note 5 - Revenue (Details Textual)", "shortName": "Note 5 - Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-01-12_GovernmentAssistanceTypeAxis-The2024AsprbardaContractMember", "name": "us-gaap:GovernmentAssistanceAwardAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "vxrt:RevenueTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R41": { "role": "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual", "longName": "995485 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual)", "shortName": "Note 6 - Liabilities Related to Sale of Future Royalties (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2016-04-01_2016-04-30_CounterpartyNameAxis-HCRPMember", "name": "vxrt:ProceedsFromSaleOfFutureRoyaltiesNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-7", "ancestors": ["p", "vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2016-04-01_2016-04-30_CounterpartyNameAxis-HCRPMember", "name": "vxrt:ProceedsFromSaleOfFutureRoyaltiesNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-7", "ancestors": ["p", "vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "longName": "995486 - Disclosure - Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details)", "shortName": "Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "vxrt:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_CounterpartyNameAxis-HealthcareRoyaltyIIILPMember_DeferredRevenueArrangementTypeAxis-RoyaltyArrangementMember", "name": "vxrt:LiabilityRelatedToSaleOfFutureRoyalties", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "vxrt:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R43": { "role": "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual", "longName": "995487 - Disclosure - Note 7 - Leases (Details Textual)", "shortName": "Note 7 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R44": { "role": "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details", "longName": "995488 - Disclosure - Note 7 - Leases - Lease Liabilities Payment Obligations (Details)", "shortName": "Note 7 - Leases - Lease Liabilities Payment Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details", "longName": "995489 - Disclosure - Note 7 - Leases - Operating Lease Expenses (Details)", "shortName": "Note 7 - Leases - Operating Lease Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual", "longName": "995490 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)", "shortName": "Note 8 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "longName": "995491 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)", "shortName": "Note 9 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2024-06-11", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-11", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "longName": "995492 - Disclosure - Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details)", "shortName": "Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "vxrt:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-CommonWarrantsMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "vxrt:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R49": { "role": "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "longName": "995493 - Disclosure - Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)", "shortName": "Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "longName": "995494 - Disclosure - Note 10 - Equity Incentive Plans (Details Textual)", "shortName": "Note 10 - Equity Incentive Plans (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "vxrt:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "unique": true } }, "R51": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "longName": "995495 - Disclosure - Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)", "shortName": "Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals":

"INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "longName": "995496 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Options (Details)", "shortName": "Note 10 - Equity Incentive Plans - Assumptions of Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "longName": "995497 - Disclosure - Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details)", "shortName": "Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "longName": "995498 - Disclosure - Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details)", "shortName": "Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "d_2024-07-01_2024-11-30_PlanNameAxis-The2022EsppMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-11-30_PlanNameAxis-The2022EsppMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "longName": "995499 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details)", "shortName": "Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "longName": "995500 - Disclosure - Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details)", "shortName": "Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "longName": "995501 - Disclosure - Note 12 - Subsequent Events (Details Textual)", "shortName": "Note 12 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30_SubsidiarySaleOfStockAxis-TheSeptember2021AtmMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "vxrt20240930_10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r42", "r613"] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r514", "r558", "r623", "r761", "r762"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r673"] }, "vxrt_AccruedClinicalAndManufacturingExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "AccruedClinicalAndManufacturingExpensesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued clinical and manufacturing expenses", "documentation": "Amount of accrued clinical and manufacturing expenses due within one year." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Other accrued current liabilities", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued professional and consulting services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r30", "r109", "r461"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r17", "r18", "r57", "r114", "r458", "r486", "r487"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r9", "r18", "r345", "r348", "r404", "r482", "r483", "r655", "r656", "r657", "r662", "r663", "r664", "r665"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-

```
unaudited" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r52" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r494", "r662", "r663", "r664", "r665", "r735", "r794" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r36", "r37", "r288" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Offering costs", "negatedLabel": "Additional offering costs under the June 2024 Offering", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r10", "r74" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r316", "r321" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r115", "r178", "r212", "r215", "r216", "r762" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r230", "r236", "r589" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Potentially dilutive securities excluded from denominator of the diluted earnings per share computation (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r161" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r339" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r84", "r95", "r113", "r137", "r165", "r167", "r172", "r173", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r340", "r342", "r375", "r454", "r519", "r580", "r581", "r613", "r630", "r701", "r702", "r748" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r105", "r117", "r137", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r340", "r342", "r375", "r613", "r701", "r702", "r748" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r356", "r357", "r601" ] }, "vxrt_AtthemarketFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "AtthemarketFacilityMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "At-the-market Facility [Member]", "documentation": "Related to at-the-market facility." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Gross unrealized gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r183" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Gross unrealized losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r184" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r180", "r220", "r453" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Estimated Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r181", "r220", "r356", "r447", "r601", "r605", "r674", "r739", "r740", "r741" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "vxrt_BARDAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "BARDAMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "BARDA [Member]", "documentation": "This item represents contractual agreements with the U.S. Office of Biomedical Advanced Research and Development Authority (\"BARDA\")." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Acquisition of property and equipment included in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r22", "r23", "r24" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r107", "r566" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details",
```

"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r107"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Money market funds, Fair Value", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r737", "r738"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r654"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "totalLabel": "Cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r21", "r65", "r134"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets:" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r65"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r107"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r33"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Securities into which warrants are convertible (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r277"] }, "vxrt_ClassOfWarrantOrRightExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ClassOfWarrantOrRightExpirationsInPeriod", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_ClassOfWarrantOrRightExpirationsInPeriod", "terseLabel": "Class of Warrant or Right, Expirations in Period (in shares)", "documentation": "Number of warrants for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Securities into which warrants are convertible (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": ["r706"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r48", "r85", "r455", "r505"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r72", "r244", "r245", "r559", "r696", "r698"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details"], "lang": { "en-us": { "role": { "label": "Common stock reserved for issuance (in shares)", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r51"] }, "vxrt_CommonStockIncreaseInSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "CommonStockIncreaseInSharesAuthorized", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_CommonStockIncreaseInSharesAuthorized", "terseLabel": "Common Stock, Increase in Shares Authorized (in shares)", "documentation": "The number of increase in shares authorized of common stock." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r620", "r621", "r622", "r624", "r625", "r626", "r627", "r662", "r663", "r665", "r735", "r793", "r794"] }, "vxrt_CommonStockOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "CommonStockOutstandingMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock Outstanding [Member]", "documentation": "Represents common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r51"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r51", "r506"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-

parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r51"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r51", "r506", "r525", "r794", "r795"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock: $0.0001 par value; 350,000,000 shares authorized as of September 30, 2024 and 250,000,000 shares authorized as of December 31, 2023; 228,176,446 shares issued and 227,476,324 shares outstanding as of September 30, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r51", "r457", "r613"] }, "vxrt_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "CommonWarrantsMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details"], "lang": { "en-us": { "role": { "label": "Common Warrants [Member]", "documentation": "Represents information pertaining to common warrants." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r19", "r122", "r124", "r129", "r448", "r467", "r468"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r39", "r99"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r38", "r573"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r138", "r139", "r259", "r265", "r405", "r425", "r452", "r570", "r572"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "vxrt_DaiichiSankyoCollaberationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "DaiichiSankyoCollaberationAndLicenseAgreementMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Daiichi Sankyo Collaberation and License Agreement [Member]", "documentation": "Royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (\"Daiichi Sankyo\") in 2009." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": ["r91"] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r91"] }, "vxrt_DebtNoncashInterestExpenseRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "DebtNoncashInterestExpenseRecognized", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "Non-cash interest expense recognized", "documentation": "Amount of non-cash interest expense recognized in relation to the sale of future royalties." } } }, "auth_ref": [] }, "vxrt_DebtNoncashRoyaltyRevenuePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "DebtNoncashRoyaltyRevenuePaid", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "vxrt_DebtNoncashRoyaltyRevenuePaid", "negatedLabel": "Non-cash royalty revenue paid to HCRP" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement Type [Axis]", "documentation": "Information by type of deferred revenue arrangement." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Domain]", "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Deferred government revenue", "terseLabel": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r650"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r7", "r29"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r7", "r29"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r81", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r287", "r289", "r317", "r318", "r320", "r598"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies",

```
"http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Dividends", "terseLabel": "Dividends, Total", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r3", "r74" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r634" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r635" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "vxrt_ESPPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ESPPMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details" ], "lang": { "en-us": { "role": { "label": "ESPP [Member]", "documentation": "Related to ESPP." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details" ], "lang": { "en-us": { "role": { "label": "Net loss per share - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r145", "r146", "r147", "r148", "r149", "r150", "r155", "r156", "r158", "r159", "r160", "r164", "r335", "r338", "r353", "r354", "r449", "r469", "r576" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r154", "r161", "r162", "r163" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r319" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r319" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r733" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "vxrt_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Member]", "documentation": "Represents employee stock purchase plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r632" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.vaxart.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-document-and-entity-information", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-
```

details", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables", "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r632"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r632"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r638"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r632"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r632"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r632"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r632"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r103", "r125", "r126", "r127", "r140", "r141", "r142", "r144", "r149", "r151", "r153", "r166", "r210", "r211", "r240", "r278", "r329", "r330", "r332", "r333", "r334", "r336", "r337", "r338", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r390", "r404", "r465", "r482", "r483", "r484", "r494", "r546"] }, "vxrt_FacilityInBurlingameCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "FacilityInBurlingameCaliforniaMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "Facility in Burlingame, California [Member]", "documentation": "Related to facility in Burlingame, California." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r737", "r738"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r260", "r280", "r281", "r282", "r283", "r284", "r285", "r355", "r357", "r358", "r359", "r360", "r366", "r367", "r369", "r412", "r413", "r414", "r590", "r591", "r594", "r595", "r596", "r601", "r605"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r356", "r357", "r358", "r360", "r601", "r740", "r743"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r362", "r364", "r365", "r366", "r369", "r370", "r371", "r372", "r373", "r445", "r601", "r606"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r260", "r280", "r285", "r357", "r367", "r412", "r594", "r595", "r596", "r601"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r260", "r280", "r285", "r357", "r358", "r367", "r413", "r590", "r591", "r594", "r595", "r596", "r601"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r260", "r280", "r281", "r282", "r283", "r284", "r285", "r357", "r358", "r359", "r360", "r367", "r414", "r590", "r591", "r594", "r595", "r596", "r601", "r605"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r356", "r357", "r358", "r360", "r601", "r740", "r743"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r260", "r280", "r281", "r282", "r283", "r284", "r285", "r355", "r357", "r358", "r359", "r360", "r366", "r367", "r369", "r412", "r413", "r414", "r590", "r591", "r594", "r595", "r596", "r601", "r605"] }, "us-gaap_FairValueMeasurementsRecurringMember": {

"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r601", "r737", "r738", "r739", "r740", "r741", "r743"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r213", "r214", "r217", "r218", "r219", "r221", "r222", "r223", "r261", "r275", "r350", "r374", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r466", "r584", "r601", "r603", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r675", "r676", "r677", "r678", "r736", "r739", "r740", "r741", "r742", "r743"] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "terseLabel": "Financial Liabilities Fair Value Disclosure, Total", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": ["r737", "r738", "r742"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Less: accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r111", "r224", "r235", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r237", "r562", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "terseLabel": "2024 (three months remaining)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r796"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r237", "r562", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r237", "r562", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r237", "r562", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r229", "r231", "r232", "r233", "r234", "r235", "r238", "r239", "r443", "r444", "r562"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r224", "r235", "r444", "r589"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r229", "r231", "r232", "r233", "r234", "r235", "r238", "r239", "r562"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r443", "r689"] }, "vxrt_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details"], "lang": { "en-us": { "role": { "label": "vxrt_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "vxrt_FinitelivedIntangibleAssetRemainingLife": { "xbrltype": "durationItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "FinitelivedIntangibleAssetRemainingLife", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_FinitelivedIntangibleAssetRemainingLife", "terseLabel": "Finite-Lived Intangible Asset, Remaining Life (Year)", "documentation": "The remaining life of finite-lived intangible assets." } } }, "auth_ref": [] }, "vxrt_FirstSetOfWarrantsExpiringApril2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "FirstSetOfWarrantsExpiringApril2024Member", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "First Set of Warrants Expiring April 2024 [Member]", "documentation": "Represents information pertaining to a first set of warrants expiring in April 2024." } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income (expense), net", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r376", "r377", "r378", "r379", "r543"] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnDispositionOfAssets", "negatedLabel": "Loss on disposal of equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": ["r659", "r694", "r695"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r60", "r529"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r60"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r110", "r225", "r446", "r581", "r588", "r602", "r613", "r681", "r682"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r7", "r226", "r227", "r228", "r588", "r602"] }, "vxrt_GovernmentAssistanceAdditionalFundingPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "GovernmentAssistanceAdditionalFundingPossible", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_GovernmentAssistanceAdditionalFundingPossible", "terseLabel": "Government Assistance, Additional Funding Possible", "documentation": "Additional amount of funding possible if study continues for government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceAwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceAwardAmount", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GovernmentAssistanceAwardAmount", "terseLabel": "Government Assistance, Award Amount", "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": ["r745"] }, "vxrt_GovernmentAssistanceAwardAmountInitialAward": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "GovernmentAssistanceAwardAmountInitialAward", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_GovernmentAssistanceAwardAmountInitialAward", "terseLabel": "Government Assistance, Award Amount, Initial Award", "documentation": "Initial amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": [] }, "vxrt_GovernmentAssistanceAwardAmountInitialAwardFixedFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "GovernmentAssistanceAwardAmountInitialAwardFixedFee", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_GovernmentAssistanceAwardAmountInitialAwardFixedFee", "terseLabel": "Government Assistance Award, Amount, Initial Award Fixed Fee", "documentation": "Amount of government assistance initial fixed fee awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceTypeAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Axis]", "documentation": "Information by type of government assistance." } } }, "auth_ref": ["r387"] }, "us-gaap_GovernmentAssistanceTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceTypeDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Domain]", "documentation": "Type of government assistance." } } }, "auth_ref": ["r387"] }, "us-gaap_GovernmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Government Contract [Member]", "documentation": "Formal agreement with government or its agency." } } }, "auth_ref": ["r705"] }, "us-gaap_GovernmentContractReceivableUnbilledAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractReceivableUnbilledAmounts", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GovernmentContractReceivableUnbilledAmounts", "terseLabel": "Government Contract Receivable, Unbilled Amounts", "documentation": "Unbilled amounts (net of unliquidated progress payments) of government contract receivables." } } }, "auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": ["r705"] }, "vxrt_GrantMilestoneCompletionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "GrantMilestoneCompletionMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Grant Milestone Completion [Member]", "documentation": "Represents the completion of milestones under grants." } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GrantsReceivable", "terseLabel": "Grants Receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": ["r651"] }, "vxrt_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_GrossProceedsFromIssuanceOfCommonStock", "terseLabel": "Gross Proceeds from Issuance of Common Stock", "documentation": "The gross cash inflow from the additional capital contribution to the entity before deducting underwriting discounts, commission, and offering expenses." } } }, "auth_ref": [] }, "vxrt_HCRPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "HCRPMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "HCRP [Member]", "documentation": "HealthCare Royalty Partners are purchasers of royalty rights." } } }, "auth_ref": [] }, "vxrt_HealthcareRoyaltyIIILPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "HealthcareRoyaltyIIILPMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "HealthCare Royalty Partners III, L.P. [Member]", "documentation": "Represents the legal entity, HealthCare Royalty III, L.P." } } }, "auth_ref": [] }, "vxrt_HimmelbergVVaxartIncEtAlMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "HimmelbergVVaxartIncEtAlMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Himmelberg V. Vaxart, Inc. et al. [Member]", "documentation": "Represents the Himmelberg V. Vaxart, Inc. et al." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r58", "r89", "r94", "r450", "r463", "r578", "r580", "r667", "r669", "r670", "r671", "r672"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r241", "r242", "r243", "r361", "r363", "r368", "r479", "r481", "r530", "r562", "r604", "r764"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r242", "r243", "r361", "r363", "r368", "r479", "r481", "r530", "r562", "r604", "r764"] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r133", "r325", "r326", "r327", "r328", "r600", "r734"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r133", "r325", "r326", "r327", "r328", "r600", "r734"] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": ["r327", "r734"] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": ["r327", "r734"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "terseLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r96", "r102", "r152", "r153", "r165", "r170", "r173", "r324", "r325", "r331", "r470", "r600"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable",

```
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r563" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpensesOther", "negatedTerseLabel": "Prepaid clinical services, long-term", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r6" ] }, "vxrt_IncreaseDecreaseInUnbilledReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "IncreaseDecreaseInUnbilledReceivable", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "vxrt_IncreaseDecreaseInUnbilledReceivable", "negatedLabel": "Unbilled receivable from government contracts", "documentation": "The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r636" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "totalLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r229", "r689", "r691" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r15", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r580", "r658", "r669" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium", "negatedLabel": "Amortization of discount on investments, net", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r61" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndCash", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r759", "r760" ] }, "vxrt_InvestmentsAndCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "InvestmentsAndCashFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Investments and Cash, Fair Value Disclosure", "documentation": "Represents the fair value amount of investments and cash." } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r737", "r738", "r742" ] }, "vxrt_June2024OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "June2024OfferingMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "June 2024 Offering [Member]", "documentation": "Represents June 2024 Offering." } } }, "auth_ref": [] }, "vxrt_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Property, plant, and equipment classified as laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r403", "r639" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r403", "r639" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r393", "r612" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r746" ] }, "vxrt_LeaseForFacilityInSouthSanFranciscoCommencedInFirstQuarterOf2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LeaseForFacilityInSouthSanFranciscoCommencedInFirstQuarterOf2023Member", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease for Facility in South San Francisco Commenced in First Quarter of 2023 [Member]", "documentation": "Represents lease for facility in South San Francisco, California in first quarter of 2023." } } }, "auth_ref": [] }, "vxrt_LeaseForFacilityInSouthSanFranciscoCommencedInThirdQuarterOf2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LeaseForFacilityInSouthSanFranciscoCommencedInThirdQuarterOf2022Member", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease for Facility in South San Francisco Commenced in Third Quarter of 2022 [Member]", "documentation": "Represents lease for facility in South San Francisco, California commenced in third quarter of 2022." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r70", "r402" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-document-and-entity-information", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details",
```

"http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables", "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-tables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r747"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Undiscounted total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r401"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r401"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r401"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r401"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r401"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2024 (three months remaining)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r747"] }, "vxrt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "vxrt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r401"] }, "vxrt_LesseeOperatingLeaseNumberOfLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LesseeOperatingLeaseNumberOfLeases", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_LesseeOperatingLeaseNumberOfLeases", "terseLabel": "Lessee, Operating Lease, Number of Right-of-Use Leases", "documentation": "Number of right-of-use operating leases." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r389"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r16", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r137", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r341", "r342", "r343", "r375", "r504", "r577", "r630", "r701", "r748", "r749"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r56", "r86", "r460", "r613", "r661", "r679", "r744"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r45", "r106", "r137", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r341", "r342", "r343", "r375", "r613", "r701", "r748", "r749"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "vxrt_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties"], "lang": { "en-us": { "role": { "label": "Liabilities Related to Sale of Future Royalties [Text Block]", "documentation": "The entire disclosure for the liabilities related to the sale of future royalties per the royalty interest acquisition agreement." } } }, "auth_ref": [] }, "vxrt_LiabilityRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "vxrt_LiabilityRelatedToSaleOfFutureRoyalties", "periodStartLabel": "Total liability related to

sale of future royalties, start of period", "periodEndLabel": "Total liability related to sale of future royalties, end of period", "documentation": "Amount of liability associated with the sale of future royalties." } } }, "auth_ref": [] }, "vxrt_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of liability related to sale of future royalties", "label": "vxrt_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent", "negatedTerseLabel": "Current portion", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to the selling costs of future royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "vxrt_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "Liability related to sale of future royalties, net of current portion", "terseLabel": "Long-term portion", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to the selling costs of future royalties. Used to reflect the noncurrent portion of the liabilities (due after one year or beyond the normal operating cycle, if longer)." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r286", "r322", "r360", "r441", "r478", "r480", "r488", "r496", "r497", "r551", "r552", "r553", "r554", "r555", "r560", "r561", "r583", "r592", "r597", "r605", "r606", "r610", "r611", "r616", "r703", "r750", "r751", "r752", "r753", "r754", "r755"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r286", "r322", "r360", "r441", "r478", "r480", "r488", "r496", "r497", "r551", "r552", "r553", "r554", "r555", "r560", "r561", "r583", "r592", "r597", "r605", "r606", "r610", "r616", "r703", "r750", "r751", "r752", "r753", "r754", "r755"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r706"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r637"] }, "us-gaap_NationalTaxAgencyJapanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NationalTaxAgencyJapanMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "National Tax Agency, Japan [Member]", "documentation": "Designated tax department of the government of Japan." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r132"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r132"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r65", "r66", "r67"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "terseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r59", "r67", "r90", "r104", "r121", "r123", "r127", "r137", "r143", "r145", "r146", "r147", "r148", "r149", "r152", "r153", "r157", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r335", "r338", "r354", "r375", "r464", "r527", "r544", "r545", "r628", "r701"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "vxrt_NonCashRoyaltyRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "NonCashRoyaltyRevenueMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Non Cash Royalty Revenue [Member]", "documentation": "Non cash usage-based right to asset." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r637"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r637"] }, "vxrt_NoncashInterestExpenseOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "NoncashInterestExpenseOnLiability", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 }, "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Non-cash interest expense related to sale of future royalties", "negatedLabel": "Non-cash interest expense related to sale of future royalties", "documentation": "Amount of non-cash accounted for as interest expense on liability in relation to the sale of future royalties." } } }, "auth_ref": [] }, "vxrt_NoncashRevenueRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "NoncashRevenueRelatedToSaleOfFutureRoyalties", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "vxrt_NoncashRevenueRelatedToSaleOfFutureRoyalties", "negatedLabel": "Non-cash revenue related to sale of future royalties", "documentation": "Amount of non-cash accounted for as Revenue in relation to the sale of future royalties." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] },

"vxrt_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "vxrt_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r579", "r582", "r668"] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "vxrt_OpenMarketSaleAgreementMaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "OpenMarketSaleAgreementMaximumAggregateOfferingPrice", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_OpenMarketSaleAgreementMaximumAggregateOfferingPrice", "terseLabel": "Open Market Sale Agreement, Maximum Aggregate Offering Price", "documentation": "The maximum aggregate offering price pursuant to the open market sale agreement." } } }, "auth_ref": [] }, "vxrt_OpenMarketSaleAgreementSalesCommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "OpenMarketSaleAgreementSalesCommissionPercentage", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_OpenMarketSaleAgreementSalesCommissionPercentage", "terseLabel": "Open Market Sale Agreement, Sales Commission, Percentage", "documentation": "The percentage of sales commission pursuant to the open market sale agreement." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r94", "r578", "r667", "r669", "r670", "r671", "r672"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details"], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r394", "r612"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "totalLabel": "Present value of future minimum payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r392"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liability", "negatedTerseLabel": "Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r392"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability, net of current portion", "label": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r392"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Right-of-use assets, net", "terseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r391"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r400", "r612"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r399", "r612"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r40", "r82", "r489", "r490"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details"], "lang": { "en-us": { "role": { "label": "Other liabilities, current portion", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r44"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r116", "r613"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r112"] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Unrealized gain on available-for-sale investments, net of tax", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r4", "r9", "r83"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Unrealized gain on available-for-sale investments", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r118", "r119", "r120", "r465"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r47"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Other prepaid", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r652", "r680"] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForLegalSettlements", "terseLabel": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": ["r5"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit",

```
"calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Shares acquired to settle employee tax withholding liabilities", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r131" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireInvestments", "negatedLabel": "Purchases of investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r63" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r64" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r50", "r263" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r50", "r506" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r50", "r263" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r50", "r506", "r525", "r794", "r795" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited" ], "lang": { "en-us": { "role": { "label": "Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r50", "r456", "r613" ] }, "vxrt_PrepaidClinicalAndManufacturingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "PrepaidClinicalAndManufacturingExpenses", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid clinical and manufacturing expenses", "label": "vxrt_PrepaidClinicalAndManufacturingExpenses", "documentation": "Amount of asset related to consideration paid in advance for clinical and manufacturing expenses." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r654" ] }, "us-gaap_PrepaidExpenseOtherNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseOtherNoncurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "Prepaid clinical services, long-term", "terseLabel": "Prepaid Expense Other, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r649" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid insurance", "label": "us-gaap_PrepaidInsurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r567", "r585", "r680" ] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid rent", "label": "us-gaap_PrepaidRent", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r568", "r586", "r680" ] }, "us-gaap_PrepaidRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidRoyalties", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PrepaidRoyalties", "terseLabel": "Prepaid Royalties", "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r569", "r587", "r680" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of common stock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r492" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from maturities of investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r20", "r63" ] }, "vxrt_ProceedsFromSaleOfFutureRoyaltiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ProceedsFromSaleOfFutureRoyaltiesNet", "crdr": "debit", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual" ], "lang": { "en-us": { "role": { "label": "vxrt_ProceedsFromSaleOfFutureRoyaltiesNet", "terseLabel": "Proceeds from Sale of Future Royalties, Net", "documentation": "The cash inflow from the sales of future royalties net pf deferred financing costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": {
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of property and equipment", "documentation": "The cash inflow
from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [
"r62" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-note-10-
equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock upon exercise of stock options", "terseLabel":
"Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2",
"r14" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr":
"debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": {
"role": { "label": "Proceeds from issuance of common stock under the employee stock purchase plan", "terseLabel": "Proceeds from Stock Plans", "documentation": "The cash
inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r2" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-consolidated-balance-
sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-
details-textual", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual" ], "lang":
{ "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r174", "r442", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r565", "r593", "r615",
"r616", "r617", "r618", "r619", "r699", "r700", "r704", "r763", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778",
"r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792" ] }, "srt_ProductsAndServicesDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-
condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-
details-textual", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual" ], "lang":
{ "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r174", "r442", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r565", "r593", "r615",
"r616", "r617", "r618", "r619", "r699", "r700", "r704", "r763", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778",
"r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived
Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [
"r8", "r402" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-
equipment-net-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Property and
equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not
intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [
"r70", "r108", "r462" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-
details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-
sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": {
"label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of
physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings,
machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r402", "r451", "r462", "r613" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables" ], "lang": { "en-us": {
"role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not
intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and
accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-
property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that
are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other
types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r70",
"r402" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit",
"presentation": [ "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_PurchaseObligation", "terseLabel": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds
to procure goods or services from a supplier." } } }, "auth_ref": [] }, "vxrt_RACapitalHealthcareFund2024Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.vaxart.com/20240930", "localname": "RACapitalHealthcareFund2024Member", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals",
"http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-
nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-
stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "RA Capital Healthcare Fund 2024 [Member]", "documentation": "Represents the securities
purchase agreement with RA Capital Healthcare Fund, L.P. in the year 2024." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-
options-details", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual" ], "lang":
{ "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r279", "r286", "r312", "r313", "r314", "r322", "r360", "r415",
"r424", "r441", "r478", "r480", "r488", "r496", "r497", "r551", "r552", "r553", "r554", "r555", "r560", "r561", "r583", "r592", "r597", "r605", "r606", "r610", "r611", "r616",
"r622", "r697", "r703", "r740", "r751", "r752", "r753", "r754", "r755" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details",
"http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": {
"role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r279", "r286", "r312", "r313", "r314", "r322", "r360", "r415", "r424",
"r441", "r478", "r480", "r488", "r496", "r497", "r551", "r552", "r553", "r554", "r555", "r560", "r561", "r583", "r592", "r597", "r605", "r606", "r610", "r611", "r616", "r622",
"r697", "r703", "r740", "r751", "r752", "r753", "r754", "r755" ] }, "vxrt_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.vaxart.com/20240930", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-
consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Registered Direct Offering [Member]", "documentation": "Represents the registered
direct offering." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components",
"http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-
related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details",
"http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty
Name [Domain]" } } }, "auth_ref": [ "r138", "r139", "r259", "r265", "r405", "r425", "r452", "r571", "r572" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-
gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-
and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development.
Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in
transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint
venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r323", "r562", "r580", "r756" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-
compensation-recognized-for-options-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial
statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-
condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": {
"label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits
with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r648", "r660", "r757", "r760" ] }, "us-
gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-
instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-
equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash
is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.
Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk
of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r107" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-
plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-
summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-
```

details"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r53", "r74", "r459", "r485", "r487", "r493", "r507", "r613"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r103", "r140", "r141", "r142", "r144", "r149", "r151", "r153", "r210", "r211", "r240", "r329", "r330", "r332", "r333", "r334", "r336", "r337", "r338", "r344", "r346", "r347", "r349", "r352", "r388", "r390", "r482", "r484", "r494", "r794"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r528", "r564", "r574"] }, "vxrt_RevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RevenueTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue"], "lang": { "en-us": { "role": { "label": "Revenue [Text Block]", "documentation": "The entire disclosure for revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r92", "r93", "r128", "r137", "r165", "r168", "r169", "r171", "r173", "r174", "r175", "r176", "r209", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r375", "r450", "r580", "r701"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities arising from obtaining right-of-use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r398", "r612"] }, "vxrt_RightOfUseForOfficeAndManufacturingFacilitiesWithInitialTermsExceedingOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RightOfUseForOfficeAndManufacturingFacilitiesWithInitialTermsExceedingOneYearMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Right of Use for Office and Manufacturing Facilities with Initial Terms Exceeding One Year [Member]", "documentation": "Represents information regarding right of use for office and manufacturing facilities with initial terms exceeding one year." } } }, "auth_ref": [] }, "us-gaap_RoyaltyArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyArrangementMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details"], "lang": { "en-us": { "role": { "label": "Royalty Arrangement [Member]", "documentation": "Category of deferred revenue by arrangement wherein certain rights are granted to exploit one or more products, under which royalties received are taken into income as revenue recognition criteria are met." } } }, "auth_ref": [] }, "vxrt_RoyaltyInterestAdditionalRoyaltiesDueEachYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyInterestAdditionalRoyaltiesDueEachYear", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyInterestAdditionalRoyaltiesDueEachYear", "terseLabel": "Royalty Interest, Additional Royalties Due Each Year", "documentation": "Amount of additional royalties due each year." } } }, "auth_ref": [] }, "vxrt_RoyaltyInterestCovenantCumulativeRemainingShortfallAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyInterestCovenantCumulativeRemainingShortfallAmount", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyInterestCovenantCumulativeRemainingShortfallAmount", "terseLabel": "Royalty Interest, Covenant, Cumulative Remaining Shortfall Amount", "documentation": "Represents the covenant for the cumulative remaining shortfall amount in a royalty interest agreement. Calculated using the aggregate amount of remaining shortfall for each annual period." } } }, "auth_ref": [] }, "vxrt_RoyaltyInterestCovenantShortfallInRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyInterestCovenantShortfallInRoyaltyPayments", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyInterestCovenantShortfallInRoyaltyPayments", "terseLabel": "Royalty Interest, Covenant, Shortfall in Royalty Payments", "documentation": "Represents the covenant for royalty interest relating to shortfalls in royalty payments." } } }, "auth_ref": [] }, "vxrt_RoyaltyInterestPercentageOfAdditionalRoyaltiesDueEachYear": { "xbrltype": "percentItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyInterestPercentageOfAdditionalRoyaltiesDueEachYear", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyInterestPercentageOfAdditionalRoyaltiesDueEachYear", "terseLabel": "Royalty Interest, Percentage of Additional Royalties Due Each Year", "documentation": "Percentage of additional royalties due each year." } } }, "auth_ref": [] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": ["r705"] }, "vxrt_RoyaltyPaymentInterestFirstPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyPaymentInterestFirstPeriodMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "Royalty Payment, Interest, First Period [Member]", "documentation": "Represents the first period of royalty repayment interest." } } }, "auth_ref": [] }, "vxrt_RoyaltyPaymentInterestSecondPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyPaymentInterestSecondPeriodMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual"], "lang": { "en-us": { "role": { "label": "Royalty Payment, Interest, Second Period [Member]", "documentation": "Represents the second period of royalty repayment interest." } } }, "auth_ref": [] }, "vxrt_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyPercentage", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyPercentage", "terseLabel": "Royalty Percentage", "documentation": "Royalty percentage received on net sales." } } }, "auth_ref": [] }, "vxrt_RoyaltyWithholdingTax": { "xbrltype": "percentItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "RoyaltyWithholdingTax", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_RoyaltyWithholdingTax", "terseLabel": "Royalty Withholding Tax", "documentation": "Percentage of tax withheld from royalty income." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r637"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r637"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r25"] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "vxrt_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Reserved for Issuance [Table Text Block]", "documentation": "Tabular disclosure of common stock reserved for issuance." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r666"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets,

excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r589", "r688"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r75"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r589", "r690"] }, "vxrt_SecondSetOfWarrantsExpiringApril2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "SecondSetOfWarrantsExpiringApril2024Member", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details"], "lang": { "en-us": { "role": { "label": "Second Set of Warrants Expiring April 2024 [Member]", "documentation": "Represents information pertaining to a second set of warrants expiring in April 2024." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r631"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r633"] }, "vxrt_September2021AtmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "September2021AtmMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "September 2021 ATM [Member]", "documentation": "Represents September 2021 ATM offering." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "vxrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Shares available for grant, canceled (in shares)", "documentation": "Represents the change in the shares available for grant attributable to shares canceled during the period under the plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Forfeited, Weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r306"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Granted, Weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r304"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Balance, Weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Balance, Weighted average grant date fair value (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r301", "r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details"], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r313"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details"], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details"], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r314"] }, "vxrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Shares available for grant, forfeited (in shares)", "documentation": "Represents the change in the shares available for grant attributable to shares forfeited during the period under the plan." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "negatedLabel": "Number of RSUs outstanding, forfeite (in shares)", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": ["r78"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Number of RSUs outstanding, granted (in shares)", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": ["r11"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "periodStartLabel": "Number of RSUs outstanding (in shares)", "periodEndLabel": "Number of RSUs outstanding (in shares)", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": ["r76", "r77"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r599"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "periodStartLabel": "Shares available for grant, balance (in shares)", "periodEndLabel": "Shares available for grant, balance (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r34"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r308"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Number of options outstanding, canceled (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r300"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Number of options outstanding, forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Number of options outstanding, granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r297"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r34"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)", "periodStartLabel": "Number of options outstanding, beginning balance (in shares)", "periodEndLabel": "Number of options outstanding, balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r293", "r294"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)", "periodStartLabel": "Weighted average exercise price, balance (in dollars per share)", "periodEndLabel": "Weighted average exercise price, balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r293", "r294"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r310"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r309"] }, "vxrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "vxrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants", "negatedLabel": "Shares available for grant, granted (in shares)", "documentation": "Represents the decrease in the shares available for grant attributable to shares granted during the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r298"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, canceled (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r300"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label":

```
"Weighted average exercise price, forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r297" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "vxrt_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "Released, Weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were released." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details" ], "lang": { "en-us": { "role": { "label": "Expected term (in years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r311" ] }, "vxrt_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased": { "xbrltype": "sharesItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "vxrt_SharebasedCompensationArrangementBySharebasedPaymentAwardNonoptionEquityInstrumentsReleased", "negatedLabel": "Number of RSUs outstanding, release (in shares)", "documentation": "Number of non-option equity instruments released by participants." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r309" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details" ], "lang": { "en-us": { "role": { "label": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r87", "r88", "r653" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r395", "r612" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r68", "r135" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r51", "r54", "r55", "r103", "r125", "r126", "r127", "r140", "r141", "r142", "r144", "r149", "r151", "r153", "r166", "r210", "r211", "r240", "r278", "r329", "r330", "r332", "r333", "r334", "r336", "r337", "r338", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r390", "r404", "r465", "r482", "r483", "r484", "r494", "r546" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables", "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r140", "r141", "r142", "r166", "r390", "r442", "r491", "r495", "r498", "r499", "r500", "r501", "r502", "r503", "r506", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r526", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r546", "r623" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-
```

gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-options-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.vaxart.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-accrued-liabilities-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-details-textual", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "http://www.vaxart.com/20240930/role/statement-note-7-leases", "http://www.vaxart.com/20240930/role/statement-note-7-leases-details-textual", "http://www.vaxart.com/20240930/role/statement-note-7-leases-lease-liabilities-payment-obligations-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details", "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies", "http://www.vaxart.com/20240930/role/statement-note-8-commitments-and-contingencies-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables", "http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r140", "r141", "r142", "r166", "r177", "r390", "r442", "r491", "r495", "r498", "r499", "r500", "r501", "r502", "r503", "r506", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r526", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r546", "r623"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common stock under ESPP (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r50", "r51", "r74"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r50", "r51", "r74", "r492", "r546", "r556"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Release of common stock for vested restricted stock units (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r10", "r50", "r51", "r74"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of stock options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "negatedLabel": "Number of options outstanding, exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r50", "r51", "r74", "r298"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock under ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r10", "r50", "r51", "r74"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of common stock", "terseLabel": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r50", "r51", "r74", "r494", "r546", "r556", "r629"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Release of common stock for vested restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r10", "r74"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r51", "r54", "r55", "r74"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r51", "r54", "r55", "r69", "r508", "r525", "r547", "r548", "r613", "r630", "r661", "r679", "r744", "r794"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r73", "r136", "r262", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r278", "r351", "r549", "r550", "r557"] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details"], "lang": { "en-us": { "role": { "label": "us-gaap_SubleaseIncome", "negatedLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r397", "r612"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r386", "r407"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r386", "r407"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r386", "r407"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r406", "r408"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-

unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r647"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activity:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-tables", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.vaxart.com/20240930/role/statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "http://www.vaxart.com/20240930/role/statement-note-7-leases-tables", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_TangibleAssetImpairmentCharges", "terseLabel": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": ["r41", "r71"] }, "vxrt_The2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2019PlanMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details"], "lang": { "en-us": { "role": { "label": "The 2019 Plan [Member]", "documentation": "Represents information pertaining to the 2019 Equity Incentive Plan." } } }, "auth_ref": [] }, "vxrt_The2022EsppMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2022EsppMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual"], "lang": { "en-us": { "role": { "label": "The 2022 ESPP [Member]", "documentation": "Represents the 2022 Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "vxrt_The2023ShelfRegistrationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2023ShelfRegistrationMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "The 2023 Shelf Registration [Member]", "documentation": "Related to the 2023 shelf registration." } } }, "auth_ref": [] }, "vxrt_The2024AsprbardaContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2024AsprbardaContractMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 ASPR-BARDA Contract [Member]", "documentation": "Represents The 2024 ASPR-BARDA Contract." } } }, "auth_ref": [] }, "vxrt_The2024AtirrpvContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2024AtirrpvContractMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 ATI-RRPV Contract [Member]", "documentation": "Represents The 2024 ATI-RRPV Contract." } } }, "auth_ref": [] }, "vxrt_The2024InducementAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "The2024InducementAwardPlanMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-details-textual", "http://www.vaxart.com/20240930/role/statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details"], "lang": { "en-us": { "role": { "label": "The 2024 Inducement Award Plan [Member]", "documentation": "Relating to the 2024 Inducement Award Plan." } } }, "auth_ref": [] }, "vxrt_TheSeptember2021AtmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "TheSeptember2021AtmMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business", "http://www.vaxart.com/20240930/role/statement-note-1-organization-and-nature-of-business-details-textual", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-", "http://www.vaxart.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "The September 2021 ATM [Member]", "documentation": "Related to the September 2021 ATM." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.vaxart.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r261", "r275", "r350", "r374", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r466", "r601", "r603", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r614", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r675", "r676", "r677", "r678", "r736", "r739", "r740", "r741", "r742", "r743"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r31"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares (in shares)", "terseLabel": "Treasury Stock, Common, Shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r31"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockCommonValue", "negatedLabel": "Treasury stock at cost, 700,122 shares as of September 30, 2024 and 507,020 shares as of December 31, 2023", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r31", "r32", "r54"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockSharesAcquired", "negatedLabel": "Repurchase of common stock to satisfy tax withholding (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r10", "r51", "r74"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Repurchase of common stock to satisfy tax withholding", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r10", "r31", "r74"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-5-revenue", "http://www.vaxart.com/20240930/role/statement-note-5-revenue-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r339"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r575", "r594", "r596", "r601", "r758"] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.vaxart.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "Unbilled receivable from government contracts", "terseLabel": "Unbilled Receivables, Current", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.vaxart.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r26", "r27", "r28", "r97", "r98", "r100", "r101"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.vaxart.com/20240930/role/statement-note-7-leases-operating-lease-expenses-details"], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r396", "r612"] }, "vxrt_WarrantExercisePriceToBeEntitledToReceiveCashConsiderationFundamentalTransaction": { "xbrltype": "perShareItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "WarrantExercisePriceToBeEntitledToReceiveCashConsiderationFundamentalTransaction", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "vxrt_WarrantExercisePriceToBeEntitledToReceiveCashConsiderationFundamentalTransaction", "terseLabel": "Warrant Exercise Price to be Entitled to Receive Cash Consideration, Fundamental Transaction (in dollars per share)", "documentation": "The exercise price per share or per unit of warrants necessary to be entitled to receive cash consideration equal to Black-Scholes valuation, as defined in the warrant, in the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant)" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r620", "r621", "r624", "r625", "r626", "r627"] },

```
"vxrt_WarrantsExpiringFebruary2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "WarrantsExpiringFebruary2025Member", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring February 2025 [Member]", "documentation": "Represents information related to warrants expiring February 2025." } } }, "auth_ref": [] }, "vxrt_WarrantsExpiringMarch2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "WarrantsExpiringMarch2025Member", "presentation": [ "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-details-textual", "http://www.vaxart.com/20240930/role/statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring March 2025 [Member]", "documentation": "Represents information related to warrants expiring March 2025." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.vaxart.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.vaxart.com/20240930/role/statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details" ], "lang": { "en-us": { "role": { "label": "Shares used to compute net loss per share - basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r155", "r160" ] }, "vxrt_statement-statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-10-equity-incentive-plans-assumptions-of-employee-purchase-plan-details", "lang": { "en-us": { "role": { "label": "Note 10 - Equity Incentive Plans - Assumptions of Employee Purchase Plan (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-10-equity-incentive-plans-assumptions-of-options-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-10-equity-incentive-plans-assumptions-of-options-details", "lang": { "en-us": { "role": { "label": "Note 10 - Equity Incentive Plans - Assumptions of Options (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-10-equity-incentive-plans-summary-of-stock-option-transactions-details", "lang": { "en-us": { "role": { "label": "Note 10 - Equity Incentive Plans - Summary of Stock Option Transactions (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-10-equity-incentive-plans-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-10-equity-incentive-plans-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Equity Incentive Plans" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-10-equity-incentive-plans-total-stockbased-compensation-recognized-for-options-details", "lang": { "en-us": { "role": { "label": "Note 10 - Equity Incentive Plans - Total Stock-based Compensation Recognized for Options (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-calculation-of-basic-and-diluted-net-loss-income-per-share-details", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net (Loss) Income Per Share (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-summary-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-11-net-loss-per-share-attributable-to-common-stockholders-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share Attributable to Common Stockholders" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-3-fair-value-of-financial-instruments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-cash-and-cash-equivalents-and-investments-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Cash and Cash Equivalents and Investments (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-estimated-future-amortization-expense-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Estimated Future Amortization Expense (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Intangible Assets (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-prepaid-expenses-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-property-and-equipment-net-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-4-balance-sheet-components-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-6-liabilities-related-to-sale-of-future-royalties-deferred-revenue-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-6-liabilities-related-to-sale-of-future-royalties-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-6-liabilities-related-to-sale-of-future-royalties-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Liabilities Related to Sale of Future Royalties" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-7-leases-lease-liabilities-payment-obligations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-7-leases-lease-liabilities-payment-obligations-details", "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Lease Liabilities Payment Obligations (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-7-leases-operating-lease-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-7-leases-operating-lease-expenses-details", "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Operating Lease Expenses (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-7-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-7-leases-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Leases" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-9-stockholders-equity-shares-of-common-stock-reserved-for-issuance-details", "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Shares of Common Stock Reserved for Issuance (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-9-stockholders-equity-summary-of-warrants-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Summary of Warrants Outstanding (Details)" } } }, "auth_ref": [] }, "vxrt_statement-statement-note-9-stockholders-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-note-9-stockholders-equity-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity" } } }, "auth_ref": [] }, "vxrt_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.vaxart.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
```

Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

```
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r285": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r286": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r323": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" },
"r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-
50-15" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r332": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r338": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-25" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r346": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r411": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":

```
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r785": { "role":

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 78 0001437749-24-034927-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-034927-xbrl.zip M4$L#!!0 (.Z";5D%WD<-F @ +|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|R%W/ M%.A7@$Q(3IS&8[1QVD\#_L&;PG]E][A@!59WK"L; S(@ QDQOH51N5-48<@^ M<)K+P!HW%0;*DI=D"DP M+AT(0X**8\ ES'WWI"0EBT)6+"I89(RMQ[U9))D0;'"!O=/ _?AVN >!R(M MG6]D4& <|^,X ;FS69*@3F+^%7R|OUV>LSJ8TT#RT\9GQH$[J>T$2%'/*D 802]O,:W*YW/TC2\6T<8^K'_9 M|>C?7W9S#ULG5J,Q=?7L?>O(G7H^QMX]8O^%Y'O"G: $W"IM)N&V;Z ILTQ: MB_B9V")0%-!S?R2)(S?)-N&;7+GA4(&N7 88&R7\5$IBWQF@,G>O$IF=377M M:3COI-FN\?,C3G0E893KP%Q1#B42HJI0>5+E&I*XYMC7)YHN^G4ILGMJ//Z6 M="^<5@4I7X5? XB%%1 ,-3ASDK9BN$FL:0L D76[X -RP7,J,9$(I=INI I.E M3]TVSO/IX'-]RE|<0|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|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|=+E7 S*0FNT?,C*G0%8I3ZP-11 M#@4@HLI4>=+E&@*_IMS7%YHN^W4ELGMJ/'Z6="^W+L1)3!K/@45V4#) 5 >FO%^^8[']+]QI+E4(\"KPT3Y^,MG8(\P M?9 D?2%Y615 _^C%P7]@K%5IIS)">D2#VSV8#KGW5ZLT>$.7OG+HSD46H>HZ M]9+'H|WTN')/K)(/|BB]YL!F7=!S+E"5ET)+|_K4.^XC^)0W0Q;3V:HR^MOB2 MNQ[KY-^]D@H0OJR!OBWOTS#2N=7ONC/=#_8 M;M88_=V9)QG['G(TLU><|!WF'@!_6[M]F :[^/7L_/SL@IV?G-P2OS>N[0EQ MO/%DC^C)4A%%$KZ5!A;_VGE(MW97H;F28W/^"BN,#.9\6U4KU<^0*A_I^%TM M>(YO"?6IBM,G0=N=0CR%P=\IQ/XD19Z]R^L75\EZRV_W$@$Q.QU7JLY QQC| MY!O3&Z/=&.WS,MKMTDPOR]-_38=+5IXO-V=]'/^7OF&O7+WX<'IU,3>6Q'6MAHN#U%1@%O\^_N^WZ6I(09_E M+SF@% WZ3!\5Z?ZS@?\#4$L#!!0 (.Z";5DUI;&10@< \Q - M97A?-S$V-#DU+FAT;>U;;7/:.!#^W/Z*/3K7DAD,F)>| &$FI227N32E">W7 M&]F6L:9"DV/ICTZF8(E>=^T^T@K+U(3WF_%U$2I)_MZVFF.>W3Z[_VW- W60:N*O;U:UHB|OSD.G%!!%=$T .\&QM%,!%2]D5,*(ZDT MX>" 6Z^Y;JU1:[1@KU/?[)0/8/06'*?2FU)-P(^(2]@^+,UTZ.R7;*L@4WI8 M"]6:$NT$5%- ?,RE*X$NA]<#1FG(:1U+00R%+_>>]6B9RSY/!#23ZAN/K,0D" M)B8=[#,!]:K+1!=").*$9,KX30=>?IY)W1VS*4W@G,[A0DZ)R!HKD#97(*&* MA?:]A/U-.ZA0K+O@SU0B50? (3,NND2"^9>L1_$232%XTN.8UX=ZO M"EQ?%1@N^;7LID1-F.B8KYI>;X=P-A$=Q2:11N8|KS^\CIC'-#0;5;=7_]] M6MQ_GA/]N^EM)0'$4.]_%%X2=XO.-FXT=U.Q1^C!,R(T M: DZH[#HYQE3=(I#4"R-6BL= 8;.Q8Q3<)O$<5ME;P=DF Z_I!@"3#/4:WB- M42PF%(Y\;K=@V:K B0!C&)D&4#9O/#RQ7ZC4>_F!Z=-;G<'!XO 4#11GIG3 M;;;KAM8@(C%,>PVS=/88 ^X^[="?!#,8,^E1@A*8" #"F7L_5"]K ZJR-'= MW>N"(84L+C6]H@+.9 5&BB;,V"+E.X@8#5$)5$BS*PKOPI#YR!)Y?"371.D* MG]_NJ+%0$YC(FY6%1A%C',6PQFEE4R+C/0Q$T3X#.'0DLXZK0Z65 4H\2.(MJ*((I3A(LQ"-FPW5$4S1<*(BEL G(>>I7[9W4GM:[BOD?HIB3I> ^JQQ M?W>OF\#[&88)5?P&+FB,N %2P#&NWOB.\|X@2>KI.7*4 628T",0$$T<[7$N M_P7YCV79U6&H>E(%AR7T?M-WW*@CU.RZ[7:K]1ZT#G;Q M>ZE_21$PIAX&<+-> ;/QZ-5(WP8DAM \8AAGVD32((LRGQC< 6P@6F,0HG3$ MH-IR25V)_5&]!O.MKDL,"&<<+>"C;;B!Q3G341%9$X,]|: K$P1556AMEX,% MU.8ALVN0IN@]^&GB ;=!:71N,>'7P(3&3X4)3&3[=1-*9]I.E,! POV#<>%" MS$! (F$&+&!=B$Q45,XYPCIP11LQ*B1TO!@3VF-?#O0]*E .6\EA=/C%TTT<$ ME|L>"S^1$ME"^^#;|_K3@V^G4YO?B5NS;'ZZ<1H6QV?I-'C|+'7-OMYQF)9-V';B-CM1 M93LK(_NI&"91,691]GEH/Q>S99_?V<_+X/U6GT6[C%LK^ MM[.:1*X<+ZR:+[OC^,9[FZ^-H-A*^*|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|S\X^LLL/9WUV M^N\/9T=GE^Q#[_I.SH]_<@N3D^ZQY>G)_#7TE\7I^_/^I<7W8_PY5I]Q+N MT&>]B[//<"G[=,&./WU\=W9R^O$2;M/'"*_JGQ?/5(XN%G7DIW!Q7U/^5'O-__OG/?_[?UK? >|>//]MOO;^X1]WY"7TQ3,1F(A'5> M-!CRA!KNR"+]_V8R#8:$\D,_|Z\|2=E1$$LO$)$'|S^+O!4OHOUBEWW@R2!. MV!]\QQJI8'N[NRM>1#,.TC'K\XB]2WCD!=*+&^P8+@#&'@6[GGL!\/ X_A^V,>XQ7;W6!JSBXO> M9SC4&,.,NE]XX]LOVZ_]IV9GO[F[W_SX_O/7YN[NW]8=.CST0@Q%@NSJ@>=* M!WC$I6#=42+$!-X8G2!R^>;A[F$-CZSTA//!$R6*09UZT G5\ 1N)QH;G'N' MM(JSB''/BQ.?^+U@7P+@_^E8@+]83"3CD8\:O!\@]B2+A_1=8@C/9TMHJ.&6 M 78,5X"] 59"Y$NZRS+H,BY!EPW#^(M\5>_#]^ D1+*@"K_)WIZ<]H\OSG]7 M9Y\^LD_OV/FG$]2-N_CWFYWL]8]UQI0/0L% ZP K\).#N_]Z^QZ&!$?8_?_L?L%(3^ _\MU^^7WF!]3__]VN1I$!8 MH3[D-)Z^U@OY6=|=?EX),X%WU][.WPT^YF[+]WA-ES:0\4 M['JB].=)OIH*UY1^]UOK1[_#WL7G_[?T^-+UGT/=O0Y&.3L^/3LM[./]TO< M\ &D5IF>]U\68B^-T64FX*<3@HNGD0? V$F .,%8"G1 (.[7MO^\?'#:.[9>- MSHN7^4Z#MVR++@M0]@+X/$"D0O#?]QJ=O?W&S[L=8$/PNT$27XF(@<&K\4+S MEC/7VHHZNW=!,F'O@]]PX+T$;*N[R.V]5U90PY 6QB=@!*::$ 23(KD.T+, M7'8@V#2)KP-?^6 7>#.0^&A_$\WFMME;ZDE:DWFU7'>6>1 "PN)(L [[%(6S M[8=I\YOZS[^3C:-.KPJ06GZ#Q^?(;]VFMUV#F/LB'WTBP|/KE=*!2;]T\X M!?- JOB=K6OIZ+HE3]9=T',MTD]_#^O_SSI2R"EY??WEBU(337"T[_3H5Z,7(M4*Q&OB;|=V+--(="CQ1S"U8ZQ1 T@^H5BM6QHX-]BUY6!#4@B_[E&0803|CI MOWNG'T_.+G^_.&6*$]J#A;UO[1;_CC@A$\9>DK9IED-F'7AD%?]43'>EY+=. M+SOG@NOP+M;GG]]?;[OIA>6*VXWR[+LH)"J]HWR[/?;]TMRA.087P!'IU<^U"/PZN6(D5 YX M-&/H.I4;HS8RA*?!#>,L]%DB_LP"I+;B^\V&&H9QA$D_H(;#U%NO.?^WQ"(>& MEX-V@WX1.)P)G^&?(I:"WR6*R_Z!;T&(Q+B:GR*;"&7FT5J]#>GH4HM] MB+|(./Q7 N#>511_"84_0M4(QSUWI0Z/#^!I=&,\+9]E4SA 3%!+P![-77?% M,?U=A_5!PPHB+\Q\4+-B2A2 =:"+/$$-"W/IX%AP7?@"9"-_H:2FQ2'N7L*C M9#")Z0SO+5:;N0:.LH|:QKH.4-W.- (8FNZ +A?B<2&>,I4(9QGA MUB>Z4PB$H0&=$N,A O,Z315R%]_]Y"PX]<|4"(4STA,%W&@EX>-@_9! MX[!F!\)B&,=#KHY&K2+H:!&Y^7^-L-XD%(,8OAV8KSE$A. KP2AG6?P90*G MXU.*!T >V04I,+0:"B(2FG(Q%P'SGF2OQIG6?.$_'3CS]WVB]>2Y8$|K%+I?X*M0=0(>!-T2W M.#*Y_QX(AT\(<+%2OU,>!:@.>$$AUFBA:K)[Y8U]UAUL@K4E.A6,,%+4]K M5WX#*"H&"LOS<+B4L1<0GP8(\2!"^DNYO")5!<@+3V.8 (-??I9 .]@,Q@,@ M>ZX)%56>(,]$>8V4^4-U ,MH>$OI/O0\3^4!F=|*=BF221 I5;0LBI9D!FTS M(-(8Z>1+]_#?;- $OY6"C(Q"]T!'"9.@[ID7!JM3CUFEZO3|[(S^>PT&K2'# M(02D?1I.9.R!\BN#E\'9$(.DRF\XQ2 I&W")C$2!@4"E@7$$:(]/'&+$WP M&=-$3+DV, #-7\.C8TO;<(^T0!*N_4IS$1W V(/8A_W M:)/14L4),"*SZ12M'[6:G&DMN51#WF1_)@6%? &\FK^4;]P@NK0MB9QCR=X" MS?2UZ%28D$QMD*R7N>499"-7"H?P/@U5+RURZ9Z]> +?RHS,F9S|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|%O'L>?.^@\U_T.]WY%&/HX M5_W6/B4C'@5_;;R@-4W+5>[9!OID;W6M/\EA!?#1C/5"K]+=O2+XK18SW\.L M"U37,K:|CUBWMOW#%EJ!M';1.YS$?D9TP7;842Z5:YH%_XV6>(KDV!;F&G1V M7Q>)!YWVZVW*4&.^N!9A/$7ATY0I'PDV".*T*=[\62*"5R47<#9-)B*$-$& MI 4_A)\ 2V? <2V(IV20+TV :4J)?PJ%2)8MY<72MNM-A:D@2_R6B? \JHR3?$4I+7^#= M=$HBJ+NQE$^-?)CT=W$S6[M^\/^6,WC^!$X=%A4, M0']:IUE"9AD%,HX D6VF< !D93'=#%@] %U@ SV&O@G'*)^|Y.X%%X&QT)Y M\|>X:\H*$M&84\0)'SF";0:321:)8H$FZV2<32@A,L6DNDBH="$9]//2[S_1_M(69+UC'$6W8J83!UJ@47Y6@1CN!-SR7_9%.?E*3C3Y_/3IKMEX8LL :##_[M2CD%A0G((:@2;^G,@T)14WVY_GUTQ/1ZF,2R#IR-R/RR2*E%Y/Q4!7G M<383/-%,"945204#]-. ;-1IM+"D:TR@(@1M_JO25/>*'1N*NB2*.LT)#T\F MI[NY7U5M? VH,J8Q;A05Q"PP"C=^OE*P/M-'>;>R"26. Z+6%BGH^F2 M1#@5HX-)5"DC@;@?8Z(S@&1 ;IN9++9HEJ^WJAXDM;*@UFSO S\O|M R5]>= MV/M4SX'G&L]RDE,|VU5VZ%JOS.=RUMU39CX_P;'[^/+PQ3*L195]VK4N >T5R=.C(D?CP0H,(ZB'$4]D*+P'9&/T9&3(Z>G85!S/LC"D^!H MRM'40XV LJ/*:?Z.9M>? 9I<;KM|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|- Z9K2(5"]I:W>!E)EQ M)W@T#*(O=_+N^^;^0U&MRFSQI(+M;A"QW&%Y\ 5SG2+ZQL0ER@"#0%44HMG M3>UHO28%9:- 1<$$6GGC1MYQ$8#I9EIS>$7XX#P@UD-CULZ4'"ZF<$@=60A4 M,&$D(E%,I,/JGO, W|HX[ZGI>'WA90D^7P[-G3GB.)F-H.]@Z8DI9X_A@' M0/4@H -@:(@N'#"3,Y4X:HYB-0K"4@(T 9.)#G>>!I[BIH'T,BEI?Y'6<4(! M"Y$[6IU0)Z[U#^I3CP^[$"/58D"@,SD%M-46QU0SI[A./+UF>+M*(;72BGV MZ#/0VH8*YMAO0+!S_5W!8WM&Y;D@-I7S*(M)[#GVL>'LPS8LM9*]6[D3310] M*DHJ+-47XS3#$J(60)\[8/"6L#Y/21XLR@U,BV(KN/ HZ%(.>GM.])[1]2' M.QA23@U6C(0C23'5V&'>H83*E^7:|'B2X-PG[*)R@VZ7^X-L9Q'5TA1;>D:;Z1*21?I M,/;1*:WT92W_R@^UL=XHG(9EN;13:+=E-V$QU"EW%6#GE<1, RM>A_W,8F,J M.=!$\$B=M8Z(D10="PJI+5R-UQA1JPWVG%GE;WW'D%:(C8?DPK PR_%!0^OP M!1EKI7A4OBES-_HJ#NGW#5W@MN#Y+!E(&(]H--F9<3G4J.SK M8L KQ95'L'Y[_HBC<7.QQ>?,#_!T$=+97ZX\-PFL%,B"D,+QM-C M 07%?@X69>]HYS(IQ'KN,N8]\B LM%HYB^(I$%*+]>?N+8AAB<;"K+A1<>'"CQ8>HI>)!&P4$LM]H.PPKK*.-3HH\VUF95<2 M6R2]#_&NC8=#B3,N0<,H05TB4:[/MEV/@4;H/#HPC82ZQY)9-P\1X,MI#'++ MY-*

*8QU%2CZ3QN=+8EHIOFQW6I[WCV%.K8 ,3Y3O6>;*M75K)"^5E MGZ(/STKTWP8%(4&A7["<-/,+#] 5 F$F<2Z>]9:1^E"'9-#G!ZI>R3PED >## MY&1>.S&7FFVW 1W"%$&;X(1[Y5316L9&Y\R:F*-_<^G(0JD+:!MY)4N6##DY MQ!X@:W(-1<<@'3>N-3> ^C$F=5U%#&H9+T39#*A8W: !4P9SC"X@MV("O@K@ MH8,,UC:- |Q0G& *;F ,W5PGT2Y$\P3% M@_*=G?=/[+;7",!A%GFZ&LY*Z=`^*NH/M(IE"L6QZ/AU.V:V3P6_+SQTNY;:/8:5P. MXQ;&(VI7.MX$\8]|S2H\1#R*9WM[=/F\9D5?G6B|CSZE6&\!V M^\;*TG40Y"KUT.:S2K(+#G.E.)AQ)6I&_ 4XE^'&2K%*!:I5C'/,X0 X_0I MVZ(:S?(>[FHVQHB1Z8F\';?.#%Q:7B[L8|6 ZD89#(M+B'6E%Y*?BS =CN5R:U M2O6WM|G:Z1H;3_1=VY>9NP\LOXMR>5P%NO4&TK?.U2^F;7U"#X;%&.<%?B+2 M+-&S;0KW"@KY 08^@W#Q$H1![EA81OTJ4<&^5SYD)0AUBS:>D90VM18|8O:$ M!YW=,3,JD%=[@6.?8]Y_H]S]*9@@(Z84$OWRBEM81[WO9/ &L",<@TGCM@*= M8%R:L35/0@6A:3V1!IF5*)#]3420(+$% MFY MNFT1WC4N3#RT+B:H9.D4O%OX'9 H=M\Q F00/[G?9H18(N9LR"9Q8B& 6LXA M#\;D/-B&-N #S!42(.(:>8V38F."X1 MJ,,:(\\.]4\BI?))Q-"PT:*955ZV,=3)L1I-OB#O.P2(M+IIF;3N5-RP$1U2 MGMB_I%Y%.X%&B^*I&1B M[I: (T4>B+*@BSI]O(YJ[K6BWQ/3]F::B%$$6O'LP=120W7!4 .YQGD7,7T@>ZO.-_Y3#<40E)/42C*F!D:A?+,@ ME4<^GVZL;8?2S%)*Z+]A+YGJN$6N;: (4U=C57(EOG+RC%TYGGY[&7EB,$6"7 M!34N>#/Z<)6]:&9T;1$D6F\@!UFI^DV=*0W2!GT\29O9-%?]MC)W@)8&J'@@B*L!3:N# C+97H*, ^EZI M#B0^*HO4214L,- 5FR8,(,@';G(BX?]\G;KIH;G-_2C!?460C0CS4XD?EZT M1_D'6#!)[(UA#0WF<>IU1G&W_+>J/9MR6ZB6/4#!V%%@Z^SB:%MW%. A_'8. M#GP$]I.NA02;%3:$GV*/@% U5=:/D'&6>- :>&N6IV;W$'T!Y3,6YA1Z&*4- MMSKJR@2,]W-3!VE1B\HB,8J-]+*]A,C"'3/&06W0@N086CW85>L,J5H0'$E M.U4_'$2^E%IYEX\&%?)2AD^F\E:P/%_B,) <%HC/0[S0:AZ0AB/D.B)3=F_"4" MXAX')0E11X7=D>S]259U:WP\P5+N=@+H716@+!45FWABM 4M1P\DI2::*JAM: M2EP'0.% ED22.EM-Y:P2X0.%QI%JYRH-]6++)LN%+;Y.!652*>]BGDVFBM5L MVJYC]Q1'V_4,VJR1BV.RBI''=NT.!]_-_^VS&3%0=E6_^RS MW%[B8%G2_ ([5]/.G'F,|*(@#- M4:,/Y<^)DQ&/C-C8.K[XI!=*C3>* B/;;AT.58")=/P<:;]9\X*H,"U43&%S M#I&EC3GW:MJMPV'D/BLJ&F\]'4$-L4F7)9Y7G)N,Z8 R/HZX+.+.2U_3$X< M|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|+7=6#,@<*!-+#:-GCESN%SW+E5D=-!M3 MVTP*:XD:A@J<6@1QI[W"J-%-/\AB^I@M8"^JK"TIAFB/T.'8\ET MPI[-*O92F$XEH]MAHW9:= (\36K),4;E24_AGBMZ<=PO7Z6@=W4GY=4P(+BB/ M"K-C<+GU+BWO3Q%FHR+#/"Y:#N69]E\E2GX^IKI2NOY-N?I%*D;.(DRS#)U+ M-Q^EM$&FK[[#CBC*[S.V^X9YD _:>A$ M?4H@IF=;(0/N \IIS)VJU\)&*]:D(""I1#??HTL5]U)O>KJ,82E[SOZ9^8H, M,I6A=E;2K?:<$KU@2T!.QS.I"I&H50>Q%|H\PGP@JEOF*6_ E]YHTSF?\H5' M$0]ID3Q=H @]^&-!P4(;8'5T13KXW0]^]J3>*M58DB579Y0$YLJWL[MQD-P)AA-#ZF.9ZY$\8S(7A) MJ=A)H#K0@=>);NMR< M.UL"74EI79.)"D+H /@[=,DS

MU4CX+X%8PQDQ C Z]Y&"$;Z)XW\8C;6.'MTB,(;/FX7\34C(+R9,O%N6C'@&_T7(WYI"G.GMO%F>:E&/CS0[/VC#*
MBB90MHB@+Z[^$;\F;+^8F55S;+P1O7&R/&Q%D?.C,*B$U>DN*DB'21G/I)^ MC@$U%X5,:H2R7D&K-I EBJ"=.)&_.23((B@8&YY9*Q3Z M@T7N)#:<*?/X'S8Q]J=-
',.5Q7P,W_D_K;Y &XK?R*S5"T/)=P7A^=&D.(;M M*<;$U\AP>MA0AQ=|;F1TL93^BI!H98\$EY3Z Z(95^ CZ;8TM1Q#4&VP+L"? M'/SKF>+*^N1 L(1:A1\%?XK4G\,.!D!-CBT#2
[MNTD$#L8ND3"HQ>T_OC+]PV6=&*\]ZXU)T$6U ;$[=+#9W1LWLAR_FK31"<-.?B2V2/>D@W=)P=?|%2+X(PH.'SR^_WN%3"' M2L\2@.K#@#C" SH9'%]_3$L 8.<)
#XL#D'F_%L!KCN--3:&6 M@Q@NTCV7/B*,E#T^S??9[K7C3R\C*F/3MP]#?YB<+L?BV,KF6GPN M#AUT6E%O47LYJ57/\4V6'I_$&_-ML3*5-)B;I&/W"$"0+Q/^(Z)0XN%FUQ'+
M:LJ>8B_8(QF!P'[%LH6C-9_1(-RI0-E20NW7?#3?V MJ!XV9+QEB^JAQ'5V:=CA-;'BO>,;_399$N[)*ID6E+'1 [K5^6]E;R0>S6
M/%YUHRPTDDX>+HEOG=AH5,5N>:;JT4%G0Q+.XK,W7]%TYU'[MB$*J1/@TQGV MT"D:-&-#8LGQB#OHO"T#1, ^)%W:"[7E,=4.4!_-'%TINCHR,C-1E6[LG3]F%L)F4./*;KN#D]
M%QLF2Y:L(_^XKBWY@YS*N=|EI&[:EM:7'L:B8C%+LS- R?!XO4A'\||JO N%1LWLAR_FK31"<-.?B2V2/>D@W=)P=?|%2+X(PH.'SR^_WN%3"' M2L\2@.K#@#C" SH9'%]_3$L 8.<)
#M@\.U:.O\5^RVNI8 /+#Q_1C'M|R&%<5Y]17;.WE4UDG0CWNh=#7ZA87A[WW M*=A::E=RA-*P:!VXR3#%OC08A/_);@C VZC>/5 8"F"/|.*"9\#W(Z@V):UU MIKK(C2K1=
]0;WQH=A1Y2LH?[Z"^]&AQBTTX+%/7,Y0Q626!5.]-//354T M+3=@+WR6.8PQ%VN7(>T3ADZ=0,V^>3L,#[M!F3NMW#\E0_U4I_ M1'O'1D=F@2Z\"U%02(_-E&!5D*G%#
[%XSU:OJW6A!O/JE-*1A?;]-I>`]O M?+&KQO=X1$X1*)C> CH(H(N\5IA18%[9X1TI;HNS38^"U@07FV(_-$][@Z9!TT;9&>,3> MTGE=6/K";H[NBC6GXD'!]P41!739?]@TQ8. +%=
<.F@PD/5?U!/L_EV!WS5Z MZ7!RPH\G./[4N?6B,(8S"9=V97)MSW<1NFOY/B\6]ST 92 F@ /!L%2C[DL= MQ1Z.L.V3.J6]{6W(-
Z54"V3>584M$W:$P.FX^2_G$,3SLTWQ.7JLF3W2MR2:*U!LN0 MP\LXOK>]J4NV>1T7B]XVM40@"\JB.5_2O*/*U'AOJJT/:GT]8 = M/?W,L=78ED6?
TV6N"FQ4W.FM:6SEHCU:6AL5"R[ACB>+]L:KPLYWSVY\-.YE M1,+>(9X40XYA:!J&WV1:9U@.QAH*(CQM\MBK8I37[9[P86[[$X6=U1DVK\WA MA6#X#[UV*2EMS?
>X>]B1=`37.*+9Q1=52FQW"*;V$X|Q"7'KITP &)TG'GIUC>VB>_PY>GM1 M#=[3!("$NEP[V_=8DR/&LXGU;'RK]
M(6I"RR5QK'BT\XW*5$!*T!R\RFU$SFQ@NWAS16^)R@1^2";9[Z4+)-K;%7MP M81<1Z,N)45&^+M A/M@@0QFW>J3B?>-KIM+3[D>8$DV>$]F?%S"Z=>9#=]3W MA!!-
!;9U<0]IW45TN4!?,,O#2]N25GO'[FL/O!+UPVG)KAMQ=:0'7MXBJ9*2 MX1?%O18'*OG2K8[IXR':WOKONC/BU]PJ]ZN%MG"E.R7K9,#\-2,/2HT9 MZCZQ<)W-
:&P!)H23Z"UN@5IFV02'V*F>(1TP>LR(#0^F4J.8Q0<%| 'D=B&9 M8OT?*!0!W;S7Z6'M'!RI)|HZVI>$K\I/2)II?E@IEVG$1X9S5E9\CL&7%ABF M]Q&=PT'W[E%0;>X)S"-
&YNO/5Q'!*#PB^ICYL0+|=>CJPRHUO45 MK6*)F!WIF"97@F6%" #W589CY.]XF2BZ,Q<5#_P9ME_38X>MX2^@;U3U49 M:%U/NN=530|WGI"7KQ-'<_FW4$;>371(_=
(9TR+C]H8&*FTM%YZ$?O?7UZSO MF$72_J4Z1W2SNG5W?RU8HRCV;@&6ZGZ^E63'YL]Z;&*P>?X5HGS[/@#"!CE MF$?N1IV;511Q@E!1YZ)Q8RN=-|KYLC#XH>
<0%)EU,UE;YH+?YY!J3M|/ IN47 MKPZBHB5!KEL%|S_%GQ!\4,0<@YL1N8XU&>EG<]=HV17>BBDO+|Z+]#85]QQ5 M<(4$SIM8Z&<'C\L[D=5T>LV56|5UM 2MKVAG%8
MJ>J^1497MUD)IN>LED=W73|K.Q*]U"M*5BHTB1#.%0#K-R.;Y6B,;4:"Q"W4 M;IK$L+&$8*J^X8V(TL@T3=6BYF7NSN6'M=,EUAV^_$MT'K"M$0D!S[=+@X.Z
MG0GVU)&E1P."MI(HFXY>&"$9LW4W#5V_SJKA/S=;%:^RQ27V7>3^),^,]4Y\I1XEWILNPX[QIDR M$$EL!33A<&"@]#D*+1**SB/ML9_[1&|>G!AFAFR@)?8V+? ?RPA 4A!B+>5F
M]R5ZN(4^O*M^8KL[!7MY&N_+"Z:^T"MR@/+>;T<' *6'3\B/K8[V#B\;MB MA__O+V\EQ6.9.K["@P&XG\[#/3Z]/\[^R_KROZ)P|9%[_(§=^Y]O[!PNMD/|X?;/_? M6EZW>|TL5B-
UU)'^^6#&?^:[-WBU_!F0T@F ?BH#+B>W*^F(F0F=V!]_/N/ M+0Y(V.>XB=^L@%K&XEM2A?U*PB3N(/R62I.CGF<:V[\ MQ+9=QG;4X9QRF^W(AK%4@UN2FAVR\GWGZ0N-
'J/0ZRR%XFO/\Q=5=5?XTTW+ M#%[J1,IWB1QKXKOXF22_=&XD42"[=DMRS-SYDQI3V?=!>X%R]SUM9T(=7LV
MX*]V<42F2,=PJGW%,/24*JIT5O:TAG'J11Q3^7UDPME8<+.)^;MGS<|SXJ M28R/-O4-6E#+'9Q4,Y$QMV;7<30%/#_\GDCTI"E^RT?.I9G&>I:%C+G72STF MXZA*|%R@F5'G=-
B+%8,T1@,Y-T>O&3;?[;;>X0BE0Z,2AY8B#'(8I;/NS)DS M='!]&?^TD&CI7DVV@S9(8I#1K6GOY#X)&<=E3OC[WAY6T^!Z@F-;3T'9MU9> M!T'ZM\8TUP$D:F+,OC4**@%/<^-[E1<-
GTR'%S4%(\QHB#_?0SS,/:WRA7)/ MS9;'.M[(H1H6P86BN1+-/A@;;U94,,J-+GNR+FLP9++#6]W%OAUH))M'4V_:N M9#YC.76T(C%=38] WB%*Z2 #R]\@9+I%>Y3|!V+(T M(#-
^_ 7G4E"DODGI\WW M2%Q@.$9AL"96^-NU*I¥+4W88CJ$@ &<(0) CLO7E0#<1^"O[EW]IDD$6(Q, MK4'8H\)%DD&V,^&8M]" 7R/%3(ZS£P" O T:3'S':0*0#L.P$8 9U3Y54" 0
MF:SU-3P'&EV(2U AC*>()0#!*;|<_W^$DUP@;3 M+;JX\M9";OHSO"_J?" 6)Y_M#VH*Q8@W(@!TTPU)FTL$@!B."]J-"L0O?=/0 M(.[B_/Y21:I_: 1?"UF!XDC@ MS^'U96CS/; 7_3!!
#A]D\'WU3 2L[!8,&HI/#1ID[$;CM) X&Y#_G:)/EH& M_[U 0>#K"[,3T;X&!*|N7$8<_E%+#FQUP0(&K0'_9:+>;@K?"U+7VGF$4PIG M@O?FX0X3@'6^13YP"0@8>7;M?8E1R$IYB
M!)T\D^FC?MGV_;DTOGU#_-?,*$I:;K\[T"INBR>?6NKR8 A0_B^A M_PUT)""K2=^6V7]-\&_+'":#)W/ 2|@/5I@+\|N+^-UZ]B6"@]@(14(Z=
M+D9BKC1%ZFAC2A3LE[%:H>K,Y[ORNO;4V15*LC:J0A7>']| V^F,=(3U#D M:Y]TEMM;V+).@7(C#5G;1=A="G"M[((7A'6+==#5]4$2VIW8WX/QS6X%7R^ZCY
M3N%OB6.% Q7U_V]<8P%?9 ;W[P-SI\%M!J /6[0(?$C^Y2=.%/R=IRH7W18_M21S)/";K> D210"*IW$W,=:3D.&H>MW3X_R#56S3PFQ=4V,*R@&$EC@QYZ.6 M:^:9PX"
(X,PH2H4!Y?V(E00)9_1R3CS7 W41UK:1+!-B8!@IXP9DL*H2B)S>F M,N=BZX<%^S0[?*>H!R>6/6.F5O0IG\J:29_>A3+C+T\@O>]0P 0R>$K&8L M6
WH0[^;I#6#\&)XXV'HE)D_\K!78YQ[$X*F<=]K2NX|OB1_]%9:39C(T?? MF+FKU)H*%1ZO0I0YLRT.^*5-...CS+;N%NLK="IJ57PX581[WR8*]Q2%JQ);Q* B1K%+>S-
MLUL9<%82P%L6*^6MA8G(7(13X,Y-C;1|#B]4S(R+#&@5^=''N'9VU$4'6E(RE-Z7RX-<-2ZFO" NGM823I@I\&2I6I80) M)L8CM?-R7KTPH;UD4G^2>V0Z5%_!KSU-
8WZ395%S'F_XZAL:=^'3BQS0A5>O M:*A!_+$N:))5XA1"C?[I15Y9@=>IRX-QEV'M5A2:>ZFJGG:%(XH$ZW;3>VT M4C[N$3,+'6PC(9?9OBV?9D/MVT^SAV. 6^L1@*X.!#@DJL?
W.ZDR+]>A67-T M3)C\/4JKG0ENKN|RDGZ#P];.4;]5==9[SE MY3&HE!Z,-[A_VFNQ]@#!BVJ:9:9QA,%[5=2U#V@2Q [_F!0=? + MI0#6XN[==4%8C!3IC>70&D]&@+,LSR1Z$<-
N!&#C*VG$LA(X58&=.WS*TJ- MVI 5;_C.#L@AXD'XCZ&?H-IM>'$. 9B?F\#C*:_.AD"QW&W\P+Y$\7 LAO^G MX8%^1BVLI@3>UY8
K$VF_!C^3R83CYB"48&!T@$Z$X:!X>O:"$![JK];(RMN1 M>;S,<+AH3,X^#FE!A2X[TL(Q$1U(T_%R
MOD1@0[C,BG!?:8CWET#WW,E+1O1]B.35N&|CF\80RK%$)D$]G<|LC^3U3^O0D M"X/6Z 1]>@R&#S;S!SUID !,%|'KPEWANR?C:/'48/ .&UQOPEW&-CW"4 M+@'
N85C'%?!9>3.@7&G!]SVT<-0)#.;;X\8|1[^'$RBYQW^$_]/< HJ(.ZO M$+@8L&9#=3!N2^ DM[4(0/(+,+Q,%A, S KD%TS]A9&]NZ3P>U^S[N.%FI1- ML"*+[ )['AG6Y.JYWQ#\1:@
'%BM75I;VR_2CDF>PS\ BSV=_8*O3O1_KX5N M G $$03]?&QO">R8_B.$X?4NDUV[E 2@Q7R_1*3JACG_2HSZ8C\[^/S& HH1 MA.,O*/QD 328L)>L8*4#WSF]WI!-Q0FLVE
(:J?,8!BPO3WEP&Y(TH"ZV]O63F?CE_I_ETST)^64, 1 MR/RGFIS_3S7)COG(-)GT[VH2AJ;$1.'O3XPCVN_F1V!V]"M8=^]LM_G]U M./>/5 # YP0#T2@O0JQ @K=##K?4"F,T[=EW(:
[W["#KO- MT%22X=]A9"\|#81S$$^]KP?>K%GRRPGD5|-CXTL24.6(U?][TE-S+E8)1"U+$K511G|@$]BGOQ^W M#Q_DM46,&EP.M7;,-%AD\N5$NPY93*B?
S;:V9E+A#%#D$9%[\YWV 0 ?#N$< M!5SIUS2)N(?]NH]FY6&]>S;2*K7_I7K/2??/$TE7=HP;X?1G]E2# R'"#[8T MXHN&BU+'PP;[%=KHO,W,'.$G ./H7])R'D#-'5M_^^E_G2YC"NG
MXS4M=-XSUH@2W0WF2W7@;`>ATB^,3;.A^OL2K%T_28_78 "F^]2UI/E+#-/] MR[/5UKOG4[CY9RKC'=C:Z^F&@]42/31L:.U#:3459O=H4^UND1L=W*+D=8:5KO"G-1NEEG(-
MP\9: 97.CP^ZC12<28F]%9>U-A)EO0!'],[> M@RC %MTJ-*P&M<1+WC996*9]]R7=K==H:N,4$!K09#WH'+$HT$P K.(?G8^M SU']H.EVWC?> ^T3_7.Q4|<6S>9W:'^$!KHU"V<
M6'?5A:WY/FA!\GK[I62>N*(1A0MQ.8SC4YQ2=[S.A'CX:PF+#31GR6/\6F M;-B)G[MFNYJ]RO-D[ZZ<2"6?Y QQ1!=$%XDPNTB]48>@#,CYDM ?T+15G78B
M&$E(OVR],*9G#3BTUMS_+$NZ-#T!X(]8^U)AWD^MN-[$[0Z/&!HNO=L9N'S>+0_+-.99_SMW:AE5,J91N\BR_@9S7/2*@SKM;P?5B_D/3C_ M)A.I^O H52)G[VK1GJ5-
3.^MDLK'C8T63=%KW4C(SXXD$8'('5SWC9Y-*@RO]8(M'DU(QE&9H\7=NM.P2 'R*!6F-TKG[&TNU]?(&XUG.R!X)U5O6C_!H"=-*S&/
MIH/$$"36'$+QACTKDZBT_C>)]O2JK@'1*70$H"WU@?.XO&ZF)>3L^AR]XU?] M4BLWM1=+XMX0@((QW3&R9FJC%R8CB2^&5S7K$Z=N)X M532YLZ/#"8KE"_G"9?/E8E.
(_+5:9>.IV?>;>[']LH]4\3TH;\?L.-]HGA"' MYD@N::WRSJ6HZ%/UF1^>VLY$W"ZDB,A2H:#N&=L;:=D^]SKV%NC3QZZ^-'Q2
MO09LG2).26AW(YVIII'4]W:3IP$]/K>=PK)G_U)L<=^%QS+4A[C#9E3N+F@\|8 MKPL9S-/1J4L?EK.WIW+;VOJ<+T?'?SM4XPX_L1_ TF2C=?OH%SY=EUDV_A&] M-
5=X&_Q<3#5']'F&Q5K|GNC52IT1],+,>;_'*W2,EC?5-$QYD=!U3K2:= M5DAB+;-P5Y@_M7IVE>U#Y[FPLFO(\#A0@LE"]>]C9KN']/--:>:HW",#IY^$1
M&Y^R;_.X:&A18D|O5&Q5[VZ'2]N_,5PX.E> ^92"I9_CA8P<54X2-<7'!Y?=U MH]=H'&YN-"C;W+YVETM.?O'Z]HKUQ*92WUO)||YUURNC7QKDC* H#F]5WK.T M/]
<_/,=3%L84R1AW28=+2$*2I86X^ESG>?74Z\.A"4-YI&*'5-N6B1+$+)\43 MR_K*=Q6KLW^L3O1R83$7H2_L7G.0$0/"06WXX5.0U M1.)*&WOGK5#-5WM-
Z7%KI5XK/M05+Y0E.T,,Y"Q3Q[,44DIP0SDK.7NJEXLK M@K?&S *OS07@EQIKH]L?.BJZ9NA]>H[;R9G:T+/Q-;DO7??Y7!^68A)A/B:A
M6%0RN"H*)5U,I.Y>$[YU[7C5PR'|$;)GTOG#1V3:RUD;^X7DD5(=#@2 39H+ MY);%M6V-R8-+!ST0E?FY9*OB@/;"W*;.C3 MVTA|%M%:T)@;$A9"+'!RE(5C,JRXW6K89
TEL]ZN,R;G-DS_H230V%T$.0) MK#W!U";'4Z[VXVR5BKEN]27';'8NCEM)9_E0]Y#?B1&)O+ITX$!(^M,/(7=" M_!O<3E\M+_?T[<#[5+ C;H=SQ8I7#>RX+
[HX+C)MG!9DWDUH6HN;DE..$&51M M3*2_3]WJRW'YU)^;*YASNY.A@[.19?= O58;G-B7$5/WP9VM2A3C+\H>RS/)7=MQ. B
MC6Z)XF66LINWHT*>)0R4%/>H=HR@>^:+1I2/C9YMH>?.;R;2O,RJS?&0=F3\ MA77&R 2K](N5N74|XQTG 1O[*_XU6|(#S/ZGIU0#SON\SRFN!TMCT\<I)/E' M]5.V38X(-JO9-
16P'^1V.U2EM26-4EZ[CS]N|*>';_'9WVW<_?"6E6[BH[WH MC-0ED962%Q%560/#!B&?4W'I\R<^Y%8[WZG-X7XN^QS3(Y!*/SQ+?/RH"\G$1;NMJE0_P-#&HF1,%GY1AT@+LA:G),
MEUB2@_D_$C.]1'0 (Z!L_+|R7Y4:F!Y],=D"L,?K]W\^M;7EP'6?SH)+@ _ MRCW]2O?5H9/4EA:O#NVX3)[YY>>ZX%G\.K2B"](.5XQ69I%PCN4=5^@N^2O MJ-/VOY3W\
(U"KO_ZNP/63M"CL^;ORB3H:.W/':A_<&1W4$<.<"0 0]NPC17P M7V\(*@4KLX3WR86N^>,9RJV1'0*]@X)%E:%**[5]> ^ MQ./WDE"Y;P:0%|H]Y@*F8Z0TSI_TMK]>9"V#Z*;Z"=)
)0>3M;95\)J^TE MN1(F4'(=@T!H%CF?T4-Q MKY>&]^:BC+,7).+>)"45Z]2XL\QF.@4XI_X6)LY42;@7,0 OMH/,#*IT?P8M MMYA'JW- <]C!X1!DNN^Y2^R/MGP&
<5A].*BSDS^_Y,9PDQ2REP2^)5,(GRC$ M,\#-QN!=[YOV4-;ODOW*P7[\^[4%OF-_ZP?8UN^;TB>U2P8OX3\6Y?_I7?;_ MW/P9'Y DLSG'OI:B_?O_ /WO5LT -
P>^%+AW'71/F^ID[PS+#F M['2/'+C@U[U#5WUF\OX&OQ0[VM#0,5ZM[8QSXZ!R+<7]\/N>GA5?\YRG,\4; M-K4Q>@'6B:GEQNW#6C[#RGB];?ME;-+.]C=1MBC_'&O-7@,IYN.
<",#KMUU@ M8T.MN1(F4'(=@T!H%CF?T4-Q MKY>&]^:BC+,7).+>)"45Z]2XL\QF.@4XI_X6)LY42;@7,0 OMH/,#*IT?P8M MMYA'JW- <]C!X1!DNN^Y2^R/MGP&
<5A].*BSDS^_Y,9PDQ2REP2^)5,(GRC$ M,\#-QN!=[YOV4-;ODOW*P7[\^[4%OF-_ZP?8UN^;TB>U2P8OX3\6Y?_I7?;_ MW/P9'Y DLSG'OI:B_?O_ /WO5LT -
P>^%+AW'71/F^ID[PS+#F M['2/'+C@U[U#5WUF\OX&OQ0[VM#0,5ZM[8QSXZ!R+<7]\/N>GA5?\YRG,\4; M-K4Q>@'6B:GEQNW#6C[#RGB];?ME;-+.]C=1MBC_'&O-7@,IYN.
<",#KMUU@ M8T.MN1

<6&?^L-X(S7A1 M@BPIQO%!0P7_P9> LN^D;XWUSY1.=Y M-RM ^'[9@T^L>;O[P?"[4 I\X]9@E(GWV-I'4\G46SH[:(%3MK U>#>79* M%(]?%:X>+R4)%*

]_92NM;.V"RH9;C4E'78W/,3&\>S?O92YPD)W>;TS+@0M: MZ6'^X4O!=9&\D*BM*-T&J)M VDJ*K_GZ8,@XKQ$FA9E=Y@#EIQ[?Y;CMU/&M MBHIPT]QQ>-*

K#69C>+')OY[LVF]DR^?LSH30N2V/529]\1CW$E1R M1&*5+/FTK',&YFAY!4UM/'-*I(U\;;XF EO&780(E*Y0G#_[A?1MJZ@=&SOW MO0P=X^4"VKEGRKC6.(IH07TU+*

(>&MDFUJZ]+&$WIMS;'V*HST#2A1?YK'8 M/=Q#MZZR=[<'F-FH:<-1"98$X Y6'MO%MPP9ELRC%2]-+_ @9NX+G4V4("

MM_0]*CH')".J^RO(3X3=T&V=$&UGVFX"L+6:;#U2?:Z4S-N8YF_.X3Y%)W6Z=C/M8Y3F$/[;*G@"8Y5Q! M4GK:VPD.=FT(CM'=^# EZQA=1QNX72/YV<$CW4$TXTV6B6OZO_Z?*

&/]V'KI1 M+=PSU;..:%W\K7X^-.?)"?$R9[.%*^083+>^IZ^].R4H?D:W),7>&- [CC$Q? M=D9VP"?#&^#0%%PYGB!MU>OO?=D.U!RXXIYME3\QFG#>XYWC;!MK:42@C%E! M\?

$CZ^;)Q7H3C\IZ6_8QD:#3MY*M*OPBF%@14Q>#^ S!-Q|K\VD&ERK$W2Z=4 MATM?R'+(CP(^ O/P LNC/HA;ZYF2GNKC'M?!%]I?(*^;?#=^UZ=UZ5F]5

M7:ZK1J67K9P=$TU!^O!-G^2+T([@;OGV3(J,#7]O:^687A,\6^^:K;>:]W!C M$E.YSZF+5;?T+H:XL^9[0OL:+HZ .-KI>]KH;MXOHXT$41U;U-PZ)"QC\?HC

ME59N3A)VMNNJ_A=C_P\S_>&26HUX(!^]E;7%%G]WMS&N]-$F@M;#6O/AXGF? M#0,Y 9]DMCFYO/H&EHHZ'!'_6"D7L C+#ZC MQ0O+<%']-_^QHVI6M_NP792H(D=I=?_7CX.?

\8B^U*VP[K@(:<,KP'8[2O[\B"]_SPH'] M37(H\O\A[ZW#HFK;=^%!%) &Z1JENT,D1D1 1 2DNZ4^/;>[_?[8^]C?W_,<0!KUKJO.*_SO"[6 M/6L@YV?I:%6OVT86_M4= D?

Q8L#288"PJ*:+A06Y\^D!P(@%-6<(H%5Z"_ND< M\-[<}8BVZ5>E9PP&DWL)NF7RB)HF@U\[(<*]' Z/+&8ZX]7MHUO#TP/C;P1>

M$2!V$_[/YRC|LWOC<5",5R;LH/^_:8MRU>E]5-,@Z'\K*NSS:RGBER#IH7_(M$>0_3E]/.UV&GWPOR,R8DTPDDC'EE0$1VB$P.W3WQ>*AYXZ*XJD0/X2&>]S MB+990=&F/2-

X]U$Q"F8:.7^H40_T-W#-2U!8]K^B]T%-_PW7?[C$57";_H/@ MWC%:#:CIA_RS,[O_&>1T)3.*7%7^.;#>_UE@*0=L>3X,_W.2F?ZS) >YIAB8 M;K([7(+D #.:TT]#@)C.'V)?/?

BB"QUC\'QA"PV8$3@<%"#<-> 'P _ M[Z"'W)>#2BR^NJUV"KL%7(?\Q9%" !\8<\WEO]P($%%6+,]"^CEV" C$0P#NK0C]5'^^@PA L5;F[

MFC%H]_I4X"[6[Z,\^&_],\O^47NF]D$7.4]+^?:V]TH$=Z>)H=_"\[5 M!-X0(;L(OH#);#_]656!70#X-I<3.GSID,R"/KFU3]MOM1+ =/>'POY/(\' M;U' "']_5=#= ^Y

F/NIF59Y@[2#5]<^W\|WU^Q]7,*;M-?)1AC\E39TMY+. M]3TIC@%292K+?,2WNS"5DIC*@BWV)LLJ;[U&CU'0";R=O$EJ*AQ'$" MDE_/G/ HYHXA^K'Q@_.V1IH*G: '6$VF:^]

[*17BB&^ZB%3[9)']^7U:A%/; M0*94<'=UWF!X*F=+\AF$;/:]\7U.A&%; BUVMCGZW/CZG1=ND)(2)KSB4H*<%Q7C'Q MX\N:,Y=<%MD*/MV]V9B4

MTCB4_H)O0:"]I_>>FX)R"DB/P.L&OL;\N<@"=:B/98F MGQ[?(>+(LE=)Z[&K\N,K+_4.LCUB%U\%G8N>A^ .0,/*OS).0+P=?4IZMQG& MH2)>@^2Z14T.J93-MN%Q/64^D-

".P>^+KJH?R,*['!G%L/LC]CC<*/V.[;\ M?BYOS)E.*&8&9I_ "]D.[Z7T:YF 70ETI4AEY1?6Z#I9\K=^9/O=#>]4]41=-MWI_;ZAPYH+40WD MI;AT2X\CPUBJ4DRM3#

[5=%545Y#I3*1L%WIG\OM9N[1QOT_7KQT MDPU<1*PU2AQB!'3VASK$KD%*=ZI.U3Z &DV6!'I<29DLD FTM(E:'>YC M+D8\2E]$#

(SDH.R]M#-4[S,>9*OOJAM[W%M1=^37XB'K1\M>?/*A1>]V)Z6H MA?C(V>7;&]COUE8%@?L]%]4&|*.R0N0#OQ/BT4@6Y4H>^U6AD>/5*\J]Z1+&?%Q%]1&TY+):-

"3=;/C3.\0UG9WF)X.X.[/;;B M*4%D B&6&$M3I]:8/>92'!V]YTP M<555)BX:R,B[-?2)QU1VNM]8F2S/PY._?4#M6J0A.)WL7LEK/#\]-:-$$;_M4%3,W*D'LS9R-+OW5H(P=MCIZ

L:4]"/2GJ0-O+R/!3&ZX9'CIA"4,TA(;\% MZVK.4-X+W+U/IH1(U:T.!@NHSSI[L"7$6]!5?]GSG+=#,_-W=A0Q:OX!6! ME$V14'IHIV3+D+" M,)UF$'K5V[A4K)M[X72NC,NH"1Q6L?

(M>M!R5 MKBF8NY ;YM=1XQ-?IA#:(?=I(R-;E;BK&1@5PP=_HK$B<.+] ^<)1K"|4L0Q M!FANE +H$Z=SC<2?Z5BK5\O7O):OP="(;A!F%6#UG9@&%9:V:#_5*]"U?%F

MY4ET^$)@&1$3PW.-IR.[-U[K8&OVFCZ6SIZ.;AS!2B4)Y\NNJ0JR)IUEA[[M1]JY\0DQ6^=*T9HWY5Y'6MPY-$E;E':OQ%>2OI[!L->;:N3^/>,?\3U&5A3[M)S"=2?

HLJ'74TN$H@(V(BCI>#9Y6"_!IQ'\WQM[!,$[,5%9SK M1&I\OIQ"7S!@>U!/2'MEE2X5LL!CNB@KA;-7;R"O(@MI6Q+XN<9T_MG.@GSHKY/>UP39#OJ_(OGIW3CG+HW32"CNV6ZH

M_;]CR8+;!87F5'BD_2@W=8WA5:1RC(.E :9UOE^]7WQ52-[A/^G-^,!,5LG]7U! Q(W@+HQ_0Y%M= MU&%ND8"](.:8GUW'(EYS.B)5O?

L2ITV'7;!43(>/R"6(8+H+H_7.G3S*GUM[HJ4IY6N'DQB@L<*@OR'-YB$AH54R-%*6F] M)4BJ^[CC^+)K?;73D+=WV,7FK; D#6QT\"8J4Q79%.(GIL]_,7>NVA3T/._S

MW>71&RM27Y[#(K(>% 325EOM(VIY=Y=J=CSMK%@$V2@]4"^_^,3@4U3G@'I2 MV]WI1..Q?,7:W T?2;NK>PM[C(>5Z^!(:>?:E>=6|SFG9GCO>7;X2/&466Q? M4-/R5%]3|

((L1#61((92#C#DER"P%X]5;1BVDB7'.[G;7GZ*ER"):(NN!U)?.MBIN):UR[0 M_*,BZLV!9G,8#>E&,4|C\)H6I 8Y;"*E7|K^)!PNNA!Y3L6N:3;IB5XOD5![[MVX"PEN"SARZ 672-X

YSMF'JIZT(W?E+Z2B[L)>]A] 42=3XFOI$ XD[GQ M?"KCD +*-.NJ@KG3]#B8@*L;S'PH8H*(T.E.IKNS,%?* M_(1A#RXO\>VI5EYAHB77/$[

P8IO0(M\W62/HK0U8@G,@).RKT(YD%SN%5K4 M7B*X:-D.#7O*8EF.P_8.W%!9?**4_5].TN_]S4DPDMJS#1.8BX+'[O%"]A0A MH!F\QZBF+GAC5KJ-)O!]T8,Y=49[*7|7NTW^A9M44-

<7'FW@GE;B8%0DHMC2O]EAO5 MU@6HQ4J9ZI3C#]9(28OVCB#YEKQ3XP^/(K@ <# (6 5^5Y-3^C1]K&W0> MD9!?]^ AI^!K'&BRS&;R!W'P5O.E_E(#E5O8^<0|PQ_",$%8R6 &:

G^?SIS$8YA.;^(^7ER"2?=D[\1B\N@71FA0J M9$BT1(L;8RI9SI7L;,CC??L>0ON6/-REH#D?9'@%:#2N!UMWIC<;2T$]%WICW M)M4)2@0_0XD0*-1=?/P%#

[I.Q='H8LM2@3>+K$X>(83,WNEO8D^)XB&&NRX!QMOE1\^#)H_GE2/4*'^_WTS1DY7">C=PR-/UQ-?4X= MTL>2>C30S$EH>4=Z8/S3N!C]?:/IS\AB5Z'}8,T.'J*0O?

>>2WW!V[SOHR2X MK6S'ILMJ&1K(%(C<9],LS0!D 15?[6/P)#Y$<(OI9)+4]WQ9)G\(3(3Y>U9 MB7APCB0:ODH%M,VI/5Q MS&\G*R+LIV*Z?

#'/EEA@L77]RQ8,7B&E'[2J3/<4=K&FRH&A"3F^XQ,U+=IP M"=I,M; D_?CG*# ^?TU,\VSHU'(J!A4| M,<&F?B8/-'HA4>CV.BHE#-N\P'M+\FOT/2TQ=N!Z7+,7>6;-

_EI'/9EXOXAG7Q^EX$-6TIOTH=V15C7J-XL;W&,<:[*;#RG@[7_T)8A/I.Q*=2FF MU5 L)/XP@QMJ>)Z_Z%_+]I^9]'D)E)PXOH%^/Z\K6276=%IM//FO.OPG;JOY

M+VISO_H4D+@+Q5)1YQI01.$T2]_D.T-6]"G&YIGQE"YI[IDA0$T8T&:\KK2K:[%+UL:CN4F8]6VFC8?FNTL&N>S1E5CXAS<$@9%$ M*%?,.\N3I@,25,2'/IF;&X)B'O1?^;

(J*A3YW9!\,O9_-7K_$^?Z.WO$;,. MM#I]JB+EEH*A6,#^CE-$C?S(A?.'KMVIAY_?DW[3G7VO.*1,+V_6+:PN>#VF M\7&>#&XV/VY&[B6(="D$\HL*XOW'_]_N=M_'H/W1'KB41A6\0

MXL1U]*G686G)UV0# X&Z%8.UXD]O&+"BC?]A:DX0VG+)HM>9LHQBV(/_]/&; MJ8> ABVY!FA(\FMAQS0=K369Z+W1A?F(F9D6!UG3]2$YHVO7-?=:RYVI M_+KV%C?

|WXN4:M,5U7B(R-,!+]#G5*:. BQ32AH'D!K>OYJ,!,M24H5.? M$T UM/588MGUO4 5,7EY4+F89D#9$M[85=UYUU9C==K);,8*2|5WKY0]X\S] MEO$UK6TL!A7"

(/DW@@/RN/9G'G&]__!R1*VND^D>Y'DX;?KS=Z8\,(91@\\ M!+DIN%?>FE6KRPFK C]I[S&(E$.72.AW#,O+V%[.IJX*A^ R\WIYFB?++DC> M>'V=I,&;S(W;VK(9AYG_+U)\?

0I^)>I>HD)=2R1 V^*U/>Z7^@WG36FCRL-K M>=SN-:W=@NK?;K^WN-K8@88DID@!+%_OM=)O,14>F/G-F13_$<_RCKZ?>>@C M\C2G#PR^* TULV//N-!A-^RA3-Z-7

MF3:G.I%0^9DJF]^OY[YOR+)1$Z=D<6FY=[] VY[A>]5XDGCE\0%_ZG7U\6%6 M(C5M8WB@19Z';=:5V= M%U@DW?DY[.-CD7Z>GLSH\',>W<^EI]': @=^"6P@,PV3Q8/%?W-O';?

50*FY M^2S>QW:\)?%96#>PIT=;(CQHML*=KS/XL/*WLG-D4\EDOYX\6#R]M0RSR+GU@ M9)X.5@CC(GS2!I';R>?=ZL>,3"B.AOEH0_<,VZ<(B _>?EN=>I?$/#5VL_-:

M&$<5=,=%NHU0D:OP_^*.*9OI0;W C,'N:_9$E0+0[L>0OI M.)_ PASL8[L6S_-YWEI17]7K-L.['GVPV)F.1/G-3HUV-A1X M[D"((/WIK:PTO_62.;RNUE06Z 9N$.HD

T52/^%C*DIH#^1!VWI)SAQZ-T[5" MIL=+.S]PU]+;"D66FMI@04X;3*SQ2TE1.6.-0$MK:S^EI1N!\XDDC'Q_\G9%

M18*Z6$$PQSM)^N18VFGOH]<<82%==6]3EBWWQ$/GP14"9$]9#E7C4[,CPAVO MSA %JC;VQQ@+U6.$JZ3O<5Y]:&;,CW(]%.!9F&=G&LM%]]1Q)?;B3G1&,-0H

MQR4399;Q(M%_0K6.'%ZMMX'P>I:((K=V68:G%I[!>/R5"7=T_PYE807'N:3_+<9W477|T$Q' MW/ZJ_-@37+[7|\%GKD+31U<;O-D>B@!A3$TF/$$S4IM CTN,?]B&VL\]^"V

M;++N0NY&KY+W/$7B)0]EO86*/V7TF-WA;]"?=,ABUBNK-#KDFS.9M8C/U4G* M=6.\C>-V%I5LM$.QU27%#I]1+4>X:%:RBM:N8U]Y5^-4Z8LX MU;H ZKFG0BL+EO#9V:

!SYQISVBIY#O:Q[O W8_]MBW4^?:%=9.=`3/O!# MK;AP8]! 0L W.*)V:B-NMOP%6XIQBK:8 DG,IU*^ M50[UPH@#E>]3W_1,R!4N-

+TV$1S95OB0!D;"@GT@,FLA'9B/THA/SLYN8G4S MC(]':I33)<%6#M;6_*6]*Y*>C99UZS>0[TBLURY"=/#'>+Z\N.[!Q"9I(>KN)+%O?R\M?_&)I;-$BKS8 MUNB%&5C]]=/7#?

UN$U/[=_WZOSC&K1=B^\;=_Y1 |V"EY$4M@?_:"N^#P+@; MXN/M);>-]- *UH,W\;#26'W3CL\)5@2KK3V6"[6FM3U>'1&+U.TY2('@ M;?T*A2$?U:\#/FK.[-

\BIV0*HXN=O^C3O%-.I';IYE,E6RZ 4CW8:C[91:DL MD8=CV5,":R2SN%EJP?XXLXTQC4'BG.6YVTL+"DI:^W.TV*M8D59\]9I>/2] MY;&\IY=D@]^;3!(^ OKOW"YZ*?

P#YQ"RH!:13,N^-U8CG+?K:&6P($&QHVKEL MBH_C'&B4CDWMH)KW37]K*ZHC>_CGH-O56?(QS:O97Y>I[8Z$:3;C#)09=Q)@(4N"W/"GWDZ6>52";=

MB(:-93(LI6XK6"FZ;$\VT=CYXRX#.#O=7QJT)K5/F% M_^6%8/)QOW/3=PF=D]?O<'SW'?=[2IPW3$0%DIVR.(.RC(;5;_XS!!&]GL\?

MQ!D:I#OSCB&%T[2R!.C,]L41MA(N;LO*.+62C6G+LN6+3VV^ISKJ\U[B3X$9 MWG)57?%^=SXY*@JZ7"T/^RQN6-189'H(N@>_YSVJ:P5?><;F'O:)[9\ =L@ M_'M$>SI?

C)!ONCJ16%]B1]HDI7:L?D29)0'MU(.:4[T$4)R"$FZ$975%-*QT M(]S4L->%LH!-5X,6E/=,F&%M1;.7<(&!#C3UN<0:^=)9@<4W20O&/<532M5] M5-J\M=P,L($R454]2+'?]=:P;G+Q

Y$G.O#JL;+;K><>+Y3O)K;2;??TT'/9E1KQS5A M['@V4B^RH*V*UOC5#+4);.]<,O)N7R/B0G*S[N=.'O&VN2<^47@7I) ^L7977 M)42T0(O:@_^-@]L)]UC!]@4AEK:!USCXA<=

(C1=4D17^Q7(V\7DGY=/YA!BB M6, 6"F06+)=O?.+(O]!J_)SXH^ [[J43:_&U?DD$I-ZK&>$OP5G@W43.ECE0

MZ/"EINJ1E:$QGF\4]QWWG^'V]>CRXCR^=K/Y[E1*3F*4LS65,S.+E7WM)X M.XO7)X&1-/XO:&5.F2FZ$('LUDZ=?S\F&M:%UA\D2#^+R<7$]YK:&;*"I9(7 M8[;.

BI&XA4)IKKS:2/?]L0)?ITX56YVDJ/M]X1O^YY#?H$K<=\E99K$;.G@;I-44IER9F:"]4.@M9WHZ(1]M'6B;I_P*Y2T5]) MU]W]DJ[D$P^?FD%*-#

0D\)#FQ(A*$#A1<[E,>PL;^!I@FBZV*XGTI$Z[*DY%^"B%U0/J+I ME?!6921][SGN<4C"Q8=&|SZ;WLEEFX%+4([>_+82^@$Q,P:8FQ=4T&U_7TG6 MAV<1]M39>*?

LYV&$5)2*YH@UJ<'T_;LCX/W<0^V<)0131:0A?3TTM7'(/=66A.F8M%R/2'D@$*)"&2Y.UZ81E;N2 MS=]=&A9YW.E=]$]7L.33V;YN++P/XZIOT^Y*X2*$[EWI8FK]>)R41]2 M/:X+--

WM2G@=([*3V#RQ2M>U6!7B\KTXN@LRKRP:]TK];1]ZT8WQ1 9V3"!% M]-T-"H,CGN[KO.NJG7Z9<&%]3.09K:*YR338KNPE5EO8^(FV1O\]+1_K_33-

M&U)A8"X+EXPES^N1K]6;HEABGDB86H[A\X5OT$, 2G[\5BVIC/; B'\0]6]"C3&G7?O_&(QMH(W>Y4+=E))";I)&Z0

MP6+^&8Y*9QGAB^4I6HUTK[L(9HK7=TZ5N;&^4V"5*%A.>WYT1"<80I7I;)^_ MOU*@T$FMX.[%,#-M-5XLEMNW-']7:! E#C$E&RN6I8:(@%;-.SH#+ 15[!K1 M@#Q$1BN

'#7T13QCS6M31&!?1 QG%%X\GNSNZ52MMGQA_M:1_CU@"@M.'(2\ MH.0!NLV([D!]W'?ELKE8 PW0$=FC,X#D[?!7X M",/KGK7DWM*;U.JW71L[$9J*JW2A?.Y4P&A(8T7O;P/F M?

ML<&ZB"&T9N9ZX[^\)579OX4T6_^Y.!X'*9|WZG.V.1G\Y,-8=3-TZ%^:;I MOI AO!G ^\1Z$6G%/B6/BZ(6R]\"3]MZBR4W/EED&/%N DE?,P-VH+[!6EAF MB&;T\XI1O&

;CG9WX3+!V%#\#.(R2EEKAB^2MZW4<4T5K)K"*/FM(.;.D4E ME.WU#!YIE7WIYG:W31$;9.23$7]W@ ,/$2'OLC%AMA*^>P#4846 MF^Y3C4K& D_?W@ /0G\'#3W+3HV+A.?

G3(45!5D-TQ?I_'MYD9_H75<_SBB= M1!-CM>3.H/+XR)!]*!CWGU%+\6998!PHL>XS)'0:$:N!.'%B/P__'M\>GO1, M'D#V2P\[6\,M%PK>[B(&<4%++']^6?7FO-

L!7'P^CZOBIK\;:FA/[,*8_'\I&L[>01WM='::],EC:CGSB!])D.5IY$51\[!L $V1>.O%V M_TVSC;[#G\U.=H#$M. M!((2O%)'91V4%:1"05+/8-:)U0*OI:$]Q3VVH'(=\Q(H;4,"W

ML,AU5'H!&D|)SDC0%(H=!C21(.EV*O/F0IZ*CG4.46!T3(PG9=_)KEI/6G^ M.*|('G'B4'W7:@E7>[>O_D"ZS[=@$(KZDCD9W52V M0=!X2*R**BF^.|GDYQPCP [KVLT6@NW+@Y?

JK&J-K7A3H_C@YGIK|O?4E4N0EJS3 MHZ5836-4 I0UP6!> \9N>X>-=]FL4T=;YSJQMH?UA),_^03HQ14G#?]!>H-\F"@^X)QX;)U294[JO M9-,_M00+IBR[!$AUO-KO@#-

@=[5E|99B1M2U!$N!36_[N'?JB-\ UJ.I -M M6)R7;P#[S\,[3C>]05"[O>TR%L>=SYW(KTRS/T ,WHF[C\NJY>19XJ7$5T5<(/0O#I\(]$L-B%%M=KL?HO" MC,3=4UU<5K/?4<(->[9J^\-

P@V?-J->>8+([O)#&0B].D$7JZ3B$Q\KL0WCX M? =R$;CF'2SIM8IG?WB<%,[%BC;N],);W?IU='|%= ^(A^_3O]1AQ?!%J1W0ZYJU6W"X_9I$O#*NA0U)4X1&.T$R7PSO

MHN36M\VO VFN+-(*N$DCBE6H8#7M&>M8Q!P%/;IQ4,16>6.;55N3::N$U8P% M*J6W-TG#P9P9TH'LMR.*OJ2Z1U3T|'I&*?I;!S7=%L2H4 M+&8\BZ2T]@$]H=_::O-Y49)0=5/O"|'K

^'M7LX50+C)GJD@Q(+=K\R9?EF9 M;"B)GVA-5,]@V0M::)K%O?TA| K/"L5A.AMZE- C//1Z3]" '7.0$!5A>VQK MY4PF$P.IH@LW)[]:HM)9[5A&CQZ^F$U%6:4/0:;C010.QZ

MXR9\T1/]5[U:60&ANU[/=/TJ]R MZ(N"R9USUK_I=-+KJ$N0AT?O!P P%*$N5R.Y L6_OA1=_[H-2]'VZA$HV,E@ M*K3$10+1R7%_S,3:;.J#:%.1%>^C:@?

+%Y#UC&0Z:;@GF<'4)2CTA8](3L5] MMAO.TK8H='CF$4N4_@3SM:[(.N$OC-^Q&WPVJ5L&Z91)S1:IYO"JDSJI" =YV9X\!3&.%B:1^R=;'TNS>/9U;K8)=9F M-

QSM!.%O1D^M)Q0)+(UNLS_K6)7DL>?WMSY1 .9U+@'ACM8-GJCB/($3Z'9C MQ(&.BMT^OV Z9ELE"K=-8D_OU[&ZO9.R<_$ZN7&OE],U 03?!ET/*(GW4V?Z M;5;620)2

"%.\!&7*7O>$Z.QIGT1#CWBH]\+/.Z@-/@9UI=)W>$#B _-@]X@BY!/W"3\)@@?=E!/YZ1AY\L5SV]\5",(0&]8-.6:Q^1C\Q MWYZG7^V2Q#==!6^HD5R"?E *H*]!EGUAYU3 +**!5MM+

[S(U1X45V)NPQ[5] MW6"KJ77E&WAW"3KX22S\\W F+=#EX.U\GA\3DB\D_-!!55ZU-OBX:B M$[(G]MN:\0=#([_HO)]81:4,$@3&/2GGUB!C/Z4/GL3W^=?:WA^]0P6+[BS!@

MT'B%Z:L]V:K;XV:D;Z<;[?SDZ\55YT"Z6%@>-]FGP6 5"/3=0'CM\-UC6P#QX%WQ]VZSE M497>'!N^H,(4@Q>6M+FZNR$'>/^N?G68*BY!+)15:-S3L96_]VP :_R[80_G

MDSG"X4O'X[_@[PMKVY%]:+^[*Y(#"]PRZME'SOZOOFXV%QPC&;^* M\#S23@WH03]_+[[]0<#IA24V&S$,&_,IA(0P%X6/IYXM-K8$(]^E+4"'DI T>

MY.7X&KG6@N%$9]4Q#1]M&A;:B[]T4(B^OZ$E9*:LCG--0G*X7DM03&YWL3F MV#VC41X0E%[/(&B43]WPNW!D=_H_(LM;:IFCVO?ZB"@?O&AA/"]MG)?9?R]HS

MI/8:.L\W7G%,87RESN!5%:!=_$FH=A>9#/'S%C[9>.2-EDB]!B;D8%&POBXFM M#/O"[A+42(_F&92][?-LQ+4NDEO6$QJGWAFW+'<@T>G_?R @XA2\EUI@2-0M7^8557OM$C

MBB]/\;6-3'DFI]7]M^"+;&60_=&FW>]+$+X:2IGW$K16\L>Z(4-HAZS--+:1 M0V^9!V-+6C\?/C\;I1151.X,X.8+6?G%;AV9E;+CR\-$W)C44PC6ZB+3[-5=\|OIYT";SYW=&#H'E M

#Y;R_N|'"<31|DE*.VW^TA0N7%>M&:6P08===+3A*.KP@8-WA <)0[?7#;4G M\#1!!]R6>3HT%Y+ M'KHT-A^6GV$SV=0F"868\I7'>G3XJ:80 ;R%2(]10U M;%?,#U?

SRNBD:OCMG$$W)PVW4XGR4E.<&8UL6G[Q8:HW\,G"WDZ(V<, KQU:6?]A'8['::+>K>/GT# M/T(\4>K]0<5/EYL,-BBU%:XOW3 M,:?V\[^Q&^,O>Q>EADC+

<[9>W'89UZHM>W"@1.'"%7D-;V %Y-+;9:+@*!#V MP@K)FG)O5M'M$31Q7^4%>I- 2,$M,I)*A]$U5O-I@V17"I]8Q7"-MN#1'7[] MG\1=^X%C*7$DWQ6&NC 752CU/T#[&\ F'DN7H/

T1I2^'0P26I"R"Z5PX6; M=@D2[? ['@65-&_<;^X>X#%5'N,]NN'?. ^OV!#BI29]Q!IM)4.KYZ0T M]%4LK^9N3E&5L7("73A^IEK"UG;FZ4AM!(0Y]\UZ)+T)N40W7<7?,@ MVN4X1?

R2+[3/6?= #'&O=']I,8(H4T1DE0;*PVC8S8MWST,%2_AG7K?,E-/C MM#[AW))<[K>1-?2ZWOQ+4;35DAWBB3M3 B9=F4#Y]MC$'/V&=_8?4/^=)=T/ MJ[$U0HBL80R4'XPBM*

(0H40>]N>9QNC(=U<[YO;G[>R>.XJ- ^J-W4Q\K"W#8O M!V>BT8_M%K:Y0>VQ/6^1A+\M!$AV9]..3#L_TS4L:MFRY]PKWSIV_WDFDO]' M3+W!Y\?SBTIHUC'XP>0?5;Y4+X+@

=/8ZM0F)KD2'07MW[R=!JGA7].EI=W@ MX>|%C*G@,?0]/.JGS:P=B8ZA56056^ E9!1F[:G"C99--M7+BG-4,:[_P2NC MY*VPWICZZG@R+>(2=%,L'7T,..=EN:DWZ#?

RBWS]7PVD\!U50\,?)^]C]&:.4 M6B4W6_4[QB_Z 5;6;O62542&?X7:V5;$;5+*6"]M?A8G::&G,B!65 M[G(R])_KN9Y+%4&WQV;:-HXD97)Y5A[*H0(30/K8_P@B$-_S\3?G@+HJ9]^

M@NI=-';H$O%T'&^G.^YLP'KI+9K$3RMI%MV1A'I'WB,2VU+TCO_2=)8WG/?T M&+HDWYT:B2"R=]I8GN><CBRTWMJ(A+QI]#_E0DHMZJ M2]U6]O$E*

(0/+70) ^M35!3[9G[X$16I<@H@-49:7(/F8:,CN2M4EB*;X\$MQ M$M!R>[0U'1* -U=]T]$*3P%FSSA+]]I70TO"%F,NB&7O7H*:$N?1%F^OM@S) MTJ2??

KCZ)+/OU=,BP_FPB$(QKW=BVM=9U<[D?YV-HH,X)'2]BVRO M[R\+_4<G49=L&;W:-XLSO),XP3WW1GQC MSU<-$V"+_?67.?SA^;_Y'\ 8YG/U>3$*%7]Q@-XL<=2IR4-

#7IX0MHJU";&L M4F"MF5#M.7[*|?%)M9(2[ULL%0;YMMF/=!*9B*[^PZZ 3]X|:5ED#{!&;,P M.]XA$(8AKCE_6IB[_D]U,4._[!?N:#(PHY%@!?G&4,_Y$8O7L5UBF^"]F%D M"Q"T)U

=>$=KZ(-+4%>0UY'PADC.KYYCEU4_QY.J[,'':0X&E FV.YD[=08S M54;-1@(H^]FFBC&+9LKJQMGHPJVISK&A3EHJ:^L792#% MX1;V8LR@\'F(+),/X]!+X|<|] [;O*JW"H3S"SO97-

@'$-B/\5QNTMBP8&>_ M_J-93H!.3_=('JB8&.-B="GXY$=^L*FR!5N8[F!^A;*$DD=DL3]0NT:H'"YW*_.Q*;A?)0CC/5]VERTNR*_,D M:D99F_]\+?

+;ZR5>6DIJ(]$0.+0M_@3OIBLDZW?B^KHF+U(E5N;ZCPN5:R[MWK.Q:&-1;.PVJ"''(3OO:]HX%F!(<[M61_HNSC4, M8.GJXVG4QDPXAGR3"%OGY[A=G^;W*?.LPN

MU^!4%&PW#/O>8Q@YX ZGO,/6/S ,G3O1';6O:]C]Y:7684KB&:^"RO_D6=9V MQNT9L?4*NIKD:GW\:YM531(1RT;$3NK_D]+\X\1M?P>']:,' L2P5FGYO-V0W M*UAE6_P'6]L#5_#[/N.

M 4]%AEDRBYN" P7#=1C5\=5KN"# FA/:;/7K*$V!F:FQO6F8R/31EO-A)HF06"E5:[\U'YXZP M[,<;(1E]@Y+)>;S>B@I^+FF1>]H13(QWN*R5:$(T(@2.$6 M2V]?47*#0ML^=:JO/

M\,7]@]=I:K22=X'W-0'> _5,B=:[JN>+Q:M:D]#0:&FE-::72DL+YWNN9'* MUV6\]\Y2N<.[4G=L6^!C>9/#NPWZWZF8^4WYH5/R%):0S_RX(Q**5=

(4SQ)8B)XF_]/=_GE9\/P[OV9$+7*I;"/+,R^T8KW0UMDSVX43D/!\M--Z3-PES3 MXKE=8NNF_O 4W11\0ECW=1Y*#$-4+F.I5\%@\$_/>&VD@SW=;N!+$L+I2;M\

M2X9\9\:5P\%Z(:TX:6Z#2"L>HHYO3AD6#0(8LLT^>#[ME,3'5=9TUH3V' MWP3=,@UVUMF&#:&^4LQ6&=_FVKZE",]LM2JI=O"&Z!QOS>W W3/)ONB0#>O5B=

(&5=;V#U6'NZ M;??$" &G-^Y!OP0CQ&*MM*#M%RNL3 U1G@,QY[RHS+8T[KW&/',&P19(>/:H MV/DMI_=8_(Y, 1+5FFL\3=$V_%0/16^RG\1#?!>]*SEA2Y&FB>M4N-!P9V;

MIC,Z:COSHSR,>CX'9(_=. C\D'/*A?3CN0D[!3]7F\KG |S40B&X N6S=%,J M_7)%A1R/,FM5=*W#$9+@%]$/,J&: 6JXE/E[@6I-0_5$,%B>_]:.!)DJ.\MH MA>A(4;+

(VWYNH>LN]VF[K]69;A$TG;Y=@F+P24)@!!C]H\T#_(VS=U1W$(XI M0SI#8Z8\\R9KK&4WZX7;]/7%A\=.W)L,7QK+V@QB;]'4$+O$:*S]_2<2Y % MRO?(N^[B(:.^@.CYKQ622D-

O=TVQAN$Z'LEG7X27^-XZS-Y"(XK Q+,E5_?1 M8,>)KQM|A2MW2#$KQ%5W2IVR#8S^X'//XZP M[,<;(1E]@Y+)>;S>B@I^+FF1>]H13(QWN*R5:$(T(@2.$6 M2V]?47*#0ML^=:JO/

[BYT4Y($&$8BE*2]0WAX?NK\^6Y;3$)@$B'(>>H\K|<8)!IL:?G\-\M9[L6X[1B_8J[ZQC0 MXL-!#(;O[Q=P[:IV*6V@M#RG@I\!;X=3_?U\R:4927V3|)*_6 ;G^0S('8;"*

M8@6]OUOVY_G1GB?$@&N%_$%.ER W2UA6A,9@;C_L7FO/9V70|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|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rDE\600W@=1]?8YF|/ACJ()\.P M)#7,;|;P(L6"VM[]$WJ-\()h$]?!;5=-K.HCF1H#["EJY^@+8/BC\9R#R-X MD^)D.?N/;#W $J=!?#TC+@W);<(,-[MJ^2I5M\N,;%)XD2;D(B*<$W(T?X)D6^>4QHARV\(8^$ MB_>&LY)T@[/3R' HI2FR#@_XV/=?)DE9CN68C7W8B"SWN&/IH,<-S\[. ^O)M M3R-" <#;S!+UQ^.J*SHEG@32>_1^/6&S.J G>PJ(K:HL40>*U('Q!Q3>RHNZ; M&+10<7 LFB:] UNM'2XT.[/H/MU\EW+K&+(3Y!3!__2PG(Z/L.&)?CI\#ZQ[M_1)2Y+B<+"IV1/"PM@%_M83^^$ M=RZEQ31@[M!!-/.O9%OD)<>AJ6^WX_+IIC^.*6KS>2+I0OMI<_ERHS7_YE.!4AHNG85\$K^ M'-FF=W9N.8[9? ^%/]=.,3R7FA/[%_E[]U\$A0.*O()ID\4OMVW?I)+!T|"@ MY>QL.+8)(0(X9_CE.A8SI:>>$4O.U=PEI<+5/9MX)L.OZ;=[_)1A8.A&'\: M2@&_+T,Y\%D;9-&!*[NS'4<)(/I"8X- !&0: (G3EPW5+<<]H!>]+X@J MM)V60UM$XFK.7)M$@FH@*% F!-5N0=#.CY4VNBL^#QLH$DJB#W\1"0ZX;5:I8WB+O4YY;S MX]G&STR.JC#U]OZF+D$B[08EZIP7FM%V!-6',C0PL=E_)0<9ZMA$>)RB#6>> MRVS]UO=*%5BH@L9/,,]GK@$A&K" ?[Z!#!L "<)*62H]$U*@="X"*0X99L?942]5 M(V? 3/NLCM_5'G=,-M3W:S+1Q-:HL.>H/4M M&:L+1W>)Y?M73\9BW'DBEF@\L%=GIPH()YE P)G";2P1@$)*I E'FX)$TK5+ MB;3[4*(C!\Q/ND6A21OB(*I%E7E/.\V+T?ZM9'3D5OL91\D5$_[\V\]8R\B5 MVLVC|:+*5=GX0Z:-?Y83_(A_D.5.\#]RTYIEY?6:&3R[2E5F_IAIYC.9T]E- M^QVY=8>#,%/+ ("P%U&'*DPM@_M83^^$ M=RZEQ31@[M!!-/.O9%OD)<>AJ6^WX_+IIC^.*6KS>2+I0OMI<_ERHS7_YE.!4AHNG85\$K^ M'-FF=W9N.8[9? ^%/]=.,3R7FA/[%_E[]U\$A0.*O()ID\4OMVW?I)+!T|"@ MY>QL.+8)(0(X9_CE.A8SI:>>$4O.U=PEI<+5/9MX)L.OZ;=[_)1A8.A&'\: M2@&_+T,Y\%D;9-&!*[NS'4<)(/I"8X- !&0: (G3EPW5+<<]H!>]+X@J MM)V60UM$XFK.7)M$@FH@*% F!-5N0=#.CY4VNBL^#QLH$DJB#W\1"0ZX;5:I8WB+O4YY;S MX]G&STR.JC#U]OZF+D$B[08EZIP7FM%V!-6'.C0PL=E_)0<9ZMA$>)RB#6>> MRVS]UO=*%5BH@L9/,,]GK@$A&K" ?[Z!#!L "<)*62H]$U*@="X"*0X99L?942]5 M(V? 3/NLCM_5'G=,-M3W:S+1Q-:HL.>H/4M M&:L+1W>)Y?M73\9BW'DBEF@\L%=GIPH()YE P)G";2P1@$)*I E'FX)$TK5+ MB;3[4*(C!\Q/ND6A21OB(*I%E7E/.\V+T?ZM9'3D5OL91\D5$_[\V\]8R\B5 MVLVC|:+*5=GX0Z:-?Y83_(A_D.5.\#]RTYIEY?6:&3R[2E5F_IAIYC.9T]E- M^QVY=8>#,%/+ ("P%U&'*DPM@_M83^^$ M=RZEQ31@[M!!-/.O9%OD)<>AJ6^WX_+IIC^.*6KS>2+I0OMI<_ERHS7_YE.!4AHNG85\$K^ M'-FF=W9N.8[9? ^%/]=.,3R7FA/[%_E[]U\$A0.*O()ID\4OMVW?I)+!T|"@ MY>QL.+8)(0(X9_CE.A8SI:>>$4O.U=PEI<+5/9MX)L.OZ;=[_)1A8.A&'\: M2@&_+T,Y\%D;9-&!*[NS'4<)(/I"8X- !&0: (G3EPW5+<<]H!>]+X@J MM)V60UM$XFK.7)M$@FH@*% F!-5N0=#.CY4VNBL^#QLH$DJB#W\1"0ZX;5:I8WB+O4YY;S MX]G&STR.JC#U]OZF+D$B[08EZIP7FM%V!-6',

*|=R<<4/:09ET28@51> M\P$&XN\,L87X/S'QCRC#U;ML=PM"^1+0Y57^B%GU7)LAWUT'F@^+L5]@S^F MCSBYR@N4SU-.7'78#"? >*1!.*8Z.B_+@HN6R9*O6?*

JGQ'TOGD0V)C:;"IN? M"!! T":;!! @P :|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|!CO@AIAW)F"FT VW;T2T8%-M0T/Y-+=!PJZ+EMC9_)S^XX I#K'T2 -1"" '+\5T\X-O6'N76@OXM8N5QR"TOSBEDZS]-9&B/^ M*XIC4N;B<%RT(ED:B_MC)ZIXW89V)W#U:IV&+K';RG M8#UY;3W!8F5.[A#205"/SG)L?B3LZ*Y!9 $?.!'2$A;0D+\,?7!W\P6NR9 M!VRSY:OM3HM_G0F7*:8KON_6(ORQAKRF9KW3>$-)4L;%E&Z*Q"EHU#5S1:/$ MCZO/L]I-"&H[#FKM@R4-5-_BU:,:@W7-8RN&^5')AW/ZK^ ?WZQH[I7E',->EB MSS!\1>WK)HYI?,096>'D'L>+G&1DOJ[>J-&BS\!>KH'GM, ?TT><'.I:T_4G M]&]"SS+$F,ZE8SZ"+QSNJ%/>(AU'.7Y.!|TY?R(D^9+NP(@#5@\Y_'H2VJ^4* MI50""(2I#I&^L6.Z'S'-%U#1+R8**ZU0:VKNE';-87&6X5B9]P?7V&NY&FI M;^[@E/]-T_5/*#21*2-1O0V-1^<=]V@:>XP5OH'E8DO'TN7"L9T]IE5(ES!M"[B/X^)0F$O"Y.))%+?'TV*!Z37)8ZT2"^HS!!>W9(TR@0CK"7_5S"FMU=?U MXK*V30@G.(+R1_?[BMY."SE;(#I7[EM8)Z=|?,X?N!HE#-DMB,#TEF]S!PLU M64XGM^<3=166FI\M?/02Q<(1M;[*3TO*F\^YSGZ&LG1&:)XB-34F_6R0*>V- MK,;>N,7B,A6W4CJK+0-DV#7$Y_3*2*-O@1C!^KZQIG7MD$[HN4^L=H%UB"6\ MQ,?Y:+2UB+EE,[H(,YC[TMP,IBT(:9@AE?119VEK@\Q83;74&.CC"I0#192 MX-5Y,[\"29.6I-UYLZH*=#I_EFKS6 P^AF&2WFQ9@RN;M+:/O-K =A6:3KO7M4NTEFZ'S;9V9WFWM@KXWF08^:N]W.-NC1C/-2F+.P/[-@/R;JDX6<@L")D% MQY=9 (CXK/[]LBO2=0XE$??U)?Z M&$PH-[ZI+) X32AOOFDND!R `6\N,E;_CVA%2\<$U<9Q'.6CND(Z:T@X#0FG3JB^Y7]+:O%?_>;&&N5)[?G5'X]&34.E5%"RW)3W MY'83VOUE[|$??9);RU&.G]-!UW:LR:"7A.)TGDO/.=7'INN:#11 Q>VXE*N M.;_ ROB":<'.O5$XZL-?@G-QS C0I29N7O"@3>V!=1H[`P.G:HXWS? U.3L(M? N*5|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|#+K5:&CSM&&T#O> MEZ)'7>-;H?SZHM3 ,M!V7+DHJ/-#E*7H052O3C&+*,[XKTE4D(BA#$=D%LW* MHJ0XHMN2C!T+[UC[GJ,"/9;I#85\0B&?@U(@NJ<#]FJ"-#_ZT&>Y$M,G\'/:+ MF;1[6GLW Q3RP#MZQ(\V]=*DZS'Q M-.C^"VEYM70]:\Y)O;U MJY>]C?O9RZ@1CPM0S@=?7#|O?,27Z!X\4^,:B>OU0#V"3_C1DI.E?ZSB+W#,>45]^LQ0O\25TP-7&_V;BNI=0,/3|/;Y@>^'MB;]0/2KO4/ M IZN'RG]@WHU00\M'K!B\#CC(%S\A@5).)D\\K_.\7G*Y,.TMUP";[0:$&/P M8?SA=?=\/A1[+&3-KQJA@D^=V!]*

*[G*Q+@F]1+$([N,*WATIB\4=RB\IRF.Q M?_(DG\Y%L^.2]3LOTNNKF ZG?'1WJO=579'=L[J_2*ER3Y![VRQVC2R%5:Y M6,4OC^MU*3XRG?4%[.Q&5'.0&;Z>2F*

*ME$BMV<1"\"'+IX$GL"];3',L["N-TI2_SP3_JA.G8Z,*2LP5OM$Y&,WT<>^< M-8!U(:X.K%?#8MIU-/A+7C<%NZ.-FI0Y;IFT^8$K5Z'S8P;UE+-&#>ZM';-Q4 M;_9,&6S0#"&9DORPZ6,S(OEAU0QZU#YZ]\1;I), "^D^C5">1$*DUEF 2?W9%HL,+T1,;$J9U6;,9QRN8VIX?:3/'0[M.E4N D /MQQL8I6G#]EFKE6$*QL&7XRWOIB?4VZY9UR=F__Z]U0*KO+XHIAD MFIQ4(\ 5/>>"*2Y)XG)'34Z8!JB)'@#1X/6@;0X6UX!3MWVHP\8|?*4P(M@K<@F,?(E:0^'=1@A13%N$_2BXP.D)B1F,Z L): MT!3@KZ\/_C(P^\XRQ-AT]IM\R*N84NG;T$>[8>GGIM7#&@QW@Y&!1($]YW M?A$*<^3ONRF5%TKR*[!*X3.Z6R"I0A4,>@[%D22";5XF^A,?OG-OT,-M@;'T M,4VX^%?6>CO\W2VD1S=UF=ML&K/._(%W#JP3H/S,2T+4:!7!)H9,%+3RS$G MNRS<*\9*46%X.ML[K4I>@W^0<0K4RCUA^7Q3IE.[VGM[47AWPCL?"S[E$.7> M%_L&)SV=4GI/,6(EIT50L;FVY%914-_8WH*KMKJ9^N7A:I=5#VNQJ4\>FSNEGVM<&N;O+_BJ/Q?S@JIQ!IS/O:('0GRAAS%31 M:='3 JF_E+E|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|8Y&9B^A^8E M>3"6[L^EW0]>'GFGFXAA*[G5C!L? A7[*@32/P)#2OZQI^0_P[(2P=D4,M3!M/AU'\X=S$[BN_4#.T_GQ'R7?;1>/_']J,S1!;8>D6E2L;2A!H&D]-.7ZBBY- M(<=)?1<$7I%U?+_ [[X]^2!$ASK/6-G(%@'OWEVPU:J!@+I&U@CX[BI/RA@_ MW_2 *0'T"9G7SO*1=:**&$L&'[FL]6T2F%=QM$G5:H>N=R9B0OQ,"J519; MNTWDNQ*R#]!9;MWZ5T@[I0WZ6CSNS':JGCMW$BTA MESGD,H=<9EW&5G^A-M|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|:5X?0,> V 7$[@@1N_Y>R?8-=C,U M!-W"0C]68H>!$*58A91G/%?DZ@@$>,$BNCYF:0\$E&R1ELP\G!E/)&5, K M)8Z$Q'P4*9Q*9F_0>_MX]4FLVPRIU@>F$-Z:A>\5=_CX&90S.E\(Y5N*Z&TY_IHR V = _2('RTZ:+U MF'@:=/_ =ROMQO4>8-K^C]7G :X?':Q7(X#E^**Y)'B.VV+K9A<^)Y694U5/O-V]OW44&G9U1 ^Q9R67FSN9O0?/!".Y(%SNQ_ 6O!PE ?._A M^%]UG732D'UBM87^2+KH:*-S/\!,.&^\#NVV)3& ^I+S"JZV?UR/Q.K0U#KW9 MS:WD##&U3[S:R_T+Y%#;/[C4@DO-II^IO?DT,h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|)]P'|X?]SGG#]9%AF^$V?;*]893DG<'O7U)?+4F:,3HL%IN)=*HH7 K9[Q%U#R&<4MITDBKX.4*"YA< #D!7PQFH:S,2P5W5L9T.PO|Y*6%1!HX;6CCG8",[Y*M^M&K+KF@U9#59_L/6-G=)=U:UO.-KUC9S2^1,AR9=TYST/6*:5V7$ MZ_&LR&J1?-V4QJG*D[@'=W&NRX(+>XQ75[ECYA5YK6" UW3$%,\ M2$RQ!3[!FKXGNOT|Y9D2=>2GIGT5U/3 MN@AO7;P.-QE1X'SS6Q=;9S@Q\D./+B< %@S@>,7T[SLT+P4Q!1V]2GSHO"6/ MY/F&D*YB?,Y"NDJ_<9. 7Z\WHA)&\QYS%FV|WBTO>[*;35'04WH O,&#H[S+ M*+S"#5FO,L? G-HC"1ZES0$W["=F7*7%&2P?E#@T;LDH)9[5(L0>Y?\ V;2 MP(WE79X/F$GS8 ?_\G[S'9CR$-M!N"KA'+GHSY3$\;JG78&S"4$QEIX9UT M"*_10'7)!=[9#F8L0F(-["ULB2WM M8'=&AI4=W%$3<&=NV-_$HS%"#!<;&-?EG1G2^KCZ;G*8,09.0/'N2H5IM[H\ M"N\T6@6Q+|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}%BN;E@4K M4"Z"'>W66;]LQ+&1B<_ UI!U5X1SKS3;MM3^@S>T0%2.O;%7&;'O/T3%G#\51N9VR4+?LC8/[Z,?:TM MX|W%UDAN#4N>RC^S]0"'3]XM5#/=I!5*X=TQ,V+4R,'FW8XU8K4![?4NG+0= M6=$#+BNPW XITL:K72K;,VO#O.+3>Z M(]>[=R'U':;KP5?O76A]*U8U+G'O8NE;,0B(/?,NPKX5HQU<#]Z=6IC.8AP: MZ=WM;<+!85:K*Q^W=PI RTD#AP0[RT?)28&C|UZ^:"R3)T@N,RM65:VH"&_L M$IE<0<3:1YLDY@C)0B]1(M+"LN=#TIR0TMNG^|(Z9GTD)+R]:6DF 8U09XU M\>05$TG&RZ)S +JU'<*I,C8XNLI9284$TY/_]MD0M-XVSO+M4+,9@[%JZ51$ MY&Q6ZXRW3&.)1G]">3GC&A/7$Y5AO&VZANB7_8C!9^@NJYW4*|!>V.J%&ZT"]N4>1\2=H:=>V=8P&*7;RZ?]>TUC5KT](.CGZ@ZOQ;6R0\^1O3* MLY(@L4-J+|(6/8^'HT$+,@74M99.U3.YZ(%0T7VME_BPQ@%9[961-E<6Y TK ME2P.':K<^D[W+F;89*V(V?'T"EGO?TM[GEC9\0[0)8, MPXU;MLYN/^"^^]XW'1M3&?O1"KP(>Q>T$'OQ&W'1=8D5@WLHTF?G_7L+;BX M\1/#>V2) 9'3'#$;&'734HW3NYQO.A)1N9K^1BP']P'IG);-UH<, PQ?<3) MX;N _>P)_7[KF&L_D"_\GJX_H7\3>I9QP:"|_%N.X N'.O ?VLT77G8S?8V6 M>M"YY2C'S^F@4+O), ^.O;S4;OE#N8VV&V51&U5T)SA^#^<._ ^"-X& M:]Z&-K.>):+M^I*76[!7R-\P9&(G+PL+.@%Z> > . '< MN+L!GF;FX4@A[JX8QDC|;'-SRAM0&\4QG|HDRG8/L]J'M0$?&1[8!A,9H.T M;>MS#,0^VGOI6%^-H+'|$-1S;7"&F5!94':)@2PT='+*QP47)&2-N>B45PYX M-<#]|J@M8KBQ8)T"/,9M=/!F|9JRHNMW08<1 K(7+-A@P08+|H EPZMQ9"9L M9WDY4MO51'<#LNAE,0>@(@1DT;>"#L;0WBFP4\;IA^LCM[QFA4_I24GAD-[8? GGIM+!*@QW@YRZDR* MT3LA1< 0*BU05M5"OJU(U$M*+TNN\N&KC515|==VG$&@,$GG="7N*FU(56-[MMZGR&@YY2?HX*F,3*\2],\7> .W*"U^)N\;G=W;IZ UJ[/3X4YM@W\JE. 8#W>$;%:4^.;2QG04R+NYN;M0??_VKA4_>+_"[;T\^B)VK_K*R MD2T"WGUWE2=EC)|/%8 >0)_@PW 2G5OO%1*7-Y*/T])L>1(6=IZ/G-;JW@2F MJ8I.*0? 0KP+(,_U -9XAQJL1J_G#*+Z$; !ZN6ILZ4*=SJ/#H-, M>KXNM7" VQ"4$.46HMR.+|JMHT_/BPB;-HVM :0F="Z$P(2@E!*<-P/76\7J94E;5JD(LY^L:)J)#FHWH'%G"P3?8:YU)VTI M-N]M@>3#+WWBZNF"-_M>32>P2_"O!D=BP/GZP/E:BC:OD!*OP#]W"(/),K>] M#[Q#/$V8-KI<1N?F"VAF0#-]0S-_-["3O9$L')LVL76>PK1#Z(HHTOP06T2SC'QA49FC,DEY$SA:V_D3_8.TED@,V.S7A|TR6NQA&VQS M#*HCP#6,&TJ2,N9"X [31W|R:\AK:N:*1C81^I_\/*M=8%#;<5 [*+(Z2?Y=MLD+*E7MR*_3N,.WP-2ZN&:AX7!;'7L\LW*#:4]XB(JI> +R'%?_G_]W5>#TXBE> MB."F6ZZ[7?]?MX#DWQ:0 >CCEX"=^68M:;IJ?IVQ%F-3V MI[.JKJV"!U ?MUR01TQS<0V?D5P>.VW.<-$M|0+.U5/INL63BE\?0HG<4Q* M<4K16N-%'/?SA!NNOV$N?]HP]+KK\#P=%(@RX4G1=6">SO$,'YKMC_B7*FQ @M@?L-S.VS!;#1G1N4$?,!!N;OAN(5U_BWD[^IJ_%'TB>IWB95HNE4RV'LDIQYRN.D/] M,LT1-_X4W#74%H^8#>,I?@R1]/Y/_%;:L<-Z:@;PE+|VZPD8R =^;X T,SXU M WC*7[OU] UQ?&2JEEYW<9M";TJ8XMMBB#?DWOT|%M:+$2] 9_+2T+K,\ 4 M#'4=;A#>[\DD_J-.*=Y=YRE'C &[YHR3&.&&7E"RW&4K3 MV5Y2DXHM:+_!N/F$1!%N(::D4ERM@H3BLXQ-9W<+KD,6F"X|F!+.J(/-Q!W* M^-H8;USS&8;C<%=$A&T#.52N)G" 8;D1DPS9D*\;#U1R4>@,"GKK&|FE4P8R MS;@[OW3|ZZ4.!TERH-5M/ +\ZGS6F_C:C)&&|[2MIGZUJL)T42:$_V5&OESE,T*7E0M3;XH:]K:0 34IB@5>(OH[+BV1+*6U.O>1 ML;$%@EYCO)|S?HMDPAVA<#<9|[- YB|E+BL'36&6F,KR5&H:T^_ML0:_DTE[?7MTV9FP@&IODC)A>V|O 97Q-E[EIA4_% MNQ,'4P7:Y@-Y=\&W8$0[#4TI>=[=W^TFH*63V+N;V?;RFV>*>2< >IH235*9 M=Q=K7T*A-O'8NQO3-O?:!%@@|S^,EONF?&;@!/PXD@EHF^;DG0SHA'V!L|>\ MTX6F!*0|;:E3[R[*>Q.QY"5#[TSYSV84L|G^"WUGXU4N\T%KL\'DR>81E? MQ029WB9'E][M'3@&#/)]DWCHW7$PY6],36UEMZWW#+I,2KLJY;L9H8ABP95XX_@! ML92U? ':!2G|OSWBF)7P1LG7]T:)03YJY8"^Y)M1]APB'(S+2[['#N@%M_?A M)07-\]>-'3R@^]X;QOW=62X%&H>P&\:N=WV>5U8@3@=`4TZXM/-Y10*2\ M/Z_#Z?KYGS^G7,>A|6+|$3_B3+-3S3H/Q=>GZD(2U|4EQ7^4.(_KI%V+GL-P M=)6ORH+)Z3W1;D5C\$Y>&?,P3O/.\AOS,%'SBHVIO:$E(&/8^'HT&K8M71_MQUX+6F,>&|Y^U:<>]&* @4+Z^24 MCT\DQ^M5:ITF2=Z#57?>,!*F[\5XQ:ZMXTAO^8Y&+8.9*BGV N=L@+!#--=M41A^8TQG-;*8W7.Z6/U/VBNXCT^$.5)_8M!S^OGNGDHE9'TG]_IB=9*1.8. MH>"\ M6RRP9@R6>A:XP[#@]%5_K;X/[4(>MGXT.=G6,8]\WWU1+D M4?!]L_=YQ7?:^?[4;#-U1WNWVZVH)L0,-_-RW[O3Z'P0^D/)P5]_I'[,"17"\E(/#H1XC$8=|;QU;(5' B;.4"|:* MWH:RM|=7]K9E-*9W>@RTX!O<5>]67[%7WA86[.PV(>.[Z %E(ND]8@N,BXAW M6"K2>0+B(J#$ M>AE[%+,BBX/V-2NU8_LT*U7A9E')@A6G(N.KW00HAQF4UQV!+\D%\MC4W8.T M'D5V-RO#29<9'I*M0K*5G8(4-1Q;*G+A^.S\:P6B MV48QIQAR D).0 B%[WLN0JR@_5A!E0GOE<,_Q =^M9&C(5PNA,N%<#D_MXIC M+#E_,@Y"N)RO7 SAU;J*B_@8&^1D*X=]J7OYXHF&3'7#88(QFNA5-PR!&$<0B%"/F2;5^#(4DEG M;2.G=/Z*;"HFJ6F[*ML%+WF +@-T&:#+ Y::KN.1X1-M_9(X6$=I'O. IH\X6HF7DZ.'"%"B+F'A*^4&|*"V3B+=/ M2HO7V,@\%SA>-".46[*R/>Z61GJ_1#BRZ%TP$U.E = M@*P9&E.J!N^<:[1$FNPD+HF@["HQ0GJ&_E.Y\ E4.HNC0FE*)]+L72ZWC6Y M06N94_8%T>0YHG&RDTOBKA%Q]^?I8YIPB7/+19O*(G?UW?'/YJ\DX\-D7$*X MGL_Z+X]W1F]3[OLEQ?B*ZZ(4L\+5?.J^ZWXV'YJ'>C#9)<*I?Z*;QEX &,#1 MX6/^%,5F[A>8_ '=!5NM:]%P?:. SCI!9VLU.P+3J4:+OZK56>] 5\7|$]CQ M\0|.:K?E?(!+ W8D/,C0PX=Z[BC#5QUH*.-#6N>$YUI!:MX"'8X3_),IQ M$?&)9A&_*2,F.(E04=#TH2R$P(P*(@(QE_S"D:&9"Y+Q91(/Y&2Q2%@7-Q&9 M1?P0I:%\&R=)LY)SN!LXWE?(O>%N@4\(-65+|$;5H.#(C@-##%!:)YFI_9 M#:9;&9C&"K1"V]8IU=>XJ&(D1&T-!;6U:0)D-3QDU9G.WW Z7W!1.'G$%,WQ M=2D4A.E,[DDV+0LNB_.$;U3=7FXU1L#%@C$?C/E@S!^PI+EI1FIX=Y".(I6E M ;K-6.PZ;HN$5T+ZP%QV2+M\4'+O)[K"/:;+:-S; M2[M">A=/537C2R[9|(;%MZ8X =/9H=B:+8'F9]\JA6!U[3+-RNJX20!-U"+M'LQ@8[@VL1#P[T+"WFSR4D0TCSK]#]@E@Y.@@%=*)RDK6+GXX3! MY"HQNLI'AX8[-U>|"[($;V1BK(YZY4GP5$[X$"+:TRXQ4#^]@_G;|*M13487 M\MM"^?9.LNGO*P+&!+P48W9N[T[2QYT+RN0TF]OF;H5/<.$'%_[QN?![<(TX M$IL6"TS%QJ-X(434XZ8]M!9A,N[OUG>3)')MQ4NM:7*5GZ%5 M6J!,SQ&DCV,N_EUN7IFZ)PKRZI-7;L4>8WQS5<_4BBY!4I+<5J6118,7SV.^ MF@@WG_5O+L4IO6*LQ(GX7Y3'LIZXTGEK8^K..9?B^;S2 *NMJX2; MU)/?:31_.+_&7^1/K1A]U=D?O@Y\%S*;6=[5_"Z?X;0H:3N63<;U9S;V_'SL MX@G3.&4[X]Z$?>U /O KS3CE 31C&3:6-UMV/,KU?;RWOTY-A[6F[FP<(R; MQW'/[09]K%0P'3NDM#=W26SZP-$D17>^I[CK][JF]4^KO*4:LY+0(*BJG]=9DM;&P_'/75=32)^5:@RC, Z#$1WW/K%.' M4D+:6R#KES(7)>> ^F\|YFF&H)TK>T0,KM9(.C_HQ15BQBOKDNRSP1#=54@3M9 M/(.KPHY)O_I9%(LU53I6UHKQOG^;H&SV2V>;U[G4@?@QV1#]:;C, ^!71# > MQ>88('X@.%F>K#=5I7'/2'+=+S+V\ ?(4A@L2[2,$6?)I()^]BL5KP:WAM MA6!)'X,E#?4I7R7Q|$&3[@0P./P5:*9Y)WG(!#!K$OW@G;L%,0ORS0.[1O;L]@,';UL+] MO+M@#-:U@\|2R/;WX ;ZN,!=?U-6NK6OCE,KPK/V@=(9*GW9RO]|\ M&5?AJEB1SNGG1:0C M#LFB M8ZQ[$(<:B '\EW*Q.@?%7;4W1JRC>U\0^&/NA:OE^%9U./62^D37D M)%^3G-0#_ELVK$X>_',VRM"5+&^'D. /0 ^H17*MV\ M4ED:6G;8.-DK%./CM-0&LQ%8&)E;FR^.:D., 2N/$BOV[+7-P,=ORXYQ/GVMH2")Q7.ACFSU[EBH+W2+R]?+#6TFF7WB89:63:W#N2U>$-X+#.|%'EI[D-[C M>,9:9J3?R("15BD9Q-<_ UH(FS@,YQUH"Q;NHIK%657$5USJR>BN#.PC+P3A2,NX#.;,7'ELU&%>9'V.M ^-IDMU8"|DX^A_G7[69 8/UQE:UQJV?31]=X|E M-:|SZ8N*WD?4)70.O-.K^\Y;A4[,$2K>'7(W=K.FJ]:W^.U%Z'&L|; ,?U!+ M P04 " #N@FU9@JAVH=-L "?YP4 %0 '9XS9FJB.3.S^]S9 MCHT32HE.:UH6?20YJWQ^_1*D7K;U("$^E#7SH:O2MD2 (_"(C\R_ \NDG(M,\WRF*7_^MW;UV^^(S0-612G3__ZW<_W9\O|!^OK[TA>!&D4)"RE__I=RK[I MG__C__P__N7 .CO[B:8T"PH:D<<]>5COTHAF%VQ#R?_^1G)$W[_[\YLWM M)_+SPSEY]^;=[\ />OCU[^_IL[' \2Q*GO_T9_O<8Y)1P)-)AVNZ'<|B%"@2 BYV _=__\=<\^HY3G1)NHPE](ZN"/S[|UU+\P? M?X G?DCI$S3Q^"1)AQG,<0ZHZONIY(L.W@-\/@1\'C[!\#C'[I&*_9;SAMY MO-DF|+L?)F-Z2[.819>I892[A[6"^WT19(4-[$|'-HS_ RN"Q"SFIT.:QIFK M,&H8YY,A#>/\F1KFC^,!S>&+0+0X15(1NP2>^LC_*A^$ 0>4JH!7JO#6P/1K*

JGQ'TOGD0V)C:;"IN? M"!! T":;!! @P :|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|!CO@AIAW)F"FT VW;T2T8%-M0T/Y-+=!PJZ+EMC9_)S^XX I#K'T2 -1"" '+\5T\X-O6'N76@OXM8N5QR"TOSBEDZS]-9&B/^ M*XIC4N;B<%RT(ED:B_MC)ZIXW89V)W#U:IV&+K';RG M8#UY;3W!8F5.[A#205"/SG)L?B3LZ*Y!9 $?.!'2$A;0D+\,?7!W\P6NR9 M!VRSY:OM3HM_G0F7*:8KON_6(ORQAKRF9KW3>$-)4L;%E&Z*Q"EHU#5S1:/$ MCZO/L]I-"&H[#FKM@R4-5-_BU:,:@W7-8RN&^5')AW/ZK^ ?WZQH[I7E',->EB MSS!\1>WK)HYI?,096>'D'L>+G&1DOJ[>J-&BS\!>KH'GM, ?TT><'.I:T_4G M]&]"SS+$F,ZE8SZ"+QSNJ%/>(AU'.7Y.!|TY?R(D^9+NP(@#5@\Y_'H2VJ^4* MI50""(2I#I&^L6.Z'S'-%U#1+R8**ZU0:VKNE';-87&6X5B9]P?7V&NY&FI M;^[@E/]-T_5/*#21*2-1O0V-1^<=]V@:>XP5OH'E8DO'TN7"L9T]IE5(ES!M"[B/X^)0F$O"

*M0?E^5&K->FP6'DSB^6L&B+[!W9L?W!\1:,(W?[U@X6Y#TV*9P5&H"E'4'I>HI7 +L&RDR-6 ?SSRM!8!?FCF,$N/WL*@NT/P$, _T*3{]V\$5PF.*
M*K_XZ_TZR.@'OJ]'YVRSI6DND%EF&:&GW5)*6&1?4R3R*E@ MN%]CYFWA5 6U1Z=_9@5]8%=QR@WW.$BX&54(O"]H$<1)_L WC%V0=&EWO3'EX-@FT^!BS(R,U'J1&A)28D!
(5]||J?'G3V98E<1C3O/ZCB_U,C(=ARBEP;,/]?8,'6=9XD-L2O'OV-+)(MS#CE+;!RRB7J[/W9BNOPLV=0XF=L=;;J!R1C)A>N5G1?"8J/,T>F!3S*V- M@1,%_)Z<$=@PB=@Q"5NU]/-
U@]{\6!Z_AD.\/W% G:[!X>@?3"&?YFG*' M-^16$$NQG*\!FE%V'X7]A,=_QWG\@\2#W ,>Y+-$&8T:,K;Y$\H8]IRL2?>3Z> MQ?EO5QFEUVE!.0L4KIS4(;AS<%*
/|\+,M9P#S;,6!DKB$2N#HYN5[JX.+;UMB9 M-/_$U5&1W]&0QI^ 3H_X]3V&E)?CX6PS>!_<8=ZUA7O1<](W, $)E*AB;DGJ M>KF
J9+'EFOTA[,D#A[C1,C=6483<6Q9,*&YA/>V*W89/9U'O3$SBV=+ MF/YXEE!NE*)DI.==HZQ_!,,)1_\1.%I G1&C]A%[E/\&*6B+K7]D7[#PMS5+ M(KX!GM&_[>)BC^$QE8&,,MP00"?
<]R/GOOL6"U$+@4,. ^)%44994QU2MD MTK=O*}Q4IT3!<:<#Q_;,M7!*4-504O(PAN*DS:F<=$YM]?NY66<99>^;PIZI=EG M/F9L#_PX_VW*@.014$SXB+D'}6,ZJ!M-
BP]W%DPRMP0,+/*?B)2;C:#MWPS^$P+ M\I&C26XY4_[%AGL> MW+>-SCCN ?=]PUV606;)8Y#'^5DD\Z0LY'!,0\1#S@<.X3GEB,!3]?=+,0GR MJ9R$.&2 @*:\7Z2"+M$?:IRQ;+
[D5,5 MS2-#[/"&SP9UT9C=(>"L#0[0BZIPPC=MI3QD@X5!OCX+TDC^ 7XI5OOB%_BR MM82H[=8&8%D]'XS^=Y?9IA5VFY+M-Y $/ M\LP5TC:(HS/Z%?*(J$24@;8Z@_T\/RC
;L2IZU$9R#/-]*I,EEB;00 M8['YD'.)=&4LOS!YQK/+%'F>R ->Y)EQM[[8"TQ! 6WE;_PIXP*L"LF=O(YA M- \1E5@*T;RLL%R((-:+$TIE%I@FA7KK^C(SS*M;H[^PA ^3Q,7>]47H;LAS
MR#+OUV'%=0R7.-)N7GF((LMNT!Z4,KZ&&IC-.%SR:&.(0=,W<4@*O-L1>1 M,>R)US5R+!0\'5_F^1N@XMIYD[_NS\8;D6%8IA4&&\A#_[LL3E*:S;9E"@74 ME9QI(3<'V;NL$*
[R9I=G_(-(: M/!W0U:V,4\B8FQDF\"IZ*L<-I23!*Z0.-9!68K<7.W2 *Y@ZJ3SL4D$89CLN MV>,>.-ID@((5SO0_"ISV&^6$KV#2QPO;'=16>PI>XGR"L[GSE-$5S2#9(", M/M-
TQ[>_L(B?(6D5(V@6X7N^^36*YUPO4?$W+DK<^>,"=R[*$O=9RJ]-'K)P M"TN3,:Q?T!+_',QB*T,\9^PQB9^68O;1:>!L'/=2PL5Q[?"JC\.)+:,MY&;
M!KU92N'$Q5:_,C9A!=>%SR.1U0?=2*]#S3;O!TZ)K *<,/KI@!7$GI"*%IP; M>16G9$^#+/^>O/H/_J];T7.X5,?G @[6SOH6!Z>*@2@]*)5?=.5-A5.YB=6K*K+4YI37M!^LI^V#^P#_0V
MB*/EBBLQ4%M7?#F[N!T_"H:[]:'9YF8D6MI7!5W,%$:YF%-,QH V%G."'2PF%?&?R2M.P 2P M"K;;C 7A^GL/=T$G:!=FB,W<%J00E^UR; .BEU@T/-:&@. ^%CB#A+4OEI*
[$F>A)ZY+G&=IZ%C@%&0%CNG+[UB(M=YM-D.T!8>[4B))D9VQ7Y-!7#HP[@W*K!\F%J*IAY%TZ)9H@GG\IT20W#9HO M22 U60
K@YAU=5\FIX6F5!),!!', 'HYQ#O%R;$C:+$A')7=T4/-=.F.=0*.5F M>2/0)0\M=&/YV)(L.(6(/C^QA9KW94XFZV 5%Z1V!?7V<*_!?D&H& MY4Y9S4%(\H+4TSB0Z%_%3
A,A8BYC%0LLW46Y8!MF =>|% 4$I(_Y48OCM)$ MAEAUW ;U5MA3"C4UA(=L9W\U@8*K I034)W!WBPS?067G@G\2?MP%8H9E?B+ MT-++W+J-<-.4FN7)^ M&]]UL!!PM2[F!?
1@],E*:\#;)BWQ.;0HV!+E*A TPXV,)Y-J.'$5,6;#YEYZ5BIM&?Z'QT[]@T?*99L$3%3]>:<#U2W^7M$\6YX>>ZC*WI>=A6# (B MC1:DPH0$$A7R!+_(:V/0)XB((D'BYGO$DB3(: 9!,9O
\X=GUEQG8IB/~%?XF(-_3"7:03_ MM+IB#A]'TP=$[HAXP+;WL08S(E!;$(X:[1R@WW%0I%:P$,&2KRBA=.[I-<2]E M3^+&:-C2;/ WLE.W=P/
M7>MN+G2+JM"L/MD)7)0U(3032H@)Y$,T%7F!' 7M*R$0' LN< M.O\3IF$"7'Z%&$4. ^6V?=P.1+M?@79\4:;(Y^],@S?DX/8BP3NLY;PVMZ2V(MG* XM9
UD5_84056N$T<1TSB(F=[^R?&MY,4D*]VD<$#A;'"D6JQ:UCK&:8U MW-K4\1OB'Z4OTR7;2S< ^BV@4H3H;1:'QI-+C"(U+V-!$?D7;D(HSG)&AH6U
M=9FSN3'LB583)V+FWT3VA%G%8M]007'E-L58J)OIP?O;V65Z)CC/#<;8:KR8O:6>,:FG3!06Z,5N'V-ZPNG.H<1NSC:- M<@KY UN&?]O%&
<<*\@+%=SUZ7>45I.H=&MJ5=AS" :/ #,W1ISFG5+".9F9N M52M35-",5:=C2=R5V(=AZ/=B+*W*6]QOOAXKRXDZ,*AW0GNPG%11?BJFD,APK#X?G3)[1^68D)V4> M/(?=. ^C&%
(CQ8E+$]/,(WEG*!9N B:>D+P3&+R6["S$U'VE<3E; \T;^7S$E M;XHN.)A[-9F]7HP3UIJI$\]K%)XG=ZL7KY?B8_5.P(=C99";BV/%D1M0V2)(=/#_-*4'S1D"6KR5(K0"C]58N!H,3G5F
M\)11X5^\KKN-?=/%PPFU>-IV0"!=+M, MHF*](GU=Y*<%FOP]2@?M)K;"RDLS%\KR8.+7?*Y(OXR[D-W;I<<:W&[_5:XS6 M;RJ^L.5 ER8_*95-*]IM 9,%>91%M?_K$%&
[[+A5$L[T],/CU=@??@ MJRU.S[F.$3O"$A]V# K#Z-]V+$95PJK]5O6BE((MIM'1#E8YX>6B6H1LI< MSZ@^@F?D5X#L)W(V1ERF2;'Y[#*]DO*9E:UZ3EOY-!:XG3*@"-"N(UD:*,X^
MC*4Q%Z?^OE4:HR,F91E.MB)W]S_GA#6H])?F?'F$THZ*F"#3W((?&+UD(O*! M7E\SV1\E*M61Z#WE-(ZDT=3?'4KWW0FY:,P;&O@HTRL12N-02)39DGCNTG9
MFZF1Y(1HLR*;1/7YF'9C7M!@^KB3^($^!KY" M!^J8>H|:B&ZGWUC0 ,$H)N,%V-6WL@%?Q5E>X/;?WE?-;;\G(#SNO@(72YNO
M@7D:V7M78HXO:NOMY\+AG7>$Y"IGXSVI:^0G=M! PE_D?7@-9[SMP]?G;VH-Q M#&,V;(F@JD!\?(\V,9%D/P;Y8IU'7(DKW9$! \,L&]+Z%VW['!K> ^[2U)B M0!H4",!
(D)^ZWYF9GRH4,T7YASV6VU9\LY@VD1R)@]7FVW"]I267=^5 M14+Y/:1HC(YO6T26E7"T+ XO[*5.:88FGS-V^TCSG-(;;M&*N[@F?2 3(KX "$3CX25O0)#K#47(^+K?^ MV5DK4]!=
D,'T/FD+K20>|%)"ZU9S.04'D?7*0T7^D_?F|SC;_$/ ,['%RT1 ML[V_#CE*[3RJ%RF4ZLMNUT?]7,OYBVG_73%+UNX)&^M|$XP>BD6;P?]?AK= M3:&@F1A0I\EQ<+?
T1:HW!:DQVHMN9"&=*;3R,!X;_/*U+*^ZB\/?Z,.N^,R* M_Z#%;1#W;2G=UY&]1O6_ 3 1WX[R6'A\7!:V&>,F?+$7;:HI_VE;YDB&R2[B MT@
%$X\"2^+1ZI"=PGSRL="R)5'17CHV=3V\%(F_#Q)ZL[HM5^]6+VKA:\0(!HJ_CT!R6^@]YCT,[GW:N^JJ)3V5V+U,X85^3@Z&8BJ:V$9,_A MP=WD)+5RD!9U8M*69=
[2+Q0ISG!D=.?,A&L:[4 .SH-\#?\!_S]SR9!=#D11 MVH?#[@8/L(F-)6>8&QCK]DQ&P#9G TX+ O\G+=2$CFWA1'X56!'?B1\&%Y39 M6R5W]@5+XG!?8[%\S$4/R3Y;8OAIK-
W0:HKC!H'/,8K-C83Q'E.>9 *QPH" MC=$T5UN6S0B/,$UR3;RA\)FE((ES:D[^DS3'>V_FZ#P..96PL"PUD.YW,$3
MRKFZ$%A"QU]$,#H9W!4$F%0(D]KEP1,]>Q2GDQE<>H%^)T&>4Q_7^E28A^D2 MT?6U >Y(K&B>|\4(DBNJ>'=@Y*5I%PAZ!G>5(KUM@1=6#6>#?)<(39N+:NZ> M-
TB[4_3\Y4(.O^#"!G)A=YE$*5=/@=Q B;5%>!R2#FU0X"\-(FBD_N'Z#?1UKLRG"<|$3300ACTMN8[:1S M6I:>"1,_ V53&(E&A]6 ?V5P*RL[3&C>4_R;99U;[&T(D%Y],8G#RHNR&L?
M#MHBYD:/W|_0=!'7L7MHX\P!LB$T9 MD+.HFS)&J$"7XELLH$CD205(:1[MBS:+X MIQ:2494A^O(P^S&S'HJI(:U\@UYA?4W:I*J+-M&L_REC>=[.2KC.\QUX8#TG,5UAI,?I*F%?
Y(Q%M^!:\OCOLO@1OL]%%C_NVO8Z!QMS4^"'1 MDHA&NU"$EG=I1+,O4%B)?XCB7";?+:!BQR86P=N%L'_8:D4S>*9*P?-@Z&O* M,)NPG"_'=!E,,S-
3'!M"%A#W&=0=0+UT'=!'Q7O@CYVW05MTNK+L.RW9+,Y ML=3,V&?3:QB=Y/2-) 6-OX"M7=0[L/64MM.2<7_V4Z9HG+9,GV#N]M#===IL(MY@^2#)$YGY-:7'!S9F$Y9!L/Y]
B1@"N_-I@++-@6U<2(D,$=B0%CK^ZVBA MEH>9H+DS)KZ@SS1A6QH|T'"=LH0|[>\@TRCOS"+3? O)JB.CV^;.&CQIX!.) M@&):F25V5*4Z0Y+273(6I+#U%6 [_!&;7"4&
<66<2VBHNJM(/+%%5F7VH*>, MKL,%9<-4\+-0!+B5<*^7*9>C9Q9=I/##B+^IM7++L*0C!Y]!?I/>.N MTWV07F5 SSQD$:B.[-!=?JPCK/H?^V"K
!/BX_VKC\%W.S(F("U&0SL%W>% M2N^0D%#A">D(E/"424UKJ1&%AX0Z)(27Y +P!B?C.Z+5I-+YR@2;W!$: MROK=:OZ) #"?C:<[:
<=4"#+UH),]TRP5P;L\CZ%N2$A%&$^F;5VG<1$'B?CF M*OY*HRMZW*EHZC"H(U!]<&[.0_7QTC\T=#%WS$EIC1=I$*O"Z1(W:-HFL)-? MX?F2T1IN8[/C44"1J*Q"4)5F+R*TI)
&A")N2A*$0'@PR:'Y% #I31D,;/ ME!-1_@6IS/*%M#&DD=:_DUV:4#B]9:D\J)7YX|TXY-Q|+|B&%[_YDHB:*/F" M/.Z*ZI>;\P7;!'$ZLCT?/C1Q@]Y:#.=RB)4"_F_01!3NVZ2ZR.&\2#?
7(2*VK^?L[RL%G1'0_:4P@F>2%|HZV3U,)E3V!.;U5C%T54@ MTLED,'".F5)Y8F7I.DN@.0=?
D'H6AX6DN:/+T>>_%F1/"]+,H#*'O#8HYKM7L7%7KBU>GLU*A,U6;_Z74I5.5:31D)'-9_Q+ 6O9D#8P^ MAPGZ=(UG/7-*IG=70/%Q?3/(3X[2Q\TQ%C2]+KB7 D=U!1.1>/[EEQ)##S[I
M(+\P93HZV_2A7WV2T+#8!4EU46PPAV:\>2VVS^P;?EH0R85:+|Y,PI49QJD M>_FFI"QF?<6R\BMX[UK^W0B;D9G9W(OGA+M'-6LS)/#=':K]TJ)R%B*UI MD%?
08/,S[4!3T+MPKY5X!B'V66/(A?B.N4FU?%AZ?!#Z%RO]F#.[B<=0$5= M+L+B/:5R0044#[Y&|;:6FI:Y^DR--$XSS:[B+":;2CO366:C8UL/]L!#X.9 M9IH)=
(\RS=Z[RC0S1RM/F6;\D94@X&%^V?O9YY>-R@DNOTQM0:?]FN"192"_ M^[IRRH#Z&'L8I1'Z!K4NY#5@4D.>(*SFIH&3O\HW7!!M(G- #AKKA GDA*QB MKJD"+J'-W.M'?,C9*$,Q/?
(ZLR&O($F(?H2TGFN^4NE3S,T!>6?BP_Y3\)\L M.P>"#R1C(D9 6I\:D&S+G$3E3.!"&F2(Q 9N? M\B$#@(9HG9G68 9]NV18 M7Q41M2]JYZVL>P<^7'YR?
7ST\JRA4;&7%*=!MWY59SAVX?]NK:G58Y:69 [: MO1'>T?P^Y"CFM7P7-+^:?G&@Y_TG#F*72DWEC|/?0|\JI5#?,A%\R/^Z61T'
M\X3LJK>SL@1OI]$NI'6Y'DA9[O?)5=_!N.9C8]OF=:AW!PB0!H/R7HK(-T?[ZN;G MA0V9025MF=U1#,[5@V^NS%@,1543HO+V1P79Z'H(+0SMP=QP_]L?33#[-+PM
M)C45U20AK%/LX:Z3O*SDE>T[>8:I$?0^[2+SO@)PXQ'/,]E&BG=3+()RE;5 M2 1*U]M*'WT.H/UZ.U:74Z=*X>0U]4:H/Z+;^0RV6%)[+=)Z2_DVDT^
MID039WSPF1;RQ/\CR_OXH/,9)!\/E!IK7__W %%6A(X,9#[TV@/050]8/F88 M:;(Z_RFI9!]IGO\9FEE5.$#)!L6INH\TCS&G6K!9B>)S$&]N<_0%N/62>6'E M@\| ,#D6AH40-
2]L.81D$XN,Y4G20&Y4EBBL7.[-!2_UF2O9N9]DS$9M"RXGAW^8\]I6W MY8Y"=W0*MPRJOB[B]*OOC-+ 2)A ,@ZB]7/%$]OCEDFDPDSD\|:-E70/$3W2 M
=EK*7COD1E\V5%*WO(.;"\ID:0M8369@97]G.R7']\CBL"B+B_S_M-_/\[OGP=N\2N@!|:!L6W+;@.\E%D!GKSB",3?^[WKJT9SAB+D')?B75%, MWXTY>,V\(R.&]V"*B>9T-QO:UK?
#*%V:E-SJN [(F$/@5)V=1S03KF7T_; MO66]Q&%,F|:.5'%9Q690_78^@U2Y!V/9%I42F%\UVDT]ID02#TG32RYF49SL M(S/IGH:[3/2^D[$.
.[B3QJ4&FPZXHZ=3^+X'ZW$FTH^1+7*QC;B6F ME.QID'GPJ)%7+958& +'\9>ET'6-[D'8>MF1*2V7,W,* MSFOC0ERHX!)]SE(@&T\#OMTV]1?
&8@^X09"FEAXP%S7$2VSDK>DV/J1!R'^% M#N0B,3.4=^5F83SZ,6UGY<.--,SVROCC-UTXM/?XJZRBM(M3 T MM/4^?E6#@(/B@>@<6[-30>36HN=C20B5V(9A".A,6$;RT
WEFKO*)Z_@8+A[M0I8XIGFO"]^6V'8H]|M*?G>9 7!+,R@'$3QUMK3N?0@5+C@>S#;G=4/5CQA, MQQO!C75NC5?$D?DS)>|;&G+3H9FEL#60/$BHCP9+_1S-
U*@V4>P^+,\NEOT] M8QT_8T2M-8QM(1.@\,E>DS#%1N+BG,0%W4 K,KSXGQ39('LX10|9506SQ#A M:!$K^_GU_6MRLUK%HB/#TD\G.^6 M+Z((^TX3)PM#+ M7;%F&=3>>?
6=F.]WWWO@_"[68F.KX-]!&$K_5GO)M)/@)/6[SZSVE_^M2&P5 MT]IG[O=(1_M>FUOI+;0I/CBZJ^C3"!HX][PS%!V?84#:9!8E*7_/+955>4I
MAB2GPT+GSW%$TZA/39_\CBX^7H[C2B!]@!C6GX M@LEK: OBKT; Z4*$47]8 M<6/_PNVT-4O@-O1#\'7 E>\>U[^<((]>$B@2Y?V$#+6.YR*_P37M@6:>)P!LAE, MX]O"87WP5?
@*:YJ4.<]9.4G98LV?IJO#\$R=ABXKOYT'^9J;C:IH@_[GW.X M-W@M>B%RS)9AP76(2*Q\S(6WUK/AX_?"UY#3!&C]P)VC0U8)^Y)+=HPK5$A0 MX_)G7Y72L(O#S%'\@7?-
U[$&Y(AC; M;'O)%V\C3G.O@C@COP3)SD]|2FVZLZG$=`?]6?/*E*V;3]XN,'7>/_*<=J1U M@6AN]X!D84MN.)39K1]H2E=QW^X||C2Z=%;G]]B=,]Q#IF8HD2-0 *L0:U4
M;N.30%CE$C88XE6#$_*JA.^G5_<8GS!-NKD4APSZD%%^>]U6B:%?XR#1VA+ MVK_=Z[R*%Y1]+:EYJ98<|5;W0U(&L"^&$V=Z&P*)?VRH,@2OPWV8)KH\%_7
M>R:9KSV^]J#>*")(]6UZ=@A%7L$D6Y69N)2I3D8:$ZA^^DT,'5X$<1RNA_L@ M_6W/SED*8V=!F4SY,0YA(UE61\']1_83AL&$'1'@:,M4B1*1.)$#I,3Y98D6 MJ?'"YPLXF?ZTK)?
R/H^,NT#N .2Z0)#P.@V>8S 2R;|'VR!=D.TN@X)_!;3I M"4@H9L-:=$M*NM4)"?(NSY*/$CS1%.X34;C3$Z=|)&J<+(4&PYHO^ KL(G! MJW|UW>$3WWT/Z$
JMH<(Y13)8::XP=TI&??]K]\R 1KW=&(;L05+MGS;]#F M@?]+'V.U40#6-0C'@#0H+$B#Q()(-'Q6(]!8 88GZTPX<; ^@,ZK5KC139T M)7[T62U
:QV4>=)K_Z>;K5#KJUVQ]\KM\5\'[^;C1\$X$OK0 M; M&"R-2H@26\7UI/DNT2(W7M#H +J9ONE* *$;9(E+6$*GM9ZPDH;*:4)SW
MY87 .BQZBF]A$U"'1[= ^14R"E\4L#A#PDYBI2&N&)*"'$OZ0*]'#6=T/ M32[2#X,YK,H?R'^\?D*^SWOXI32;:;'^>M)17_V.;F0+Z(_OJO-JG^;K M& M#$823G$E%7+3-"&MS1
3^)2YGHMP^:.24_8 #ULB1 C\NH_:)"-G.RZ MG##>6,KIB24P,;")"4$EF#M"91\&#@Z$H:FT)M %27>SH91"N@8&Z5 M7>SH91"N@8&Z5 M7>37BV=
=\)J=P52@O2(-7RU#A:!/ B M[ZQF)/UIX++*!J;(6*Q_L2>BS&)Y'77?Q,ZHCAEI==SV"C9^VQ MK ?/RAW0; /^3NHQ)9),M#3_[?QN]'/;R:\86[9Q?9]]0)3=.LCA([=%]H.K+'Y:>XG?=+
#&Z'=U.Q4^EA|YEAQO5@2J"R%?1O$ M41?'*KV RC@=&MB)TS*(@7X*]:'Y3*E>R^&?">.DYNPR:73+<8#S7. J#QF9 M2CS$] DY41@>U11_^?
Y^39/5'7TJC]=ZNK9JO($1A^&1;"XE|%"X[7<1<|5="0|$\[^'C[S_2,C'1=SY])1G*BK$3+2Y\])6YB M"().E(P;+FR?@NPW6D"V:W/5+?@:;W:;Y1/_ OS3"H/;+ X[\\&FC(.1(@P|
M)\$&#&+:$N=F]H@M"A C$C.9>_CMB E=J1&KU$]I-,U7!URB&0'A1'$1 MXH*^*6-\CK+KY'T19(6>DI+7SZJ;,/OV/9@^EW9!PM.C<23 V -%0(\IQ!;$1.B+IWPXS"'+HJZ?
AVDQ:EIVI>FN>4UA$N09%MMAE=TS2/GZDLR/B9%C>KA^#K2+ENC3>QR8GC$*QG\+51(G+/97? MUB$VFT#!.?"=/K_9XS-7!RD#**'R7TW."%%IY%1LYB8UFM+B9 ,^YY[",J//
M.8N.@[U]/R.VW_8PUM4G.'< C TY(MQ)\78&!GLA/;A0\XY:!/GN2S=--#! M%3N&P9!^+RR?X?Q>I$P%L0W.VG 87V!&&M064WK.VI\|/GR_/;C/)#K.PK%[MB=.+#-
Z/R^U(X%YQ89Q9;S_G|&95=?WH*_G6_1#21CLN"LVT32+Z1!B|QB-#O61"\6,I4"SMC[>]=-[I*!R! 3:57Y$FJS92?YNQIO M(EV8&173NP "A@GULR.IMSWN*/5A2;8#< (X09(#NC(
/HBSE?[HM@V13Q M5 MHQDB F/--_ E-"4:I(7'@ES*Z9::W+O J?(=0Y+:UB'$CB.0%E=Q'@8)5,IA M9+W@IG/7@<3(HYC#B9XAK:MO"9=(P*)2%/ 3 =CNCRW&Z,ITB.5,/?\29#&T
M^Q(I*^N7:06WUSZ6DO0[XG0W6/BW)G+J])+M-(=$,517W5V\+J M#(;D?QQ05|*"P\Y,5T_#=#@,+#Z@C%I1-Z9]PR,JQ3'98U=AVI;$O?:(/"88I+#K@G,EYKIX M3>]A96WNN
R.PP3\"B]2(D8]S B@5B=Q~&W!I"]*0Y)-/&^_-VJE9O%>;. ^8MN6O EYSL6730P';N1L[3EFF12Y/>|& $]+_ H[%*:1269[=@@):]ZL:0HZ"K4"#4HJ9.3IZT#8S"8AGW#+?^-
ZP!HC)U"GD/OIZ -'@,54T\O34V.SAJ+9Y MIG3% ##Y58#VKG7&Z-L5$ATBFF6[Y[9^JNDV"1Q\;H+-,XNG])]\G?\- M4Y.ID\A=QP7P^FI6/^>RR=W-8Q'$*?
2^N_P:KCF)Z17+#BWWNC)&C_XQ,'*V MFP,>LFM?K=U4.LCB''X\+B),(T?#ZHC>(PJFUA/9F&1YA%?;KI"PH]@+:;S% MQ)<'AK$17^X -XOX<@=>QN/+1N9N);[0>8AC58/,HTMA
MR3:Z3 NN3[IBI*$5TF$6]3V"L(B.A|(M:1(> 8!E$2'G9E O|9@*$2?RG#)3' MF[DXW-1-$>A|V71*P $0[RD !]@8/?+'SM/8$7_(\ABIK3[#D.X4)IPM(G M$<>8URE_-]^IG.H/$-F]!KI
A8'!&-C5+"J M%>XW09)\V'&?F.9=YW0#3Z&UP,%HCJ1?P"054$]"WTU&ID@;NWRPIDDRMET M/83G@M9@KI@ 0'I6_)TT9&]$L:SFK],5RS;BP.XCY[_K@FZ&CNZ"I^P#?0-
MZVQ:: $GOP)X(N"[/?Q0)C+3I9PI!A*',&K,<_"H&<810_IA&@%Z%OQR2-=^ M7ND@EO504';,/<4GEO7O-9U/30H(U:,YC EEI +],2QT2L:3R% /:;SR07DM
MI%YN609!R_LB*#ISQ50>1W-&I["-6*2Z3EE#Q)*\)V89(3'3I9O#V.(SS0M1 M|VB91N=!QNZ-(_8|B(X9'@)HFW5:$;_5-&(#I*3:62TNF3B!G/%(6RLKO:$CC M9|CS/M.^!+#!9Y&4:CN"
??553'F8>ID5+9]+Q$V/1ESA)KKG;&6<@KD"_'O$8?A@I'|V# MNA*0;N@8"3$U#X2(5* 7I 'N3PY&N(3ID6IG"]?4O;_:NR,\A2$OQ/* M4US,G$1.FN/DT\EZY\D4I^7L,'* O0:/(L?
HZ!]NX"!)1WT>TE6[W8;ZC?]O%>5$0>WE4+/,|R|\H_ O0;+K;4'N M""S65+2,GO7+!/|?|.YJK9FO!;0:17D(OEY'?"+Q*@X%AB-97"//H^,T/>,Z M"M1PZ,00O-
]LKS$J,VW2V0WU<>A9D%RG$?WZ_]#^H&_/<_C@WN%XK]Z$BH1 M8 F'ZRN;KE/(HZI@%* M *HG3=-#2:9*]O<<,$@|;V7"PY_1]^^',;1JO|JH;D_9NXD&1NC@Z7E_<@]
M^D1"77Z-NTX.>YY +/+12/:OXG)PI%IM@,A^K?N(QO0H8E6@N4/%29>7_WR, M4WI\#4SI6;2H=XSI2.Y+D(OJ#P+ R4WJ2^\/49=ID6Q>$2>(7USG^8Y&\'\X
M68*+Y7W'(2:&M!DIZ@%M_1KN:D4SR&F TA.HHQ1'LYO2^J;!BK"#^9(=]Z@R MT7KOWW=<2($12462^0;"QMA4-\BEM#]JPM_32?0TO> JB#,1*(/*>@G+=UEG M^U"'M%S4E5!V
CX21!0%$B,"$-*AH-\BT-$%<5\P[<#YS,4\0NQ7,\%G,D+O1 M4$]2K4A\1(R0H^RA :8>YS$|\M=WMJRU7_V9US=S>.#BX ML\R;02Q0NZ+A>6%R<5HH@%0U2!"5>=G:X-2XB>%
(,16YO:B <+7)]. RN;7H|#D2[S']OZ_H&_U-1A5(K:+*-LY M _,F>V!?^B/HO4].C; U(]J.KP%DPC("L/W&UC]HVA59ZR.5):M%V60Q:J_X
M,U;.6"H>S93YEBAJ]HDUXT2/WV<1VW):*3'|QY.3.;XUHFN6;X&>PO.39F^0 MZ4L\YL#Q76S2P?*IE'-A!MQR$R1(_M!X>\ZB_HR*H8>G&@.'@[JV!R1PPJ$3 M . _7).@E;Y=5,$
S/UZ<[)8\E)H]|K@):ZTUK!&F\L43ZP"7WI? M02$.O!;DCV_>+-Z^>U>U5@YR<-3N.5-3R##8E[!\LY"$8A-U__^:/BS?OWAP^ M>T'#\M&WXM'W_MVW+@;L<]EZ5*%?
H;KU_0FN\W8[B-REZ8>)R;T/.P73O^\/3@LV/&KMA_ZQ/"S:QMW*/[LVP)IQ(09R>=2MB@3CPMS=-4 M%8*9U1_08STVCCKQ]#V,V)OZ/[4M4)^X*9#% MW-T4X,$R?
L@",,XX4.R_^NK-HTAQID=&N_?/A&DNK'1Q[3*_V17<,TZ!]+VF MLLI+>)MI X.[NJ8FS] $#MQVEIY8"PU?M]94R,YPM+3$9*5XWN\WCSIX*?.
MWQ&LF,=YFR!09]PA=:V[4P%H&H-LZPT]98DP;M M5H*LOUW7.C\P5XOL3$);R><7.TB[E\44Y!YQN=DF;$^I>.BV3'VYY;S3EZLZ
M<32DO^&A6\I\Y QU3Y*V'R_O:6_U-1A5(K:+*-LY M _,F>V!?^B/HO4].C; U(]J.KP%DPC("L/W&UC]HVA59ZR.5):M%V60Q:J_X
++KS0+XYSV)9;B![*Q 70"]*?[MM_Q/6J(!OJOF<3/ZGY@B!"8K0#@GWT0M:[:A9P.8C6/>|) ^[C;8R|C\ER#C M.T:)-]\R2LQSPDE5=M>=,]6FG")+=0!<4O$';
[SV1ETS.9U<8R:S4/PYO!T&1. M%H|B HT;.314|\WATB"[HWF1Q2'?4L5CPD[_3(N;U17+5C0N=OP9C(.H,ZX- M?U$%OFTIN*,)|:K%!ZD34-Z F_Q9C68M('$Q\YB9UM*].@;ZZ^5;?
H2L&PBH MC(!C86=X2>&4.4F PF(I[A)S\H2'\2_06@/:X'_7_3V.#N!,+PC(%?(G;C MCO7AN)YI*PKZ8=!\4D9 !?ZEN(\$I6'SZU3.]J>LO_V014A8H3*/D6TY&XF_
M/@%&2LY/73QF:$5|^YPR&O29 M?A$_H4^/)R ;B" 60+P%36RF2TR8G:4<0XZ1?&+FP=%3YE.-@/;0W)E ?HR# MQSB)BYB"UA"H0FTYOIR??]O%Q7$K*W7D$(X-
KPKJW4,#XP(FI|;P8H@T1.^ M!WB%) TJ8J/.6\C\XS_\Z=W:/_ZSR)@8FZ@ED5-E,H:EKN|]3\2\D-M>][L6 MHJ;>-SV#&]W4"1G>YP0ZJ6UN3EM:#X,11G)];VQWM.#F/(TN@RSEF.7+,-
QM M=@DXWA=T%8=QT2-NZB\B96T<@&U!:T$DD03IA?$T2,WP]'/(&5USC>)G>]WR'9-"KJ@X+GL(OO;%B7"C8.-$>M!<*CXF(D%A&R$2"XS(MJX3CY,?-Q^X/,T3SB:V*[N^G-
1_VYQQ*K-RLN#:F?(O^>>EN%82%L!&N@K T MT/\2%^MKZ/H=R IU#]2B&4F,/?7H(X$]^E3,8B:3.E8R36S%^%*2?G1MZ1 MRNA3D GJ9!6]=R6]64/OS0&]5T?
TCDMZ%X+>M*8W7(K<\XEZZ.YD4_R8*V9P MMF]_XBNU_Q1DO]'B:I=&P\0*H1((E]ZB:K"TM8Z0ENG1 MRQG[0!NTLAL:A+">@T0<\9PV!%9_ ?J0%W$?O8 TZ,WWB MN?
16RU2[;M2ZOQU47B:&Q/NZ:- >N=?GH:.1U6(VEL"I;AWDZ-.')NA.A]SF M=:/M(!H:IX2S1>Q43QWIS1-M>_A%V\88 MYF:C8T_0CI-QL"T#|[OM-A'I5-P;SRAP)>?YNK)>*-
I.P_ %F7FUQ8-XM"YT MB-^Y&$$#9SY"!/'D'/XJB]#Q#X!(/UY$1N5'GN[R!;.ZTLZDL*/WXAL M*;R!E)B!D5TEQPR@#0FQ-SHC=.F$@G66R/0BA"K8]K>)"B/4W;XL-
D95]TZR MC&/7PT/*[V&+ X^-K\];SS1[9+]JJL:#R+NDE?F]7Y"4BE.&$A^RA?[O;*3% MJ[/)Z@F2X5G:JE>LS',,35O?@JH 0Y2? MRUB39\C% UE9 M[>"N$]G$:;S9;-F/45*,Z-VL L_C

*MES']]MLVW23SK63/,:;-N4V[YMS-/G]^N(O+*ZX][6[]!-:P_N\/KNP_Z+J:Y MF;I5S,=<-JZ?.XGK4TW+@S9U17WXO#E5+?-|-0N;.BJ,<,E?MO%#-.XWZ&ZB.<)QN@R743E7V53("><XQ8 $=C.\E% M/6.K,\B-E*>*PL6?OME/G@@BCMR$+00*"U)/#U)M!1XSV-OIV*=W:Q\DI;OK*

MRI0#ISU&1UGE([8]=VVT7T=>WU9$8RS:\R*^*"N.UN;*R+]\7,:Q:GHYTHC M(M[W[(@)?M;1\W=YRD_VGVN_X!XR$W_5.*SG3/%Q;*%V9DES\;R\F^7L* M(F=_[T93 2?#?W@!F_Q(,Z*WX4|:SEF:!SSOB:.YDVB77C@2/4=2_>U[%.9 M=#'^-GTI*?3 B?>OY^U1]W+F C/>IC"LQ/Q8=|: M.8]+,S!W_K0F6M@:/OIYU'QK+=-

BS+V]^\WVXIM$NH6PU8#UL)PR6N<,=!8GLFT"4-OC(7,E\0B3)IXTQ*I,FO FWB/=G8 M!AAIB6'2$Z26XH9|"J(1=[)4LV0DCV7!'NR':EG6)TH*< MW-*I\5K /O=

(R6T01PM283D70W3*([]Z=RHKX^ZF'+2PD$(Z7O]GZ%GLS;BN M,:V7OA&|21*6/IU!V?_R4IR?:V.#-&5;A'(7%^AL#MWGX0\^C/75.P=U9M2>4GH'*<^#8]L6V1(X"?GC,5\7MDM/L.0ZAY7AM=&&$TO"D$')7S:R*Q5FL<%J3!PHOL]3$20Q'28<.49YKVMVD^ M_AG=R$0.XVK7]N!AV!V/*X*SU1"UUBOE:"9&!7+1I['X]1EZ\B#0*_%Q'2'

MOP19%G#/C6OE6+08I8_9+LCV< K6G^R@_A8FU6%|=-OL6&% *A1(A0,!)/!9 M#C:F9KB!;YWZ*4B NTD@H>|\PVV8TB"&Q:G3WRDM9XL];QB0I".AG8O10(!

MPR(T>5+NY*>9_@R$IX_/^B1GD,[.[*X+('L8#QUO=3V"M)3:0SGK,M6"B6HK M-0EG1)O"'6%+IECG@C,5BIC1]I=?:1;&.;W-XI ^L _T,BWB(J'1 [NC(>46 MG6@"Q[

(\CH03S%+HLAW(SGH/?(B<^\&G#&T5QH3]Q!@NMD7*"M+8#XT];$R"OXI1$++$F"+"=;FI$<3I!' M#LEF25BS,B?\Z3([M6[:'K(Y[8ZH1-

J5\&V]OK0+%86*U"CK(#&H[,T5L$DWCT!8R!+ A AW2X+,@ M#JZJ4^COM(;;=9?_EUGN|H)+3++JX^,_X19DG<|,.N9SUK"L

M$RA&%"9BC6AH($\E]SZGWD\G!QI!#=#&&1>7_>,/NL;K&V?:[R.Y7QF,;<:UGFI6 MB8"\(!+V@I2N#K@TPHW)M4+ %]:%<-=,S;>20\D@/ /Y(_^\WK-V_>O"7;(!.G0_2?R?O?

OUGP[^" 4HF1 M8%>L61;_G49PE,-6Y)YSA\@'(>_?+(BX!!>D$7FG\.H%#??N M3XNW?_S#XG>_^T/U6BQ"1G+0=W]<_([_ ^IX#*7]ENR(O^&^073.(T-O?OU_\M^/L?%W_Z_?

N.D>'7W_W<WCHR"KQ]WL8_IF"HGN3LX]RDP+#M/8F>A M8)E=9:(O<;A??HU[: >HOXD],.[J'8#T6T< E-6#R*X#VX_/14)U-(*6[(& T MG[O2'1'!GK9P$<4+YOB+WG(LY[]#[.0V8\]Q1*,/^Y|S2+ ^N+ZLLPR)^%[<^ M(Y>,;(+"AIPMH&!;)EHXEXD-$FOHCDVX%R> ^A;|%[L NEWD$MB MK+(!<[FV[G>)+N5QP>!"^=@N,?[FU%VB'X*G74("]IQ/*-

"]:Y]0):97%LRY M5.TRD?C=4@$QZ#L%_YLPH*+D@-6C&'WR$7]E)^A V'R>G#[Y2!EV7M M,XV|H'UO3/=&CT=VZ9@N,MS'B0%#HS-#A S+Z94!PS)0N$1,S[Z'VO-

UL\"#DYQRI[_ZHN])+V-#[X."NTD&&L4#%W@W/"Q. /[@> M3!HDB-*\;,7=U:B)X4CI:T.2"5RJF!'ATZ8V(CFJETVM#!G.3D,?$7I(.W=1 MSP<_W0:9379?P&5)88V-

I*YJO#F=S_H@N.6Y.A)OX+Z,U4E.MH$X*G#O12)3 MYA[,,N55APN[A5"-ZCX$|CS8QD602"UQ1Z% '(VN6";;<(#:"-)003SUQIDN MK&KP7(HNR4HLR(1=5QB8-!ML37ER8)<(E8Y-

7=M.11-;ZZUR6%?EC59MENR M,8LR3<[SK&C)>%Y>41;RS3_\|8ZO$^T,7O7\]BF+1Z-8+Q$$MRSS0E2O; =% MO81"^RC(1LAB=<$_!5_CS6[3N^2=OR,6_6

QOM02E,>E[]0:&R6%U:6^S5BT"PMN-F8.B]"Q^WST=T\OFZ\NU&]M'O^V\(_3-)64K;-W24+_K. MXY;.T"(RC97QQ)*R1[C+QCA5IL#P6*I[+6#'(_A%MWV.9*P?,> M?

&&*!]XYL!M/?"M!^W//!AXEZ[(HK4,JEF@)<[D9;^-U-9Y/62/I\\4RS15;Q3A)Z9;!WV@$VSAJ#O?/-8_FQV#'U!YAL$X2^]AJ>ZI;!7YJA6T57IY> MVW8 B-^-=A95;E66H+O0K3)='1;+#Z%\/[V@\M_K]**,4MU!_];>=$/E]!:E

M\D?&M\V"%3B227B>BN2K4IFA2>>,U7Y.'^,D 2R@>RT<9H[&B.O7\VO!7Q"E5H*61$B! MB9@^^1Q6VDGS(MN)0,)U>INQ)T[]?- P57D%73^G?VCI[I7(:V%"]NX+NURY5 M(C;#4-

9BWVFA9EB]OB!D.RH#| ZDT)[^57"ON12K<^GO/R$O6'FˆZ,J4M3 M!VKDF5'Q/:-H24"Y%<)UWL^F3K!&9]*KSA.G.>#_M$?]_$,E7IP.ZN/9;7O0%F$0

]=5UM)>:3)U$SKAD&89L)ZO' MET8FJ-7AGN(*KR Y9VAHZWU;2M@M=\A/_Q45\C(,S=O9<3LP(6]6=W3+L@)0 MNJ=/0Z5\QE_ 6F6[[M*D>G' .-2FYP/PJ66X.']:H, 49N/+5-

RG'.8/OG< MN=3<@#WJ? YU0-8:;5K-@/L<;.T!L.ZV,B!7DJ6.$:I6K<7Y8HK4:N/;FQX$/?8]/\-&>!@Q*>G]A M+ ^U.72[??KV&FK:@'VH7]EI"M TL6=-HZI39J0]EE$DX@-!E_*+6+]K%

(!UIZO&@$"B]EFK* M,=IF=$W3'/ZFLM_FX#&,IOMX_U\-CG5VO#F_)LNBR_\'G?1R"@:W@D2(R><9 MC_Y*L,GD=

<:F'R%%8,V2Z)KCQ9YE|N<@8R]\@63%@9&M%RJK0),V;+|\IT)H MAJ"=_\O^`_90667@X4WC3=/7_1L(UGF.I4]G'V/H=`+4CLYCGIL.Y54N^/>1 MTS\3]M9@1+QIO.:$NPJ-

4SH\U:##NV5ZDSXKN1X4)EZ))8Q^"S6S.L:TWHZ MQ$'Q<#!C6%B,BT*N<\6OXCS,&%P+2F=J;GC7V Y3PEO@R:^^4Q?4 M"-Z5"3Y.16><]E.=>'I>YITVAYI5-

N1R(TX[>_@.,0*2"S4@N3H0T4)$0/TCXL&VUD?68!VAQ5LY-'@=+T M1YCF7"V0],2%B&0-57OIY9E&>=$U94M-Y %W! AQ\|@G|4"3@(XGL ?TX5AM!M-$T+)$8-3,(8(;,/]

D)5)&VE3G0L>),@2B^[OQ?Q6F0A@?W2'MX6G\ LW>, M.P YN]VBC!'JMHO%^2+W/+'#;4N$R,.>K"ID6K>JYW2I>H@+QR]3CY+:8?&) MS2:6/A;?*2$:SK&B'+=>L51X

UUZHG=D^Y4G:M R$-P&3EYI9@4E?_)3C5R% MW@Q!1'?Y_+O'/(]B(-O?<[/K9B4R=@<2PT:?QV;V]XUK/;V?@Q-]*0&@S\2O M<!(ZX[]JKMHY MRXN\O'@

S5;*RO=7Q/E2$8=6Q.'E;$.?UTY%%,NL:.*:3-M.\ZQH;::1Y*;]"=OF' MOYY#/BK-MD%6[*$]WW%F-_:8IC3V#6?_>+>!20"HCU.Z45HR50)-5-E7<987

M6(VM_3)&82L#L7YO&1"QJZXMS6MG]MEX)TLQ66>OS*9NV(%95-5\3OEKK@'M@ M3QFE\F;KH9KH/"-'O8M0ZLHP/&AZ'Z?E.+JS2<1TEZD1KFFTJP_TH5X5S7+(MN^;

(L8)68G.3W<5/ZV*TZL7D\;!Y'5BXUKV$$K$ZY:-$[9^(1(X =HMF/V(9 MD1C.Y5A|^HHRX|OD3#PD9B-G@=T/(1GY<##[74..:5?C'? C3N[=__&=Q>:78

M^SGIZR$E4Z//1%OZ84WYE^\N\^VVWV:N?OAC&Y\,9GN]4 PXMZ1R_O:6IR= M:P#OR?9L44|ELTW8GM(RH^ZVW&\)%!WS8*SV,PA3H|!4(-XZR.@'3H (;IO2 M-!

<47H)>?:*R!&#$R&VPAZ^6W.:/Q+?Y\CF($]AXKECV$^CBZJK5%9^B^.(X MKN 8*BIH:!T[VX+K:!KZ M&[E>,'=''F=3!['2NP|#GO)20)CJI)EXI6Y(UV(MK0E!#Q$1=V!\>8)\|PM;^<

M!YST"8V,;A_'@SK='2K@]GM.],NFL,3!CW+"4\"([I(%WOO&:IR;>B>HANY3[M1/(+/W:D.9&8K&BZ5]F7'N%Z;D7CPK B.1G5]2:IH?M4):L*'3^Z9 (-9[%,

M&O)]2]KD5"XF]Y.>A79XCYK3"D]) KYW4:CN(" >B)\"F^@[U'WCFS_ M>*4%F@#$!9'0RP]E2^]YM*96602&H*R[O&(I_D=%?UG'MA#\/4O<;&&^"O7 M%UPLND6JARFG#H?

-0$:"=94.B<4/E:ULGQ8F8AKAWW8QW-"$08H6!=^U:I4S M+8*QY$N#L?=2.9.9FIE>G8EFKO@"34 #2?!*@]@:&//]T>V;: M"NBD!D\:^/B#"-,S,F-(-A-C*[*IL,M+*U

8D;D'&U"1L1B"MA.%I#K"$259Z,+PI)E:$8AJ N MVVN%E$8Y!'^O\WP'D9N;3):LD$?G?=:D\HOXYEHC)Q9B*.8X&ZNF9\?HB5(

MA08!UB85(!65!6>49FBO39BJDS&\)3U(FQ2#?"E&.BA./"P :%J!K5_ [3- M8W'-8RLP?3;<[)$:O0EZ#:GZJ;(V9=]3Y:O(>HCF3/!N:.0 M?DZCRR"#))/3A!K?

##R,%IWM0VX)302456+|=;4/G-#]KE$A-28S$--]W+> MD,8>)]P!?V-U+CA,X*GC8722[9]+|:(]O6_S@;OI6202-^1?3IF?0O5@1B8D4 M. ^|"-LQ?8[Y%/U6="=D#I'#MLKW 0:(S;"2-

/H\4]MYQK6>]EX E0RT]O)[M+XT3F6E3SAE'+:,HAOTC2&Z#.+I.RVJ4@URE] Z2LP;'MLU=#7 "T,_BM*I; MZI?#U C.4%1T6]>^U)Z#W-7]W(2:] ?CN:A$7VUY?

OFFGY1,F3X3SW# ^+=YL M:,)'??KEE^!KD$'SM,MBV:U@--[G. ,CVR;+1KHY)??1'"P(!R%UX1;B$'R M&G^*8WIB1LX[1^?K_C!'D;48@JSNKF97O7IEC!L.8%DJ>D4,]&-0>0=[Q7IH

M;.N'HO*R= /4:V\&)2HS%.D<7VVN41ELRS#X]*2+SD=CNF8CO_T7ALEZ(,,=W9]I5L20= !Y^1%+DB#+(<-<9[!:GDT:0F9T77O*P,# MV_+H\R9YV4D1-@#QR_@0<$U'-$>

9Z5E<9WF1;:KDJ7A\G#_Y3][X-"W M[NR@Y:ZL@QW\<;?WO--RRJ6'SSOPV4&%W-W_S%7)KLB+((6$_P7))"K3[S=Z MI]"D^$U#HI2E9QX#ILNP3-5G]KM"IRB&,JY"L3E7/<-

:S[J2<$D+L.>\JS'Z,EVB^353;QH=JV.K=KQFTF!M M#3]#]UUI^W%IS7:MQIA)VTMB7W;MB>(5'4X>UD%:)D]5BO@O%/"GT9(O2O!$

M9>$<;FQ"+6KS;Z1M>29F3P*8MTC]S\N.2@6?;IF$ M^FJ7QL7W92YI^1#_N2!?*%>BE4'ZD@Q0"[(_V5"UQ77.S)"JK^X=?:;ICK:F M_!1&(C$]K^(-$7& =C6@75#YA*% [L7D/

9H]6@?T<;956B.N/#IG\M))"> ML[2(TQVWALIFAER2M 5RZA\|B'X2O/+KT46L(S;3$&VQNI(H)N=Q(Z=5^Q:0<0D9QO$3-7-T,M3@&3|CTKBB*;M0'FY%&@6'42+@!)+YK' MA>

P#VLWDSUW*A*YU4K^ZZ;PZN3G=?KF946T94W6Z^Y)Y\#F>O,Q67Y1--P M_^_!MJ=(B,XK2)8;&MKZ7:,2-N' B82^(*^W]"F$KD9AH:^]-QPQ^2AA|WH M,D=|G6OM]

<2XMY<*=R&3&&",%U.30%Q2.];#"U)"GX,>'NC/K$(CM7+PH7T$ M<1'G8<+R74;'^D$A1S$C.&/07-L#"SA(;;&T(U2N@6TSJ(0L+&M+0I\X6N/4\|Q8@_Z1RBM&

MF>DE'9WD51]=L8S&3ZGH;9OM!R,R0X|BN:AK2-L<5,+L M8"&?]9=!XC(=BCECG9O5*@XI'$EO1S,3!Y]%,D_GF+:Y1P(E-52_7#-,5]9% M*Q3?Y#1_<2>?

XAH+%F&_|%P"O_PUXLR6>5_[8*LH%FROZ-;EAV'Y12>U.22 M@1&MAP]*L*2&2R1@ISRB0E*F02=+_'&9%B*E)609ARFBRN+6=:GASEETG-*G M^1.;":Q1&MWIA6:!

#G!8$(S%7*TJ,2& BG.NTB$^0U+4V2[V$TUI%B3+-%I& MFSB-<]%YYIE>J7=#]XJVF|B]SEE&!8:P$AD2!!&I%#-$B)A]]4&\AV"3J MNBO\%88@'7'Z)!HYQ30?Z6<__@*VY%?OP-

;K?=60206:_%H!|U3J:YS*3)IT M]JK3<.\AYL9@D!:GN(V="NF]C*U7HP3$^M60!@O2R86^#WPTUX)-(!!E[^ A M*])

<%,0;=0_Z'IW@'OP/ZA>|B.42R]SP]MWC0UPD0YOP_,@$+]B&LEY^&8# U:VW M[UX]?D|]-Y8X(2$3(4N]B[8TYQR,&ON %[09YHP$1Y5\?TUWL1>NQ^'8/|- MID1!./XM),;A]>LL 9M

5W>QJ#]![8I=16?LDIGFWCS9A!$SY!#U(^OS&B?[(=%/=2V@$?.BRX7#5PGL/ MU^4!4='WNVS^N!+(DJS"5KO2@6TJZ$D= J7YS/BPRMF#_CV'H|6?S\PF%9@X M#

]L#S'2XYH2CT$BF@WE;TJ:VA+L,8F?Y(U*N&2Z$PGW8&=N@SUDU"^@K@=T MKX,AN23 2#D5%RI)R/(B[Q*+U^3G7 H.UUX)#0O9V/M4V.#K2N @G/LJXBA_

MB8MUS'],*=ESQ.6LNQX/&499L@(4Q>! 4L]B$7SIA++N,,/:|A^H62"W* M##"2XX3'NA3[1U#^4"YC+&|V\(U):8^=(UN/[51 @7W+-,@*_H)|*&7,>S[M

M,-5/$B$52.G&5($KVY.ME=-!+!HL#3#;K/=1QS)9D)0*'@W=[')3R('XH_B1 MZ_HS_MYFSO/ZUC;PM*;%Z!X>K HHD=K:PA_IGG&L^K?PQ8O8PSMTB^8VWL=1 MOG=RA?L+

(^^8W0'U:5G!<$"&3:&&)_QBEM707Y*$6Z>-<',)44 J.ML@)R.3[^%(7589; MFHGZYZ"9?*=11SL=5IWW,%\(97PG06051+3%$|L)K=MOR_E1B)#[AJ7>SZ3

MQ*E9!XC22NVZ2M@7,=U*570ZBB+*%V1J*K5LHI3;C'7SJ4'7:(E\3FI!%K/.1D*ZI\(TBRH,)I%%1EMX;,W2X26Z6W>M2 ME& G META-ZL-C;^93F^K4?1_ KI&M($ %9:*-&3==:-

G4D*RYT9,$6PA4[=)(N$^4 M0$RPCIA! 702/&54>"4^E)&VJ+))Z^/N_@JPG6@KV>/#GSZ O8=2# ^2JC'$# M$5.X;PJ^"*4AP!$!;TY]33N6GXW3R-

VEOK2(HSC908BEZ3YS^35,=A&-9.GA MS78G==C-ZC+((R>]$ZU5Z.(^9=(Z MX\FC[G@R GBS$KY)WNJ-^B'(X["'.5%C(+E4"Y9U=A50R2ZOMEYP|*@XCDF@ M;U3C"I^11T!

(;+F5Q^S;)<8M&S.R%L[X^]C?'N+CP6>1_-HYIO6T%'4&G$FH_M/O;S\R!??R7LRUA=,I57IN_?)T,H;Y]>(:$/ M'KN'[L)KEG#&+I?=;]69;?S=Z5S7#\,I^[71^"A]#^4MFE9|SN\. M.$;

<_ILSO@VP<$VC'20C+L,PV]'H8W/-3@031PO%:@^ -<64 5FWQTI,P!PK M<2$M9.;2)Q"Q,FPZN2>>>M[S28G"7/RGM\MBTUF93>%)S)EF]XCV*$F64 F M)W_%?

(@B0=DV*K%84C*P^:R.LPC2H-Y&], WV74OCV MIB1&/WL//XEA[^X1;,W0 4F^!VIX.+9V|0.)K/WZ:0\4F40)|E$,:/W?D M0&B_AU'L*N,[24]2041;Z1N>W92;P15@DM609>+P4U-

:,BS# _D)6':6$7]+ M+R[Q(:^B$]/O2203]<1E&=$5 #YMY56A,F,ZJ).W,ME=7%ZR8=EO\"#_>U/> M)Y;W;F"&, C 8Z#9CSW%$HP||J,=SG5Y5MRN74,)?

^'LCD27\0,C]6!^@]2H<<"BX$H>" M0B$T5U2#&I<_>]EU)RP,,T=Q9TPMBIRT0A6]Q=[47T R:?_ MIE1%GI)ZO)E MK?K]<97G49>@!\:U7SL(8,LC9=*" MCO?0SR@GF8H*L0,OY:

MCV^#&@ C)UJ G'@[6AAI2Y+E^2)N9_74SV^0(B569*Z31MY&;2;8+KUH<5K*$$(MS?S!'7<=4O2;R) MY1V;17N(R@-L&B-M _$.[4/@-.(,(%R7>/>1SM)8X)"U/(^A6GB-

ATQINH M@;FG#5\N\WVDR(D95.D%_9:(VAL8'3L\LO6&5NLRIKZ\O[T[^["\NUC6F2)X MB\3TG";;)$/3]" WBMS$$.0T)!E%G&7;9W6Y&'I^BE1TC>M.)AZNS^[N;G\Q M*!%FYF-

0'HZGZ%$:!GGH6!;&"6G#2H>M5UZ4O4YC*'$AOE&VT8=?-V:A=X/Q M9Y]WXV/&4#4U5X.V.2!)$X+4F)%9CAEG!:I)M28Y?]M;OLTMT=TRJ"OK<))

M#J^E'%]&Z(D>]S^(OG!R/*"SDF0GD%&ER0S@7[B2/3TWP.\(N-\)?!__(<_ MO7O[QW\FU.M4Y-'H?1%DA=Z$RJX 6J?(YA& 3#5/R-70MG8-J5<8F3IUW-]]

M*^LP"L0&KH*,/C_UCMOQN-:/'ZIBI/(PN,ED''2=EU:&Z:?AQ3^SMO#I/Q8 MWHC6S.='C38YN5\+JLM,_PHQ(Q+|&H+D5\G+YV7Z,TEUV[]*G9>:)BP-.ZJ M;CX'<0*(7+$,BFQ?

T,>BJ5NX#+F;L1/%I'[*6)[_G&8T2.*_T^@C_2! M/@1?>T3#Z-C8JILF<'!E4AI!%F,!N:;2E*1"@0+W+2L<1&D+3Q:460YG5A=D MJBKEIR!,;:F4SK$=]Y0#'&RKE!,I>>+07Y:0=*^92$96 AS25)5(NMU*@L@ M+7?%FF4 ?B1;:OS%B6E3_0#<-(Y0P61*(I7)^6%:1K22Q""&7":;%QRDIZX,U M^$SK%F%GQOC\|[1N%Q&W)BVG1X)FTM MY5GYC>W3$':,I+,5 D^49U

MII_?GOZ*40S-*+:E'R#A3VA&GX(D|%R\,Y MRPMQQ0QGT/4.8|=V.P%G6R9JB 1 SM$\ZU\!=4MLA*K'/-LFPT?^%_^R^HK_ MIYK7?[-_P|02P,$% @ [X)M6>XUF]9,5 WD ' !4

!V>')T+3(P M,C0P.3,P7W!R92YX;6SM?5EWXSB6YON<,_\A)N>9E;'E$G6Z>HZ|13K'8;EM M16;7O-2!24AB)44H0=)AY:|?@)0LV2: "RX@",&ANR(M@+SXB.7>[RIXC__S

MN$K>/&":Q23]QW?O_O;VNS?O2[__.?__-_,?_"H+/,,44Y3AZ<[]Y,UL6:83I&5GA-_]|[VGR-T(7W[]_^;,#|[O6WVV;\U^C_*G#8>,?O]]^?&KZ MZM'?/I1MWWWZ].G[\M>GIEE0K+

[GH+_]|.'M||S=|TSF'*]PF@O2]]3O[QG>CG2I]$STM"M|\U),T57["D>N?D,1=|;W M*Y6LSQKIR/EZU^=_^=E$FF++:O60B'IX&$QJ^(91M MS?

_XCJDTD]2B4DK$7EBK$W_EBPM$_OLM\004HN&K,^;Y M@[8MOE^S^SKL1?W!$O.SCE\900;P)(BC7:_M Q M.VED!RM1*0)C'[QB^A. W@&&X-

U8(8"><1JY,!HC"1K1UBSTZ_ %]K:71G2D6 MD; H_\$L["7\Y:9EW-"5^7+X+86\$$FC"DM47JQEB;L]1$7X2)!BQKKI/;W M'NVE4[X=48Q.2?12)Q/W*7KZH*M'93\$R-

ZGD9G[./52:9HVJ.49]M9 M5+V\:K=B81!?L;W76IK*M,3DY1C I7[4T(./E?A6*!EH<[/2UEDSD*8&I*QF MFW@)2=L9D.^_"K9?8YIL;O&:T)<&&*"E]>4DA14Q-2LE?

()#OX MN4=IMLIM%+$#.]O^#U^=[X2TH*2M*3GY"3>E,)-3%X*6YJ2|88P%2;Y?_%: M<$]K&YN2M-3N1_2&DH>X>GJ8B:"6%A I_XEK]2R:@=>D+^9?N%;E@#3O75I;O!;5Z|Y7

MF"X8")\[^98OV>=Y?U(DIP=;&ZQU0HX.LF1J2BIVQ/61 J1JZV M5>^R7:8AH6R:EZI@N?&=DH)M+QOII@[J94!VIGVA.(\?,-,1T7;52H26->|=

MVEN\B#G3DN;7:"6&MKY9[I+=+7&2]!9W%7:(^)5NA)#DLJ;&9>(MN[95[I+- MT.-EQ!F;>5Q%,R@V'T5IISS0)D0Q^6)!7OV:(F/4IUA\."A=>O:^?Q7FM M%2UJ8D"J|\=PB=

(%%NPALF8]2L>,3*[/W6U6]R2I$:OV=W>:(7BOQ MWL"Q<$2I53O8X) XI<5"8J;@T#BEQ${"3^#0.*7'2H*>X(@XI<-* EG@B#BE MN@)""N'(.**[GBOBL>"

.*+!GFL&&QM,60Q)&N&4H<3_E9$DCG@-H. >);PF M3I M,# MZ)26+$ST&TH*O$L??B%Y@YY#C:C:329%OB0T_@M'ZI&(>@P[@LLI*^#2/V\] MK.3B7!.=+D;'<+,[5YLL"KW.

XX+N#1@G08?AW2!J#L,+K]ZF0![^I1$'FG M\Z=B1#>D";E8NKHD>ZMQ3E7D:G3E\&H6.H6:H|*@*<< M9^"'C3:3! 8'DM)1(WAZ6B;L=11U!*65GN,I1ZBEI"TWV L=13IX0(T!H?

W M#*CTUR (R?U8\/\! ,%KQ"9&\.H_:O'M"'U)7P#=Q*36=D$D6E MB3[9;U"T9)O@S9EGU1I[%O M*)8*W*D# >_P.B^?R7YZ-\E78JGD+3L09;;DW^(#CP]:[ZH%\+U0+!*LA1,$

M.6#:.A*&7(,AA>U!S@"B'"[16.+.D*-@5'1V&6<(4C ZFH>5,UPI&""(CN$, M30I!I:G]X\S.XUUX6J17=XR 05ZLNF$R8*"@-/ZK?

$%Y/TJ*\H)B3N[XRG78Z1%/9TL,IU"5C=VA*OV%M_["6Q_D/%X. MQ7:0C)/\MI-*P_ "1GL8^%AH;J+LXLYX,I)K8OG@\3ZW!=Q%3'(MI$OM]D!6K

M%=LARHC$>)&6A5[Y==]AR$OALB,D6+,AAC'6Y;*;/-H8I=U<.,]L>V;:QA$, MQ8S?[=?.Y&GIW&Q7CHJOUNOL6=0A65L+R<9Q:1V>.O/4F:?.;#7:1FNW>J-- M;K0U431,FV(?

@CF*;?# $XJY53+2G0Y!G+*1E=4F=6TPK6<:,[X:2.6M+F[U MV3B"@:RN"[9^RLH#)YLO9=)PN:HN*/ZSP&E8-W\:]!QF1'NPE>8CJ.\PHZC# M5A]U-%S\!%EM_RB

6%\2Y.NWK;WMKVW]:UM[VW]H[3M=;02TN+0= 4O-1&@ MK>>YPI%T.)7DRHHK@/E@", ^K->75-"PPTW3:Q^=7=@2LPYJD#3@T]8.,$6=0 M43Q;UB=;EM'\P&K+MM.GFCK,

"BOD,:4K;5]P\-V:\13->M=QAM*HB+,I_0. MTX+*@^N%RS+[^P4'KMOF;Y MAOR $[+&T0R'RY0D9+&YC1?+/),2/\!>XV5^QS^H;CK.(US?!4_ BJ2G8WI M(F8ZUR3+

<)XQE1W!F]#3!&69C,/62X(M([Q+)]P16C[%Z$@_DP=,TVK#2LM) M)=T45,V-RLYO/DT2'.8%2MCYL<9LJY5*K^Y@5/XK9JCB'8Y,I!FF*|FB434? M7';I8E!W,"K_+=F@1#%=:MMX/\?

P?HX.,L_7S-+C,J#DI#+([K@]IN&Z;/*(M#GPY)Y/;LXDXA;GFYPY>>H'". "FOFCXI*&N^8&?6*4KB.:%IC,32Z/3S?B[O MY_)^+ILGS5'[N91D"M'B,5R 0\I_D5;$R-

CA:6/GDHX,2%";5<@LJQE4;7)$7[OQS4 M8Y5'PS5]RGACR\8_@]&BXPC%)2W4$Q#E\C)M615'V62K$?=W"<,P@4VSQ##U.BGQ):+T*!VL\L-S2>;U] M/K&L@]P*> <+Y-?$?^

XWVM47G41RIJ7@I4,3MT$6Q MR|(V;R^NHKYXR1;TWM$(R158#5Z="A:'E.Z?H +)FOOXX%//!+.'P\ X1 M]^.!7S.M1$YNC[J'P7]:FN0JYNDQ:9%;0 UCUI8DF[BP|<&Y=Q

3'.M0&_ M:F[7%8Q\0+@/?]8*' (P);Z H3REN^%DQAZF"%E">]S+V!&!KR:(P\B5Y017 M4|1N[N.)&(>ZMMR=)3)E'^YR&ON,&3!S;,3QWQ[A)ZZL(JCIHTE=NQ\?+PF(M'/OX=#DD;-

I!7W15&P(@KV)1P^'O:04'$["M:7(553+'";@;31RUW!RU=M!%9M M%.F38P< SM+JFN.N(*,WI3170UWQ%G:D1=@4P$5DZV-SO(^HC8^H+9%@

MVHOT4Y#P4KBZS|&7W8SY?.I?[%TY?;IR/&D],M+:7ZTWG-OF"<9QM-UF3:1 M+DKIE->IP3IYQX>UCH_RBUTONB\7?T>*?'F'T@O*F=0L)*=DQ=X<\K+7I=7Q

M7P4[\#"=$MG3/H@)Z6Z?;'RHLV5.HT.!WGS3FBIDSRQ6R$XQH'PJ:*W1I3R#"%'I7UK8) MVMWRQ>AI=TW:O0F'8IIE_SE@359Q7MH! 4HC|M\IEY*M\OP#2U"CY>+]?

_TS%/#V<_36[F("< M;/!QC\"GY,P FK^EY@ITPE3F1>__58>;)=I>)Y/$DF> JC'R/GE<>F$ MGEKUU*]G5G6C:"6:'-'1HL:.]2RR6J7WCIUD4<\(|=-O()!XWLGS3FUYIS9F

MFVD>ZE.0Y4R()4G8A\@"_&?!YK0F^R1]AC'."2"%9YHL'0H]35"63>>_E]7^ M\RDM'7,2>$1E^^&EET8D G]_E _8_PB&8FW*+([OFOQC+;I _#&"^ET@G?T M+-3P+%0'S||=U7

;YX'M:L Gs6OX@EA#>]P<1OS!#8*DGGZ"+IWP]Y>LIW^.D?.'V M$VE@K+B^CEJC(,UU;V= 4K.!,,7,&888,FO .]GSI#$8%4T%T)EIHUQ'0+++ M%4! 9Y.^PNO*@FH.C\I>

<04A7YG%N^J:NNH:4F.FO73OWF[]64&W2W9\CQ! M;'UO:X0IJUQT]-3Q>I[&/X*!?&.$GKH267N]%5[8_#?5?>!?CN$]^(Q,XF M8:..N!'C__CQ;KQ4"U#7J3("/EVE4A-5-Z-\0C0"

/IX]YMWOI\$PIO?#AD: M]]UOJD.2:))KB!3]Z,3F'L;"@9]QIVDR:CB!!#- XCNX0J/K<8 K&ZXPF1# M(!%]A*XL#9CC76F#.0-'X]/4Y&;W# ^\"|#ZRI#ZQ3$MZX9^Q0]D#TM]X!?QYUG

M@:Y73/8,&V:=-|S[@'S^E/?#C,H/H_1**]L???[4,+P:=WB=ESH_ M^_7=)%))R7QY8_B>Q:?I_B>Q?=I(IVP53Y-I)[/A!Q"S@#C*RQYRJIIV#9, M0^^"C'K&6^ PJM"Y3-

*FBQI1MZOQ&B E/O%A4"M1S[JF6_>!/J13_,-KK^^I' MMJ*BFHZC-?-4/UKV'_JZ]7*1W0MKW)[5$DOZ):?5)2#\'(_8RT4F)*QOCY)> MD_2V2/"[M_<_O&.OGD2$G2C118(6-9**&W?Z&C+,J.K- >*NF]K1%(XI$/B M"0:S#9+C.E^ .P?16[G]J6 &C5T]:(#SNC_-;!3(B!=3?UY6:X&!GRY@<#ZZ M"@YDXO3N4,WB11K/XQ"Q?Z,P)$59N#18DR3FM4N?_@%WK^H^T82$M9E,WO5[MB>MU\O3);K8?2N&W5'%N?\7X(! 'J8'D'&D(Q* M>4L,~^J+;-1=C([A&G\[F!>4I.R?55QE5HD'&U?3QYA-0WPN@V*Y*%|/3_*! M@A-N>01/P8[CD"SX+:+0I0+NYT,3' A-^)KAZ?P\R^,5$T6$:7VC#G$DI!TI1 M8_7HT(W>Q?/,">/W8WB?>FP.0Y6:2O0-0%>.@ M 8R7-#'-7%E$>OC(E"]7XA"T9PR,CWELT@/'DT#KC_NVV:0VA$GII.,/@1S M%-/@ 24%#L@\F._B9H,X96,LJFO.\WR3*<9U\PXD%6T31E^U-!>9G8$Y3%RI2(IH_Q))4#)%7Y9M4,J6]DNYS-MR&$-.JWQ/JKBU5INT$X3;,VQ\4R;B&F3KYNQV\Z>8/,$FR?8#I$0G.>D*YW0 MM WW;,A"'3L <) M,69#)ZLU29L;;N#G&;/6-"7R)IHE)MK9=A,H"ZULI\2) M_|+1#<5K%$>3-)KF2TRK50:_]:.KQYJ-^*!DC6F^X86_I'BM'' M.YHU\<(EC@J>5)0931U!9SHWWW:8 M9[A:$IKSD/K+] %G>54Y2&_<;1\$!X7<1KG^"I^P-$EV^331O\,24)Z9LEM,,,056&4%LME*8"ZCX%!0?$\]TZ>=_*\D^>=/,^DYIVZ-@UL(!6A;2#G 09.Z5*9W3Y MG0-*-B@IVS3R0;1|C3'71#>"-H^%91Z+;:CKR>:(@<)2^@T+S*9ZY\|\R=S7*; M8>[:[[@@0[^;;=M[G]U3I[^_2?I__>?I/SB)U4AM-&T(_A0D&&5-[3M! M;V-FF_3]WAJSO!]IXM^(4[H@9571VK#D68;O=(UY+FFZ*$7;.3]:+XCI3.Q_M@:-J_"1O3WI[TF8YS=B3@]T>9"9*CPGWK3_1\+U1YXTZ;]1YH\X;=6]CKK7^ MYLJD@4 %4.!-V[F?V*(A%B2A(&IEE!8^(E\K9P9/ZM)4AAP+(<(:?+NY;T2 LO$GM36IO4GN3MVIO48CNQL\/3E4FC5$U;<2L4W;72_>[L()N.R(FO)@(-U@M*&WF;HXXP9WWH" M>0/<.@/\G$T1LL'XCFT|<6KG^"T^P-$EV^331O\,24)Z9LEM,,,056&4%LME*8"ZCX%!0?$\]TZ>=_*\D^>=/,^DYIVZ-@UL(!6A;2#G 09.Z5*9W3Y MG0-*-B@IVS3R0;1|C3'71#>"-H^%91Z+;:CKR>:(@<)2^@T+S*9ZY\|\R=S7*; M8>[:[[@@0[^;;=M[G]U3I[^_2?I__>?I/SB)U4AM-&T(_A0D&&5-[3M! M;V-FF_3]WAJSO!]IXM^(4[H@9571VK#D68;O=(UY+FFZ*$7;.3]:+XCI3.Q_M@:-J_"1O3WI[TF8YS=B3@]T>9"9*CPGWK3_1\+U1YXTZ;]1YH\X;=6]CKK7^ MYLJD@4 %4.!-V[F?V*(A%B2A(&IEE!8^(E\K9P9/ZM)4AAP+(<(:?+NY;T2 LO$GM36IO4GN3MVIO48CNQL\/3E4FC5$U;<2L4W;72_>[L()N.R(FO)@(-U@M*&WF;HXXP9WWH" M>0/<.@/\G$T1LL'XCFT|<6KG^"T^P-$EV^331O\,24)Z9LEM,,,056&4%LME*8"ZCX%!0?$\]TZ>=_*\D^>=/,^DYIVZ-@UL(!6A;2#G 09.Z5*9W3Y MG0-*-B@IVS3R0;1|C3'71#>"-H^%91Z+;:CKR>:(@<)2^@T+S*9ZY\|\R=S7*; M8>[:[[@@0[^;;=M[G]U3I[^_2?I__>?I/SB)U4AM-&T(_A0D&&5-[3M! M;V-FF_3]WAJSO!]IXM^(4[H@9571VK#D68;O=(UY+FFZ*$7;.3]:+XCI3.Q_M@:-J_"1O3WI[TF8YS=B3@]T>9"9*CPGWK3_1|+U1YXTZ;]1YH\X;=6]CKK7^ MYLJD@4 %4./-V[F?V*(A%B2A(&IEE!8^(E\K9P9/ZM)4AAP+(<(:?+NY;T2 LO$GM36IO4GN3MVIO48CNQL\/3E4FC5$U;<2L4W;72_>[L()N.R(FO)@(-U@M*&WF;HXXP9WWH" M>0/<.@/\G$T+1LL'XCFT|<6KG^"T^P-$EV^331O\,24)Z9LEM,,,056&4%LME*8"ZCX%!0?$\]TZ>=_*\D^>=/,^DYIVZ-@UL(!6A;2#G 09.Z5*9W3Y MG0-*-B@IVS3R0;1|C3'71#>"-H^%91Z+;:CKR>:(@<)2^@T+S*9ZY\|\R=S7*; M8>[:[[@@0[^;;=M[G]U3I[^_2?I__>?I/SB)U4AM-&T(_A0D&&5-[3M! M;V-FF_3]WAJSO!]IXM^(4[H@9571VK#D68;O=(UY+FFZ*$7;.3]:+XCI3.Q_M@:-J_"1O3WI[TF8YS=B3@]T>9"9*CPGWK3_1|+U1YXTZ;]1YH\X;=6]CKK7^ MYLJD@4 %4./-V[F?V*(A%B2A(&IEE!8^(E\K9P9/ZM)4AAP+(<(:?+NY;T2 LO$GM36IO4GN3MVIO48CNQL\/3E4FC5$U;<2L4W;72_>[L()N.R(FO)@(-U@M*&WF;HXXP9WWH" M>0/<.@/\G$T1LL'XCFT|<6KG^"T^P-$EV^331O\,24)Z9LEM,,,056&4%LME*8"ZCX%!0?$\]TZ>=_*\D^>=/,^DYIVZ-@UL(!6A;2#G 09.Z5*9W3Y MG0-*-B@IVS3R0;1|C3'71#>"-H^%91Z+;:CKR>:(@<)2^@T+S*9ZY\|\R=S7*; M8>[:[[@@0[^;;=M[G]U3I[^_2?I__>?I/SB)U4AM-&T(_A0D&&5-[3M! M;V-FF_3]WAJSO!]IXM^(4[H@9571VK#D68;O=(UY+FFZ*$7;.3]:+XCI3.Q_M@:-J_"1O3WI[TF8YS=B3@]T>9"9*CPGWK3_1|+U1YXTZ;]1YH\X;=6]CKK7^ MYLJD@4 %4./-V[F?V*(A%B2A(&IEE!8^(E\K9P9/ZM)4AAP+(<(:?+NY;T2 LO$GM36IO4GN3MVIO48CNQL\/3E4FC5$U;<2L4W;72_>[L()N.R(FO)@(-U@M*&WF;HXXP9WWH" M>0/<.@/\G$T+

*.%SY6R;&I(Q#JY*QCX>^I]=3XI M***^K*.?=13|=[Q%_OH.INEO'SL>9'4"1OK;-%W%NT4F0'\"5T%N\=LN",K M>&@]JZ"'4HCV5]L;RQ_40\U$%^-!'94=[S[T.@X:.K1#D@$'"?124M'>.&H_+.))]E'8&"QU)68O[Z M*'|I[IY@.OFTQPJ9-LU*.W(%X&"[5"B_!S-#5F('#O)Q&W$]EKZ#NTA&;?#U M$< /A\XI*\U ;0HXLMZ,;YV!" >[H=?.UL+;AJK3P/%MZ*AS#5]HZ05"]5/OR_SU.#/#';T2WSE[|\K;^M_ M)\Q4+4TW'W_Y^^#AXOKZ[_]O_R\?)BX\!H^;SB^5B>O.SM^]^_'CQ|L?S;>6 M_?A..3L[>_?.GZGX#W*;+37X//(-L2CC7]|\PZ^#1_D7VCZ_-GEY_POPT=- MJ]O.\[..4|\^6D_OQ%?PFT8KVJZ^M@O-=[KIN-14V?QY1XL;&3RKO/OWUR\/ MZH1-;?BP_NS6@/32#|*NZ*:AF^S?'^^_O'-M:CICRYY2%V87VE+:M7]OUE3F M1.'1[^LGE\];(1D_FDWT&O5:O5%3&F$CGE-S7V9L,8ECZHQ$*^$W_$?-|''' M=M<]/_]JZ0>>:[/'M9-^]@Z^7XQGW7-*,S*F2,]MRUC3< _$-_V6W5E+_R;);B\8L0R6OC7(^K,T:([5]NA=#?ARW]B">9N+,S;/LS=!1+U[4BL MK>+7G7BFQFS-FK*E7]|_^GRE0_J-8TP*AF;GF/E?4M?-*;'3SM\L3K MS/2FC;A):=3?L6>7F8X^.EB-/\9L 6]ZUGA;#W_^]&PO"\432::VRP$B35\DS7 M7M=9_\OE+]C:FAZHVM*#("Z/E,YBY8A_L3P#D?F-BO[20YIKKVB))43!U^_XMUX$Z4FH-I=+_ "_DP853KD[\0\L'578/U.3-#IOVAU/|\"';DPS_ . '8_U.K MD<_,Y$!@&AF]D*$/^4\ >7)GV2XU2(THRCM0(+PAHIRW6N?-)KG[2FHUOXTIM*"^A() ^S9N_Z'=V%7/XPL[84X M|HL!,@:0<2S[G%#/M=Z3&=6XR3PG==TD|;>*;KXG8VBM-J93W7@Y)_ WIV>Y M[X?ZE#GDAOT@]]:4FOZ'52(^KA*'V?HX^)VC_X^=$Z4^<]]7^A\T_2FDJ^G. MS*#0HFF9C'^G/Y_S#C+;?ZEK&C/!8L-K>.*&2XZN^B-[=N^Y6=;^X-/#65%7 M@I=G-2XI)N7* X3T_-*$B7^Y@+FPJ7$-L_S\&WNI$!U%E$TM2C^G7^3[?1 M:K4^O%OJ1C;=NF>/NL-MG7L#WZSKUV70 MQPKQ+? O%3#9YV/|F6D L,)JH_/X%!GO?E2>U_QZOU2U3R P2\1[I&J_!B 5&9_.I.E>M,Y_3MHPM*NX#-GF3YH@'\V#TJ:#SV& M<*/2YI]>1_K*IBJW,N(WJM*H]^KM7EVI+/5%7^J 9^K^QI\>/H7=*53I^84U MG>HN[Y0S,#6N:D!%@)G1&72+]Q*>Y2K?T<|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|;S;G>3=[@ 8W^|:M\5XBO7/8CK=!';S=S17I*%.VJXS/J3F(]^0'S@.,^JUV0=2)SCLRN49!A(2\E@((,IV!?]2T(F;L?7IAL=F)-22NIO=W.X MP&JFW>K[:%G:#]TP4O:TM7-/$|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|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|%=28#4^-_ M^)[!$TQ,N!ORU3+9RU=_U0DI,$'N:*Z_3LU//:Q9?[R$^ +M=7)RQ?VQ SQ MZ_EWU^,,15\LH'AM M$"^4#82C1'"4=]W"C_@QFW]Q1V&<-$/&DN690?0

=PV!%03[ZFVL>=;G>E]53XLP0X*3,D4Y^"S1B2S4Y',DCBZB[152<# M5?6FGE_Q2&-C7=5=-#6YRW4S=97F>^92W63:);5-W7QT(OS]Y+,WG803!R8& M7G$_N55M-_,Y<@0MD'1(35V[^0A(K9]5Y?.5<#&WLV&R1$TCU9K.;#9AIJ,_`M,:*:\)Z1-X;E./&G5HJM",I_+773%UW-@(;4>CE(@J::X&9+X"8& ^;>CH?T M.>WVFB3F+_;K$36"N4A>;|WF|G456Z/(A +FRM)_'2-8!1G;7A*Z>[8/K:/ MYZV.507)67L$"[WDXGD%&YV"U#O|T6-ZEP(;*1WA3J_::F%M)(3],6&?.G<@M,IBWNU7H26%@C_JBWNU^M%Z9]|"=35OT4Z3?E\G^WFM@FF%C-\D8&6[6Q?Y76 M+5C?YXU^0>K\G&C-Q(&I9>8E*)|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|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|=L)'*PLAG20#M)!.DA'#CH%7!/+<&3DMGCF,VNI$W,JCL2=F6#-^(*D$FYFRAMBVQ,IB#ISMOOWH9VM=[!"DGRD!M>TA>DK(!,>XTT>Z;?.3P,D.M8^TA>DK(!,>XTT>Z;?-D#N:U4V^TSM!+*T)&4#S*#V0,*:9:@WQF)N/7:_,E"-6FNJD[+H\W M/F%*94GR >(.2>VZI@E0!'IGL(2A_51/J]IL2>8+8J9EN84E+0]XUW73H83E MK($)F"@L\@A+-RXM>=>UV6&$1>E4N^U\G5]4%I26)6F)2U?>=0%X(&GI5146 MYFMBOB;203I(!^D@G9+1P>#]CL'5I3/JU]L43HRMEL.GCSMKM6ML=9X '#CQMJ<\BGE5;1IZ&4U$^Y)&/N!+UNX93.YZ/LT;^A1TP)H3RL20?;.(=:XJ@9B4? MG5ZUJ>2;8XCR@=2*QO)!KTAAWBNIET|_=>K7=*^H.'$)D0[203(!^D@'8R2M'B=*VNC.EH^X&Y93AMBHK$YYI?]FH[N]YK!%NG#FM:E:4_8%.)[.X28.3 J\ MJO255K75S;?*6LQ4_BP?H!##O>Z:VON(=II(^Z <.[F?!8 P5PD,,<=9-EU1^Z@NOFL)=W&G*S80CCWXLZ= M|+HY=T X-ZKU;@&]76.,,=6"!#!24ZDS@05)L#()8H[$9@9UF49JE.%DMKT[9N./?BSNLDW3]|\O1LN^< #(Z+4+$$*N76_*+3MD6[H[DO:DVU-Z6PC)U(">&X/-BD:Y:#0&$BEI6X\1BYI#*#V"H^MIJ(+<06 MZBW$5L&P):O>>N5'9I+2=>6- -UI]L1.CYT?A9FYZP2D@W20 M#M0]./M+3V=&>$QMEZ^\Z^[+E64S&/.%9]O,5%^&-C4=G]9GJIL\??DC V7#AO0YK1&5; <&"SR= MO-1LM-1G<37 =]WE.;C81(ZP2.:!KI&?$W=+LQ>=W.4D1G@W&YBM>YVNH'F32)'&C+"> 2 MN8;MQAXKH<,/.7%CXAN"4C*AN[F'@N7-2WTO!O-$2$2TI2-H2W]ECKH/[& M,:(LUSF;7@PW!LJP9HF35VPW#1+LK[NKH#;.^ZR0.&!.7^>D*"*&,B-GN"'3MDGKMSCZ+KJQD9ILG6NVTU]3<0[$Y ;')749V-S5K;0U*#,E-#4K,ET M2+8^/(:I:57ZS6JSEV]3WJQ*>"6V.FG>2(=I(-TD [2*08=C+?N&&]=*LF, M ==2>?1KDCE7JX'3C(Y:TJV29GJN#A*Q:E(16=-SN=*2/6@4M&H*O4U%_)) MOXQ%J3A)J5B3OJ[@:)=) . MTD$Z2 ?I8,Q3TI@GT WN&S ?"7N>|=L)'*PLAG20#M)!.DA'#CH%7!/+<&3DMGCF,VNI$W,JCL2=F6#-^(*D$FYFRAMBVQ,IB#ISMOOWH9VM=[!"DGRD!M>TA>DK(!,>XTT>Z;?.3P,D.M8^TA>DK(!,>XTT>Z;?-D#N:U4V^TSM!+*T)&4#S*#V0,*:9:@WQF)N/7:_,E"-6FNJD[+H\W M/F%*94GR >(.2>VZI@E0!'IGL(2A_51/J]IL2>8+8J9EN84E+0]XUW73H83E MK($)F"@L\@A+-RXM>=>UV6&$1>E4N^U\G5]4%I26)6F)2U?>=0%X(&GI5146 MYFMBOB;203I(!^D@G9+1P>#]CL'5I3/JU]L43HRMEL.GCSMKM6ML=9X '#CQMJ<\BGE5;1IZ&4U$^Y)&/N!+UNX93.YZ/LT;^A1TP)H3RL20?;.(=:XJ@9B4? MG5ZUJ>2;8XCR@=2*QO)!KTAAWBNIET|_=>K7=*^H.'$)D0[203(!^D@'8R2M'B=*VNC.EH^X&Y93AMBHK$YYI?]FH[N]YK!%NG#FM:E:4_8%.)[.X28.3 J\ MJO255K75S;?*6LQ4_BP?H!##O>Z:VON(=II(^Z <.[F?!8 P5PD,,<=9-EU1^Z@NOFL)=W&G*S80CCWXLZ= M|+HY=T X-ZKU;@&]76.,,=6"!#!24ZDS@05)L#()8H[$9@9UF49JE.%DMKT[9N./?BSNLDW3]|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|=L)'*PLAG20#M)!.DA'#CH%7!/+<&3DMGCF,VNI$W,JCL2=F6#-^(*D$FYFRAMBVQ,IB#ISMOOWH9VM=[!"DGRD!M>TA>DK(!,>XTT>Z;?.3P,D.M8^TA>DK(!,>XTT>Z;?-D#N:U4V^TSM!+*T)&4#S*#V0,*:9:@WQF)N/7:_,E"-6FNJD[+H\W M/F%*94GR >(.2>VZI@E0!'IGL(2A_51/J]IL2>8+8J9EN84E+0]XUW73H83E MK(*)F"@L\@A+-RXM>=>UV6&$1>E4N^U\G5]4%I26)6F)2U?>=0%X(&GI5146 MYFMBOB;203I(!^D@G9+1P>#]CL'5I3/JU]L43HRMEL.GCSMKM6ML=9X '#CQMJ<\BGE5;1IZ&4U$^Y)&/N!+UNX93.YZ/LT;^A1TP)H3RL20?;.(=:XJ@9B4? MG5ZUJ>2;8XCR@=2*QO)!KTAAWBNIET|_=>K7=*^H.'$)D0[203(!^D@'8R2M'B=*VNC.EH^X&Y93AMBHK$YYI?]FH[N]YK!%NG#FM:E:4_8%.)[.X28.3 J\ MJO255K75S;?*6LQ4_BP?H!##O>Z:VON(=II(^Z <.[F?!8 P5PD,,<=9-EU1^Z@NOFL)=W&G*S80CCWXLZ= M|+HY=T X-ZKU;@&]76.,,=6"!#!24ZDS@05)L#()8H[$9@9UF49JE.%DMKT[9N./?BSNLDW3]|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|=L)'*PLAG20#M)!.DA'#CH%7!/+<&3D MGCF,VNI$W,JCL2=F6#-^(*D$FYFRAMBVQ,IB#ISMOOWH9VM=[!"DGRD!M>TA>DK(!,>XTT>Z;?.3P,D.M8^TA>DK(!,>XTT>Z;?-D#N:U4V^TSM!+*T)&4#S*#V0,*:9:@WQF)N/7:_,E"-6FNJD[+H\W M/F%*94GR >(.2>VZI@E0!'IGL(2A_51/J]IL2>8+8J9EN84E+0]XUW73H83E MK(*)F"@L\@A+-RXM>=>UV6&$1>E4N^U\G5]4%I26)6F)2U?>=0%X(&GI5146 MYFMBOB;203I(!^D@G9+1P>#]CL'5I3/JU]L43HRMEL.GCSMKM6ML=9X '#CQMJ<\BGE5;1IZ&4U$^Y)&/N!+UNX93.YZ/LT;^A1TP)H3RL20?;.(=:XJ@9B4? MG5ZUJ>2;8XCR@=2*QO)!KTAAWBNIET|_=>K7=*^H.'$)D0[203(!^D@'8R2M'B=*VNC.EH^X&Y93AMBHK$YYI?]FH[N]YK!%NG#FM:E:4_8%.)[.X28.3 J\ MJO255K75S;?*6LQ4_BP?H!##O>Z:VON(=II(^Z <.[F?!8 P5PD,,<=9-EU1^Z@NOFL)=W&G*S80CCWXLZ= M|+HY=T X-ZKU;@&]76.,,=6"!#!24ZDS@05)L#()8H[$9@9UF49JE.%DMKT[9N./?BSNLDW3]|\O1LN^< #(Z+4+$$*N76_*+3MD6[H[DO:DVU-Z6PC)U(">&X/-BD:Y:#0&$BEI6X\1BYI#*#V"H^MIJ(+<06 MZBW$5L&P):O>>N5'9I+2=>6- -UI]L1.CYT?A9FYZP2D@W20 M#M0]./M+3V=&>$QMEZ^\Z^[+E64S&/.%9]O,5%^&-C4=G]9GJIL\??DC V7#AO0YK1&5; <&"SR= MO-1LM-1G<37 =]WE.;C81(ZP2.:!KI&?$W=+LQ>=W.4D1G@W&YBM7>VYNH'F32)'&C+"> 2 MN8;MQAXKH<,/.7%CXAN"4C*AN[F'@N7-2WTO!O-$2$2TI2-H2W]ECKH/[& M,:(LUSF;7@PW!LJP9HF35VPW#1+LK[NKH#;.^ZR0.&!.7^>D*"*&,B-GN"'3MDGKMSCZ+KJQD9ILG6NVTU]3<0[$Y ;')749V-S5K;0U*#,E-#4K,ET M2+8^/(:I:57ZS6JSEV]3WJQ*>"6V.FG>2(=I(-TD [2*08=C+?N&&]=*LF, M ==2>?1KDCE7JX'3C(Y:TJV29GJN#A*Q:E(16=-SN=*2/6@4M&H*O4U%_)) MOXQ%J3A)J5B3OJ[@:)=) . MTD$Z2 ?I8,Q3TI@GT WN&S ?"7N>|=L)'*PLAG20#M)!.DA'#CH%7!/+<&3DM

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|,NM%&S)1'OO AN:SP9_"G9+'5 5+Y$'LD>!_6/:8269JRI0F MXHU$&P7.B:IGDLBZ0TY47O2Q(7Q9KU5:]0{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{XV4XT%B'5%,!V.15CP- .7/5!J;RMDR#0 #6T&B*+.065F(T2F$;!%\8DGCR+35,::H11##6ZT749KGQ_RM98.$@"H M#'75!AR_WSUS[-E+*O5?HXB-OD-)VK^U1E_W-+S;IX>O <&>8'I.!D7+7,5_>7Y9^&3- >5^\^WW[_%KK&"5R$$?3I:.!^QEJ*TW%4\']]#GZ< M>-'*^_]G3}6KAT_]?U;[-T^?'CXH]OZ]+FR7.V'4SF"A%_]5F3!QB@V,(IJ.:$_^O_N/SQ5E"^WU\-0X?98 MIKCWWX*/@OCG['5;SL;+ M]BV8&G\7#5'+$;DI'KL72IS+S1PKL+'?F2H#-UFDWGC\/M,4G/J*=IK'.G < M_%LP/-N;58_L5.$'T:4K[4,RCTY"B#B"LPJ-(6-_%;.G6| LE&_PY<16/@%2 MC|*I3++Q"?_R1[VC1F;J^H\)?0%M)R*W;.BM0>26%;DU:HUG06F&<*O\N-4L M*&X1/Z9U:!U:9R-?R*3P?)\<;U60N(&7/90?Q$F+%:UC6VCP_GY ?8]X7+A* M(<4@? HN?,7:KS#%>]1GK%'M2ZFD=6BY! M 7U\G6#<5W;8$,9H)"J CIC/:]]JCFF'[#]S;88VP:"%X[]#.;PW8;>-[-NM ML&9SL1PF]LG[MK+SLZH9B"]WQD>.+;Q"^&[Y% S@9IED8IDS%#:4N2. AG)V#TE@S7!AITU7O_49V M:L&T^7?@W?CL#82O%0P'AS;]E3A\(L82);Z KG]OL:DVGZ;ML]%)=0?\,1/ M(*YU3.C? R4#0'@C]6R!UZZGB6WFB_|$LW],6P+Q^OSI01:GV=,8,FYS"1>0V ML&L.59[P@Z,KYHZT/3T39$: ME5HK7W\8B=&R(W=]!S&Z5^-2^2.=R*;0L)2LS7!9:[(490RL?ZN]BYY M24$V\R PY$$@R)/Y".AQ-[[AR/'@XD9*CM.L7*R:M5)RLR-K-E^!=;3$&[GJC&.UNJ5^"'|>IX'K$L=CFH7:!U: M)^-UCL]VI'>3&_.U;K:60W_(@YPV5F8QI04["))Q4# M*59)BDHZV5X59(@C MB=A')O[!Q7#1XL'#BEUSSQKE\.\7!/%.%M?C+8*HO*?M$S_VA>R7K1H9 R+[K'8'I7OM)77:1=L+TDQSXF&M_(1K?<6FZG:R$T1$$ M26\;B=."\9=X<9I%/ZU5'B.QY",,.\MB(QE) [QMBFES2~]G6V6]4N^4+H6[M(AYLC001P*=+-IP'9{@=FZ<3KMPJ;IR3-/,[+6V*MG?NZP=ZIJ!>X_O&A# M0$0W@7@<9DVI.+|,%4MH2 M*>RRN5@*B,]MRDP4)Z* DMB\^ZK>)[MW4VAVIBXH+ELV%3\]>2V[N.R]0(F4 M!FVO50(5OB"H=K+8'.\X1K5[RBX2NP-ZAW,.VKU>T3"=PJ[(D)6NST-YME3# M<4LA2&(6C*? $L1IDF4Q_WEOF:#YT[JQ'X9KHOVEV]3."_1L?W+DMSW%11V:) M;ZVE%T(Y)XE: NR/EZC)Z37J98N5"F#UP-(73_)*2?12QZR MO7G(DJ4_K6%,'F)GDLCL2O%&^8[*=? JR^P[*N9.'NU& M\1.AUXR3/_+,+:*M-;35W4\BV\YHJU+K-8Z"NDIGZV!~3>M0^L<& M>%VC4X >*(3MTEFMY+]D\&.LT?9F8U"DT5":#4-6#4O66^:",VNEI\!3Z M8MRYB-7W\&I7M:;9J;3]!X3LEM@%I^)@ F<@TN4<8H8IU\M46G$S%2+JSW?_CME\$E]3XLI#H 2G>1 MP5K17;[7.K9UUH+I^.IM5EC;7H95GUW>SZWA1.6.$N98F5GHN' 6O+M$;@.J M*8=REQS*;A9#J,_5!9^+^F3VAX &%KN7F\&OJWP:X"<7.4YG'F!!4)"P/A+K MLY@[O5^L;_+X{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}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|'NP3=F$[K5|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

*:K/)B"$@>SG&N[#9R;*(9";|(%VRQQ/YK:3 MR|S6V67M/$+Q5. 4=?@@3A]>^|G;)W}!O"Y*P0K8RMLRI\OOOC\I5_^%CO\)9 MGGL4?U8"Y4W5DD.9|]B\U4;23N"..92U\(?S9?;&]!':I5:K;9R.N)4 M++&?(*(X&!9"D1#_ZND'OV<+]]7\V##,GS58QQSQ5?08W@,//!XQ7*Q5=E\[BL:S;G0:&[@.>,YY<'%<+G8-%_6\(DS M2+?(!)GRFZI,+#R9GVY-AUUX8KX*.D\5#A/?X@-[FV@#OGI>%+>["QDO4"|S M5&WV+B<,!=+1\U4UA@)\[&W&T"&@#"TVTAQ%YW-/%,2;"L!#T;4Q0[#BYR#G MU! 18(D7N!6>(IYCH-KP)T!-!82>#C1#@G&L3$ 0F19|$'Q%2V.P > "WS\AV M5$/5%*P"J*@KHJA8R:P;T8$ZUH>$+ GR,:\^4EQ/+AW|H8+G$1L+(JN-Q1KJA3*

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

{R^NTE/Z0NN8)A,&, M&]^)'G.\% P'L_>5V2V0M''S)}(%D=&4N9?&=Y?UF77ATQT;(.Z9!EM!2 M8611/Z^26QOS$!LGZ3\3;_"Y&;#!DQTT$JO\!^=+8+1^#0?.KX3 :W)8XN&2 M;0UHQ8-'8/#,NO.N$$EQ_-M(I;ZF}_07.[!U42T$F<;1" %&/Y7&@))//-: M*MA(7$ZG\0H_^VQfVOQ:<-6S*;&!D.]^24;V'=@49Q 9LDLO@B;#+XI//]]2 M4+MA&(U6,_WGCD_^6MQ? 7WC^+^A53 M>;Z(J),O)"Yf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fN]%$*7QCZB5%IE%4.TJ_&?!M%9O$EE4;\@#S MNM7MZ/U-^2,V-N114-<]HR7;"OFWI-S-:>HG&XBW;$>:!%ZT3&_S2.N%)!7/8Y M78. [KDV0+.VU5*)=KK;FRTQ:O/%S@!J/EKQ4)3=II-&F9B@S@C MZ>Z M44;0$;(F3^QIXDI]%FHC5Q1:>V62&$U/SVG1.4N3D?UN2C/)++;M?;,Z M.TSPH.!O&K8W%_6"XB+GH? D4#PCD%O :^_(E+ &$#-!$8SF@OCHBH<3#WME! M*+MKB97@_)0]P<)R<2,O"&7'>.HEQ(M'PZ[_I,I8HH#<4EDBCQ?YMV1-_K@! M$Y\3VV5KB[5I"@MK%5R K=-%)*9R;80K)K37;76.DU9+-]K++C/1-L1=LY6" M6XX7WTJOE1_*s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{FIG2PE*1!>S EB5Z M@6V'DT!#D5FLPV;J(-.I;V=)E4]VJ< ^1^S<"K\[CT^24;#[+>B,:PZ2I+[B M#&N M?F!25)82/IE;7_?E7TS,4/%L4\;(.YA5NU]#7'[NZZ,677@/@4:I((_MU-&IHUL#VLJK Q]2M=C? *7*262]3\%=Q8$7&BHR/C(P/((7ZM=6G/R34Y?I,_M(Y4_"A,VP(3O,AY)(8-"!NY#T08@)\S[%^'!H3"BSACQFXM7Z$=KJBAJGH1UP_*<.I,Y6%[06'*N"X3>$108Z93S/;M<\Z6]!DH MW^^M3/UT-;K_B[#R;C[C18MNX]H5],[@-ZRI(/S2A450 M19_=R82V;K3[>>DH\A"B80\&LFK/'PL\&MF'^%@F$"SO(]UPA;:U?:SDD=B>@`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fQ/AIZU-/,=B?L!)VG'P)!N'<1OP1P..B,UCO*!A$C,&42.'>1+6>_7Q(N$NFZSW>&!#.M,$)((M9H 27B4P"7K#=.FIIPB1W"V= GBQU M.CCN(HHLMS:NW,A'Y\)++M9EL+:=7)I MAE=>E;!UPO# X97, TH'UA2@8P"X MDS-O:G?$@<1*:"OBU"PM"& HI, JD^C3V', =[Y'(JB*9\+5I5OXB>[f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`-O"^I/ET^H%:<.?VDFS#5^DCD+0#H^$%U'NZ86]Z)^#/YW M<'-'RQA^TK7++[^?-./+^9:%1*M-\3U#X[IH4P:NB)^@F8 HEI]_79590*NR% MJ9KN"'\&4"6W9HR,P!+FI?O MR)8$P,(*5,JBP8MB4&F 0-,&2%42$#6 //QU>1A>T)&_K&LN"_'+)"\;,,.@Q MLT-<@XYX.TI9[AI[PK]A&# P;6C8X .6!9E1RG=3HS(HF55FWI=5W;L 1")HG MJ2IY<_M;0.O^>GM]354"X/\+SN@H)!PXD4!/!"\/X[$[-C3PN&WPE$*^Q_1 M7U?CFQAR/+O^W O"(#]'^W3?,=I"'?6Y+#50R\AHJ/2-4 9.51YW]:WB#BAA M^Y R^@I^NIM@!DA[L05_ATW_M6\2,#A9Z!61T US\X^) *]..]?X=!QX%"5 M:?I*AXX#AQ0?4CAT/'Q(;71]?#6^&E^-&N_8/S/$)F6ETZ^TV@T+F.F/G\Y M8[$'YG@SO#\\OO3=G"2G51U8CLL9N7?=HF1XH#>3NEXW@8&].JG1DU*.MH1QIWNTAH_^*$B4G"]'PAXO^,;W;4NBOT#\)?_4OFP1TN^O?TI[FDU7;,5^MQ? W%*WIQQE)ZW87\9T6/U$V,+X$MP'X&&5RI#0?J+[%U&M-M2'#>Q*2K.U$9>K=3C5.KR.J5DM5IZ_FF8MW))J/W>\MUJ!59*;+.'UD9SS=!-MZTY67.U]LESKN*YD5? O[O>.HT^(E*NYIMZ-H1-%(=312K[)IA31RIAO=@(112/5 M4T8#YSCE5>B\;>M>HAZ^D?)WQ^A;^VO=\@P!K>10DB62S@+4X[TBG8AT21FZK/ ML;*&Q\C#EH;.H6HAH:=Y41B$!HN'!2,\[""4;\OZ'G3'224^6-SMQ=/P22KU M\=<"&H%_96G$+BT\2I78^.Z)%5/9T8!.W_3O6&;CNQ?^'PN3 ARIZ[A!3%?] M\G35PT)@.;>6L.;8 3CCP2>>>?'B?V.")]]_",1R$5-(G/BU>C\5T4V5<>*4K MK!(#/YGW1D(+X<>SZYCL#;2\MLF%YXNO\+EL4X1VJZ@A2[O96:1T#D=]*M0\ MWA)"5VXAV0^B^PBHK4LDW];EZH#R$;6*I\K:O&:=/'.T^,'COS1(Y\WL]V,66]HPGD9WJK1XC'@#&7B.2!U M@R9??]HLDBC2YLR!*+ F$;/$'@M8B]'.82WM1NNTT>K^"[? U'9">7*\P$_[T M-9C-EMRLA/R+! +++FGHN>K6RV[E;0"6>_F4TKRCXM 75$RQ3,&@LRS>2I1JXF*CR50PXX3EWC MS-I9??

*O9!1SC|Z`MT`#=+.8&S,*_Z`+61(?:A>Y:{@AP7(OS65\{\Y\R&K)-Q&PX#]\,\(]J0<\C#MX_S,ROC=<`MO6J?G)X9;3#L&>@T,^3%?L3>O)`TQ^,P:1TNX);1?J.%=HCSR8^"^<*3P-6^M_QV:UV9D1NB;,H JV$_1;,;\D1DP&!9>_OL'?/93H01M-ID(34"D<1B5H.T]`MJC3[GN_*+8**=C4*O2'S-;Q7`*S2-0(2)_DIP'2NS7SOP4;O.IR2/6*2(P2@`M$@>:>:<]$91"@,/*Z,_JU:,I;-@LIZ`%G-/B$@[M?=8V-QVQ$SOTR*S;$DIM\`MA+O4DA]MQQ%P7CT0;(W(:(W,F&LZ=+U@PO\UGP61$\H+A?2# `MXJLM=MS6=N^S`M>V1D8-\$ 1[HB#&+'C9G\.D))@F9,]?^6@36DIV9#]:?;+XM`O1;K!9@ M-(*"OJY\/CA/GHX\WV$A\-T$;OS:J-F&2IL,2,UO>#H9QL*P_(F14`M+0Q2NF$;DPZ_Z63#@A.0QR1>2?1?5;O+_\G__:KJ@'*.H%TZ# M__K+:=LX^2@^!=H7.QA%08!\$K6$:@I\\ FD9*8T&ACDPY*$]R0PDF/7(&M`M0]I4QE1Y: MC\2<@#T"IV4X43B!M2]/9/K`RT%%&$SSP>#PM4N00#1!K_0T/%:Q ^E!(K`MB,>#6?#-@>M&\,3"#&+S,-$_81B'B;E05MJ^/#1]^%XWI]D#21KQ+D("$R;,A-O6?" ;AD!7M#4R4 :4\E=`MC388D=5EG'4Z.IEB,|[L52=@9=\WON:__5I-#'=>Y8;]\L=Z"%BPf8Q&"H(MAG_ B%*%02INMSX&YIAIH"^"!*-O#!!:.@#UX'$,P62=>0-%HA&=-A,TJ&. 4 M0Q.ORN,`-8WYAF 8 6"F8[.QOR]00M%4=!'SZAANEQA0VR%+?KP*IR,^6#: M#C%P6'EVX*9V"DN &.=>!`^BKHHQ=>-YT:$-N4D<<+,,8"8@ K:. M+D$AOD*3>_$[HCEK\=M1WI?WGKGT^F/>@^P)S:O%,T$>NXO?@:2T1_8,-K/X M"\X8>EK%H2DV2\-]GM_Y,WI,\O.^5H&*\KO\>0*&{BEZ6NP>F!/ 9VHC7(6 MJ1,.K,QA<#XS=A!!\8S3F.+-0"7 03U76J?L 95Q@=%-[0HY"MBEP!Z0MEN*@R+.*%IEAE648,E#LU(1U>2Z261`-`ME*)YB(S=&PM%X(ZVE$OLT6R!<#/D&@6I<8$OD^3#X>FK=2OD;|`X& SVR#2!`MV9Q>TU/B7]R-90:>2W/#XFQBV?SI9.GZNDG_&9Z0 :(]N=#"0WG3F,`7 MCH&I6GI)WV$4AI&L130`3WB+D) D4]@^,A&U$K=J +;&G">_ ,0%M%QZ05 M:?XZ$XNDX\0\>;% QO#%,Z63#@A.00JB?6C^AQ?+0D!7$,2AH_Q\(28 BNPR MXC:]^P" ,":,O$U;UT3L@_U'-L?15,8 M_^E-U\91& $(^/)P8@_'>X15< B@F$ 8F1:NC$X%!&<9\'=AL3J>$&$_A1Y MKH[@4]RI9?O ?@:!;#X.2=XSL.[N)[!JQ,,X'3UF,:0RG<88$UZGU!1=4##" MP^1]CAPG11;_U+5_QU23\SO7M(3\7'K@M/')BE+QZIH#S]\)Y^#5 _.)IA > MGV/+ ^YC-C-\9GY"0&TQ|$)R810&$ 70RM(&GC":NYWCW<\H-X#+<@H!J*.M&M^02U!\(# M #Y.-X,:9+,#9_0$5X;HIH>;@-_F:&2IL,2,UO>#H9QL*P_(F14

*5'AT*I(GEO&"IF/.;IW6_L1N4$DJ703KI).=_>PUX>#$EO0TLVS]S2,DGX9[OJY5VG=.;|KUTV63 M=79N]1Z{P1=6X]\Y42H2*WC"C*Q.-,|T&69EB+ M7M6]W|BF\?"4>M):D\1[ME_KT]RORBX>7-#I6-"\?/+[$M%4+?U|/CX]UG|UZ MNV,YH&)E,J=K4J;WF0-VQ@5P $?W5PH8U4D5H5BIFLD!W7OSFML42-5Z/'_K M<2;L>PT/>DN..FLY@F8!>6W2Z[V6A5}[FM5?K.%D1,\EZG9)F+1X"NR5KE33+ M%AJODF8W)(UU^Y1#_E7*|OG|'$$BK0PZ=XZ$CMQ?CW;9NI^_V0XXSYI&T&ZL MQ8A<|YK:+3*WV2U<.$_<&LL6AKO+KBP-H&>99L\VG"X+I'JG M#;&]-(K|VH7:.G;F@<37';3=13W=6=V=L0HO#P^/[._.99YXZ%S'_M O1C3'GT0@=S]1!M((Q29R2\$!9PD 7[BNM00!*9\HS_;4#_O,CQ'R2TV[\4H1,4(N] M4DN#.!K16CRMUTS+0ZHA=L3],;7"J=Z ,)>4Y MIW)%BZ@M^1(U:XW".U,-EQ?F7H ->? @7V%#1;'*)*?\;0!)?^[8B_O_&"S#; MGK*6_? &ACBBO[M>@'(@:>XOL,C,Z0Q&N"M&06>8SXC1@(\<(4!:F&@[%`XVS MU*2EB+B! >'7N3'&X WOOPYN]RMF%RW? 3YV'UUBA385IFB37QW?N)L4F+<"8> M!\37 C/!;Z"P'1<6426>"SQV:/*HX|KBSAV.-J MQ&1=I93>E2LM*E9T.QXY2RK(1[0>P0X]!-LZ?Y.,I-K4^;..A;D# M-Y"\;!QP4OO3*PN20)QE(YZAX6*IJ%TYTI.2&KKOU^[SU5&^SN4GEXQXHKWN^]0]XO3!-54]>M3)-I>GI@NNWR6N;UN!OQ.] M,F/K=T? 4/I)+NN,T&G."@/Y&UV.VOE.S_FD:1#|?,.)2[UOJH:*0:K*]R[OQ M3_I_8WH=MN7VN-_^;0R"ZS',>-.ZY"Z3V4X.RM*^1?U#'92E_8.B_>U<%ENR M/QBRW\Z-U.X1V$X.RE*]H? K#&Y2E^H-5<6P\PI+Q")\OT==39Z@7>?1&^'R=Q M':0D.|LDH5E)=N#$MFS]4TML]MB\R[&Y2;?5G4[-EQ:*_F"AZ!%Q=@Y,[*V7 M.$\;9VZ]+O&4$?'U;>L_P)>D=#$"Z";G6KH6- >)13(6O=2_<&%$9R3E*5+/ M/9Z=XA?,W5'<9_3%,.(-_;P[HPNB)1EHV(;2)4N(($,$W! [MX;@HS23) MNHG?]IU%0CUZ3%)<-';"%(0P>? D$@[@21N#^&WHV/6^\'TX/N7,=VZ/>&/MA+0>I8CV[07!A%#<;T1,22VP3_E ;$ZQZ/NIT\'ITM'C?Z8[>ER4BQYR'=XC<M;IP@\P@2W5/P881>=[QKSP]Q\EGL],5 Q#'B?D/+7I*(-)$0U+B$WBC*PA3' MG=..46U>0+>>&,_A16]$@GL6F^_L,*_M$L UUAV8.#Q="7P]< 9^""1,1>Z2',&=8.ZIT$"29$3B|"C0ZP@Y+XUZ/U0E M"6<,Y|C? @'Y-!Z]&5!+GK5@0!_G>0A426U.R'#}^/CCCMYUO6/S2 0 ROX'[P"1D!!71#E%3SG M#;0;PX+!U^^ DX"/OLI-YR>^D42^4(LH<?4/6VE1V+?9_5S@I] MUYQWL,&DVCA? >VF$XV^;V1]@N,;@0"DNJ+5$\7O]7WDUZ$=45HJ4#V M$?WPF+6>4I!86+5>T#++0]3W)W+'^F2FZU/5\3$%#2TQ*Z,7WC|=75Y=_ MLLSQ>BF1=F'UY495/TZZN#=BLB? M5!8/42>2I"8J@8),UHO&0CX(J!2@+V"" MV0 :PSHOL'\>,'Z]'D)R]^_U'\D.E#?0A5.E>?U^66O"8L9P>-6,O;WY^N?"M\>-\XJ)*846I.+HZLM%_H1L'7C<&Z,M MA)KRA";X1^U;S7D? 12PLWL3?*OF)W2.U;<47X?(7O5?4'UYHU@SM>)s#*\HJ"%_MZPC&T$FGUBZ6RD%6Q-HO8V_"]9-R.3;+]KZ!L2+^2_=2>3OYLR.M9*.E4G\,,?> MY!,$O@+MZG\R+R9]V2P"6CF,,>^ 58*+C_\EUH'SP4V5T%@YU/E?_=XF?-M__M%SLG$R 4^EFPLN7CW9,>TIH+D2DMT&_M$.EJC(JO2^3J&\V,H8&"Q\U_>_M:/P"%@XE2Z_FLD%+Y!85E4TEQ)',SQZ"KV A0FO7@.1"T;- B]*$>Q IXXV M.=GE2RDE'O*T5CZ $,][6!R&7V9CO'3&PK S:8Z3[!:DH$1I/0;/ MTSH,NQ#H\.5?|Q.8ZV 9:TF'7*8*D)6/Y@A/M+P_?5+G.A M'POMP@%-:L;3 MUFFM4SXC'XT*OF)W2.L@1;,$4FW<4>FS*^%2Y; P6&KW:[9R30+A6_I.I7K'M4.9AV69>N+K0)O'X07IL_<4Y;R'+7>=3I7+&G;]#C\3+V!TW-99VSUI= K*.M(I- SR2S#G46M$8ES8?\>G3;3FC=*0=G7? [0*O/BI9!$US!8 :G8=6_O3M^.M??NXO?CB_??WUW1"M+JUILDZE835=90%&;^P@$=DY:QB5?6,J#W;W7Z\]Z; MBO65/SUY7K7D'}Y6+SGNW3H6_/O7-Y_\|(?N \0,"$5823\$P2>.NP&/(W.;:?%*C|5BX$2%"\B%&;AT^4O]0F0/'KM5S8?V*

JV6IP?A4SA^E;-W#6A8/=2[/GD6XK)",JQFEOT!R@W+D88R+L\0\&'N9 !=0OM MU!R\K9'UA65,<%S!$HKY77AV]1=9#*MW?C^0%1.B|>C;$O0'&E&],1 M.C3!]Q+%0!JC"-8MC#!L8<)O<^5BUI5Z/9$D@PQ5 53I1=P#C@0"Y=?.MFF)408AWCZ9=@(]$08+ZFI6GL+8M\B&Z!D&)=KCO!OX"\M+ Q(Q2B!*DQ37!E MH4/O6CLG&JP@BI*8O9 &$9;/C-#8!$,RL0Z,+.)6V^ M7;"AXG7X^UP/@Y0E"-39*%ZGV6Y\,(2P7YHGD0X@5(U!T-?#*4S]f M8)N1[3#77U\;717$GB&".T_PNLXY5\R]"CCB)V;Y4KAIM/#76NT MLZ5Q2^.5-%YTD.8_6_*VY+WCY(UTFH=B(_!!<)2FZ6V MG3G^D9ZC+,5$'+=2S4V,NB>LLP+O]B8Q[!#W7GM*6G'>+G%66G#]L99*+ MNL#)3 XH|[JVQSM39<.U23K_1MNO")N;TQ9:Q6,8/G \L%N\0$Y+= /7U\ MR765%,"H4@63:P M,+ 6WJ2U=Y+T(Y3D"DH:|!++YKQ=8,&N;T Q>%,X89<$#@R,.T M;+P* VT'TY1#&*9$H4>7\PD$4]$Q=R5@^ XF20_@CBGOH0#HU-&-@BT$ (\'K$9Q5 MAJE.&% (BL;J^988EF:$<@)("Q0>85$$.'XQ;_>(E?>|O'4/^V8M_"!@"D*^E M,DMERXM<"IHAK5;E&3L8"$NB4Z!<|WHD9:5|*\0ZI:(W#*,@NO;I0GX-H##; M"1U<>Z^S81<*#_\|2U)_(&=> (/!2N^#Z';W8!=6Y# C/MC7 E="(+1SVC]$B?3QPA4R@.O(QNSO*$B#%Y-F"&(=USN*^ M$DT&'_\D.)PJR/2YT=UKT "-Y8.A&F"H"Y4@8:P_H@/!R\'MCNHC'/%*

.&Z^8OE1 MZ]1M-S995Z-B$,\L(6R?$##HG|GFKN3N$8&MNK2IOCZ3 ?:9R(GEC?.V#TSZ M+MGC5@1NPSUM;K(BPZ$)W-W=^^:9>],>;L&TQZ_C[H"<-:5KGJ1\0-)UK;5, M-\^(2P\?5)V\V2+Q7;.MGC.GI,8 C/6MUG6<&D2>W3Z^)[HFPWMAOK!=T= M#5'__UQKBWTA >PQ|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|S 4MYIL<|L_^GRX[URR_7H=@50^MU_)0$/TXAI%I34R@-%Z M^1HY7JXS3'L G96R(\'>HTL'\)/RB^=TIF^CXA33USFV;_I(()O>LA0NV>PF5 M2\|13:53VES8->?"?D?? X*XEPUK*>024\U\!O-]P_1_P8DL_EGY6H^&<^RT MB'P22S^6?E:FGQ;03\??CZ6?NYY?U_#^CA*010.QW=AN;#>V&|N-[<9VLW?= MV-R>)3VNGZ+PVODNXI'S5G13U_GPYNKR #-U%N=$-+:]!P.R=;3:PYB)3L MQT$,K2V#65E"V!%"Z+CM\[:E!4L+1 N=[69>6EK8&5IHU-U.?GB>*?D)4Y3V'VQIR1ZWH78WW8X]87>DQVT(4K=1WS4TN]W8C(/8_G.WT]XR M7NR.L9!;#^J4>;:!,>$^fj;^^^V+),!8]6B=0J-D8&P84WZ+C$\.P\T<«# M1141LONSPS^TWJIG=%?V>Z>&8S#H+%Z6<(K,>P57Z9(C2B.Z?=1' +2+<>P'3L.E5^$5L'&OA\YG M+^X-G19]W>P0{J 7"P5WQ6!T8V!^S/Z>=]JU37>&L%DAQ.GEXVRP"$_5B.M/#_$L27#*$X'7A!(I'MG'&2)T^C\(E.B/K8$>=IPV@/I]>C50LO#GG*PH.1 M3N!O!M|B>$=X7$U,8MGYZ9!&(W[V1))H9.RNP,=CD<*X&$,R4]!YI[,8!A(7 MEC,1O0B+XLQ8SZZ ?:3Y&A*PKDV_G_,&.S[*\]5^&O#Z M&LO:K)UN9%E=9Z5U ICNM-A+A=" (P*G\]K 8JN9]P6PA>,[@8COO3HU.GH.A_A.Z?A M((+[@+?+2>.R@?

MCU_>MNK-,_B \K9SUNZ;9^<[BUMVW?2;U':GIS!%TLY M'QZ3=FLEKG0EHKZL\.5^BF@/,QN7KC1J?IZJ H\0?U(7F+N.(\%(O;KVX[UQ/T@TE6+8:M8;S]
[MF:O<.Z.D<[&F9O@X@FWFN7U2=&R?M\Z54 MY]Q/(!T#E[$?8E'NP'GW4U6O_,H@2H52YN]4J8T+4)VO"!2\T?*.&^TCC^OE M-3H]_HNPEQ1"DMG$-
\%HY*UZ4]67^^,%72]4R]^'7GX&84-OP2[-><}{(BO'0^_M+_^Y*.6M\E2/?>%MF9M_M;9GZ?,>N3V>|O>M.JF2"S6?VSFUT74KFH63V-FI-_M%(IK((55]ZZ4 &O?4X ARCU\A$^[(
L,SQ&9K!R<>}(8>&NST"!:#5!6<3^_M3M=##YN¥!5<2L[-VE0%%X;(2E? FI0SM/M,2,<>-+XA<^+EQWFJS<.4 BZ& MUSAS_JA]!VI:?G:.'7]"X7P>?UDG4+8*I"+,+.M"46[-3MA-C?
JC=K'+]_6 M9#FS:WL9N3?CZN@C>:.<_WU]!";5URN M7-4LHEL:C\.4WGJHYR!B%DH@+]%7:3>-9<(Q^NE/D8_85E;_7H^EKZ&1K.T M;<7.'F_-
K)OC1NW;FP]K,B6+,/[=^QF%T6@"BH4J6H^8?2//P".T.[MW1'= MKKLRXIN+3YMBQ#=>T%.P[GA]U/42P;.UO&EYTV[7%&^^??=^4[SY%@LU^)8U M+6O:[5]&-3]=O-
X4:WRNB*P7&FYTF[?(JZ\O'JW*:Z\U#7-[9%IW3N'N36S M&/>(%U5GM\9\K,7 MC<:@+K*.. Z\D.IQYN4R:Y8]XL I_9D(?N*O1HWI7!Z>+=/V_6FG/&O+8J MJS.OZQVOUX,SG&
!C\5CBDK$G]<91]|E1J_GLR/>?35>'Y5U%#I>W;NS?P6R# M$'.^1$G-.;.6.SYJM,]+H6NWC]NGYV8E+$4L!12;].N168N7:QNF+!%H81W&: M.-"Z3,P,* 4DC@+G*RJ5>
<03/THU<$,SOUY50-,UWUF+-"*=+F&=HK!?4[VY M%"/0*[0PR.+03X9%'91BS?#<3B/^Q_JZ,/@^QCSAVHU@JR?0$OSP/UPW.IC(-M'G Z&EPJ7I);/P@HU]$K5%NR6O
-015SA=T90RP&D>)((6'85UIN*KS-G5 MG&]9;UB:S71// H8>A?7IU@S,%8U ^$7G!Q,;\ %KPA)L1Q%=L'RMCP0UQ$_ M>V*C1B -8-V-(&.-1&%5MO>6VYAQ5 M*X3Z"FR]N>-
U04]X"F.^-(+Z3&'0]%<(IWGY>B1%9&V MX2](@;.@4>8O$E=E6#V0=R.P8I"D] %[*1J26QL(#B3.K<1C",/9O"+_ +9PZT&%G7N_^\B6L.O(K=^0\3YX[W[Z_ M^_/=%^?
3U]U:U^U1V;=4W("A^2FZ\X(-'Y$0<[OS;ICE 89RVAP_^+'<@;5R_*IY_EQ\^ M?OKT\=+Y],Z=5;8VNQ&70S\(_+'S20B[!)M=>CY9IP !{#9L=AN.JL 9"'NV MUXNRD.XK\P/=
[LTF]Z9:QU[?]M\E(F_=QL/L[F9>(2PS!!{!L@,PO.N?+KY] M/\[O#F9>ICSH)A+DM:*;G'X^/(Y,?__]_+Y,!T%K_Y_4$L! A0# M% @ [H)M607>1PV8" OSX T (-!
&5X7S"%\W,38T.34N:'1M4$L! A0#% M @ [H)M6?'V;5:Y5 FOL$ T (!$!D &5X7S"')T+3(P,C0P.3,P+GAS9%|+ 0(4 Q0 (M .Z";5E2[SD[FPT ,?, 5 " 8')T+3(P,C0P M.3,P7V-
A;"YX;6Q02P$"% ,4 " #N@FU9IJ(Q.T-0 POP8 %0 M @ %5'0$ =GAR="TR,#(T,#DS,%]D968N>&UL4$L! A0#% @ M[H)M68*H=]'3; G^<% !4 (!RVT! '9X7S$P<2YH=&U02P4& L
"P"Q @ L^@# end XML 79 vxrt20240930_10q_htm.xml IDEA: XBRL DOCUMENT 0000072444 2024-01-012024-09-30 0000072444 2024-11-06 0000072444 2024-09-30
0000072444 2023-12-31 0000072444 us-gaap:GovernmentContractMember 2024-09-30 0000072444 us-gaap:GovernmentContractMember 2023-12-31 0000072444
vxrt:NonCashRoyaltyRevenueMember 2024-07-012024-09-30 0000072444 vxrt:NonCashRoyaltyRevenueMember 2023-07-012023-09-30 0000072444
vxrt:NonCashRoyaltyRevenueMember 2024-01-012024-09-30 0000072444 vxrt:NonCashRoyaltyRevenueMember 2023-01-012023-09-30 0000072444 us-
gaap:GovernmentContractMember 2024-07-012024-09-30 0000072444 us-gaap:GovernmentContractMember 2023-07-012023-09-30 0000072444 us-
gaap:GovernmentContractMember 2024-01-012024-09-30 0000072444 us-gaap:GovernmentContractMember 2023-01-012023-09-30 0000072444 us-gaap:GrantMember 2024-
07-012024-09-30 0000072444 us-gaap:GrantMember 2023-07-012023-09-30 0000072444 us-gaap:GrantMember 2024-01-012024-09-30 0000072444 us-gaap:GrantMember
2023-01-012023-09-30 0000072444 2024-07-012024-09-30 0000072444 2023-07-012023-09-30 0000072444 2023-01-012023-09-30 0000072444
vxrt:CommonStockOutstandingMember 2024-06-30 0000072444 us-gaap:TreasuryStockCommonMember 2024-06-30 0000072444 us-gaap:AdditionalPaidInCapitalMember
2024-06-30 0000072444 us-gaap:RetainedEarningsMember 2024-06-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000072444 2024-
06-30 0000072444 vxrt:CommonStockOutstandingMembervxrt:June2024OfferingMember 2024-07-012024-09-30 0000072444 us-
gaap:TreasuryStockCommonMembervxrt:June2024OfferingMember 2024-07-012024-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:June2024OfferingMember 2024-07-012024-09-30 0000072444 us-gaap:RetainedEarningsMembervxrt:June2024OfferingMember
2024-07-012024-09-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMembervxrt:June2024OfferingMember 2024-07-012024-09-30 0000072444
vxrt:June2024OfferingMember 2024-07-012024-09-30 0000072444 vxrt:CommonStockOutstandingMember 2024-07-012024-09-30 0000072444 us-
gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000072444 us-
gaap:RetainedEarningsMember 2024-07-012024-09-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000072444
vxrt:CommonStockOutstandingMember 2024-09-30 0000072444 us-gaap:TreasuryStockCommonMember 2024-09-30 0000072444 us-gaap:AdditionalPaidInCapitalMember
2024-09-30 0000072444 us-gaap:RetainedEarningsMember 2024-09-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000072444
vxrt:CommonStockOutstandingMember 2023-12-31 0000072444 us-gaap:TreasuryStockCommonMember 2023-12-31 0000072444 us-gaap:AdditionalPaidInCapitalMember
2023-12-31 0000072444 us-gaap:RetainedEarningsMember 2023-12-31 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000072444
vxrt:September2021AtmMember 2024-01-012024-09-30 0000072444 vxrt:CommonStockOutstandingMembervxrt:September2021AtmMember 2024-01-012024-09-30
0000072444 us-gaap:TreasuryStockCommonMembervxrt:September2021AtmMember 2024-01-012024-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:September2021AtmMember 2024-01-012024-09-30 0000072444 us-gaap:RetainedEarningsMembervxrt:September2021AtmMember
2024-01-012024-09-30 0000072444 vxrt:RACapitalHealthcareFund2024Member 2024-01-012024-09-30 0000072444
vxrt:CommonStockOutstandingMembervxrt:RACapitalHealthcareFund2024Member 2024-01-012024-09-30 0000072444 us-
gaap:TreasuryStockCommonMembervxrt:RACapitalHealthcareFund2024Member 2024-01-012024-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:RACapitalHealthcareFund2024Member 2024-01-012024-09-30 0000072444 us-
gaap:RetainedEarningsMembervxrt:RACapitalHealthcareFund2024Member 2024-01-012024-09-30 0000072444 vxrt:June2024OfferingMember 2024-01-012024-09-30
0000072444 vxrt:CommonStockOutstandingMembervxrt:June2024OfferingMember 2024-01-012024-09-30 0000072444 us-
gaap:TreasuryStockCommonMembervxrt:June2024OfferingMember 2024-01-012024-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:June2024OfferingMember 2024-01-012024-09-30 0000072444 us-gaap:RetainedEarningsMembervxrt:June2024OfferingMember
2024-01-012024-09-30 0000072444 vxrt:CommonStockOutstandingMember 2024-01-012024-09-30 0000072444 us-gaap:TreasuryStockCommonMember 2024-01-012024-09-
30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000072444 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000072444 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000072444 vxrt:CommonStockOutstandingMember 2023-06-30 0000072444 us-
gaap:TreasuryStockCommonMember 2023-06-30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000072444 us-gaap:RetainedEarningsMember 2023-06-
30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000072444 2023-06-30 0000072444 vxrt:CommonStockOutstandingMember 2023-07-
012023-09-30 0000072444 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30
0000072444 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30
0000072444 vxrt:CommonStockOutstandingMember 2023-09-30 0000072444 us-gaap:TreasuryStockCommonMember 2023-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMember 2023-09-30 0000072444 us-gaap:RetainedEarningsMember 2023-09-30 0000072444 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000072444 2023-09-30 0000072444 vxrt:CommonStockOutstandingMember 2022-12-31 0000072444 us-
gaap:TreasuryStockCommonMember 2022-12-31 0000072444 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000072444 us-gaap:RetainedEarningsMember 2022-12-
31 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000072444 2022-12-31 0000072444 vxrt:September2021AtmMember 2023-01-012023-
09-30 0000072444 vxrt:CommonStockOutstandingMembervxrt:September2021AtmMember 2023-01-012023-09-30 0000072444 us-
gaap:TreasuryStockCommonMembervxrt:September2021AtmMember 2023-01-012023-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:September2021AtmMember 2023-01-012023-09-30 0000072444 us-gaap:RetainedEarningsMembervxrt:September2021AtmMember
2023-01-012023-09-30 0000072444 vxrt:The2023ShelfRegistrationMember 2023-01-012023-09-30 0000072444
vxrt:CommonStockOutstandingMembervxrt:The2023ShelfRegistrationMember 2023-01-012023-09-30 0000072444 us-
gaap:TreasuryStockCommonMembervxrt:The2023ShelfRegistrationMember 2023-01-012023-09-30 0000072444 us-
gaap:AdditionalPaidInCapitalMembervxrt:The2023ShelfRegistrationMember 2023-01-012023-09-30 0000072444 us-
gaap:RetainedEarningsMembervxrt:The2023ShelfRegistrationMember 2023-01-012023-09-30 0000072444 vxrt:CommonStockOutstandingMember 2023-01-012023-09-30
0000072444 us-gaap:TreasuryStockCommonMember 2023-01-012023-09-30 0000072444 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000072444 us-
gaap:RetainedEarningsMember 2023-01-012023-09-30 0000072444 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000072444
vxrt:June2024OfferingMember 2023-01-012023-09-30 0000072444 vxrt:RegisteredDirectOfferingMember 2024-01-012024-09-30 0000072444
vxrt:RegisteredDirectOfferingMember 2023-01-012023-09-30 0000072444 vxrt:AtthemarketFacilityMember 2024-01-012024-09-30 0000072444
vxrt:AtthemarketFacilityMember 2023-01-012023-09-30 0000072444 vxrt:RACapitalHealthcareFund2024Member 2023-01-012023-09-30 0000072444
vxrt:June2024OfferingMember 2024-06-012024-06-30 0000072444 vxrt:June2024OfferingMember 2024-06-30 0000072444 vxrt:RACapitalHealthcareFund2024Member 2024-
01-012024-01-31 0000072444 vxrt:RACapitalHealthcareFund2024Member 2024-01-31 0000072444 vxrt:TheSeptember2021AtmMember 2021-09-152021-09-15 0000072444
vxrt:TheSeptember2021AtmMember 2024-01-012024-09-30 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30
0000072444 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000072444 us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000072444 us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000072444 us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0000072444 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-09-30 0000072444 us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-09-
30 0000072444 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-09-30 0000072444 us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-09-30 0000072444 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-
30 0000072444 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31
0000072444 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0000072444 us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0000072444 us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0000072444 us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0000072444 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-
31 0000072444 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000072444 us-gaap:CashMember 2024-09-30 0000072444 us-gaap:MoneyMarketFundsMember 2024-09-30
0000072444 us-gaap:USTreasurySecuritiesMember 2024-09-30 0000072444 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-09-30
0000072444 us-gaap:CashMember 2023-12-31 0000072444 us-gaap:MoneyMarketFundsMember 2023-12-31 0000072444 us-gaap:USTreasurySecuritiesMember 2023-12-31
0000072444 us-gaap:RoyaltyMember 2024-09-30 0000072444 vxrt:BARDAMember 2024-09-30 0000072444 vxrt:BARDAMember 2023-12-31 0000072444
vxrt:LaboratoryEquipmentMember 2024-09-30 0000072444 vxrt:LaboratoryEquipmentMember 2023-12-31 0000072444 us-gaap:OfficeEquipmentMember 2024-09-30
0000072444 us-gaap:OfficeEquipmentMember 2023-12-31 0000072444 us-gaap:LeaseholdImprovementsMember 2024-09-30 0000072444 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0000072444 us-gaap:ConstructionInProgressMember 2024-09-30 0000072444 us-gaap:ConstructionInProgressMember
2023-12-31 0000072444 vxrt:FacilityInBurlingameCaliforniaMember 2023-12-31 0000072444 us-gaap:DevelopedTechnologyRightsMember 2024-01-012024-09-30
0000072444 us-gaap:IntellectualPropertyMember 2024-01-012024-09-30 0000072444 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000072444 us-
gaap:DevelopedTechnologyRightsMember 2023-12-31 0000072444 us-gaap:IntellectualPropertyMember 2024-09-30 0000072444 us-gaap:IntellectualPropertyMember 2023-
12-31 0000072444 us-gaap:RoyaltyMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember 2024-01-012024-09-30 0000072444
vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember 2024-07-012024-09-30 0000072444
vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember 2023-07-012023-09-30 0000072444
vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember 2024-01-012024-09-30 0000072444
vxrt:NonCashRoyaltyRevenueMembervxrt:DaiichiSankyoCollaborationAndLicenseAgreementMember 2023-01-012023-09-30 0000072444 us-gaap:ForeignCountryMemberus-

gaap:NationalTaxAgencyJapanMember 2024-01-012024-09-30 0000072444 us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember 2024-07-012024-09-30 0000072444 us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember 2023-07-012023-09-30 0000072444 us-gaap:ForeignCountryMemberus-gaap:NationalTaxAgencyJapanMember 2023-01-012023-09-30 0000072444 srt:MaximumMembervxrt:The2024AtirrpvContractMember 2024-09-30 0000072444 vxrt:The2024AtirrpvContractMember 2024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AtirrpvContractMember 2024-07-012024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AtirrpvContractMember 2024-01-012024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AtirrpvContractMember 2024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AtirrpvContractMember 2023-12-31 0000072444 vxrt:The2024AsprbardaContractMember 2024-01-12 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AsprbardaContractMember 2024-07-012024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AsprbardaContractMember 2024-01-012024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AsprbardaContractMember 2024-09-30 0000072444 us-gaap:GovernmentContractMembervxrt:The2024AsprbardaContractMember 2023-12-31 0000072444 us-gaap:GrantMember 2022-11-30 0000072444 vxrt:GrantMilestoneCompletionMember 2023-07-012023-07-31 0000072444 vxrt:HCRPMember 2016-04-012016-04-30 0000072444 vxrt:HCRPMembervxrt:RoyaltyPaymentInterestFirstPeriodMember 2016-04-30 0000072444 vxrt:HCRPMembervxrt:RoyaltyPaymentInterestSecondPeriodMember 2016-04-30 0000072444 vxrt:HCRPMember 2024-01-012024-09-30 0000072444 vxrt:HCRPMember 2023-01-012023-12-31 0000072444 vxrt:HealthcareRoyaltyIIHLPMemberus-gaap:RoyaltyArrangementMember 2023-12-31 0000072444 vxrt:HealthcareRoyaltyIIHLPMemberus-gaap:RoyaltyArrangementMember 2024-01-012024-09-30 0000072444 vxrt:HealthcareRoyaltyIIHLPMemberus-gaap:RoyaltyArrangementMember 2024-09-30 0000072444 vxrt:RightOfUseForOfficeAndManufacturingFacilitiesWithInitialTermsExceedingOneYearMember 2024-09-30 0000072444 vxrt:LeaseForFacilityInSouthSanFranciscoCommencedInThirdQuarterOf2022Member 2021-09-30 0000072444 vxrt:LeaseForFacilityInSouthSanFranciscoCommencedInFirstQuarterOf2023Member 2021-09-30 0000072444 vxrt:HimmelbergVVaxartIncEtAlMember 2022-07-272022-07-27 0000072444 vxrt:HimmelbergVVaxartIncEtAlMember 2022-11-022022-11-02 0000072444 2022-08-042022-08-04 0000072444 2024-03-31 0000072444 2024-06-11 0000072444 vxrt:June2024OfferingMember 2024-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2024-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2023-12-31 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000072444 vxrt:The2019PlanMember 2024-09-30 0000072444 vxrt:The2019PlanMember 2023-12-31 0000072444 vxrt:The2024InducementAwardPlanMember 2024-09-30 0000072444 vxrt:The2024InducementAwardPlanMember 2023-12-31 0000072444 vxrt:CommonWarrantsMember 2024-09-30 0000072444 vxrt:CommonWarrantsMember 2023-12-31 0000072444 vxrt:ESPPMember 2024-09-30 0000072444 vxrt:ESPPMember 2023-12-31 0000072444 2024-04-012024-04-30 0000072444 vxrt:FirstSetOfWarrantsExpiringApril2024Member 2024-09-30 0000072444 vxrt:SecondSetOfWarrantsExpiringApril2024Member 2024-09-30 0000072444 vxrt:WarrantsExpiringMarch2025Member 2024-09-30 0000072444 vxrt:WarrantsExpiringFebruary2025Member 2024-09-30 0000072444 vxrt:The2019PlanMember 2019-04-23 0000072444 vxrt:The2019PlanMember 2020-06-08 0000072444 vxrt:The2019PlanMember 2021-06-16 0000072444 vxrt:The2019PlanMember 2022-08-04 0000072444 vxrt:The2019PlanMember 2024-06-11 0000072444 vxrt:The2024InducementAwardPlanMember 2024-02-27 0000072444 vxrt:The2024InducementAwardPlanMember 2024-01-012024-09-30 0000072444 vxrt:The2019PlanMember 2024-01-012024-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000072444 srt:MinimumMembervxrt-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000072444 srt:MaximumMembervxrt-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000072444 srt:MinimumMembervxrt-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000072444 srt:MaximumMembervxrt-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000072444 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000072444 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0000072444 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0000072444 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0000072444 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0000072444 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0000072444 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0000072444 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0000072444 vxrt:The2022EsppMember 2022-08-04 0000072444 vxrt:The2022EsppMember 2024-06-11 0000072444 vxrt:The2022EsppMember 2024-01-012024-09-30 0000072444 vxrt:The2022EsppMember 2024-09-30 0000072444 vxrt:The2022EsppMemberus-gaap:SubsequentEventMember 2024-11-30 0000072444 vxrt:The2022EsppMember 2024-05-31 0000072444 vxrt:The2022EsppMember 2023-11-30 0000072444 vxrt:The2022EsppMember 2023-05-31 0000072444 vxrt:The2022EsppMember 2024-07-012024-11-30 0000072444 vxrt:The2022EsppMember 2023-12-012024-05-31 0000072444 vxrt:The2022EsppMember 2023-06-012023-11-30 0000072444 vxrt:The2022EsppMember 2022-12-012023-05-31 0000072444 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000072444 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000072444 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0000072444 us-gaap:WarrantMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0000072444 us-gaap:WarrantMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0000072444 us-gaap:WarrantMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000072444 us-gaap:WarrantMemberus-gaap:CommonStockMember 2023-01-012023-09-30 0000072444 vxrt:EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0000072444 vxrt:EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0000072444 vxrt:EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0000072444 vxrt:EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0000072444 vxrt:TheSeptember2021AtmMember 2021-09-152024-10-18 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y0000072444Vaxart, Inc.false--12-31Q32024 0.00010.000150000005000000000.00010.000135000000025000000022817644622747632415395985315345283370012250702024800055000245500010300028400010010006Qtrue2024-09-30false001-35285DE59-1212264170 Harbor Way, Suite 300South San FranciscoCA94080650550-3500Common Stock, $0.0001 par valueVXRTNASDAQYesYesNon-accelerated Filertruefalsefalse22747981122035000347550003667600049580005910003008000308500004069000281500066456000455360009476000117310006011600002153600024846464537000-40957400027000-100068442000578050001666740009183000040000446000662000754000489300001285300000165500003380000493300021010001351500041340001506600015002000515551475000-17822000-54801000-66447000102200072300019410002076000631000207000204500057300022000-5500026000-59000-14062000-17361000-54879000-65003000180003900084000087000-14080000-17400000-54963000-65090000-0.06-0.11-0.28-0.4522745288315202611219365566014581017 5-14080000-17400000-54963000-65090000430001300028000288000-14037000-17387000-54935000-64802000228119936230000-688331-56500053102900 0-450457000-16000800014000-0-010000-0-0100001105000090000090004546000000000-0-0117919000-0-0-0900000247500002475000000043000430000000-140800000-140800000228176446230000-700122-574000533503000-46453700027000684420001539598531500 0-507020-3660004677310 00-409574000-1000578050007719641100000880100008802000153846152000009943000099450005000000500000375400000375450003803000030000003000050242300031200000312000 0-0-019310220800 0-0-0-0208000000028000280000000-549630000-549630000228176446230000-700122-574000533503000-46453700027000684420001520162381500 0-33246-310004599120 00-374799000-240008507300064958000000001059280000-0-0-0800000384300003843000000013000130000000-174000000-174000000152081196150 00-43838-390004637550 00-392199000-110007152100013419942913000004379920 00-327109000-299000110597000136222010000014290000143000016000000100 0-13602000136030005472000017000001700030106100029800002980001637660000000-0-0438383900-0-0-0390000010417000010417000000028800028800000 0-650900000-650900001520811961500 0-43838-390004637550 00-392199000-110007152100 0-54963000-650900000661400062930 00-0-550004730005100009146000104170002045000573000359600031400 0-241700040400030850000-01170000-27600006011600 0-0940000-26990000-192100065447000 0-625000-60920 00-37419000-569320005100001975000012000048717000274970001750000058200000-317270002884800037545000001360300088020001430000994500003000017000208000390003120002980005642600015309000-12720000-127750003475500046013000220350003323800022035000331590000790002203500033238000029600087000140 00 NOTE 1. Organization and Nature of Business   General   Vaxart Biosciences, Inc. was originally incorporated in California in March 2004, under the name West Coast Biologicals, Inc. The Company changed its name to Vaxart, Inc. (“Private Vaxart”) in July 2007, and reincorporated in the state of Delaware. In February 2018, Private Vaxart completed a business combination with Aviragen Therapeutics, Inc. (“Aviragen”), pursuant to which Aviragen merged with Private Vaxart, with Private Vaxart surviving as a wholly-owned subsidiary of Aviragen (the “Merger”). Pursuant to the terms of the Merger, Aviragen changed its name to Vaxart, Inc. (together with its subsidiaries, the “Company” or “Vaxart”) and Private Vaxart changed its name to Vaxart Biosciences, Inc.   In June 2024, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by the Company in an underwritten registered direct offering of 50,000,000 shares of the Company’s common stock, at a price of $0.80 per share. The gross proceeds to the Company from such offering were $40.0 million, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds were $37.5 million.   In January 2024, the Company entered into a securities purchase agreement (the “2024 Securities Purchase Agreement”) with RA Capital Healthcare Fund, L.P. pursuant to which 15,384,615 shares of the Company’s common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65 per share pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-270671) (the “2023 Shelf Registration”). The gross proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, the net proceeds were $9.9 million.   In September 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “September 2021 ATM”), pursuant to which it may offer and sell, from time to time through Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (together, the “sales agents”), shares of its common stock having an aggregate offering price of up to $100 million. The Company filed a prospectus supplement with the SEC on September 16, 2021, a subsequent prospectus supplement with the SEC on May 9, 2023 and paid sales commissions of up to 3.0% of gross proceeds from the sale of shares. In the nine months ended September 30, 2024, 7,719,641 shares were issued and sold under the September 2021 ATM for gross proceeds of $9.1 million, which, after deducting sales commissions and expenses incurred to date, resulted in net proceeds of $8.8 million. Since September 30, 2024, the Company has not raised any additional capital under the September 2021 ATM. Effective October 18, 2024, the September 2021 ATM was terminated as further detailed in Note 12.   The Company’s principal operations are based in South San Francisco, California, and it operates in one reportable segment, which is the discovery and development of oral recombinant protein vaccines, based on its proprietary oral vaccine platform. 500000000.840000000037500000153846150.651000000009900000100000000.037719641910000088000000 NOTE 2. Summary of Significant Accounting Policies   Basis of Presentation, Liquidity and Going Concern - The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the SEC assuming the Company will continue as a going concern.   The Company is a clinical-stage biotechnology company with no product sales. Its primary source of capital is

from the sale and issuance of common stock and common stock warrants as well as funding from the Biomedical Advanced Research and Development Authority ("HHS BARDA"), a division of the Administration for Strategic Preparedness and Response ("ASPR") within the United States ("U.S.") Department of Health and Human Services. As of September 30, 2024, the Company had cash, cash equivalents and short-term investments of $58.7 million.   Based on management's current plan, the Company expects to have cash runway into 2026. The Company will be dependent upon raising additional capital through placement of its common stock, notes or other securities, borrowings, or entering into a partnership with a strategic party in order to implement its business plan. There can be no assurance that the Company will be successful raising additional capital in order to continue as a going concern.   The condensed consolidated balance sheet as of December 31, 2023, included in this document, was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to these rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and footnotes related thereto for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2024 (the "Annual Report"). Unless noted below, there have been no material changes to the Company's significant accounting policies described in Note 2 to the consolidated financial statements included in the Annual Report. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year or any future periods.   Basis of Consolidation - The unaudited condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation.   Use of Estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.   Concentration of Credit Risk - Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.   The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating.   Revenue Recognition   Revenue from Government Contracts   Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned ("firm fixed-price milestone"). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned ("cost-plus-fixed-fee"). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed, as detailed in Note 5.   Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.   Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not yet effective and concluded that they are either not applicable to its operations or their adoption is not expected to have a material impact on its financial position or results of operations. 58700000 Basis of Consolidation - The unaudited condensed consolidated financial statements include the financial statements of Vaxart, Inc. and its subsidiaries. All significant transactions and balances between Vaxart, Inc. and its subsidiaries have been eliminated in consolidation.   Use of Estimates - The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.   Concentration of Credit Risk - Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.   The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating.   Revenue Recognition   Revenue from Government Contracts   Under firm fixed-price milestone contracts, the Company recognizes the firm fixed-price revenue as the milestones are substantially complete and the firm fixed-price for the milestone is earned ("firm fixed-price milestone"). Under cost reimbursable contracts, the Company recognizes revenue as allowable costs are incurred and the fixed fee is earned ("cost-plus-fixed-fee"). Reimbursable costs under the contract primarily include direct labor, subcontract costs, materials, equipment, travel, and approved overhead and indirect costs. Fixed fees under cost reimbursable contracts are earned in proportion to the allowable costs incurred in performance of the work relative to total estimated contract costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed, as detailed in Note 5.   Payments to the Company under cost reimbursable contracts are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited has been recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.   Recent Accounting Pronouncements The Company has reviewed all significant newly-issued accounting pronouncements that are not yet effective and concluded that they are either not applicable to its operations or their adoption is not expected to have a material impact on its financial position or results of operations. NOTE 3. Fair Value of Financial Instruments   Fair value accounting is applied for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring basis (at least annually). Financial instruments include cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued liabilities that approximate fair value due to their relatively short maturities.   Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable

inputs reflect market assumptions made by the reporting entity.   The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;   Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and   Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.   The following table sets forth the fair value of the Company's financial assets that are measured on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Financial assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Money market funds </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Commercial paper </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,234</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-

align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Financial assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Money market funds </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury securities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The Company held no financial liabilities measured on a recurring basis as of September 30, 2024 or December 31, 2023.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times,

serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial assets:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,361</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
185580000018558000034019000034019000026570000265700018558000366760000552340003140300000314030000495800004958000031403000495800003636100000 NOTE 4. Balance Sheet Components   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (a) </td><td style="vertical-align:top;"> Cash, Cash Equivalents and Investments </td></tr> </tbody></table>   Cash, cash equivalents and investments consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Amortized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">Gross Unrealized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Estimated</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Cash and Cash</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Short-Term</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gains </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Losses </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Equivalents </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investments </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash at banks </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury securities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Commercial paper</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,652</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,684</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,711</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,035</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Amortized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">Gross Unrealized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Estimated</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Cash and Cash</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Short-Term</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gains </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-

align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Losses </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Equivalents </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investments </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Cash at banks </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury securities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,714</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,713</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New

Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> As of September 30, 2024 and December 31, 2023, all investments were available-for-sale debt securities with remaining maturities of 12 months or less.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (b) </td><td style="vertical-align:top;"> Accounts Receivable </td></tr> </tbody></table>   Accounts receivable consists of $0.55 million of government contract receivables from HHS BARDA, and $40,000 royalty receivable totaling $0.59 million as of September 30, 2024 and a total of $3.0 million of accounts receivable for royalties as of December 31, 2023. For further information on HHS BARDA receivables, see Note 5.   An allowance for expected credit losses over the life of the receivables is reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. The Company has provided no allowance for credit losses as of September 30, 2024 and December 31, 2023.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (c) </td><td style="vertical-align:top;"> Unbilled Receivable from Government Contracts </td></tr> </tbody></table>   Unbilled receivable, which was earned and not yet billed, consists of government contracts from HHS BARDA of $3.1 million and zero as of September 30, 2024 and December 31, 2023, respectively, as detailed in Note 5.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;vertical-align:top;"> (d) </td><td style="vertical-align:top;"> Prepaid Expenses and Other Current Assets </td></tr> </tbody></table>   Prepaid expenses and other current assets consist of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Laboratory equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,714</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,448</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Office and computer equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,985</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Construction in progress </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,064</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,562</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated depreciation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,588</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,831</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,476</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Depreciation expense was $1.0 million for each of the three months ended September 30, 2024 and 2023, and $2.8 million for each of the nine months ended September 30, 2024 and 2023. There were no impairments of the Company's property and equipment recorded in the three and nine months ended September 30, 2024 or 2023.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (f) </td><td style="vertical-align:top;"> Prepaid Clinical Services, Long-Term </td></tr> </tbody></table>   Prepaid clinical services, long-term were $60.1 million and zero as of September 30, 2024 and December 31, 2023, respectively. The long-term prepaid clinical services represent amounts the Company has paid to clinical research organizations that will be utilized in over one year.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (g) </td><td style="vertical-align:top;"> Right-of-Use Assets, Net </td></tr> </tbody></table>   Right-of-use assets, net are comprised of facilities of $21.5 million and $24.8 million as of September 30, 2024 and December 31, 2023, respectively. The right-of-use of additional leased premises in California commenced in 2023, resulting in an additional $3.1 million right-of-use assets recorded in the year ended <em style="font: inherit;"> December 31, 2023.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> <p style="font-family: "Times New Roman", Times, serif; margin: 0pt; text-align: left; font-size: 10pt;"><i>(h)</i></p> </td><td style="vertical-align:top;"> <p style="font-family: "Times New Roman", Times, serif; margin: 0pt; font-size: 10pt;"><i>Intangible Assets, Net</i></p> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Intangible assets are comprised of developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. As of <em style="font: inherit;"> September 30, 2024, developed technology and intellectual property had remaining lives of 5.1 years and 3.3 years, respectively. As of <em style="font: inherit;"> September <em style="font: inherit;">30, <em style="font: inherit;">2024, there have been <em style="font: inherit;">no indicators of impairment. Intangible assets consist of the following (in thousands):</p> <p style="margin: 0pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> Intellectual property </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(791</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Intangible assets, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,289</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Intangible asset amortization expense was $0.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.5 million for each of the <em style="font: inherit;">nine months ended <em style="font: inherit;"> September <em style="font: inherit;">30, <em style="font: inherit;">2024 and <em style="font: inherit;">2023.</p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;">As of <em style="font: inherit;"> September 30, 2024, the estimated future amortization expense by year is as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year Ending December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Amount</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (three months remaining)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">182</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">732</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">727</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">637</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (i) </td><td style="vertical-align:top;"> Goodwill </td></tr> </tbody></table>   Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, was $4.5 million as of both September 30, 2024 and December 31, 2023. As of September 30, 2024, there have been no indicators of impairment.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (j) </td><td style="vertical-align:top;"> Deferred Government Revenue </td></tr> </tbody></table>   Deferred government revenue represents amounts received from HHS BARDA contracts where the earnings process is not yet complete. The Company will recognize deferred government revenue once the earnings process is complete. Deferred government revenue was $65.4 million and zero as of September 30, 2024 and December 31 2023, respectively.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (k) </td><td style="vertical-align:top;"> Other Accrued Current Liabilities </td></tr> </tbody></table>   Other accrued current liabilities consist of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif;

font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Accrued compensation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued clinical and manufacturing expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,309</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">312</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued professional and consulting services </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">371</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">211</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other liabilities, current portion </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">535</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,764</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Amortized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">Gross Unrealized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Estimated</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Cash and Cash</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Short-Term</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gains </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Losses </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Equivalents </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investments </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash at banks </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-

left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,477</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Money market funds </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,558</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">33,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Commercial paper </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,652</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,657</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,684</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,711</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,035</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,676</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Amortized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">Gross Unrealized</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Estimated</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Cash and Cash</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Short-Term</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gains </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-

align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Losses </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Equivalents </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investments </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Cash at banks </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,352</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Money market funds </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">31,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> U.S. Treasury securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,714</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,713</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,958</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

3477000347700034770001855800018558000185580003399700022000-0340190000340190002652000500-0265700002657000586840002700005871100022035000366760003352000335200033520003314030003140300031403000495900010004958000495800039714000100039713000347550004958000550000400005<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Prepaid clinical and manufacturing expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,637</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">984</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid insurance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">258</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid rent </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">517</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other prepaid </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">988</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">333</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses and other current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,069</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,815</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table>
16370009840004880002580005170004880009880007520004390003330004069000028150000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Laboratory equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,714</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,448</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Office and computer equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Leasehold improvements </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,985</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Construction in progress </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">141</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total property and equipment </td><td style="width: 1%; font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,064</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,562</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated depreciation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,588</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,831</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,476</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr>
</tbody></table>
13714000134480001120000110500040890000398500014100024000190640001856200095880006831000947600011731000100000028000000601000000215000002480000031(
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Developed technology </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Intellectual property </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: accumulated amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(791</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Intangible assets, net </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,289</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr>
</tbody></table>5000000500000080000800005080000508000013400007910003740000428900010000020000050000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;">
<tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 (three months remaining) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">182</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">732</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">731</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">727</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">637</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,740</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 18200073200073100073100072700063700037400006540000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical and manufacturing expenses</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,309</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">312</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued professional and consulting services</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">371</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">211</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other liabilities, current portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">535</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,764</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,634</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 45110004576000130900031200037100021100057300053500067640005634000 NOTE 5. Revenue   Royalty Revenue Related to Sale of Future Royalties   The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir in Japan. Based on information provided by Daiichi Sankyo, the Company believes the expiration of the last patent related to Inavir is in August 2036, at which time royalty revenue will cease. The Company’s royalty revenue is seasonal, in line with the flu season, so the majority of the Company’s royalty revenue and non-cash royalty revenue related to the sale of future royalties are earned in the first and fourth fiscal quarters. The royalty revenue related to Inavir recognized for the nine months ended September 30, 2024 and 2023, was zero. The Company recognized non-cash royalty revenue related to the sale of future royalties of $40,000 and $0.4 million for the three months ended September 30, 2024 and 2023, respectively, and $0.7 million and $0.8 million for the nine months ended September 30, 2024 and 2023, respectively. Both royalty revenue and the non-cash royalty revenue related to the sale of future royalties are subject to a 5% withholding tax in Japan, for which $2,000 and $23,000 was included in income tax expense for the three months ended September 30, 2024 and 2023, respectively, and $33,000 and $38,000 for the nine months ended September 30, 2024 and 2023, respectively, further detailed in Note 6.   Revenue from Government Contracts   The Company recognized revenue from government contracts with HHS BARDA of $4.9 million and $12.9 million for the three and nine months ended September 30, 2024, respectively, consisting of revenues from the 2024 ASPR-BARDA Contract (as defined below) and the 2024 ATI-RRPV Contract (as defined below) described in more detail below. Unbilled receivable from government contracts consists of government revenue from HHS BARDA, which was earned and not yet billed. As of September 30, 2024, the amount of unbilled receivable was $3.1 million and deferred revenue was $65.4 million.   2024 ATI-RRPV Contract   In June 2024, the Company entered into an agreement (as modified, the “2024 ATI-RRPV Contract”) with Advanced Technology International, the Rapid Response Partnership Vehicle’s Consortium Management Firm funded by HHS BARDA, which was modified in September 2024 to increase funding and provide for the manufacturing of a vaccine candidate targeting the KP.2 strain. Pursuant to the 2024 ATI-RRPV Contract, the Company will receive funding of up to $456.1 million to conduct a Phase 2b comparative study evaluating the Company’s oral pill COVID-19 vaccine candidate against an mRNA vaccine comparator approved by the U.S. Food and Drug Administration and manufacture a COVID-19 vaccine candidate targeting the KP.2 strain. The 2024 ATI-RRPV Contract currently makes available an aggregate amount of up to $96.5 million, consisting of fixed fee amounts totaling $67.9 million and reimbursement of costs incurred in trial preparation and execution activities. The 2024 ATI-RRPV Contract further contemplates additional funding up to $359.6 million if the Company and HHS BARDA decide to continue with the Phase 2b comparative study. The Company accounts for the 2024 ATI-RRPV Contract under Accounting Standards Codification 958-605 and recognizes revenue as the firm fixed-price milestone is earned and allowable cost-plus-fixed-fees are incurred. Reimbursable costs under the 2024 ATI-RRPV Contract primarily include direct labor, subcontract costs, materials, travel, and approved overhead and indirect costs. The 2024 ATI-RRPV Contract contains terms and conditions that are customary for contracts with HHS BARDA of this nature, including the U.S. government having the right to terminate the contract for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. Revenue from government contracts recognized on the 2024 ATI-RRPV Contract was $4.0 million for the three months ended September 30, 2024 and $4.2 million for the nine months ended September 30, 2024, based on costs incurred and the achievement of a firm fixed-price milestone under the 2024 ATI-RRPV Contract. Deferred government revenue represents

amounts that have been received from HHS BARDA and the earnings process is not yet complete. Deferred government revenue in current liabilities was $64.8 million and zero as of September 30, 2024 and December 31, 2023, respectively.   Management believes that if the 2024 ATI-RRPV Contract were to be terminated prior to completion of the Phase 2b comparative study, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Cost reimbursement payments to the Company are provisional payments subject to adjustment upon annual audit by the government. Management believes that revenue for periods not yet audited will be recorded in amounts that are expected to be realized upon final audit and settlement. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly in the period that the adjustment is known.   2024 ASPR-BARDA Contract   In January 2024, the Company was awarded a contract (as amended, the "2024 ASPR-BARDA Contract") by HHS BARDA with a base and all options value of $9.3 million. Under the 2024 ASPR-BARDA Contract, the Company received an award to support clinical trial planning activities for a Phase 2b clinical trial that would compare the Company's XBB vaccine candidate to an mRNA comparator to evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. The 2024 ASPR-BARDA Contract originally had a period of performance term that was set to expire in July 2024, but the Company entered into an amendment in July 2024 that extended the period of performance expiration date into October 2024. The Company accounts for the 2024 ASPR-BARDA Contract under Accounting Standards Codification 958-605 and recognizes revenue as donor-imposed conditions are met. Revenue from government contracts recognized on the 2024 ASPR-BARDA Contract was $0.9 million and $8.7 million for the three and nine months ended September 30, 2024, respectively, based on the achievement of certain milestones under the 2024 ASPR-BARDA Contract. Deferred government revenue represents amounts that have been received from HHS BARDA and the earnings process is not yet complete. Deferred government revenue in current liabilities was $0.6 million and zero as of September 30, 2024 and December 31, 2023, respectively.   Grant Revenue   In November 2022, the Company accepted a $3.5 million grant to perform research and development work for the Bill & Melinda Gates Foundation (the "BMGF Grant") and received $2.0 million in advance that was recorded as restricted cash and deferred revenue. The Company received an additional $1.5 million in July 2023 upon completion of certain milestones. The Company recognizes revenue under research contracts only when a contract is executed and the contract price is fixed or determinable. Revenue from the BMGF Grant was recognized in the period during which the related costs were incurred and the related services rendered, as the applicable conditions under the contract were met. Costs of contract revenue were recorded as a component of operating expenses in the condensed consolidated statements of operations and comprehensive loss. The Company recognized revenue from the BMGF Grant of zero and $1.7 million for the three months ended September 30, 2024 and 2023, respectively, and zero and $3.4 million for the nine months ended September 30, 2024 and 2023, respectively. The Company fully recognized revenue from the BMGF Grant during the year ended December 31, 2023.   0.044000040000070000080000000.052000230003300038000490000012900000310000065400000456100000965000006790000035960000040000004200000648000000930000(
NOTE 6. Liabilities Related to Sale of Future Royalties   In April 2016, Aviragen entered into a Royalty Interest Acquisition Agreement (the "RIAA") with HealthCare Royalty Partners III, L.P. ("HCRP"). Under the RIAA, HCRP made a $20.0 million cash payment to Aviragen in consideration for acquiring certain royalty rights ("Royalty Rights") related to the approved product Inavir in the Japanese market. The Royalty Rights were obtained pursuant to the collaboration and license agreements (the "License Agreement") and a commercialization agreement that the Company entered into with Daiichi Sankyo. Per the terms of the RIAA, during the first royalty interest period of April 1, 2016 through March 31, 2025, HCRP is entitled to the first $3.0 million and any cumulative remaining shortfall amount plus 15% of the next $1.0 million in royalties earned in each year commencing on April 1, with any excess revenue being retained by the Company. Further, during the second royalty interest period beginning April 1, 2025 and ending on December 24, 2029, HCRP is entitled to the first $2.7 million and any cumulative remaining shortfall amount, plus 15% of the next $1.0 million in royalties, with any excess revenue being retained by the Company. A shortfall occurs when, during an annual period ending on March 31st, for the first royalty interest period of April 1, 2016 through March 31, 2025, the Company's royalty payments fall below $3.0 million; and $2.7 million for the second royalty interest period of April 1, 2025 and ending on December 24, 2029, excluding the period of April 1, 2028 through December 24, 2029. In the event there shall remain any cumulative remaining shortfall amount as of December 24, 2029, any royalties received from Daiichi Sankyo subsequently by the Company would be payable to HCRP until the cumulative remaining shortfall amount has been paid.   For avoidance of doubt, the RIAA states, in the event there is a remaining cumulative remaining shortfall amount as of December 24, 2029, the Company shall not be obligated to pay HCRP any royalty payment beyond what the Company is paid from Daiichi Sankyo. The cumulative remaining shortfall amount is the aggregate amount of the remaining shortfall for each annual period, which was $6.0 million and $7.0 million as of <em style="font: inherit;"> September <em style="font: inherit;">30, <em style="font: inherit;">2024 and <em style="font: inherit;"> December 31, 2023, respectively.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; margin: 0pt 7.2pt 0pt -2pt;">Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the RIAA, this transaction was accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. The Company has <em style="font: inherit;">no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. To record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement and the payments that will be passed through to HCRP over the life of this agreement. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The royalties earned in each period that will be passed through to HCRP are recorded as non-cash royalty revenue related to sale of future royalties, with any excess <em style="font: inherit;">not subject to pass-through being recorded as royalty revenue. When the pass-through royalties are paid to HCRP in the following quarter, the imputed liability related to sale of future royalties is commensurately reduced. The Company periodically assesses the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company adjusts the amortization of the liability and interest rate. As a result of this accounting, even though the Company does <em style="font: inherit;">not retain HCRP's share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability, including the related interest, is fully amortized.</p> <p style="font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">The following table shows the activity within the liability account during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, <em style="font: inherit;">2024 (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liability related to sale of future royalties, start of period</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,426</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-cash royalty revenue paid to HCRP </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-cash interest expense recognized </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,045</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total liability related to sale of future royalties, end of period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,875</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current portion </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,747</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Long-term portion </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   2000000030000000.151000000270000000.151000000300000027000006000000700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr

style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Total liability related to sale of future royalties, start of period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,426</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-cash royalty revenue paid to HCRP</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-cash interest expense recognized</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,045</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total liability related to sale of future royalties, end of period</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,875</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,747</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Long-term portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 64260003596000204500048750002747000212800 0 NOTE 7. Leases   The Company has obtained the right of use for office and manufacturing facilities under six operating lease agreements with initial terms exceeding one year. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise.   In September 2021, the Company executed a lease for a facility in South San Francisco, California, with an initial term expiring on March 31, 2029. This lease has two separate components, one commenced in the third quarter of 2022 and the other in the first quarter of 2023, resulting in an additional right of use asset of $15.0 million and $3.1 million, respectively.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">As of <em style="font: inherit;"> September 30, 2024, the weighted average discount rate for operating leases with initial terms of more than <em style="font: inherit;">one year was 9.8% and the weighted average remaining term of these leases was 4.4 years. Discount rates were determined using the Company's marginal rate of borrowing at the time each lease was executed or extended.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">The following table summarizes the Company's undiscounted cash payment obligations for its operating lease liabilities with initial terms of more than <em style="font: inherit;">12 months as of <em style="font: inherit;"> September 30, 2024 (in thousands):</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year Ending December 31, </p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 (three months remaining)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,031</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,207</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,348</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Undiscounted total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: imputed interest </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,393</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Present value of future minimum payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current portion of operating lease liability </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,882</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease liability, net of current portion </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,319</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The Company is also required to pay for operating expenses related to the leased space. The operating expenses are incurred separately and were not included in the present value of lease payments. Operating lease expenses for the three and nine months ended September 30, 2024 and 2023 are summarized as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr

class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Lease cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,554</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,554</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,661</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,617</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Short-term lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Variable lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">459</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,401</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Sublease income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,040</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,017</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,059</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   1500000031000000.098P4Y4M24D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255,

255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 (three months remaining) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,511</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,031</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,207</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,389</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,348</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Undiscounted total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,393</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Present value of future minimum payments</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current portion of operating lease liability</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,882</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease liability, net of current portion</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,319</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
110800045110005031000520700053890001348000225940004393000182010002882000153190000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Lease cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Variable lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">459</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,381</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,401</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Sublease income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,040</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,017</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,059</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 155400015540004661000461700010000100002900041000496000459000138100014010002000-054000-020400002023006017000605900 0 NOTE 8. Commitments and Contingencies   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (a) </td><td style="vertical-align:top;"> Purchase Commitments </td></tr> </tbody></table>   As of September 30, 2024, the Company had approximately $8.5 million of non-cancelable purchase commitments, principally for contract manufacturing and clinical services which are expected to be paid within the next year. In addition, the Company has operating lease commitments as detailed in Note 7.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (b) </td><td style="vertical-align:top;"> Indemnifications </td></tr> </tbody></table>   In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with certain officers and directors which provide, among other things, that the Company will indemnify and advance expenses incurred in connection with certain actions, suits or proceedings to such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and the Company's Bylaws. The Company currently has directors' and officers' insurance.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (c) </td><td style="vertical-align:top;"> Litigation </td></tr> </tbody></table>   From time to time the Company may be involved in legal proceedings arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it in excess of established reserves, in the aggregate, is indeterminable to its consolidated financial condition or cash flows. However, any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of management's attention and resources that are needed to run the Company successfully, and could have a material adverse impact on its business, financial condition and results of operations.   In August and September 2020, two substantially similar securities class actions were filed in the U.S. District Court for the Northern District of California. The first action, titled Himmelberg v. Vaxart, Inc. et al. was filed on August 24, 2020. The second action, titled Hovhannisyan v. Vaxart, Inc. et al. was filed on September 1, 2020 (together, the "Putative Class Action"). By Order dated September 17, 2020, the two actions were deemed related. On December 9, 2020, the court appointed lead plaintiffs and lead plaintiffs' counsel.   On January 29, 2021, lead plaintiffs filed their consolidated amended complaint. On July 8, 2021, all defendants moved to dismiss the consolidated amended complaint. On May 14, 2021, the court granted lead plaintiffs' request to amend the consolidated amended complaint and denied defendants' motions to dismiss as moot. On June 10, 2021, lead plaintiffs filed a first amended consolidated complaint, and on August 9, 2021, lead plaintiffs filed a corrected first amended consolidated complaint. The first amended consolidated complaint, as corrected, named certain of Vaxart's current and former executive officers and directors, as well as Armistice Capital, LLC ("Armistice"), as defendants. It claimed three violations of federal civil securities laws; violation of Section 10(b) of the Exchange Act and SEC Rule 10b-5, as against the Company and all individual defendants; violation of Section 20(a) of the Exchange Act, as against Armistice and all individual defendants; and violation of Section 20A of the Exchange Act against Armistice. The first amended consolidated complaint, as corrected, alleged that the defendants violated securities laws by misstating and/or omitting information regarding the Company's development of a norovirus vaccine, the vaccine manufacturing capabilities of a business counterparty, and the Company's involvement with Operation Warp Speed ("OWS"); and by engaging in a scheme to inflate Vaxart's stock price. The first amended consolidated complaint sought certification as a class action for similarly situated shareholders and sought, among other things, an unspecified amount of damages and attorneys' fees and costs. On July 8, 2021, all defendants moved to dismiss the first amended consolidated complaint. By Order dated December 22, 2021, the court granted the motion to dismiss by Armistice with leave to amend and otherwise denied the motions to dismiss. On July 27, 2022, lead plaintiffs filed a notice announcing that they had reached a partial settlement (the "Partial Settlement") to resolve all claims against the Company and its current or former officers and/or directors in their capacity as officers and/or directors of the Company (the "Settling Defendants"). Pursuant to the Partial Settlement, the Company agreed to a settlement amount of $12.0 million with $2.0 million to be paid by the Company and the remainder to be paid by the Company's insurers. On November 2, 2022, the Company paid the $2.0 million settlement amount with respect to the Putative Class Action pursuant to the terms of the settlement agreement reached in that case. On November 14, 2022, lead plaintiffs filed a second amended consolidated class action complaint that purported to include new allegations to support claims against Armistice. By Orders dated January 25, 2023, the court approved the Partial Settlement and entered judgment dismissing with prejudice all claims asserted in the Putative Class Action against the Settling Defendants. <p style="font-family:'Times New

Roman';font-size:10pt;font-variant:normal;margin:0pt;"> On October 23, 2020, a complaint was filed in the U.S. District Court for the Southern District of New York, entitled Roth v. Armistice Capital LLC, et al. The complaint names Armistice and certain Armistice-related parties as defendants, asserting a violation of Exchange Act Section 16(b) and seeking the disgorgement of short-swing profits. The complaint purports to bring the lawsuit on behalf of and for the benefit of the Company and names the Company as a "nominal defendant" for whose benefit damages are sought. Following discovery, a motion for summary judgment was filed by Armistice and the Armistice-related party defendants to dismiss the complaint. On March 27, 2024, the court granted the motion for summary judgment and dismissed all claims in the complaint in their entirety. On April 11, 2024, the Plaintiff timely filed a notice of appeal of the court's decision to the Second Circuit Court of Appeals, commencing appellate proceedings. In June 2024, Plaintiff filed a motion to the court of appeals to stay the appeal pending efforts to re-instate the complaint in the district court, which was granted by the court of appeals. In July 2024, Plaintiff filed a motion with the district court seeking to set aside the judgment and to re-instate the complaint. On August 15, 2024, the district court denied Plaintiff's motion to set aside the judgment. On September 10, 2024, Plaintiff re-filed its appeal with the Second Circuit Court of Appeals, which is currently pending.   On January 8, 2021, a purported shareholder, Phillip Chan, commenced a pro se lawsuit in the U.S. District Court for the Northern District of California titled Chan v. Vaxart, Inc. et al. (the "Opt-Out Action"), opting out of the consolidated Himmelberg v. Vaxart, Inc. et al. and Hovhannisyan v. Vaxart, Inc. et al. class actions, (together, the "Putative Class Action"). Because this complaint is nearly identical to an earlier version of a complaint filed in the Putative Class Action, the Opt-Out Action has been stayed while the Putative Class Action is pending.   85000001200000020000000 NOTE 9 . Stockholders' Equity   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (a) </td><td style="vertical-align:top;"> Preferred Stock </td></tr> </tbody></table>   The Company is authorized to issue 5,000,000 shares of preferred stock, $0.0001 par value per share. The Company's board of directors may, without further action by the stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 5,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a change of control or other corporate action. No shares of preferred stock are currently outstanding, and the Company has no present plan to issue any shares of preferred stock.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (b) </td><td style="vertical-align:top;"> Common Stock </td></tr> </tbody></table>   As of September 30, 2024, the Company was authorized to issue 350,000,000 shares of common stock, $0.0001 par value per share, which includes an increase of 100,000,000 on June 11, 2024, when the Company's stockholders approved an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock from 250,000,000 to 350,000,000 shares. Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company's directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders. Holders of common stock are entitled to receive such dividends, if any, as may be declared from time to time by the Company's board of directors at its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically. As of September 30, 2024, no dividends had been declared by the board of directors.   In June 2024, the Company entered into an underwriting agreement with Oppenheimer & Co. Inc., relating to the issuance and sale by the Company in an underwritten registered direct offering of 50,000,000 shares of the Company's common stock, at a price of $0.80 per share. The gross proceeds to the Company from such offering were $40.0 million, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds were $37.5 million.   In January 2024, the Company entered into the 2024 Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. pursuant to which 15,384,615 shares of the Company's common stock were sold to RA Capital Healthcare Fund, L.P. at an offering price of $0.65 per share pursuant to the Company's 2023 Shelf Registration. The gross proceeds from the 2024 Securities Purchase Agreement were $10.0 million and, after deducting offering expenses, the net proceeds were $9.9 million.   In the event of the Company's voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all the Company's assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied. There are no sinking fund provisions applicable to the common stock.   The Company had shares of common stock reserved for issuance as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Options issued and outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">21,407,462</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">17,938,726</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> RSUs issued and outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,036,238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,126,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2019 Equity Incentive Plan available for future grant </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">16,957,020</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,685,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2024 Inducement Award Plan available for future grant </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,727,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">140,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">227,434</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2022 Employee Stock Purchase Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,362,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,631,718</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,043,664</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The approved increase of reserved common stock for 2019 Equity Incentive Plan and 2022 Employee Stock Purchase Plan is detailed in Note 10.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (c) </td><td style="vertical-align:top;"> Treasury Stock </td></tr> </tbody></table>   The Company generally withholds shares of its common stock to cover employees' portion of required tax withholdings when employee equity awards are issued or vest. These shares are valued at cost, which equals the market price of the common stock on the date of issuance or vesting. The Company had 700,122 and 507,020 treasury shares as of September 30, 2024 and December 31, 2023, respectively.   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:18pt;"> </td><td style="width:18pt;vertical-align:top;"> (d) </td><td style="vertical-align:top;"> Warrants </td></tr> </tbody></table>   In April 2024, 70,663 of the warrants outstanding as of March 31, 2024, expired unexercised. The following warrants were outstanding as of September 30, 2024, all of which contain standard anti-dilution protections in the event of subsequent rights offerings, stock splits, stock dividends or other extraordinary dividends, or other similar changes in the Company's common stock or capital structure, and none of which have any participating rights for any losses: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46.9%;"> Securities into which warrants are convertible </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrants Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 15.1%;"> Expiration Date </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29,150</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">March 2025</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common Stock</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.125</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> February 2025 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,914</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">22.99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 2026 </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table>   In the event of a Fundamental Transaction (a transfer of ownership of the Company as defined in the warrant) within the Company's control, the holders of the unexercised common stock warrants exercisable for $2.50 and those exercisable for $3.125 shall be entitled to receive cash consideration equal to a Black-Scholes valuation, as defined in the warrant. If such Fundamental Transaction is not within the Company's control, the warrant holders would only be entitled to receive the same form of consideration (and in the same proportion) as the holders of the Company's common stock, hence these warrants are classified as a component of permanent equity.   50000000.000103500000000.000110000000025000000035000000005000000000.840000000375000001538461506.651000000099000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:

"Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Options issued and outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">21,407,462</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">17,938,726</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> RSUs issued and outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,036,238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,126,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2019 Equity Incentive Plan available for future grant </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">16,957,020</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,685,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2024 Inducement Award Plan available for future grant </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,727,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">140,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">227,434</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2022 Employee Stock Purchase Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">2,362,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,065,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,631,718</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,043,664</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 2140746217938726303623821263731695702056858061727500014059622743423629021065325456317182704366470012250702070663 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46.9%;"> Securities into which warrants are convertible </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrants Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Exercise Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 15.1%;"> Expiration Date </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29,150</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">March 2025</p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common Stock</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">100,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.125</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> February 2025 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Common Stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,914</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;

margin-left: 0pt;">22.99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 2026 </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,596</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 291502.51005323.1251091422.991405962.53.125 NOTE 10. Equity Incentive Plans   On April 23, 2019, the Company's stockholders approved the adoption of the 2019 Equity Incentive Plan (the "2019 Plan"), under which the Company is authorized to issue incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units ("RSUs"), other stock awards and performance awards that may be settled in cash, stock, or other property. The 2019 Plan is designed to secure and retain the services of employees, directors and consultants, provide incentives for the Company's employees, directors and consultants to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which employees, directors and consultants may be given an opportunity to benefit from increases in the value of the Company's common stock. Following adoption of the 2019 Plan, all previous plans were frozen, and on forfeiture, cancellation and expiration, awards under those plans are not assumed by the 2019 Plan.   The aggregate number of shares of common stock authorized for issuance under the 2019 Plan was initially 1,600,000 shares, which was increased through an amendment to the 2019 Plan adopted by the Company's stockholders (a "Plan Amendment") on June 8, 2020, to 8,000,000, by a Plan Amendment on June 16, 2021, to 16,900,000, by a Plan Amendment on August 4, 2022, to 28,900,000, and by a Plan Amendment on June 11, 2024, to 43,900,000. Further amendments to the 2019 Plan to increase the share reserve would require stockholder approval. Awards that are forfeited or canceled generally become available for issuance again under the 2019 Plan. Awards have a maximum term of ten years from the grant date and may vest over varying periods, as specified by the Company's board of directors for each grant.   On February 27, 2024, the Company's board of directors adopted the Vaxart, Inc. 2024 Inducement Award Plan (the "2024 Inducement Plan"). The 2024 Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the board of directors or the independent members of the board of directors. The board of directors reserved 3,000,000 shares of the Company's common stock for issuance under the 2024 Inducement Plan, subject to adjustment as provided in the plan document. The terms of the 2024 Inducement Plan are substantially similar to the terms of the 2019 Plan, with the exception that incentive stock options may not be issued under the 2024 Inducement Plan and equity awards under the 2024 Inducement Plan (including nonqualified stock options, restricted stock, restricted stock units, and other stock-based awards) may be issued only to an employee who is commencing employment with the Company or any subsidiary or who is being rehired following a bona fide interruption of employment by the Company or any subsidiary, in either case if he or she is granted such award in connection with his or her commencement of employment and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.   A summary of stock option and RSU transactions in the nine months ended September 30, 2024, is as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Option Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unvested </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSU Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Available </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Exercise </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSU Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For Grant </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Balance as of January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,685,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,938,726</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,126,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Authorized under 2024 Inducement Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Authorized under 2019 Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">15,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(7,167,480</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,248,437</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,919,043</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(38,030</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">0.78</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Released</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(571,884</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.51</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Forfeited </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,872,626</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(1,435,332</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(437,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.43</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Canceled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">293,568</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(306,339</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">3.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">18,684,520</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">21,407,462</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">2.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">3,036,238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.19</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table>   As of September 30, 2024, there were 21,407,462 options outstanding with a weighted average exercise price of $2.50, a weighted average remaining term of 6.83 years, and an aggregate intrinsic value of $538,000. Of these options, 12,618,062 were vested, with a weighted average exercise price of $3.02, a weighted average remaining term of 5.40 years, and an aggregate intrinsic value of $379,000.   The Company received $30,000 for the 38,030 options exercised during the nine months ended September 30, 2024, which had an intrinsic value of $7,000, and received $17,000 for the 54,720 options exercised during the nine months ended September 30, 2023, which had an intrinsic value of $31,000. The aggregate intrinsic value represents the total pre-tax value (i.e., the difference between the Company's stock price and the exercise price) of stock options outstanding as of September 30, 2024, based on the Company's common stock closing price of $0.85 on September 30, 2024, which would have been received by the option holders had all their in-the-money options been exercised as of that date.   The weighted average grant date fair value of options awarded in the nine months ended September 30, 2024 and 2023, was $1.01 and $0.78, respectively. Their fair values were estimated using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 20%;"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 16%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 16%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.7% - 4.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.5% - 4.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New

Roman", Times, serif; font-size: 10pt; width: 62%;"> Expected term (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.50 - 6.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">128.9% - 130.8</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127.8% - 133.8</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table>   The Company measures the fair value of all stock-based awards on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. Total stock-based compensation recognized for options, RSUs and ESPP was as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Research and development </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,814</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,404</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,489</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">661</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,657</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,275</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,475</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,843</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,146</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,417</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   As of September 30, 2024, the unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs expected to vest was $15.9 million, which the Company

expects to recognize over an estimated weighted average period of 2.3 years.   On August 4, 2022, the 2022 Employee Stock Purchase Plan (the "2022 ESPP") was approved by the Company's stockholders. The Company initially reserved 1,800,000 shares of the Company's common stock for purchase under the 2022 ESPP, which was increased by 1,800,000 shares through an amendment to the 2022 ESPP adopted by the Company's stockholders on June 11, 2024, to 3,600,000 shares. The 2022 ESPP generally has a six-month offering period comprised of one purchase period. In May 2024, the 2022 ESPP had a one-time modification following the end of the six-month offering period ended May 31, 2024, to commence the follow-on offering period on July 1, 2024 for a five-month offering period. The purchase price of the stock is equal to 85% of the lesser of the market value of such shares at the beginning of the six-month offering period or the end of such offering period. During the nine months ended September 30, 2024, the Company received $0.3 million and issued 502,423 shares under the 2022 ESPP. As of September 30, 2024, 2,362,902 shares are available and reserved for future issuance under the 2022 ESPP.   The estimated fair value used for the five-month offering period beginning July 1, 2024 and ending November 30, 2024, was $0.28 per share. The estimated fair value used for the six-month offering period beginning December 1, 2023 and ending May 31, 2024 was $0.27 per share. The estimated fair value used for the six-month offering period beginning June 1, 2023 and ending November 30, 2023 was $0.54 per share. The estimated fair value used for the six-month offering period beginning December 1, 2022 and ending May 31, 2023 was $0.46 per share. As of September 30, 2024, the unrecognized stock-based compensation cost related to outstanding ESPP expected to be recognized is $41,000 by November 30, 2024. The fair value of the 2022 ESPP shares was estimated using the Black-Scholes option pricing model using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Five-Month Offering Period Ending November 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six-Month Offering Period Ending May 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six-Month Offering Period Ending November 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Six-Month Offering Period Ending May 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected term (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">102.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84.7</td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table>   160000080000001690000028900000439000003000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Option Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Unvested </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSU Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Available </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Exercise </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSU Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For Grant </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Balance as of January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,685,806</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,938,726</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,126,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times,

serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Authorized under 2024 Inducement Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0pt;"> Authorized under 2019 Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">15,000,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(7,167,480</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,248,437</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,919,043</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"> Exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(38,030</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">0.78</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"><p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Released</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,872,626</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(1,435,332</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(437,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.43</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%; padding: 0; margin: 0"><p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Canceled</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">293,568</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(306,339</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family:

"Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">3.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>

family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected term (in years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">102.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">98.6</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">84.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">— </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">— </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">— </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table>0.0530.0530.0540.046P0Y5M1DP0Y6MP0Y6MP0Y6M1.020.7520.9860.8470000 NOTE 11. Net Loss Per Share Attributable to Common Stockholders   The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(54,963</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(65,090</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: &

font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,090,220</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,629,741</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,763,739</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,840,178</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,080</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(54,963</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(65,090</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares used to compute net loss per share – basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">227,452,883</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">152,026,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">193,655,660</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">145,810,175</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Net loss per share – basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.28</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(0.45</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> </tbody></table> -14080000-17400000-54963000-650900002274528831520261121936556601458101750-0.06-0.11-0.28-0.45 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Options to purchase common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">21,568,098</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,151,747</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,435,908</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,019,217</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

*inherit;">not offer or sell any additional shares of its common stock under the September 2021 ATM or the related prospectus and prospectus supplement. From September 15, 2021 to October 18, 2024, the Company sold 17,501,561 shares of common stock for aggregate gross proceeds of approximately $28.6 million pursuant to the September 2021 ATM.   17501561286000000 Item 5. Other Information   During the quarter ended September 30, 2024, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Item 408 of Regulation S-K.   *

-8?20$3;8T.P6BP^0"X9 M9K>]9!:G